{"c99640294d5862d4482de51f9a442deaf09b53be": [["overlapping open reading frames (ORFs) named 1a and 1b.", [["open reading frames", "DNA", 12, 31], ["ORFs", "DNA", 33, 37], ["1a and 1b", "DNA", 45, 54]]], ["Both ORFs are directly translated from the viral genome, resulting in two large polyproteins (pp1a and pp1ab), which are autoproteolitically cleaved to release the replication-transcription complex components (8) .", [["pp1a", "GENE_OR_GENE_PRODUCT", 94, 98], ["pp1ab", "GENE_OR_GENE_PRODUCT", 103, 108], ["ORFs", "DNA", 5, 9], ["viral genome", "DNA", 43, 55], ["polyproteins", "PROTEIN", 80, 92], ["pp1a", "PROTEIN", 94, 98], ["pp1ab", "PROTEIN", 103, 108], ["replication-transcription complex components", "PROTEIN", 164, 208], ["the viral genome", "PROBLEM", 39, 55], ["two large polyproteins", "PROBLEM", 70, 92], ["viral genome", "OBSERVATION", 43, 55], ["large", "OBSERVATION_MODIFIER", 74, 79], ["polyproteins", "OBSERVATION", 80, 92]]], ["The 3= one-third of the genome includes the genes encoding the structural spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, as well as the genusspecific proteins characteristic of each CoV, which are expressed from a nested set of 3=-coterminal subgenomic mRNAs (sgmRNAs) (2, 7, 8) .", [["membrane", "ANATOMY", 99, 107], ["membrane", "CELLULAR_COMPONENT", 99, 107], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 117, 142], ["CoV", "GENE_OR_GENE_PRODUCT", 205, 208], ["structural spike (S), envelope (E), membrane (M)", "PROTEIN", 63, 111], ["nucleocapsid (N) proteins", "PROTEIN", 117, 142], ["genusspecific proteins", "PROTEIN", 159, 181], ["3=-coterminal subgenomic mRNAs", "RNA", 251, 281], ["sgmRNAs", "PROTEIN", 283, 290], ["envelope (E), membrane (M), and nucleocapsid (N) proteins", "TEST", 85, 142], ["the genusspecific proteins characteristic of each CoV", "PROBLEM", 155, 208], ["a nested set", "TEST", 235, 247], ["coterminal subgenomic mRNAs", "PROBLEM", 254, 281], ["genome", "OBSERVATION", 24, 30], ["spike", "OBSERVATION_MODIFIER", 74, 79], ["each CoV", "OBSERVATION", 200, 208], ["subgenomic mRNAs", "OBSERVATION", 265, 281]]]], "PMC7420073": [["According to the Office on Women's Health (U.S. Department of Health & Human Services, 2018), sexual assault on college campuses is most common among females age 18\u201324 with 1 in 5 women experiencing some type of unwanted sexual activity.", [["sexual assault", "DISEASE", 94, 108], ["Human", "ORGANISM", 71, 76], ["women", "ORGANISM", 180, 185], ["Women", "SPECIES", 27, 32], ["Human", "SPECIES", 71, 76], ["women", "SPECIES", 180, 185]]], ["Title IX was intended to hold federally funded education entities accountable to prevent discrimination on the basis of sex, interpreted to also include sexual harassment, rape and sexual assault.", [["sexual harassment", "DISEASE", 153, 170], ["sexual assault", "DISEASE", 181, 195], ["Title IX", "GENE_OR_GENE_PRODUCT", 0, 8], ["Title IX", "PROTEIN", 0, 8]]]], "a75d3138c39f6b174ac52ba4bd1c1b8090237e3a": [["the immunity of patients with COVID-19 and killing sars-cov-2 by the human body's own immune function have become the key factors of current anti epidemic.In this paper, 208 patients with COVID-19 who were diagnosed in our hospital from January 30, 2020 to March 17, 2020 and received early nutrition intervention were reviewed.", [["body", "ANATOMY", 75, 79], ["COVID-19", "CHEMICAL", 30, 38], ["patients", "ORGANISM", 16, 24], ["sars-cov-2", "GENE_OR_GENE_PRODUCT", 51, 61], ["human", "ORGANISM", 69, 74], ["body", "ORGANISM_SUBDIVISION", 75, 79], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 16, 24], ["human", "SPECIES", 69, 74], ["patients", "SPECIES", 174, 182], ["human", "SPECIES", 69, 74], ["COVID", "TEST", 30, 35], ["killing sars", "TEST", 43, 55], ["cov", "TEST", 56, 59], ["early nutrition intervention", "TREATMENT", 285, 313]]], ["The effects of early whole protein intervention and high fiber whey short peptide intervention on nutrition index, immune function and prognosis were studied.Data and methodsClinical data:Data and methodsAll patients were recruited from Yichang Central People's Hospital in Hubei province.Since January 29, 2020, all inpatients with COVID-19 have been given five-step treatment of enteral nutrition intervention.", [["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["early whole protein intervention", "TREATMENT", 15, 47], ["high fiber whey short peptide intervention", "TREATMENT", 52, 94], ["nutrition index", "TEST", 98, 113], ["COVID", "TEST", 333, 338], ["enteral nutrition intervention", "TREATMENT", 381, 411]]], ["46 Since February 8, 2020, the regimen shifted to whole protein prophylactic enteral nutrition.Methods: On the basis of conventional diet, all common type patients, took orally 50g whole protein( Homogenate diet, including milk protein and soybean protein)as enteral nutrition every day.", [["patients", "ORGANISM", 155, 163], ["milk", "ORGANISM_SUBDIVISION", 223, 227], ["milk protein", "PROTEIN", 223, 235], ["soybean protein", "PROTEIN", 240, 255], ["patients", "SPECIES", 155, 163], ["the regimen", "TREATMENT", 27, 38], ["whole protein prophylactic enteral nutrition", "TREATMENT", 50, 94], ["orally 50g whole protein( Homogenate diet", "TREATMENT", 170, 211], ["milk protein and soybean protein)", "TREATMENT", 223, 256], ["enteral nutrition", "TREATMENT", 259, 276]]], ["According to the condition of severe and critical patients, individualized nutrition programs were developed in a total of 206 patients.", [["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 127, 135], ["individualized nutrition programs", "TREATMENT", 60, 93], ["severe", "OBSERVATION_MODIFIER", 30, 36]]], ["Since February 22, 2020 , 49 patients with slow recovery after preventive nutrition intervention with whole protein,received enteral nutrition intervention with high fiber whey short peptide instead of whole protein(Brand: fanting,batch No.: 20191005, 20200223,specification: 200ml / bottle, nutrition ingredients in each bottle: 8g nano short peptide, 1g amino acid, 3.0g nano soybean dietary fiber, 4.0g oligofructose).Methods: On the basis of traditional diet,daily oral administration of high fiber whey short peptide was given as enteral nutrition, with no more whole protein.", [["oral", "ANATOMY", 469, 473], ["amino acid", "CHEMICAL", 356, 366], ["4.0g oligofructose", "CHEMICAL", 401, 419], ["amino acid", "CHEMICAL", 356, 366], ["patients", "ORGANISM", 29, 37], ["1g amino acid", "SIMPLE_CHEMICAL", 353, 366], ["oral", "ORGANISM_SUBDIVISION", 469, 473], ["patients", "SPECIES", 29, 37], ["preventive nutrition intervention", "TREATMENT", 63, 96], ["whole protein", "TREATMENT", 102, 115], ["enteral nutrition intervention", "TREATMENT", 125, 155], ["high fiber whey short peptide", "TREATMENT", 161, 190], ["nutrition ingredients", "TREATMENT", 292, 313], ["nano short peptide", "TREATMENT", 333, 351], ["1g amino acid", "TREATMENT", 353, 366], ["nano soybean dietary fiber", "TREATMENT", 373, 399], ["traditional diet", "TREATMENT", 446, 462], ["daily oral administration", "TREATMENT", 463, 488], ["high fiber whey short peptide", "TREATMENT", 492, 521], ["enteral nutrition", "TREATMENT", 535, 552]]], ["Among them, 20 patients each drank 3 bottles a day, 7 patients each drank 2 bottles a day,and 22 patients each drank 1 bottles a day.Those taking 2-3 bottles per person per day were recruited as the study subjects.12 patients were excluded from the study for the duration less than 2 days or their light or severe types.", [["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 97, 105], ["person", "SPECIES", 162, 168], ["patients", "SPECIES", 217, 225], ["the study", "TEST", 245, 254], ["severe", "OBSERVATION_MODIFIER", 307, 313]]], ["15 common patients (2 of 2 bottles, 13 of 3 bottles) were used as the treatment group, to study nutritional status and immune indicators.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["the treatment group", "TREATMENT", 66, 85]]], ["Among 206 confirmed patients with covid-19, those of light, severe, and critical types, or death, or those with non continuous intervention till discharge or with incomplete detection indexes were excluded.", [["death", "DISEASE", 91, 96], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["non continuous intervention", "TREATMENT", 112, 139], ["incomplete detection indexes", "TEST", 163, 191]]], ["According to the sex and age of the treatment group, 51 common cases were matched as the control group.There was no significant difference between general situation of the two groups(p>0.05)(table1) As for data of treatment group and control group,according to the duration of the disease,the acquisition standard took 3-7 days as the node.", [["node", "ANATOMY", 335, 339], ["node", "MULTI-TISSUE_STRUCTURE", 335, 339], ["significant difference", "PROBLEM", 116, 138], ["treatment group and control group", "TREATMENT", 214, 247], ["the disease", "PROBLEM", 277, 288], ["no", "UNCERTAINTY", 113, 115], ["significant", "OBSERVATION_MODIFIER", 116, 127], ["difference", "OBSERVATION_MODIFIER", 128, 138], ["disease", "OBSERVATION", 281, 288], ["node", "OBSERVATION", 335, 339]]], ["16.17 Through the contrast between groups and before and after intervention, the therapeutic effect of high fiber whey short peptide on patients with COVID-19 was studied.Data and methodsThe data was input into spss19.0 statistical software for processing, and each variable is represented by X \u571f s.", [["COVID-19", "CHEMICAL", 150, 158], ["COVID-19", "CHEMICAL", 150, 158], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["intervention", "TREATMENT", 63, 75], ["high fiber whey short peptide", "TREATMENT", 103, 132], ["COVID", "TEST", 150, 155]]], ["T test is used to compare the mean of measurement variables .The counting data is checked by X 2 .", [["T test", "TEST", 0, 6], ["The counting data", "TEST", 61, 78]]], ["P < 0.05 has statistical significance.Clinical nutrition analysis of patients with COVID-19In this study, 206 patients with COVID-19 were treated with whole protein.", [["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 110, 118], ["COVID", "TEST", 83, 88], ["this study", "TEST", 94, 104], ["COVID", "TEST", 124, 129], ["whole protein", "TREATMENT", 151, 164]]], ["These patients include mild, common, severe, critical and dead patients.At the time of admission, the proportion of people whose hemoglobin, total protein and albumin were lower than normal was relatively high.", [["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 63, 71], ["people", "ORGANISM", 116, 122], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 129, 139], ["albumin", "GENE_OR_GENE_PRODUCT", 159, 166], ["hemoglobin", "PROTEIN", 129, 139], ["total protein", "PROTEIN", 141, 154], ["albumin", "PROTEIN", 159, 166], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 63, 71], ["people", "SPECIES", 116, 122], ["mild, common, severe, critical and dead patients", "PROBLEM", 23, 71], ["hemoglobin", "TEST", 129, 139], ["total protein", "TEST", 141, 154], ["albumin", "TEST", 159, 166], ["mild", "OBSERVATION_MODIFIER", 23, 27], ["severe", "OBSERVATION_MODIFIER", 37, 43]]], ["151 of the 152 people who tested prealbumin were lower than normal.", [["people", "ORGANISM", 15, 21], ["prealbumin", "GENE_OR_GENE_PRODUCT", 33, 43], ["prealbumin", "PROTEIN", 33, 43], ["people", "SPECIES", 15, 21], ["prealbumin", "TEST", 33, 43]]], ["The average value of 151 human prealbumin was 149.08mg/l.", [["human", "ORGANISM", 25, 30], ["prealbumin", "GENE_OR_GENE_PRODUCT", 31, 41], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["The average value", "TEST", 0, 17], ["human prealbumin", "TEST", 25, 41]]], ["99.34% of the patients were in a negative nitrogen balance state.", [["nitrogen", "CHEMICAL", 42, 50], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["nitrogen balance", "OBSERVATION", 42, 58]]], ["The mean value of prealbumin was 147.36mg/lin 140 patients with no obvious abnormal liver function ,and was 171.05mg/l in 11 patients with obvious liver function abnormality.", [["liver", "ANATOMY", 84, 89], ["liver", "ANATOMY", 147, 152], ["abnormal liver function", "DISEASE", 75, 98], ["liver function abnormality", "DISEASE", 147, 173], ["prealbumin", "GENE_OR_GENE_PRODUCT", 18, 28], ["patients", "ORGANISM", 50, 58], ["liver", "ORGAN", 84, 89], ["patients", "ORGANISM", 125, 133], ["liver", "ORGAN", 147, 152], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 125, 133], ["The mean value", "TEST", 0, 14], ["prealbumin", "TEST", 18, 28], ["obvious abnormal liver function", "PROBLEM", 67, 98], ["obvious liver function abnormality", "PROBLEM", 139, 173], ["no obvious", "UNCERTAINTY", 64, 74], ["liver", "ANATOMY", 84, 89], ["liver", "ANATOMY", 147, 152], ["function abnormality", "OBSERVATION", 153, 173]]], ["The screening criteria of liver function abnormality:Clinical nutrition analysis of patients with COVID-19AST >100u/L,ALT >100u/L,STB > 42.8\u03bcmol/L,GGT >100u/L, ALP >275u/L, the decrease of prealbumin in these patients had no significant relationship with liver function damage( Table 2) . .", [["liver", "ANATOMY", 26, 31], ["liver", "ANATOMY", 255, 260], ["liver function abnormality", "DISEASE", 26, 52], ["liver function damage", "DISEASE", 255, 276], ["liver", "ORGAN", 26, 31], ["patients", "ORGANISM", 84, 92], ["ALT", "SIMPLE_CHEMICAL", 118, 121], ["ALP", "GENE_OR_GENE_PRODUCT", 160, 163], ["prealbumin", "GENE_OR_GENE_PRODUCT", 189, 199], ["patients", "ORGANISM", 209, 217], ["liver", "ORGAN", 255, 260], ["ALT", "PROTEIN", 118, 121], ["GGT", "PROTEIN", 147, 150], ["ALP", "PROTEIN", 160, 163], ["prealbumin", "PROTEIN", 189, 199], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 209, 217], ["The screening criteria", "TEST", 0, 22], ["liver function abnormality", "PROBLEM", 26, 52], ["Clinical nutrition analysis", "TEST", 53, 80], ["COVID", "TEST", 98, 103], ["19AST", "TEST", 104, 109], ["ALT", "TEST", 118, 121], ["STB", "TEST", 130, 133], ["GGT", "TEST", 147, 150], ["ALP", "TEST", 160, 163], ["the decrease of prealbumin", "PROBLEM", 173, 199], ["liver function damage", "PROBLEM", 255, 276], ["liver", "ANATOMY", 26, 31], ["decrease", "OBSERVATION_MODIFIER", 177, 185], ["liver", "ANATOMY", 255, 260]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 8, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Low value standard: hemoglobin < 115g / L, total protein < 60g / L, albumin < 35g / L, prealbumin < 280mg / L.Comparison of prealbumin between two groupsThroughout the course of the disease, prealbumin in both groups was lower than normal.In the control group, prealbumin didn't differ between adjacent nodes(P>0.05), and was significantly higher at the discharge node than at the admission node(p=0.000).In the treatment group, prealbumin descended at the first node(p=0.721), and was significantly higher at the second node than at the first node (P = 0.004),and at the discharge node than at the admission node(p=0.001).The four nodes of the treatment group and the control group were compared,at the second and discharge nodes, prealbumin at the treatment group was no higher than that in the control group.", [["nodes", "ANATOMY", 303, 308], ["node", "ANATOMY", 364, 368], ["node", "ANATOMY", 391, 395], ["node", "ANATOMY", 463, 467], ["node", "ANATOMY", 521, 525], ["node", "ANATOMY", 544, 548], ["node", "ANATOMY", 582, 586], ["node", "ANATOMY", 609, 613], ["nodes", "ANATOMY", 632, 637], ["nodes", "ANATOMY", 725, 730], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 20, 30], ["albumin", "GENE_OR_GENE_PRODUCT", 68, 75], ["prealbumin", "GENE_OR_GENE_PRODUCT", 87, 97], ["prealbumin", "GENE_OR_GENE_PRODUCT", 124, 134], ["prealbumin", "GENE_OR_GENE_PRODUCT", 191, 201], ["prealbumin", "GENE_OR_GENE_PRODUCT", 261, 271], ["nodes", "MULTI-TISSUE_STRUCTURE", 303, 308], ["prealbumin", "GENE_OR_GENE_PRODUCT", 429, 439], ["node", "MULTI-TISSUE_STRUCTURE", 463, 467], ["node", "MULTI-TISSUE_STRUCTURE", 521, 525], ["node", "MULTI-TISSUE_STRUCTURE", 544, 548], ["node", "MULTI-TISSUE_STRUCTURE", 582, 586], ["prealbumin", "GENE_OR_GENE_PRODUCT", 732, 742], ["hemoglobin", "PROTEIN", 20, 30], ["albumin", "PROTEIN", 68, 75], ["prealbumin", "PROTEIN", 87, 97], ["prealbumin", "PROTEIN", 124, 134], ["prealbumin", "PROTEIN", 191, 201], ["prealbumin", "PROTEIN", 261, 271], ["prealbumin", "PROTEIN", 429, 439], ["prealbumin", "PROTEIN", 732, 742], ["hemoglobin", "TEST", 20, 30], ["total protein", "TEST", 43, 56], ["albumin", "TEST", 68, 75], ["prealbumin", "TEST", 87, 97], ["prealbumin", "TEST", 124, 134], ["the disease", "PROBLEM", 178, 189], ["prealbumin", "TEST", 191, 201], ["prealbumin", "TEST", 261, 271], ["P", "TEST", 309, 310], ["prealbumin", "TEST", 429, 439], ["the treatment group", "TREATMENT", 641, 660], ["prealbumin", "TEST", 732, 742], ["disease", "OBSERVATION", 182, 189], ["normal", "OBSERVATION", 232, 238], ["nodes", "OBSERVATION", 303, 308], ["significantly", "OBSERVATION_MODIFIER", 326, 339], ["higher", "OBSERVATION_MODIFIER", 340, 346], ["node", "OBSERVATION", 364, 368], ["node", "OBSERVATION", 391, 395], ["first node", "ANATOMY", 457, 467], ["significantly", "OBSERVATION_MODIFIER", 486, 499], ["higher", "OBSERVATION_MODIFIER", 500, 506], ["second", "OBSERVATION_MODIFIER", 514, 520], ["node", "OBSERVATION", 521, 525], ["first node", "ANATOMY", 538, 548], ["node", "OBSERVATION", 582, 586], ["node", "OBSERVATION", 609, 613], ["four", "OBSERVATION_MODIFIER", 627, 631], ["nodes", "OBSERVATION", 632, 637], ["treatment", "OBSERVATION_MODIFIER", 645, 654], ["nodes", "OBSERVATION", 725, 730], ["higher", "OBSERVATION_MODIFIER", 773, 779]]], ["There was no significant difference between the two groups (P > 0.05).", [["P", "TEST", 60, 61], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Throughout the course of the disease,the number of lymphocytes in the treatment group and the control group increased gradually.", [["lymphocytes", "ANATOMY", 51, 62], ["lymphocytes", "CELL", 51, 62], ["lymphocytes", "CELL_TYPE", 51, 62], ["the disease", "PROBLEM", 25, 36], ["the treatment group", "TREATMENT", 66, 85], ["disease", "OBSERVATION", 29, 36], ["lymphocytes", "OBSERVATION", 51, 62], ["increased", "OBSERVATION_MODIFIER", 108, 117], ["gradually", "OBSERVATION_MODIFIER", 118, 127]]], ["There were significant differences between the two groups from admission node to the second node and to discharge node (Treatment groupP = 0.001/0,Control group P = 0.018/0).The number of lymphocytes in the treatment group was higher than that in the control group.", [["node", "ANATOMY", 73, 77], ["node", "ANATOMY", 92, 96], ["node", "ANATOMY", 114, 118], ["lymphocytes", "ANATOMY", 188, 199], ["node", "MULTI-TISSUE_STRUCTURE", 73, 77], ["node", "MULTI-TISSUE_STRUCTURE", 92, 96], ["node", "MULTI-TISSUE_STRUCTURE", 114, 118], ["lymphocytes", "CELL", 188, 199], ["lymphocytes", "CELL_TYPE", 188, 199], ["Treatment groupP", "TREATMENT", 120, 136], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["differences", "OBSERVATION_MODIFIER", 23, 34], ["node", "OBSERVATION", 73, 77], ["node", "OBSERVATION", 92, 96], ["node", "OBSERVATION", 114, 118], ["number", "OBSERVATION_MODIFIER", 178, 184], ["lymphocytes", "OBSERVATION", 188, 199], ["higher", "OBSERVATION_MODIFIER", 227, 233]]], ["There was no significant difference between the two groups (P > 0.05)( Table 6 ).", [["significant difference", "PROBLEM", 13, 35], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["21 1.62\u00b10.75 0.650 Note: P value is the p value of the comparison between two groups of corresponding nodes.", [["nodes", "ANATOMY", 102, 107], ["nodes", "MULTI-TISSUE_STRUCTURE", 102, 107], ["P value", "TEST", 25, 32], ["corresponding nodes", "PROBLEM", 88, 107], ["nodes", "OBSERVATION", 102, 107]]], ["Table 7 Ratio of lymphocyte below normal value in two groups x 100% .", [["lymphocyte", "ANATOMY", 17, 27], ["lymphocyte", "CELL", 17, 27], ["lymphocyte", "CELL_TYPE", 17, 27], ["lymphocyte", "TEST", 17, 27]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 8, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In the control group, the percentage of lymphocytes and the percentage of lymphocytes below normal were stable.", [["lymphocytes", "ANATOMY", 40, 51], ["lymphocytes", "ANATOMY", 74, 85], ["lymphocytes", "CELL", 40, 51], ["lymphocytes", "CELL", 74, 85], ["lymphocytes", "CELL_TYPE", 40, 51], ["lymphocytes", "CELL_TYPE", 74, 85], ["the percentage of lymphocytes", "TEST", 56, 85], ["lymphocytes", "ANATOMY", 40, 51], ["percentage", "OBSERVATION_MODIFIER", 60, 70], ["stable", "OBSERVATION_MODIFIER", 104, 110]]], ["The curve of lymphocyte number in treatment group was similar to that in control group, and the percentage change curve of the number of lymphocyte below normal value in the treatment group decreased significantly at the second node. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.03.20083980 doi: medRxiv preprint day till discharged from hospital.", [["lymphocyte", "ANATOMY", 13, 23], ["lymphocyte", "ANATOMY", 137, 147], ["node", "ANATOMY", 228, 232], ["lymphocyte", "CELL", 13, 23], ["lymphocyte", "CELL", 137, 147], ["node", "MULTI-TISSUE_STRUCTURE", 228, 232], ["lymphocyte", "CELL_TYPE", 137, 147], ["treatment group", "TREATMENT", 34, 49], ["the percentage change curve", "PROBLEM", 92, 119], ["The copyright holder", "TREATMENT", 368, 388], ["curve", "OBSERVATION_MODIFIER", 4, 9], ["lymphocyte number", "OBSERVATION", 13, 30], ["percentage", "OBSERVATION_MODIFIER", 96, 106], ["change", "OBSERVATION_MODIFIER", 107, 113], ["curve", "OBSERVATION_MODIFIER", 114, 119], ["number", "OBSERVATION_MODIFIER", 127, 133], ["value", "OBSERVATION_MODIFIER", 161, 166], ["decreased", "OBSERVATION_MODIFIER", 190, 199], ["second", "OBSERVATION_MODIFIER", 221, 227], ["node", "OBSERVATION", 228, 232], ["med", "ANATOMY", 272, 275]]], ["A total of 65 patients were used as a control group to compare rehabilitation speed.The average length of stay in the control group after March 4 was 6 days, minus the median standard time difference of 0.47 days, as the average speed of turning negative in the control group.There was no significant difference between general situation of the two groups (P > 0.05).The rehabilitation speed of the treatment group was significantly faster than that of the control group (P = 0.015) ( Table 8) .", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["a control group", "TREATMENT", 36, 51], ["rehabilitation speed", "TREATMENT", 63, 83], ["average", "OBSERVATION_MODIFIER", 88, 95], ["length", "OBSERVATION_MODIFIER", 96, 102], ["no", "UNCERTAINTY", 286, 288], ["significant", "OBSERVATION_MODIFIER", 289, 300], ["difference", "OBSERVATION_MODIFIER", 301, 311]]], ["One bottle of high fiber whey short peptide per day was taken as enteral nutrition intervention for all 12 common patients, as a 1-bottle treatment group.With the same comparison method,there was no significant difference between general situation of the two groups (P > 0.05),or between rehabilitation speed of the two groups (P = 0.836) ( Table 9 ).", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["high fiber whey short peptide", "TREATMENT", 14, 43], ["enteral nutrition intervention", "TREATMENT", 65, 95], ["a 1-bottle treatment group", "TREATMENT", 127, 153], ["no", "UNCERTAINTY", 196, 198], ["significant", "OBSERVATION_MODIFIER", 199, 210], ["difference", "OBSERVATION", 211, 221]]], ["Discussion\uff1a SARS-CoV-2 infects the host using the angiotensin converting enzyme 2 receptor and causes covid-19, and this receptor is expressed in many organs, including the lungs and intestines.", [["organs", "ANATOMY", 151, 157], ["lungs", "ANATOMY", 173, 178], ["intestines", "ANATOMY", 183, 193], ["angiotensin", "CHEMICAL", 50, 61], ["SARS-CoV-2", "ORGANISM", 12, 22], ["angiotensin converting enzyme 2 receptor", "GENE_OR_GENE_PRODUCT", 50, 90], ["organs", "ORGAN", 151, 157], ["lungs", "ORGAN", 173, 178], ["intestines", "ORGAN", 183, 193], ["angiotensin converting enzyme 2 receptor", "PROTEIN", 50, 90], ["SARS-CoV-2", "SPECIES", 12, 22], ["the angiotensin converting enzyme 2 receptor", "TREATMENT", 46, 90], ["covid", "TEST", 102, 107], ["lungs", "ANATOMY", 173, 178], ["intestines", "ANATOMY", 183, 193]]], ["[1] [2] [3] [4] [5] Gene sequencing found that,the expression level of ACE2 receptor in digestive tract is almost 100 times of that in respiratory organs.", [["digestive tract", "ANATOMY", 88, 103], ["respiratory organs", "ANATOMY", 135, 153], ["[1] [2] [3] [4", "SIMPLE_CHEMICAL", 0, 14], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 71, 84], ["digestive tract", "ORGAN", 88, 103], ["organs", "ORGAN", 147, 153], ["ACE2 receptor", "PROTEIN", 71, 84], ["Gene sequencing", "TEST", 20, 35], ["ACE2 receptor in digestive tract", "PROBLEM", 71, 103], ["digestive tract", "ANATOMY", 88, 103], ["respiratory organs", "ANATOMY", 135, 153]]], ["6 ACE2 and TMPRSS2 are the determinants of SARS-CoV-2 entry into cells, ACE2 is highly expressed in the absorptive intestinal epithelial cells, and the small intestine is rich furin protease.", [["cells", "ANATOMY", 65, 70], ["absorptive intestinal epithelial cells", "ANATOMY", 104, 142], ["small intestine", "ANATOMY", 152, 167], ["ACE2", "GENE_OR_GENE_PRODUCT", 2, 6], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 11, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["cells", "CELL", 65, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["absorptive intestinal epithelial cells", "CELL", 104, 142], ["intestine", "ORGAN", 158, 167], ["furin", "GENE_OR_GENE_PRODUCT", 176, 181], ["ACE2", "PROTEIN", 2, 6], ["TMPRSS2", "PROTEIN", 11, 18], ["ACE2", "PROTEIN", 72, 76], ["absorptive intestinal epithelial cells", "CELL_TYPE", 104, 142], ["furin protease", "PROTEIN", 176, 190], ["ACE2", "TEST", 2, 6], ["TMPRSS2", "TREATMENT", 11, 18], ["SARS", "TEST", 43, 47], ["CoV", "TEST", 48, 51], ["ACE2", "TEST", 72, 76], ["furin protease", "TREATMENT", 176, 190], ["absorptive", "ANATOMY_MODIFIER", 104, 114], ["intestinal epithelial cells", "OBSERVATION", 115, 142], ["small", "OBSERVATION_MODIFIER", 152, 157], ["intestine", "ANATOMY", 158, 167], ["rich furin protease", "OBSERVATION", 171, 190]]], ["[1] [2] [3] [4] Electron microscopy revealed viral inclusion .", [["[1] [2] [3", "SIMPLE_CHEMICAL", 0, 10], ["Electron microscopy", "TEST", 16, 35], ["viral inclusion", "PROBLEM", 45, 60], ["viral inclusion", "OBSERVATION", 45, 60]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.03.20083980 doi: medRxiv preprint structures in endothelial cells of the blood vessels of patients with COVID-19, and in histological analyses, the small intestine showed endotheliitis (endothelialitis) of the submucosal vessels,and an accumulation of inflammatory cells associated with endothelium,as well as apoptotic bodies.", [["endothelial cells", "ANATOMY", 356, 373], ["blood vessels", "ANATOMY", 381, 394], ["small intestine", "ANATOMY", 456, 471], ["endothelialitis", "ANATOMY", 494, 509], ["submucosal vessels", "ANATOMY", 518, 536], ["inflammatory cells", "ANATOMY", 560, 578], ["endothelium", "ANATOMY", 595, 606], ["CC", "CHEMICAL", 0, 2], ["endotheliitis", "DISEASE", 479, 492], ["endothelial cells", "CELL", 356, 373], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 381, 394], ["patients", "ORGANISM", 398, 406], ["small intestine", "ORGAN", 456, 471], ["endothelialitis", "CANCER", 494, 509], ["submucosal vessels", "MULTI-TISSUE_STRUCTURE", 518, 536], ["inflammatory cells", "CELL", 560, 578], ["endothelium", "TISSUE", 595, 606], ["endothelial cells", "CELL_TYPE", 356, 373], ["inflammatory cells", "CELL_TYPE", 560, 578], ["patients", "SPECIES", 398, 406], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["COVID", "TEST", 412, 417], ["histological analyses", "TEST", 429, 450], ["endotheliitis (endothelialitis) of the submucosal vessels", "PROBLEM", 479, 536], ["inflammatory cells", "PROBLEM", 560, 578], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["endothelial cells", "OBSERVATION", 356, 373], ["blood vessels", "ANATOMY", 381, 394], ["small intestine", "ANATOMY", 456, 471], ["endotheliitis", "OBSERVATION", 479, 492], ["submucosal vessels", "ANATOMY", 518, 536], ["accumulation", "OBSERVATION_MODIFIER", 544, 556], ["inflammatory cells", "OBSERVATION", 560, 578], ["endothelium", "OBSERVATION", 595, 606], ["apoptotic bodies", "OBSERVATION", 618, 634]]], ["7 The vascular endothelium is an active paracrine,endocrine,and autocrine organ that is indispensable for the maintenance of vascular homoeostasis.", [["vascular endothelium", "ANATOMY", 6, 26], ["endocrine", "ANATOMY", 50, 59], ["autocrine organ", "ANATOMY", 64, 79], ["vascular", "ANATOMY", 125, 133], ["vascular endothelium", "TISSUE", 6, 26], ["organ", "ORGAN", 74, 79], ["vascular", "MULTI-TISSUE_STRUCTURE", 125, 133], ["vascular endothelium", "ANATOMY", 6, 26], ["active", "OBSERVATION_MODIFIER", 33, 39], ["paracrine", "OBSERVATION", 40, 49], ["autocrine organ", "OBSERVATION", 64, 79], ["vascular", "ANATOMY", 125, 133], ["homoeostasis", "OBSERVATION", 134, 146]]], ["8 Endothelial dysfunction is a principal determinant of microvascular dysfunction by shifting the vascular equilibrium towards more vasoconstriction with subsequent organ ischaemia,inflammation with associated tissue oedema.", [["Endothelial", "ANATOMY", 2, 13], ["microvascular", "ANATOMY", 56, 69], ["vascular", "ANATOMY", 98, 106], ["organ", "ANATOMY", 165, 170], ["tissue", "ANATOMY", 210, 216], ["Endothelial dysfunction", "DISEASE", 2, 25], ["ischaemia", "DISEASE", 171, 180], ["inflammation", "DISEASE", 181, 193], ["oedema", "DISEASE", 217, 223], ["Endothelial", "CELL", 2, 13], ["microvascular", "TISSUE", 56, 69], ["vascular", "MULTI-TISSUE_STRUCTURE", 98, 106], ["organ", "ORGAN", 165, 170], ["tissue", "TISSUE", 210, 216], ["Endothelial dysfunction", "PROBLEM", 2, 25], ["microvascular dysfunction", "PROBLEM", 56, 81], ["shifting the vascular equilibrium", "PROBLEM", 85, 118], ["subsequent organ ischaemia", "PROBLEM", 154, 180], ["inflammation", "PROBLEM", 181, 193], ["associated tissue oedema", "PROBLEM", 199, 223], ["Endothelial", "ANATOMY", 2, 13], ["dysfunction", "OBSERVATION", 14, 25], ["microvascular dysfunction", "OBSERVATION", 56, 81], ["vascular", "ANATOMY", 98, 106], ["organ", "ANATOMY", 165, 170], ["ischaemia", "OBSERVATION", 171, 180], ["inflammation", "OBSERVATION", 181, 193], ["tissue", "OBSERVATION_MODIFIER", 210, 216], ["oedema", "OBSERVATION", 217, 223]]], ["9 A large number of clinical studies have shown that 3% -79% of patients with covid-19(which was not certified by peer review)have digestive system symptoms.", [["digestive system", "ANATOMY", 131, 147], ["digestive system symptoms", "DISEASE", 131, 156], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["clinical studies", "TEST", 20, 36], ["covid", "TEST", 78, 83], ["digestive system symptoms", "PROBLEM", 131, 156], ["large", "OBSERVATION_MODIFIER", 4, 9]]], ["[10] [11] [12] [13] [14] [15] In this study,99.34% of patients with covid-19 were found In the later period of treatment the incidence of lymphocytopenia in the treatment group was significantly lower than that in the control group and literature reports.60% of human lymphocytes are distributed in the intestinal system.dipeptides and tripeptides can be actively .", [["lymphocytes", "ANATOMY", 268, 279], ["intestinal system", "ANATOMY", 303, 320], ["lymphocytopenia", "DISEASE", 138, 153], ["dipeptides", "CHEMICAL", 321, 331], ["[10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 0, 29], ["patients", "ORGANISM", 54, 62], ["human", "ORGANISM", 262, 267], ["lymphocytes", "CELL", 268, 279], ["intestinal system", "MULTI-TISSUE_STRUCTURE", 303, 320], ["dipeptides", "SIMPLE_CHEMICAL", 321, 331], ["tripeptides", "SIMPLE_CHEMICAL", 336, 347], ["human lymphocytes", "CELL_TYPE", 262, 279], ["patients", "SPECIES", 54, 62], ["human", "SPECIES", 262, 267], ["human", "SPECIES", 262, 267], ["this study", "TEST", 33, 43], ["covid", "TEST", 68, 73], ["treatment", "TREATMENT", 111, 120], ["lymphocytopenia", "PROBLEM", 138, 153], ["human lymphocytes", "TREATMENT", 262, 279], ["dipeptides and tripeptides", "TREATMENT", 321, 347], ["lymphocytopenia", "OBSERVATION", 138, 153], ["human lymphocytes", "OBSERVATION", 262, 279], ["intestinal system", "ANATOMY", 303, 320]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 8, 2020. . https://doi.org/10.1101/2020.06.03.20083980 doi: medRxiv preprint absorbed,directly providing nutrition for intestinal lymphocytes,and improving the immune function of patients.", [["intestinal lymphocytes", "ANATOMY", 425, 447], ["CC", "CHEMICAL", 0, 2], ["intestinal lymphocytes", "CELL", 425, 447], ["patients", "ORGANISM", 485, 493], ["intestinal lymphocytes", "CELL_TYPE", 425, 447], ["patients", "SPECIES", 485, 493], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv", "TREATMENT", 366, 373], ["intestinal lymphocytes", "PROBLEM", 425, 447], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["intestinal lymphocytes", "ANATOMY", 425, 447]]], ["[34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] These changes of prealbumin and lymphocytopenia in the treatment group may be the reason that the rehabilitation speed of the treatment group is significantly faster than that of the control group.(which was not certified by peer review)Most patients with COVID-19 developed severe anorexia at the time of admission.", [["[34] [35] [36] [37] [38] [39] [40] [41] [42] [43", "CHEMICAL", 0, 48], ["lymphocytopenia", "DISEASE", 92, 107], ["anorexia", "DISEASE", 342, 350], ["[34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45]", "CHEMICAL", 0, 59], ["[34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45]", "SIMPLE_CHEMICAL", 0, 59], ["prealbumin", "GENE_OR_GENE_PRODUCT", 77, 87], ["patients", "ORGANISM", 302, 310], ["patients", "SPECIES", 302, 310], ["prealbumin", "TEST", 77, 87], ["lymphocytopenia", "PROBLEM", 92, 107], ["the treatment group", "TREATMENT", 111, 130], ["COVID", "TEST", 316, 321], ["severe anorexia", "PROBLEM", 335, 350], ["lymphocytopenia", "OBSERVATION", 92, 107], ["severe", "OBSERVATION_MODIFIER", 335, 341], ["anorexia", "OBSERVATION", 342, 350]]], ["[9] [10] [11] [12] [13] [14] [15] The acceptance of patients is an important factor of oral nutritional supplements.", [["oral", "ANATOMY", 87, 91], ["[9] [10] [11] [12", "CHEMICAL", 0, 17], ["[9] [10] [11] [12] [13] [14] [15]", "CHEMICAL", 0, 33], ["[9] [10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 0, 33], ["patients", "ORGANISM", 52, 60], ["oral", "ORGANISM_SUBDIVISION", 87, 91], ["patients", "SPECIES", 52, 60], ["oral nutritional supplements", "TREATMENT", 87, 115]]], ["Nano short peptide solves the taste problem of short peptide, and improves the acceptance of COVID-19 patients.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["Nano short peptide", "TREATMENT", 0, 18], ["short peptide", "PROBLEM", 47, 60], ["COVID", "TEST", 93, 98]]], ["It is an important factor for the successful implementation of this clinical nutrition treatment.(which was not certified by peer review)In consideration of the limited number of cases in this study,we call for large-data double-blind controlled trials in the epidemic areas to examine these results carefully and provide a scientific basis for reducing the harm of the epidemic.", [["this clinical nutrition treatment", "TREATMENT", 63, 96], ["this study", "TEST", 188, 198], ["blind controlled trials", "TREATMENT", 229, 252]]]], "7c4cf4696e04c54841d693ab185b9fd22e235e1d": [["This result emphasized that wartime control measures, such as putting cities on lockdown to limit population mobility in Jiangsu Province, resulted in dramatic reductions in COVID-19 cases.IntroductionPneumonia cases infected by unexplained new coronavirus were first reported in December 2019 from Wuhan, China [1, 2] .", [["Pneumonia", "DISEASE", 201, 210], ["coronavirus", "ORGANISM", 245, 256], ["wartime control measures", "TREATMENT", 28, 52], ["COVID", "TEST", 174, 179], ["IntroductionPneumonia cases infected", "PROBLEM", 189, 225], ["unexplained new coronavirus", "PROBLEM", 229, 256], ["dramatic", "OBSERVATION_MODIFIER", 151, 159], ["reductions", "OBSERVATION_MODIFIER", 160, 170], ["Pneumonia", "OBSERVATION", 201, 210]]], ["The World Health Organization named this novel coronavirus disease as coronavirus disease 2019 (COVID-19) on February 11, 2020.", [["coronavirus disease", "DISEASE", 47, 66], ["coronavirus disease", "DISEASE", 70, 89], ["coronavirus", "ORGANISM", 47, 58], ["coronavirus", "SPECIES", 47, 58], ["this novel coronavirus disease", "PROBLEM", 36, 66], ["coronavirus disease", "PROBLEM", 70, 89], ["COVID", "TEST", 96, 101], ["coronavirus disease", "OBSERVATION", 47, 66]]], ["COVID-19 is similar to severe acute respiratory syndrome (SARS) andIntroductionMiddle East respiratory syndrome that can cause fever and serious respiratory symptoms, such as cough, wheezing, and dyspnea [3] [4] [5] .", [["respiratory", "ANATOMY", 145, 156], ["acute respiratory syndrome", "DISEASE", 30, 56], ["SARS", "DISEASE", 58, 62], ["Middle East respiratory syndrome", "DISEASE", 79, 111], ["fever", "DISEASE", 127, 132], ["respiratory symptoms", "DISEASE", 145, 165], ["cough", "DISEASE", 175, 180], ["wheezing", "DISEASE", 182, 190], ["dyspnea", "DISEASE", 196, 203], ["COVID", "TEST", 0, 5], ["severe acute respiratory syndrome", "PROBLEM", 23, 56], ["SARS)", "PROBLEM", 58, 63], ["Middle East respiratory syndrome", "PROBLEM", 79, 111], ["fever", "PROBLEM", 127, 132], ["serious respiratory symptoms", "PROBLEM", 137, 165], ["cough", "PROBLEM", 175, 180], ["wheezing", "PROBLEM", 182, 190], ["dyspnea", "PROBLEM", 196, 203], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["respiratory syndrome", "OBSERVATION", 36, 56], ["respiratory syndrome", "OBSERVATION", 91, 111]]], ["This novel coronavirus can quickly spread from person to person and can lead to widespread outbreaks when infected individuals travel to different areas or countries.", [["coronavirus", "ORGANISM", 11, 22], ["person", "SPECIES", 47, 53], ["person", "SPECIES", 57, 63], ["This novel coronavirus", "PROBLEM", 0, 22], ["coronavirus", "OBSERVATION", 11, 22]]], ["With the celebration of Chinese New Year from January 24 to January 25, 2020, more than five million people left Wuhan, and some of them were infected with the 2019 novel coronavirus (SARS-Cov-2), [6, 7] .", [["coronavirus", "DISEASE", 171, 182], ["SARS", "DISEASE", 184, 188], ["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107], ["coronavirus", "SPECIES", 171, 182], ["Cov", "TEST", 189, 192]]], ["After a rapid increase in the number of new confirmed cases outside Hubei Province, all 31 provinces in mainland China (autonomous regions and municipalities directly under the central government) had reported COVID-19 cases.IntroductionChina was actively responding to the outbreak of the disease and implemented the national security strategy for COVID-19, which turned to so-called wartime control measures, and put cities in Hubei Province on lockdown on January 23, 2020 [8] .", [["COVID", "TEST", 210, 215], ["the disease", "PROBLEM", 286, 297], ["COVID", "TREATMENT", 349, 354], ["rapid", "OBSERVATION_MODIFIER", 8, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22]]], ["In other areas outside Hubei Province, the epidemiologic characteristics of COVID-19Introductionwere unclear as well as whether wartime control measures were able to control the disease.IntroductionOn January 22, 2020, the first confirmed case of COVID-19 was found in Jiangsu Province.", [["COVID-19", "CHEMICAL", 247, 255], ["COVID", "TEST", 76, 81], ["wartime control measures", "TREATMENT", 128, 152], ["the disease", "PROBLEM", 174, 185], ["COVID", "TEST", 247, 252], ["disease", "OBSERVATION", 178, 185]]], ["On January 24, 2020, the People's Government of Jiangsu Province initiated wartime control measures for COVID-19.", [["People", "SPECIES", 25, 31], ["wartime control measures", "TREATMENT", 75, 99], ["COVID", "TEST", 104, 109]]], ["Jiangsu Province, which is located at 116.60\u00b0-121.67\u00b0 east longitude and 31.01\u00b0-34.89\u00b0 north latitude on the central coast of China, has the nearest distance with 537.2 km from Hubei Province.", [["central", "ANATOMY_MODIFIER", 109, 116], ["coast", "ANATOMY_MODIFIER", 117, 122]]], ["This study aimed to estimate the effect of wartime control measures by analyzing the incidence trend and epidemic of COVID-19 after early imported cases in Jiangsu Province from Hubei Province.", [["COVID-19", "CHEMICAL", 117, 125], ["This study", "TEST", 0, 10], ["wartime control measures", "TREATMENT", 43, 67], ["COVID", "TEST", 117, 122]]], ["The findings of this study can serve as a standard reference for controlling COVID-19.wartime control measuresOn January 24, Jiangsu province officially launched the so-called wartime control measures, known as the first-level response to major public health emergency.", [["COVID-19", "DNA", 77, 85], ["this study", "TEST", 16, 26], ["COVID", "TEST", 77, 82], ["the so-called wartime control measures", "TREATMENT", 162, 200]]], ["As follows:wartime control measures1.", [["wartime control measures1", "TREATMENT", 11, 36]]], ["Governments at all levels must report the epidemic of COVID-19 to the state council and take measures in epidemic prevention and control.wartime control measures2.", [["epidemic prevention", "TREATMENT", 105, 124], ["wartime control measures2", "TREATMENT", 137, 162]]], ["Collect, estimate, report and release emergency information every day.wartime control measures3.", [["wartime control measures3", "TREATMENT", 70, 95]]], ["Put cities with epidemic and cross-provincial epidemic areas on lockdown to limit population mobility.Data collectionThe time series of observations of COVID-19 cases from January 22 to February 18, 2020 was obtained from the websites of Bureau of Health and the People's Government of Jiangsu Province.", [["People", "SPECIES", 263, 269], ["Data collection", "TEST", 102, 117], ["COVID", "TEST", 152, 157]]], ["The information included the number of confirmed cases, number of suspected cases, gender, and contact history.Statistical analysisThe dates of illness onset and the geographical locations of COVID-19 cases were plotted.", [["illness", "DISEASE", 144, 151], ["Statistical analysis", "TEST", 111, 131], ["illness onset", "PROBLEM", 144, 157], ["COVID", "TEST", 192, 197]]], ["Close contacts were defined as people who did not take effective protection and have been within 1 m of a suspected case or laboratory-confirmed SARS-Cov-2 infection any time from two days before the onset of illness or an asymptomatically infected person any time from two days before sample collection.", [["sample", "ANATOMY", 286, 292], ["SARS", "DISEASE", 145, 149], ["infection", "DISEASE", 156, 165], ["illness", "DISEASE", 209, 216], ["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37], ["person", "SPECIES", 249, 255], ["SARS", "PROBLEM", 145, 149], ["Cov", "PROBLEM", 150, 153], ["2 infection", "PROBLEM", 154, 165], ["illness", "PROBLEM", 209, 216], ["sample collection", "TEST", 286, 303], ["infected", "OBSERVATION", 240, 248]]], ["Confirmed cases referred to laboratory-confirmed cases of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 58, 78], ["SARS-CoV-2", "ORGANISM", 58, 68], ["CoV-2", "SPECIES", 63, 68], ["SARS-CoV-2", "SPECIES", 58, 68], ["SARS", "PROBLEM", 58, 62], ["CoV", "PROBLEM", 63, 66], ["2 infection", "PROBLEM", 67, 78], ["SARS", "OBSERVATION", 58, 62], ["infection", "OBSERVATION", 69, 78]]], ["Statistical analyses were conducted with GraphPad Prism 8.0 and ArcGIS 13.0.", [["Statistical analyses", "TEST", 0, 20], ["GraphPad Prism", "TEST", 41, 55], ["ArcGIS", "TEST", 64, 70]]], ["7 The cumulative number of confirmed cases gradually increased from one on January 22 to 631 on February 18 ( Fig 1A) .", [["gradually", "OBSERVATION_MODIFIER", 43, 52], ["increased", "OBSERVATION_MODIFIER", 53, 62]]], ["No new confirmed cases were reported after February 18.", [["new", "OBSERVATION_MODIFIER", 3, 6]]], ["Since the first confirmed case in Jiangsu Province on January 22, the number of cases had gradually increased to a maximum of 39 cases by January 30 and remained at a stable trend until February 8 (Fig 1B) .", [["stable", "OBSERVATION_MODIFIER", 167, 173]]], ["Since then, a downward trend was observed, and three, two, and zero cases were reported on February 17, 18, and 19, respectively.", [["a downward trend", "TEST", 12, 28]]], ["The number of suspected cases increased from 36 on January 31 to 45 on February 5 and then declined.", [["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["A marked drop was observed in the day-on-day growth rate of the total confirmed cases and suspected cases (Fig 1C) .Proportion of COVID-19 casesIn the first five days after the first confirmed case, all reported cases had lived or traveled to Hubei Province (Fig 1D) .", [["A marked drop", "PROBLEM", 0, 13], ["COVID", "TEST", 130, 135], ["marked", "OBSERVATION_MODIFIER", 2, 8], ["drop", "OBSERVATION", 9, 13]]], ["As of February 18, the number of confirmed COVID-19 cases was 631 without deaths: 49 mild cases, 572 common cases, six severe cases, and four critical cases.", [["COVID", "DISEASE", 43, 48], ["deaths", "DISEASE", 74, 80], ["COVID", "TEST", 43, 48], ["mild cases", "PROBLEM", 85, 95], ["six severe cases", "PROBLEM", 115, 131]]], ["Since then, no new case was reported.", [["no", "UNCERTAINTY", 12, 14], ["new", "OBSERVATION_MODIFIER", 15, 18]]], ["Moreover, COVID-19 cases were more common in men than in women (Fig 1F) .Proportion of COVID-19 casesTo estimate the effect of wartime control measures for COVID-19, we analyzed the COVID-19 epidemic after the first confirmed case from Wuhan in Wuxi.", [["men", "ORGANISM", 45, 48], ["women", "ORGANISM", 57, 62], ["men", "SPECIES", 45, 48], ["women", "SPECIES", 57, 62], ["COVID", "TEST", 10, 15], ["COVID", "TEST", 87, 92], ["wartime control measures", "TREATMENT", 127, 151], ["COVID", "TEST", 156, 161], ["the COVID", "TEST", 178, 187]]], ["In February, a fast decline in the number of cases who were residents or travelers to Hubei Province was observed, and an increasing number of cases were close contacts.Proportion of COVID-19 casesWe also found that confirmed cases were travelers from Japan, Shanghai, Xinyang, Nanning, Huai'an, and Yunnan Province.", [["a fast decline", "PROBLEM", 13, 27], ["COVID", "TEST", 183, 188], ["Nanning", "TREATMENT", 278, 285]]], ["Those from Hubei Province were excluded.Proportion of COVID-19 casesNotably, one case was confirmed on February 12 who arrived at Wuxi from Wuhan on January 23.", [["COVID", "TEST", 54, 59]]], ["This result showed that COVID-19 had an incubation period of 19 days.Proportion of COVID-19 casesAs of February 16, the number of cumulative confirmed cases was 55 in Wuxi, China.Proportion of COVID-19 casesSince then, no new case was reported.", [["COVID", "TEST", 24, 29], ["COVID", "TEST", 83, 88], ["COVID", "TEST", 193, 198]]], ["No difference was found between the sexes (male, 27; female, 28) (Fig 2B) .Geographical distribution of COVID-2019 casesOn January 22, the first COVID-2019 case was found in Suzhou.", [["COVID", "TEST", 104, 109], ["difference", "OBSERVATION_MODIFIER", 3, 13]]], ["Since then, more cites reported new cases.", [["new", "OBSERVATION_MODIFIER", 32, 35]]], ["New cases were reported in six cities on January 23 and in 12 cities on January 31 (Figs 3A, B, C, D) .", [["New cases", "PROBLEM", 0, 9]]], ["Evidently, COVID-2019 cases were concentrated in Nanjing, Suzhou, and Xuzhou with a high population density (over eight million people) ( Fig 3G) .DiscussionOn January 22, the first confirmed COVID-2019 case was reported in Jiangsu Province [9] .", [["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["COVID", "TEST", 11, 16], ["a high population density", "PROBLEM", 82, 107], ["high population", "OBSERVATION_MODIFIER", 84, 99], ["density", "OBSERVATION", 100, 107]]], ["This case who returned to Suzhou from Wuhan on January 10 went to a fever clinic for medical treatment and was immediately transferred to designated medical institutions for isolation.", [["fever", "DISEASE", 68, 73], ["medical treatment", "TREATMENT", 85, 102], ["isolation", "TREATMENT", 174, 183]]], ["The number of new confirmed cases had increased gradually, up to 39 cases on January 31, and then had gradually decreased.", [["new", "OBSERVATION_MODIFIER", 14, 17], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["gradually", "OBSERVATION_MODIFIER", 48, 57], ["gradually", "OBSERVATION_MODIFIER", 102, 111], ["decreased", "OBSERVATION_MODIFIER", 112, 121]]], ["The day-on-day growth rate of cumulative confirmed cases and suspected cases showed a downward trend after January 25 and February 3, respectively.", [["a downward trend", "PROBLEM", 84, 100], ["downward", "OBSERVATION_MODIFIER", 86, 94]]], ["This finding presented the latest epidemiology of human infections with SARS-CoV-2 after wartime control measures in areas outside Hubei Province.DiscussionIn Jiangsu Province, of the 613 COVID-2019 cases, 42.6% (n = 269) were residents or travelers to Hubei Province, whereas 38.0% were close contacts.", [["infections", "DISEASE", 56, 66], ["SARS", "DISEASE", 72, 76], ["human", "ORGANISM", 50, 55], ["SARS-CoV-2", "ORGANISM", 72, 82], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["SARS-CoV", "SPECIES", 72, 80], ["human infections", "PROBLEM", 50, 66], ["SARS", "PROBLEM", 72, 76], ["wartime control measures", "TREATMENT", 89, 113], ["infections", "OBSERVATION", 56, 66]]], ["The remarkably increased number of close contacts with SARS-CoV-2 indicated that people were susceptible to SARS-CoV-2, and person-to-person transmission of the SARS-CoV-2 was important for coordinating current screening and containment strategies [10, 11] .", [["SARS", "DISEASE", 55, 59], ["SARS", "DISEASE", 108, 112], ["SARS", "DISEASE", 161, 165], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 55, 65], ["people", "ORGANISM", 81, 87], ["SARS-CoV-2", "ORGANISM", 108, 118], ["SARS-CoV-2", "ORGANISM", 161, 171], ["people", "SPECIES", 81, 87], ["person", "SPECIES", 124, 130], ["person", "SPECIES", 134, 140], ["SARS-CoV", "SPECIES", 55, 63], ["SARS-CoV", "SPECIES", 108, 116], ["SARS-CoV", "SPECIES", 161, 169], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["number", "OBSERVATION_MODIFIER", 25, 31]]], ["This result indicated that SARS-CoV-2 was transmitted in Jiangsu Province, and the second-generation transmitted cases appeared.", [["SARS", "DISEASE", 27, 31], ["SARS-CoV-2", "ORGANISM", 27, 37], ["SARS-CoV", "SPECIES", 27, 35], ["SARS", "PROBLEM", 27, 31]]], ["The epidemiology of human infections with SARS-CoV-2 in Jiangsu was also found in other areas outside Hubei Province [12, 13] .", [["infections", "DISEASE", 26, 36], ["SARS", "DISEASE", 42, 46], ["human", "ORGANISM", 20, 25], ["SARS-CoV-2", "ORGANISM", 42, 52], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["SARS-CoV", "SPECIES", 42, 50], ["human infections", "PROBLEM", 20, 36], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["infections", "OBSERVATION", 26, 36]]], ["Finding out whether the cases were infected with SARS-CoV-2 in transportation facility or destination was difficult.", [["SARS", "DISEASE", 49, 53], ["SARS-CoV-2", "ORGANISM", 49, 59], ["SARS-CoV", "SPECIES", 49, 57], ["SARS", "PROBLEM", 49, 53], ["infected", "OBSERVATION", 35, 43]]], ["Therefore, wartime control measures for COVID-2019, including limited population movements, were coercive but feasible [14] .", [["COVID", "TEST", 40, 45]]], ["This finding suggested that the SARS-CoV-2 might begin to spread in the community, and close communication with one another should be prohibited [15] .", [["SARS", "DISEASE", 32, 36], ["SARS-CoV", "SPECIES", 32, 40], ["the SARS-CoV-2", "PROBLEM", 28, 42]]], ["However, from February Research suggests that the main route of human-to-human transmission of 2019-nCoV is probably through touch and respiratory droplets with an estimated reproductive number (R0) of 2.2 (95% CI 1.4-3.9) [18] .", [["respiratory droplets", "ANATOMY", 135, 155], ["human", "ORGANISM", 64, 69], ["human", "ORGANISM", 73, 78], ["2019-nCoV", "ORGANISM", 95, 104], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 73, 78], ["respiratory droplets", "PROBLEM", 135, 155], ["CI", "TEST", 211, 213], ["respiratory droplets", "OBSERVATION", 135, 155]]], ["Compared to MERS and SARS, SARS-Cov-2 has higher overall human-to-human transmission potential [19] .DiscussionAfter the first confirmed case in Hubei province, soon the number of COVID-2019 cases exhibited signs of exponential increase with 78 824 confirmed cases, 2 308 suspected cases and 2788 deaths so far [20] .", [["SARS", "DISEASE", 21, 25], ["SARS", "DISEASE", 27, 31], ["deaths", "DISEASE", 297, 303], ["human", "ORGANISM", 57, 62], ["human", "ORGANISM", 66, 71], ["SARS-Cov-2", "DNA", 27, 37], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 66, 71], ["SARS", "TEST", 21, 25], ["SARS", "TEST", 27, 31], ["Cov", "TEST", 32, 35], ["COVID", "TEST", 180, 185], ["exponential increase", "PROBLEM", 216, 236]]]], "e9952ce2cec1cdb4807558687a533feee5a04e80": [["COVID-19, coronavirus disease 2019.", [["coronavirus disease", "DISEASE", 10, 29], ["COVID", "TEST", 0, 5], ["coronavirus disease", "PROBLEM", 10, 29], ["coronavirus disease", "OBSERVATION", 10, 29]]], ["Graphic design support courtesy of Ink&Pixel Agency.The current landscapeMore than 10 federal departments and agencies currently invest in critical nutrition research.", [["landscape", "OBSERVATION", 64, 73]]], ["The NIH is the largest funder, with nutrition research investments estimated at $1.9 billion annually (\u223c5% of total NIH funding) for fiscal year 2019.", [["nutrition research investments", "TREATMENT", 36, 66], ["total NIH funding", "TREATMENT", 110, 127], ["largest", "OBSERVATION_MODIFIER", 15, 22]]], ["Approximately 25% of this funding (1.3% of total NIH funding) focuses on diet for the prevention or treatment of disease in humans.", [["humans", "ORGANISM", 124, 130], ["humans", "SPECIES", 124, 130], ["humans", "SPECIES", 124, 130], ["this funding", "TREATMENT", 21, 33], ["total NIH funding", "TREATMENT", 43, 60], ["disease in humans", "PROBLEM", 113, 130], ["disease", "OBSERVATION", 113, 120]]], ["The USDA is the second-largest funder of US nutrition research, with an estimated annual budget of \u223c$0.17 billion for fiscal year 2019 across several institutes and services.", [["largest", "OBSERVATION_MODIFIER", 23, 30]]], ["The USDA works to provide Americans with safe, nutritious, and wholesome food and works to ensure the foods and beverages our nation produces optimally benefits human and animal health and to address food insecurity through the administration of 15 federal nutrition assistance programs.", [["human", "ORGANISM", 161, 166], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166], ["15 federal nutrition assistance programs", "TREATMENT", 246, 286]]], ["Several structures work to improve research coordination within the USDA, although a recent USDA workshop and Government Accountability Office (GAO) report identified gaps and opportunities in nutritionThe opportunitySeveral specific priority areas in nutrition research have been identified by various federal and nongovernmental organizations.", [["specific", "OBSERVATION_MODIFIER", 225, 233], ["priority", "OBSERVATION_MODIFIER", 234, 242], ["areas", "OBSERVATION_MODIFIER", 243, 248], ["various", "OBSERVATION_MODIFIER", 295, 302], ["federal", "OBSERVATION_MODIFIER", 303, 310], ["nongovernmental organizations", "OBSERVATION", 315, 344]]], ["Greater federal coordination and investment in nutrition research could accelerate discoveries across these critical areas (Figure 2) .The opportunitySeveral lines of evidence support a strong return on investment (ROI) for an expanded and coordinated nutrition research effort.", [["investment in nutrition research", "TREATMENT", 33, 65]]], ["As stated by the FDA Commissioner in 2018 at the National Food Policy Conference, \"Improvements in diet and nutrition offer us one of our greatest opportunities to have a profound and generational impact on human health .\u2026 The public health gains of such efforts would almost certainly dwarf any single medical innovation or intervention we could discover.\"The optionsAny new federal nutrition research investment and coordination structure must leverage, harmonize, and catalyze the existing efforts being led across multiple federal departments and agencies.", [["human", "ORGANISM", 207, 212], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 207, 212], ["intervention", "TREATMENT", 325, 337], ["new", "OBSERVATION_MODIFIER", 372, 375]]], ["Two major complementary strategies were identified: 1) a new authority for robust cross-governmental coordination of nutrition research and other nutrition-related policy and 2) strengthened authority, investment, and coordination for nutrition research within the NIH.The optionsSpecific promising options to advance these 2 strategies were identified (Box 1); and for each option, potential advantages and disadvantages, executive and legislative considerations, and paths forward are discussed.", [["nutrition research", "TREATMENT", 117, 135], ["these 2 strategies", "TREATMENT", 318, 336]]], ["Improved coordination between federal departments and agencies conducting nutrition research was identified as having tremendous potential for accelerating essential basic, clinical, public health, and translational discoveries.", [["coordination", "OBSERVATION_MODIFIER", 9, 21]]], ["Increased authority, coordination, and funding for nutrition science within NIH was also identified as being essential for accelerating needed discoveries.", [["coordination", "OBSERVATION_MODIFIER", 21, 33]]], ["The cross-government strategy and within-NIH strategy were identified as complementary, with benefits accruing independently and further synergies to be gained by joint implementation.Box 1Promising cross-governmental and NIH options to strengthen and accelerate national nutrition research 1 1 Additional relevant priorities to strengthen federal nutrition research within other departments and agencies, such as DoD, USAID, and FDA, were recognized and should be the subject of future reports.Box 1Further complementary actions to accelerate federal nutrition research were identified at USDA.", [["The cross-government strategy", "TREATMENT", 0, 29], ["national nutrition research", "TREATMENT", 263, 290], ["Box", "TREATMENT", 495, 498], ["federal nutrition research", "TREATMENT", 544, 570], ["joint", "ANATOMY", 163, 168]]], ["First, to increase investment in nutrition research for the Agricultural Research Service (ARS) including its network of Human Nutrition Research Centers, the National Institute of Food and Agriculture (NIFA) extramural research programs, and the Economic Research Service (ERS) programs, which assesses demographic, social, informational, and economic determinants of dietary consumption and associated health outcomes.", [["Human", "ORGANISM", 121, 126], ["Human", "SPECIES", 121, 126]]], ["Second, to expand USDA research that evaluates and improves major ongoing efforts for public guidance and education on nutrition.", [["public guidance", "TREATMENT", 86, 101], ["nutrition", "TREATMENT", 119, 128]]], ["And third, to build the robust evidence base and collaborations needed to strengthen the positive impacts of the \u223c$100 billion/y federal investments in nutrition assistance programs.ConclusionsThis white paper identified many stark and growing national challenges related to nutrition.", [["nutrition assistance programs", "TREATMENT", 152, 181]]], ["The opportunities to be gained by greater coordination and investment in federal nutrition research are clear, with potential for large and rapid ROI.", [["large and rapid ROI", "PROBLEM", 130, 149]]], ["This white paper identified and described 2 priorityIntroductionThe US faces remarkable food and nutrition challenges.", [["The US", "TEST", 64, 70], ["nutrition challenges", "TREATMENT", 97, 117]]], ["More Americans are sick than are healthy, with diet-related illnesses playing a major role including obesity, type 2 diabetes, cardiovascular diseases, cancers, food allergies, and more (1) .", [["cardiovascular", "ANATOMY", 127, 141], ["cancers", "ANATOMY", 152, 159], ["obesity", "DISEASE", 101, 108], ["type 2 diabetes", "DISEASE", 110, 125], ["cardiovascular diseases", "DISEASE", 127, 150], ["cancers", "DISEASE", 152, 159], ["food allergies", "DISEASE", 161, 175], ["cardiovascular", "ANATOMICAL_SYSTEM", 127, 141], ["cancers", "CANCER", 152, 159], ["obesity", "PROBLEM", 101, 108], ["type 2 diabetes", "PROBLEM", 110, 125], ["cardiovascular diseases", "PROBLEM", 127, 150], ["cancers", "PROBLEM", 152, 159], ["food allergies", "PROBLEM", 161, 175], ["obesity", "OBSERVATION", 101, 108], ["diabetes", "OBSERVATION", 117, 125], ["cardiovascular", "ANATOMY", 127, 141], ["diseases", "OBSERVATION", 142, 150], ["cancers", "OBSERVATION", 152, 159]]], ["The incidence and prevalence of many of these conditions have increased dramatically in recent decades.", [["conditions", "OBSERVATION", 46, 56], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["dramatically", "OBSERVATION_MODIFIER", 72, 84]]], ["In addition to burdens on health and productivity, these diet-related diseases are creating tremendous strains on health care spending, health disparities, government budgets, economic competitiveness of American businesses, and military readiness.", [["related diseases", "PROBLEM", 62, 78], ["burdens", "OBSERVATION_MODIFIER", 15, 22]]], ["Innovations in food and nutrition should improve human health while also preserving our natural resources, a crucial new area of intersecting science and policy.IntroductionMany of these strains in food and nutrition have been further exposed and exacerbated by COVID-19 (2) .", [["COVID-19", "CHEMICAL", 262, 270], ["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["new", "OBSERVATION_MODIFIER", 117, 120]]], ["This includes, for example, challenges related to hunger and food insecurity; major diet-related comorbidities for hospitalization and death from COVID-19 such as diabetes, obesity, and hypertension; insufficient evidence on optimal population resilience through better nutrition; and the need to further improve the surveillance on and coordination of food production and supply chains (3) (4) (5) (6) (7) (8) (9) .IntroductionWhile advancing nutrition research has provided evidence to describe the general contours of healthy eating patterns, it has also highlighted many critical new, unanswered questions on food and nutrition and the national challenges we face (10) .", [["death", "DISEASE", 135, 140], ["diabetes", "DISEASE", 163, 171], ["obesity", "DISEASE", 173, 180], ["hypertension", "DISEASE", 186, 198], ["5) (6) (7) (8)", "SIMPLE_CHEMICAL", 396, 410], ["hunger", "PROBLEM", 50, 56], ["food insecurity", "PROBLEM", 61, 76], ["death", "PROBLEM", 135, 140], ["COVID", "TEST", 146, 151], ["diabetes", "PROBLEM", 163, 171], ["obesity", "PROBLEM", 173, 180], ["hypertension", "PROBLEM", 186, 198], ["the surveillance", "TEST", 313, 329], ["obesity", "OBSERVATION", 173, 180], ["hypertension", "OBSERVATION", 186, 198], ["new", "OBSERVATION_MODIFIER", 584, 587]]], ["In addition, no concrete action has emerged to successfully harmonize and leverage nutrition research across the government, despite consistent recommendations over at least 5 decades for a robust coordinating federal entity (13) .", [["no", "UNCERTAINTY", 13, 15]]], ["A major, new federal effort to strengthen and coordinate nutrition research could rapidly generate the necessary evidence base to address multiple national challenges, providing major benefits and ROI.IntroductionThe aim of this white paper is to evaluate key issues relevant to such a scientific effort, including the following:Introduction1) The mounting diet-related health burdens facing our nation and the corresponding economic, health equity, national security, and sustainability implications; 2) The current federal nutrition research landscape and existing mechanisms for its coordination among the diverse departments and agencies working to address these challenges; 3) The opportunities for and potential impact of new fundamental, clinical, public health, food and agricultural, and translational scientific discoveries related to nutrition; and 4) The best strategies to further strengthen and coordinate federal nutrition research, including relevant advantages, disadvantages, and potential executive and legislative considerations for a path forward.IntroductionThis white paper is intended to invite comment and discussion from all stakeholders who care about strengthening nutrition research, whether to improve health, lower public and private health care spending, reduce disparities, promote business innovation, reinvigorate rural communities, preserve our national resources, or strengthen national security.", [["multiple national challenges", "TREATMENT", 138, 166], ["key issues", "PROBLEM", 256, 266], ["federal nutrition research", "TREATMENT", 920, 946], ["new", "OBSERVATION_MODIFIER", 9, 12]]], ["Key audiences for this white paper include the following:Introduction\u2022 Elected and appointed federal officials in both executive and legislative branches; \u2022 Federal science agency leaders and program and policy staff; \u2022 Federal military leadership; \u2022 The academic community; \u2022 Clinical and scientific professional organizations; \u2022 Nonprofit advocacy groups; \u2022 Allied health professional organizations; \u2022 US businesses whose efforts, employees, and competitiveness can be benefited by federally supported nutrition discoveries; \u2022 The media, who communicate key nutrition-related messages; and \u2022 The public who rely on and desperately need advances in federally supported nutrition research to help improve and sustain their health and communities.IntroductionThis white paper was informed by extensive background research and stakeholder conversations.", [["nutrition research", "TREATMENT", 670, 688], ["branches", "ANATOMY_MODIFIER", 145, 153]]], ["The writing group reached out to all 10 departments and agencies participating in the ICHNR, particularly for assistance in estimating their relevant budget for nutrition research.", [["nutrition research", "TREATMENT", 161, 179]]], ["We also reviewed feedback received through the American Society for Nutrition (ASN) request for member input regarding the concept of a National Institute of Nutrition and through a related panel session and Q&A at the ASN Nutrition 2019 annual scientific conference.", [["Nutrition", "TREATMENT", 158, 167]]], ["We also sought input from members of the Nutrition Action Alliance (NAA), a coalition of organizations working to advance federal nutrition research, nutrition education, and nutrition monitoring and surveillance, among other activities, and which includes ASN, Academy of Nutrition and Dietetics, American Society for Parenteral and Enteral Nutrition, Association of Nutrition Departments and Programs, Institute of Food Technologists, National Board of Physician Nutrition Specialists, Society for Nutrition Education and Behavior, and The Obesity Society.", [["NAA", "CHEMICAL", 68, 71], ["Obesity", "DISEASE", 542, 549], ["federal nutrition research", "TREATMENT", 122, 148], ["nutrition education", "TREATMENT", 150, 169], ["nutrition monitoring", "TEST", 175, 195], ["surveillance", "TEST", 200, 212], ["Parenteral and Enteral Nutrition", "TREATMENT", 319, 351], ["Obesity", "OBSERVATION", 542, 549]]], ["The writing group used these document reviews, one-on-one conversations, stakeholder interviews, and additional discussions to maximize candid, confidential reflections following Chatham House Rules on the past and present state of federal nutrition research, the challenges and opportunities, and the best available strategies for moving forward.IntroductionWe hope this white paper provides an objective, informative summary of the 1) burdens, 2) current federal nutrition research landscape, 3) opportunities, and 4) options for strengthening national nutrition research.", [["strengthening national nutrition research", "TREATMENT", 532, 573]]], ["Ultimately, we hope it helps lay the foundation for accelerated advances in nutrition research to help improve and sustain the health of all children, adults, families, and communities.The BurdenPoor nutrition is contributing to major increases in diet-related obesity and type 2 diabetes, as well as continuing high rates of other chronic diet-related diseases such as cardiovascular diseases, cancers, and other conditions (1) .", [["cardiovascular", "ANATOMY", 370, 384], ["cancers", "ANATOMY", 395, 402], ["BurdenPoor", "CHEMICAL", 189, 199], ["obesity", "DISEASE", 261, 268], ["type 2 diabetes", "DISEASE", 273, 288], ["cardiovascular diseases", "DISEASE", 370, 393], ["cancers", "DISEASE", 395, 402], ["children", "ORGANISM", 141, 149], ["cardiovascular", "ANATOMICAL_SYSTEM", 370, 384], ["cancers", "CANCER", 395, 402], ["children", "SPECIES", 141, 149], ["nutrition research", "TREATMENT", 76, 94], ["obesity", "PROBLEM", 261, 268], ["type 2 diabetes", "PROBLEM", 273, 288], ["related diseases", "PROBLEM", 345, 361], ["cardiovascular diseases", "PROBLEM", 370, 393], ["cancers", "PROBLEM", 395, 402], ["increases", "OBSERVATION_MODIFIER", 235, 244], ["obesity", "OBSERVATION", 261, 268], ["diabetes", "OBSERVATION", 280, 288], ["cardiovascular", "ANATOMY", 370, 384], ["diseases", "OBSERVATION", 385, 393], ["cancers", "OBSERVATION", 395, 402]]], ["Since the 1970s, Americans' diets have changed significantly.", [["Americans' diets", "TREATMENT", 17, 33]]], ["For example, both portion sizes and frequency of snacking have increased, with each linked to greater calorie intake (14, 15) .", [["both", "OBSERVATION_MODIFIER", 13, 17], ["portion", "OBSERVATION_MODIFIER", 18, 25], ["sizes", "OBSERVATION_MODIFIER", 26, 31], ["frequency", "OBSERVATION_MODIFIER", 36, 45], ["snacking", "OBSERVATION", 49, 57], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["greater", "OBSERVATION_MODIFIER", 94, 101]]], ["Among US children, substantial increases in daily calories since the 1970s are entirely attributable to increased foods eaten outside from home, mostly from fast food (16) .", [["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17], ["substantial", "OBSERVATION_MODIFIER", 19, 30], ["increases", "OBSERVATION_MODIFIER", 31, 40]]], ["Consistent with prior health messaging to reduce total fat, the percentage of energy from carbohydrates increased from 42% to 48% of calories in men and 45% to 51% in women between 1971 and 2004, primarily due to higher consumption of starches, grains, and caloric beverages (17, 18) .", [["carbohydrates", "CHEMICAL", 90, 103], ["fat", "TISSUE", 55, 58], ["men", "ORGANISM", 145, 148], ["women", "ORGANISM", 167, 172], ["men", "SPECIES", 145, 148], ["women", "SPECIES", 167, 172], ["prior health messaging", "TREATMENT", 16, 38], ["carbohydrates", "TREATMENT", 90, 103]]], ["Between 1977 and 1994, intake of processed breakfast cereals increased by 60%, intake of pizza by 115%, and intakes of snack foods like crackers, popcorn, pretzels, and corn chips by 200% (19) .", [["pretzels", "ANATOMY", 155, 163], ["pizza", "ORGANISM_SUBDIVISION", 89, 94], ["corn", "SPECIES", 169, 173], ["corn", "SPECIES", 169, 173], ["corn chips", "TREATMENT", 169, 179]]], ["Between 1965 and 2002, the intake of caloric beverages increased from 12% to 21% of all calories, representing an average increase of 222 calories/d per person (20) .", [["person", "SPECIES", 153, 159], ["caloric beverages", "TREATMENT", 37, 54]]], ["This change was due to increased intake of sweetened fruit drinks, alcohol, and especially soda.", [["fruit", "ANATOMY", 53, 58], ["alcohol", "CHEMICAL", 67, 74], ["alcohol", "CHEMICAL", 67, 74], ["alcohol", "SIMPLE_CHEMICAL", 67, 74], ["increased", "OBSERVATION_MODIFIER", 23, 32]]], ["Over this time, the average portion size of a sugar-sweetened beverage increased by >50% (21) .The BurdenIn more recent years, with growing public awareness of the critical role of nutrition in overall health, some aspects of US diet quality have modestly improved, such as reductions in soda and small increases in whole grains, fruits, and nuts/seeds (22, 23) .", [["whole grains", "ANATOMY", 316, 328], ["fruits", "ANATOMY", 330, 336], ["sugar", "CHEMICAL", 46, 51], ["sugar", "SIMPLE_CHEMICAL", 46, 51], ["grains", "ORGANISM_SUBDIVISION", 322, 328], ["fruits", "ORGANISM_SUBDIVISION", 330, 336], ["nuts", "ORGANISM_SUBDIVISION", 342, 346], ["a sugar", "TEST", 44, 51], ["small increases in whole grains", "PROBLEM", 297, 328], ["portion", "OBSERVATION_MODIFIER", 28, 35], ["size", "OBSERVATION_MODIFIER", 36, 40], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["improved", "OBSERVATION_MODIFIER", 256, 264], ["small", "OBSERVATION_MODIFIER", 297, 302], ["increases", "OBSERVATION_MODIFIER", 303, 312], ["whole grains", "OBSERVATION_MODIFIER", 316, 328]]], ["Nevertheless, intakes of these and other healthful components remain far below dietary guidelines, with 45.6% of adults and 56.1% of children continuing to have poor-quality diets overall, and most of the remainder having intermediate-quality diets, with very few Americans having ideal diets (22, 23) .", [["children", "ORGANISM", 133, 141], ["children", "SPECIES", 133, 141]]], ["While less well documented by national surveillance data, the levels and types of food processing have substantially changed in the past 50 y.", [["national surveillance data", "TEST", 30, 56], ["the levels", "TEST", 58, 68]]], ["Ultra-processed foods now contribute \u223c60% of all calories in the US food supply (24) .", [["Ultra-processed foods", "TREATMENT", 0, 21]]], ["These changes in our nutrition and corresponding diet-related illnesses are associated with rising health care costs, widening diet-related health disparities, and weakened national security and military readiness (25) .The BurdenBetween 1980 and 2018, the percentage of US children with obesity increased from 5.5% to 19 .3%, whereas the percentage of adults with obesity increased from 15% to 42.4% (26) (27) (28) (29) (30) .", [["obesity", "DISEASE", 288, 295], ["obesity", "DISEASE", 365, 372], ["children", "ORGANISM", 274, 282], ["children", "SPECIES", 274, 282], ["related illnesses", "PROBLEM", 54, 71], ["obesity", "PROBLEM", 288, 295], ["obesity", "PROBLEM", 365, 372], ["obesity", "OBSERVATION", 288, 295], ["obesity", "OBSERVATION", 365, 372]]], ["Nearly 3 in 4 American adults are now either overweight or obese (26, 31, 32) .", [["adults", "ORGANISM", 23, 29], ["obese", "PROBLEM", 59, 64], ["obese", "OBSERVATION", 59, 64]]], ["Across all preventable risk factors for disease in the US, poor diet is now the leading cause of poor health, associated with more than half a million deaths per year-or more than 40,000 deaths each month (1) .", [["deaths", "DISEASE", 151, 157], ["deaths", "DISEASE", 187, 193], ["disease", "PROBLEM", 40, 47]]], ["Along with suboptimal diet, adiposity and physical inactivity are shared risk factors for illness and death (33) (34) (35) (36) (37) .", [["physical inactivity", "DISEASE", 42, 61], ["illness", "DISEASE", 90, 97], ["death", "DISEASE", 102, 107], ["adiposity and physical inactivity", "PROBLEM", 28, 61], ["illness", "PROBLEM", 90, 97], ["death", "PROBLEM", 102, 107]]], ["Over the last 20 y, the number of adults with diabetes has more than doubled (38) , and today, >100 million Americansnearly half of all adults-suffer from diabetes or prediabetes (39) .", [["diabetes", "DISEASE", 46, 54], ["diabetes", "DISEASE", 155, 163], ["prediabetes", "DISEASE", 167, 178], ["adults", "ORGANISM", 136, 142], ["diabetes", "PROBLEM", 46, 54], ["diabetes", "PROBLEM", 155, 163], ["prediabetes", "PROBLEM", 167, 178], ["diabetes", "OBSERVATION", 46, 54], ["diabetes", "OBSERVATION", 155, 163]]], ["Cardiovascular disease afflicts \u223c122 million Americans and causes \u223c840,000 deaths each year (40) .", [["Cardiovascular", "ANATOMY", 0, 14], ["Cardiovascular disease", "DISEASE", 0, 22], ["deaths", "DISEASE", 75, 81], ["Cardiovascular disease afflicts", "PROBLEM", 0, 31], ["disease", "OBSERVATION", 15, 22]]], ["Many of these diseases disproportionately affect older Americans, and as our nation's demographics shift toward an aging population, the burden of diet-related ailments on society will accelerate (41, 42) .", [["these diseases", "PROBLEM", 8, 22], ["diseases", "OBSERVATION", 14, 22]]], ["In short, more Americans are sick or suffer from major medical conditions than are healthy, and much of this is related to diet-related illness.The BurdenAlthough the general contours of healthy eating patterns have been outlined by important advances in nutrition science, many questions remain unanswered (10) .", [["illness", "DISEASE", 136, 143], ["contours", "OBSERVATION_MODIFIER", 175, 183]]], ["Modern nutrition science is still evolving, with a rapidly growing but still relatively nascent repertoire of research methods, foundational science, and large-scale interventions to investigate and address diet-related diseases.", [["research methods", "TREATMENT", 110, 126], ["large-scale interventions", "TREATMENT", 154, 179], ["related diseases", "PROBLEM", 212, 228]]], ["For most of the 20th century, the focus of nutrition research was on isolated vitamins and minerals and their role in clinical nutrient deficiency diseases.", [["nutrient deficiency diseases", "DISEASE", 127, 155], ["vitamins", "CHEMICAL", 78, 86], ["vitamins", "SIMPLE_CHEMICAL", 78, 86], ["minerals", "SIMPLE_CHEMICAL", 91, 99], ["isolated vitamins and minerals", "TREATMENT", 69, 99], ["clinical nutrient deficiency diseases", "PROBLEM", 118, 155], ["nutrient deficiency", "OBSERVATION", 127, 146]]], ["This effort led to major accomplishments, such as documenting the role of individual nutrients in diseases such as pellagra (vitamin B-3 deficiency), rickets (vitamin D deficiency), and scurvy (vitamin C deficiency), among others, and then quickly mobilizing innovative technology such as fortification of staple foods, along with well-coordinated policy and programmatic responses, to address these conditions.", [["pellagra", "DISEASE", 115, 123], ["vitamin B-3 deficiency", "CHEMICAL", 125, 147], ["rickets", "DISEASE", 150, 157], ["vitamin D", "CHEMICAL", 159, 168], ["scurvy", "DISEASE", 186, 192], ["vitamin C", "CHEMICAL", 194, 203], ["vitamin B-3", "CHEMICAL", 125, 136], ["vitamin D", "CHEMICAL", 159, 168], ["vitamin C", "CHEMICAL", 194, 203], ["vitamin B-3", "GENE_OR_GENE_PRODUCT", 125, 136], ["vitamin D", "SIMPLE_CHEMICAL", 159, 168], ["vitamin C", "SIMPLE_CHEMICAL", 194, 203], ["individual nutrients in diseases", "PROBLEM", 74, 106], ["pellagra (vitamin B", "TEST", 115, 134], ["deficiency)", "PROBLEM", 137, 148], ["rickets (vitamin D deficiency)", "PROBLEM", 150, 180], ["scurvy (vitamin C deficiency", "PROBLEM", 186, 214], ["innovative technology", "TREATMENT", 259, 280], ["staple foods", "TREATMENT", 306, 318]]], ["In comparison, the shift of nutrition science to focus more meaningfully on diet-related chronic diseases, such as heart disease, strokes, cancer, diabetes, obesity, brain health, and autoimmune and inflammatory diseases, is much more recent, largely begun only since the 1980s.", [["heart", "ANATOMY", 115, 120], ["cancer", "ANATOMY", 139, 145], ["brain", "ANATOMY", 166, 171], ["chronic diseases", "DISEASE", 89, 105], ["heart disease", "DISEASE", 115, 128], ["strokes", "DISEASE", 130, 137], ["cancer", "DISEASE", 139, 145], ["diabetes", "DISEASE", 147, 155], ["obesity", "DISEASE", 157, 164], ["brain health", "DISEASE", 166, 178], ["autoimmune and inflammatory diseases", "DISEASE", 184, 220], ["heart", "ORGAN", 115, 120], ["cancer", "CANCER", 139, 145], ["brain", "ORGAN", 166, 171], ["chronic diseases", "PROBLEM", 89, 105], ["heart disease", "PROBLEM", 115, 128], ["strokes", "PROBLEM", 130, 137], ["cancer", "PROBLEM", 139, 145], ["diabetes", "PROBLEM", 147, 155], ["obesity", "PROBLEM", 157, 164], ["brain health", "PROBLEM", 166, 178], ["autoimmune and inflammatory diseases", "PROBLEM", 184, 220], ["chronic", "OBSERVATION_MODIFIER", 89, 96], ["diseases", "OBSERVATION", 97, 105], ["heart", "ANATOMY", 115, 120], ["disease", "OBSERVATION", 121, 128], ["strokes", "OBSERVATION", 130, 137], ["cancer", "OBSERVATION", 139, 145], ["diabetes", "OBSERVATION", 147, 155], ["obesity", "OBSERVATION", 157, 164], ["brain", "ANATOMY", 166, 171], ["autoimmune", "OBSERVATION", 184, 194], ["inflammatory", "OBSERVATION_MODIFIER", 199, 211]]], ["Yet, the investment and pace of progress have been insufficient to address the burgeoning rates of diet-related illness and the associated societal and economic consequences.The BurdenFor example, in detailed reviews of available research by the 2015 Dietary Guidelines Advisory Committee (DGAC), numerous areas were identified as having only moderate, limited, or insufficient (not assignable) scientific evidence for making dietary recommendations (Supplemental Table 1 ).", [["illness", "DISEASE", 112, 119], ["moderate", "OBSERVATION_MODIFIER", 343, 351]]], ["These include, for instance, evidence that healthier dietary patterns favorably influence body weight or obesity in adults (moderate evidence) or children or adolescents (limited); reduce the risk of type 2 diabetes in adults (limited) or children (not assignable); or are associated with lower risk of colorectal (moderate), breast (moderate to limited), lung (limited), or prostate (not assignable) cancer; age-related cognitive impairment, dementia, or Alzheimer disease (limited); depression in adults (limited) or children, adolescents, or postpartum mothers (not assignable); or bone health in adults (limited) or children and adolescents (not assignable).", [["body", "ANATOMY", 90, 94], ["colorectal", "ANATOMY", 303, 313], ["breast", "ANATOMY", 326, 332], ["lung", "ANATOMY", 356, 360], ["prostate", "ANATOMY", 375, 383], ["cancer", "ANATOMY", 401, 407], ["bone", "ANATOMY", 585, 589], ["obesity", "DISEASE", 105, 112], ["type 2 diabetes", "DISEASE", 200, 215], ["colorectal (moderate), breast (moderate to limited), lung (limited), or prostate (not assignable) cancer", "DISEASE", 303, 407], ["cognitive impairment", "DISEASE", 421, 441], ["dementia", "DISEASE", 443, 451], ["Alzheimer disease", "DISEASE", 456, 473], ["depression", "DISEASE", 485, 495], ["body", "ORGANISM_SUBDIVISION", 90, 94], ["children", "ORGANISM", 146, 154], ["children", "ORGANISM", 239, 247], ["colorectal", "MULTI-TISSUE_STRUCTURE", 303, 313], ["breast", "CANCER", 326, 332], ["lung", "ORGAN", 356, 360], ["prostate", "ORGAN", 375, 383], ["cancer", "CANCER", 401, 407], ["children", "ORGANISM", 519, 527], ["bone", "TISSUE", 585, 589], ["children", "ORGANISM", 620, 628], ["children", "SPECIES", 146, 154], ["adolescents", "SPECIES", 158, 169], ["children", "SPECIES", 239, 247], ["children", "SPECIES", 519, 527], ["adolescents", "SPECIES", 529, 540], ["children", "SPECIES", 620, 628], ["adolescents", "SPECIES", 633, 644], ["obesity", "PROBLEM", 105, 112], ["type 2 diabetes", "PROBLEM", 200, 215], ["colorectal (moderate), breast (moderate to limited), lung (limited), or prostate (not assignable) cancer", "PROBLEM", 303, 407], ["cognitive impairment", "PROBLEM", 421, 441], ["dementia", "PROBLEM", 443, 451], ["Alzheimer disease", "PROBLEM", 456, 473], ["depression", "PROBLEM", 485, 495], ["obesity", "OBSERVATION", 105, 112], ["colorectal", "OBSERVATION", 303, 313], ["moderate", "OBSERVATION_MODIFIER", 315, 323], ["breast", "ANATOMY", 326, 332], ["moderate", "OBSERVATION_MODIFIER", 334, 342], ["lung", "ANATOMY", 356, 360], ["prostate", "ANATOMY", 375, 383], ["cancer", "OBSERVATION", 401, 407], ["dementia", "OBSERVATION", 443, 451], ["bone", "ANATOMY", 585, 589]]], ["Considering specific individual foods and nutrients, the 2015 DGAC concluded that evidence is only moderate that coffee consumption is associated with reduced risk of type 2 diabetes, cardiovascular disease, or certain cancers and is limited for caffeine intake and lower risk of cognitive decline and Alzheimer disease or increased risk of miscarriage, stillbirth, or low birth weight.", [["cardiovascular", "ANATOMY", 184, 198], ["cancers", "ANATOMY", 219, 226], ["coffee", "CHEMICAL", 113, 119], ["type 2 diabetes", "DISEASE", 167, 182], ["cardiovascular disease", "DISEASE", 184, 206], ["cancers", "DISEASE", 219, 226], ["caffeine", "CHEMICAL", 246, 254], ["cognitive decline", "DISEASE", 280, 297], ["Alzheimer disease", "DISEASE", 302, 319], ["miscarriage", "DISEASE", 341, 352], ["stillbirth", "DISEASE", 354, 364], ["low birth weight", "DISEASE", 369, 385], ["caffeine", "CHEMICAL", 246, 254], ["cardiovascular", "ANATOMICAL_SYSTEM", 184, 198], ["cancers", "CANCER", 219, 226], ["caffeine", "SIMPLE_CHEMICAL", 246, 254], ["type 2 diabetes", "PROBLEM", 167, 182], ["cardiovascular disease", "PROBLEM", 184, 206], ["certain cancers", "PROBLEM", 211, 226], ["caffeine intake", "TREATMENT", 246, 261], ["cognitive decline", "PROBLEM", 280, 297], ["Alzheimer disease", "PROBLEM", 302, 319], ["miscarriage", "PROBLEM", 341, 352], ["stillbirth", "PROBLEM", 354, 364], ["low birth weight", "PROBLEM", 369, 385], ["moderate", "OBSERVATION_MODIFIER", 99, 107], ["coffee consumption", "OBSERVATION", 113, 131], ["diabetes", "OBSERVATION", 174, 182], ["cardiovascular", "ANATOMY", 184, 198], ["disease", "OBSERVATION", 199, 206], ["cancers", "OBSERVATION", 219, 226], ["cognitive decline", "OBSERVATION", 280, 297], ["Alzheimer", "OBSERVATION", 302, 311], ["increased", "OBSERVATION_MODIFIER", 323, 332], ["miscarriage", "OBSERVATION", 341, 352]]], ["The 2015 DGAC found limited evidence to address additives, such as aspartame and risk of cancers or preterm delivery.", [["cancers", "ANATOMY", 89, 96], ["aspartame", "CHEMICAL", 67, 76], ["cancers", "DISEASE", 89, 96], ["aspartame", "CHEMICAL", 67, 76], ["aspartame", "SIMPLE_CHEMICAL", 67, 76], ["cancers", "CANCER", 89, 96], ["aspartame", "TREATMENT", 67, 76], ["cancers", "PROBLEM", 89, 96], ["preterm delivery", "TREATMENT", 100, 116], ["cancers", "OBSERVATION", 89, 96]]], ["Evidence was considered moderate for any specific sodium target (e.g., 2400 mg/d) for blood pressure control or risk of cardiovascular outcomes; limited or not assignable for potassium intake and these outcomes; moderate or limited for low-calorie sweeteners and body weight or diabetes; and limited for replacing saturated fat with monounsaturated fat for reducing cardiovascular risk.The BurdenThe 2015 DGAC identified multiple specific areas of research needs (Supplemental Table 2 ).", [["blood", "ANATOMY", 86, 91], ["cardiovascular", "ANATOMY", 120, 134], ["body", "ANATOMY", 263, 267], ["fat", "ANATOMY", 324, 327], ["cardiovascular", "ANATOMY", 366, 380], ["sodium", "CHEMICAL", 50, 56], ["potassium", "CHEMICAL", 175, 184], ["diabetes", "DISEASE", 278, 286], ["monounsaturated fat", "CHEMICAL", 333, 352], ["sodium", "CHEMICAL", 50, 56], ["potassium", "CHEMICAL", 175, 184], ["sodium", "SIMPLE_CHEMICAL", 50, 56], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["cardiovascular", "ANATOMICAL_SYSTEM", 120, 134], ["potassium", "SIMPLE_CHEMICAL", 175, 184], ["body", "ORGANISM_SUBDIVISION", 263, 267], ["fat", "TISSUE", 324, 327], ["fat", "TISSUE", 349, 352], ["cardiovascular", "ANATOMICAL_SYSTEM", 366, 380], ["any specific sodium target", "PROBLEM", 37, 63], ["blood pressure control", "TREATMENT", 86, 108], ["cardiovascular outcomes", "PROBLEM", 120, 143], ["potassium intake", "PROBLEM", 175, 191], ["low-calorie sweeteners", "TREATMENT", 236, 258], ["diabetes", "PROBLEM", 278, 286], ["replacing saturated fat with monounsaturated fat", "TREATMENT", 304, 352], ["reducing cardiovascular risk", "PROBLEM", 357, 385], ["moderate", "OBSERVATION_MODIFIER", 24, 32], ["moderate", "OBSERVATION_MODIFIER", 212, 220], ["diabetes", "OBSERVATION", 278, 286], ["Burden", "OBSERVATION_MODIFIER", 390, 396], ["multiple", "OBSERVATION_MODIFIER", 421, 429]]], ["Examples include the need to conduct research on 1) the dietary needs and intakes of older adults, whether polypharmacy plays a role in nutritional adequacy, and whether comorbidities, such as poor dentition, musculoskeletal difficulties, arthralgias, vision loss, and other age-related symptoms, affect their ability to establish and maintain proper nutritional status; 2) nutrition transitions from early childhood to adolescence to identify how and why diets change so rapidly during this period, the driving forces behind these changes, and effective programs to maintain positive nutrition habits established in young children; 3) the validity, reliability, and reproducibility of new biomarkers of nutritional status; 4) the effects of fortification strategies and supplement use on consumer behaviors and diets related to calcium, vitamin D, potassium, iron, and fiber; and 5) design approaches to quantify diets in large population-based studies.The BurdenOverall, advances in science have identified numerous new opportunities for research and pressing scientific questions that must be addressed ( Figure 2 ).", [["musculoskeletal", "ANATOMY", 209, 224], ["musculoskeletal difficulties", "DISEASE", 209, 237], ["arthralgias", "DISEASE", 239, 250], ["vision loss", "DISEASE", 252, 263], ["calcium", "CHEMICAL", 829, 836], ["vitamin D", "CHEMICAL", 838, 847], ["potassium", "CHEMICAL", 849, 858], ["iron", "CHEMICAL", 860, 864], ["calcium", "CHEMICAL", 829, 836], ["vitamin D", "CHEMICAL", 838, 847], ["potassium", "CHEMICAL", 849, 858], ["iron", "CHEMICAL", 860, 864], ["children", "ORGANISM", 623, 631], ["calcium", "SIMPLE_CHEMICAL", 829, 836], ["vitamin D", "SIMPLE_CHEMICAL", 838, 847], ["potassium", "SIMPLE_CHEMICAL", 849, 858], ["iron", "SIMPLE_CHEMICAL", 860, 864], ["children", "SPECIES", 623, 631], ["comorbidities", "PROBLEM", 170, 183], ["poor dentition", "PROBLEM", 193, 207], ["musculoskeletal difficulties", "PROBLEM", 209, 237], ["arthralgias", "PROBLEM", 239, 250], ["vision loss", "PROBLEM", 252, 263], ["related symptoms", "PROBLEM", 279, 295], ["fortification strategies", "TREATMENT", 742, 766], ["calcium", "TREATMENT", 829, 836], ["vitamin D", "TREATMENT", 838, 847], ["potassium", "TREATMENT", 849, 858], ["iron", "TREATMENT", 860, 864], ["fiber", "TREATMENT", 870, 875], ["based studies", "TEST", 940, 953], ["musculoskeletal", "ANATOMY", 209, 224], ["numerous", "OBSERVATION_MODIFIER", 1009, 1017], ["new", "OBSERVATION_MODIFIER", 1018, 1021]]], ["These topics, discussed further in \"The Opportunity\" section below, include fundamental questions about foods and diet quality in relation to obesity, insulin resistance, diabetes, cancers, and other conditions; the interactions between diet, physical activity, the microbiome, and immunity and other key health defenses; and the health effects of various forms of food processing, additives, fermentation, and probiotics.", [["cancers", "ANATOMY", 181, 188], ["obesity", "DISEASE", 142, 149], ["diabetes", "DISEASE", 171, 179], ["cancers", "DISEASE", 181, 188], ["insulin", "GENE_OR_GENE_PRODUCT", 151, 158], ["cancers", "CANCER", 181, 188], ["obesity", "PROBLEM", 142, 149], ["insulin resistance", "PROBLEM", 151, 169], ["diabetes", "PROBLEM", 171, 179], ["cancers", "PROBLEM", 181, 188], ["other conditions", "PROBLEM", 194, 210], ["fermentation", "TREATMENT", 393, 405], ["probiotics", "TREATMENT", 411, 421], ["obesity", "OBSERVATION", 142, 149], ["insulin resistance", "OBSERVATION", 151, 169], ["cancers", "OBSERVATION", 181, 188]]], ["Other topics include personalization of nutrition based on each person's background, habits, genes, microbiome, medications, and existing diseases; how hunger and food security influence wellness and key approaches to address this interaction; the intersections of plant and animal breeding and farming practices with nutrition and sustainability; and many other questions.", [["person", "SPECIES", 64, 70], ["personalization of nutrition", "TREATMENT", 21, 49], ["medications", "TREATMENT", 112, 123], ["existing diseases", "PROBLEM", 129, 146], ["animal breeding", "TREATMENT", 275, 290]]], ["Thus, we have learned much, but the present state of science remains far from offering a sufficient understanding of many crucial facets of food and nutrition fundamental to human health (43) (44) (45) (46) (47) .", [["human", "ORGANISM", 174, 179], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179]]], ["Scientific progress is being made, but at the current pace it may take many decades to meaningfully understand and reduce the prevalence and impact of the broad range of diet-related chronic diseases that we face.The BurdenThe economic costs of nutrition-related diseases are staggering and ever rising.", [["chronic diseases", "DISEASE", 183, 199], ["chronic diseases", "PROBLEM", 183, 199], ["related diseases", "PROBLEM", 255, 271], ["chronic", "OBSERVATION_MODIFIER", 183, 190], ["diseases", "OBSERVATION", 191, 199], ["Burden", "OBSERVATION_MODIFIER", 217, 223], ["economic", "OBSERVATION_MODIFIER", 227, 235], ["diseases", "OBSERVATION", 263, 271], ["staggering", "OBSERVATION_MODIFIER", 276, 286]]], ["As a share of our economy, total US health care expenditures have nearly tripled since 1970, from 6.9% to 17.9% of Gross Domestic Product (GDP) (48, 49) .", [["GDP", "SIMPLE_CHEMICAL", 139, 142], ["Gross", "OBSERVATION_MODIFIER", 115, 120], ["Domestic Product", "OBSERVATION", 121, 137]]], ["These increases are harming government budgets, competitiveness of US businesses, workers' wages, and livelihoods of families.", [["increases", "OBSERVATION_MODIFIER", 6, 15]]], ["And, \u223c85% of total US health care expenditures are related to management of diet-related chronic diseases (50) .", [["chronic diseases", "DISEASE", 89, 105], ["related chronic diseases", "PROBLEM", 81, 105], ["chronic", "OBSERVATION_MODIFIER", 89, 96], ["diseases", "OBSERVATION", 97, 105]]], ["For example, the total direct health care and indirect economic costs of cardiovascular diseases are estimated at $316 billion/y; of diabetes, at $327 billion/y; and of all obesity-related conditions, at $1.72 trillion/y (51, 52) .", [["cardiovascular", "ANATOMY", 73, 87], ["cardiovascular diseases", "DISEASE", 73, 96], ["diabetes", "DISEASE", 133, 141], ["obesity", "DISEASE", 173, 180], ["cardiovascular", "ANATOMICAL_SYSTEM", 73, 87], ["the total direct health care", "TREATMENT", 13, 41], ["cardiovascular diseases", "PROBLEM", 73, 96], ["diabetes", "PROBLEM", 133, 141], ["all obesity", "PROBLEM", 169, 180], ["cardiovascular diseases", "OBSERVATION", 73, 96], ["diabetes", "OBSERVATION", 133, 141], ["obesity", "OBSERVATION", 173, 180]]], ["These economic costs exceed the annual budget appropriations of most federal departments and agencies, such as (for fiscal year 2020) the budgets of the USDA ($150 billion) (53) , DoE ($72 billion) (54), DHS ($51 billion) (55), DoJ ($33 billion) (56) , NIH ($42 billion) (57), CDC ($12.7 billion) (58), EPA ($9.5 billion) (59) , and FDA ($5.9 billion) (59) .The BurdenRising health care expenditures are straining government budgets and private business growth; limiting the ability to support other national, state, and business priorities; contributing to stagnating wages; and bankrupting individuals, families, and small businesses (60, 61) .", [["DHS", "TEST", 204, 207], ["DoJ", "TEST", 228, 231], ["NIH", "TEST", 253, 256], ["CDC", "TEST", 277, 280], ["EPA", "TEST", 303, 306], ["FDA", "TEST", 333, 336], ["small", "OBSERVATION_MODIFIER", 619, 624], ["businesses", "OBSERVATION", 625, 635]]], ["Improving what Americans eat would have a significant impact on reducing diet-related chronic diseases, lowering health care spending, and creating new opportunities for innovation and jobs.", [["chronic diseases", "DISEASE", 86, 102], ["chronic diseases", "PROBLEM", 86, 102], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["diseases", "OBSERVATION", 94, 102]]], ["Although advancing science has elucidated the broad outlines of healthy eating patterns for making many general dietary and policy recommendations, numerous critical questions remain unanswered, with corresponding scientific debate and public confusion.", [["confusion", "DISEASE", 243, 252], ["public confusion", "PROBLEM", 236, 252]]], ["There is a large and growing appetite among American citizens for credible, rigorous nutritional science information, both for general health but also for treating many specific diseases and ailments.", [["a large and growing appetite", "PROBLEM", 9, 37], ["many specific diseases and ailments", "PROBLEM", 164, 199], ["large", "OBSERVATION_MODIFIER", 11, 16], ["growing", "OBSERVATION_MODIFIER", 21, 28]]], ["Many American adults remain unaware of foundational federal guidance on nutrition (63, 64) , and use the internet or other sources for seeking guidance on what to eat (65) .The BurdenPoor nutrition also contributes to profound disparities.", [["profound disparities", "PROBLEM", 218, 238], ["profound", "OBSERVATION_MODIFIER", 218, 226], ["disparities", "OBSERVATION", 227, 238]]], ["Prior to COVID-19, food insecurity was a significant challenge for 1 in 8 Americans (66, 67) , and is expected to more than double this year.", [["COVID", "TEST", 9, 14], ["significant", "OBSERVATION_MODIFIER", 41, 52]]], ["A total of 37 million Americans, including 11 million children, experienced food insecurity in 2018 (68, 69) .", [["food insecurity", "DISEASE", 76, 91], ["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62]]], ["The dramatic increase in unemployment with COVID-19 is expected to cause food insecurity for an additional 18 million US children, bringing the total to 40% of all US youth (70) .", [["COVID-19", "CHEMICAL", 43, 51], ["children", "ORGANISM", 121, 129], ["children", "SPECIES", 121, 129], ["dramatic", "OBSERVATION_MODIFIER", 4, 12], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["unemployment", "OBSERVATION", 25, 37]]], ["Americans are also experiencing ever-widening disparities in diet quality and diet-related chronic diseases by race/ethnicity, education, and income (22, (71) (72) (73) (74) (75) .", [["chronic diseases", "DISEASE", 91, 107], ["chronic diseases", "PROBLEM", 91, 107], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["diseases", "OBSERVATION", 99, 107]]], ["Poor diets lead to a harsh cycle of lower academic achievement in school, lost productivity at work, increased chronic disease risk, increased out-of-pocket health costs, and poverty for the most vulnerable Americans (76) .", [["chronic disease", "DISEASE", 111, 126], ["increased chronic disease risk", "PROBLEM", 101, 131], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["chronic", "OBSERVATION_MODIFIER", 111, 118], ["disease", "OBSERVATION", 119, 126], ["increased", "OBSERVATION_MODIFIER", 133, 142]]], ["Addressing these profound diet-related disparities experienced by rural, low-income, and minority populations requires a better understanding of their multilevel and interrelated individual, social, and environmental determinants, and corresponding translational solutions (77) (78) (79) (80) .", [["profound", "OBSERVATION_MODIFIER", 17, 25], ["diet", "OBSERVATION", 26, 30]]], ["As one example, the 2015 DGAC concluded that the current body of evidence on the links between access to retail food outlets and dietary intake was limited and inconsistent (81) .The BurdenOur national nutrition challenges also diminish military readiness (82) .", [["BurdenOur", "CHEMICAL", 183, 192], ["The BurdenOur national nutrition challenges", "TREATMENT", 179, 222]]], ["For much of human history, governments have prioritized nutrition to enable a high-performing, able military.", [["human", "ORGANISM", 12, 17], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17]]], ["During World War II, for example, recognition of the national security threat of undernutrition produced strong federal actions, such as creation of the first RDAs by President Franklin D Roosevelt in 1941 and of the National School Lunch Program by Congress in 1945 (83) .", [["undernutrition", "DISEASE", 81, 95], ["undernutrition", "PROBLEM", 81, 95]]], ["Today, we face very different nutritional challenges: 71% of young people between the ages of 17 and 24 do not qualify for military service, with obesity being the leading medical disqualifier (25) .", [["obesity", "DISEASE", 146, 153], ["people", "ORGANISM", 67, 73], ["people", "SPECIES", 67, 73], ["obesity", "PROBLEM", 146, 153]]], ["Since 2010, Mission: Readiness-a group of >750 retired US generals, admirals and other top military leaders-has produced several reports documenting the national security threat of childhood obesity (25, 84, 85) .", [["obesity", "DISEASE", 191, 198], ["childhood obesity", "PROBLEM", 181, 198], ["obesity", "OBSERVATION", 191, 198]]], ["In addition, obesity and other diet-related chronic diseases are common among veterans, with more than one-third of veterans seen at the Veterans Health Administration (VHA) being obese (86) .", [["obesity", "DISEASE", 13, 20], ["chronic diseases", "DISEASE", 44, 60], ["veterans", "ORGANISM", 116, 124], ["obesity", "PROBLEM", 13, 20], ["chronic diseases", "PROBLEM", 44, 60], ["obesity", "OBSERVATION", 13, 20], ["chronic", "OBSERVATION_MODIFIER", 44, 51], ["diseases", "OBSERVATION", 52, 60]]], ["Food insecurity is common among veterans seen at the VHA and is associated with suboptimal control of medical conditions (87) (88) (89) .", [["Food insecurity", "DISEASE", 0, 15]]], ["Both obesity and food insecurity are common and often coexist in active-duty military families (90, 91) .", [["obesity", "DISEASE", 5, 12], ["food insecurity", "DISEASE", 17, 32], ["Both obesity", "PROBLEM", 0, 12], ["obesity", "OBSERVATION", 5, 12], ["food insecurity", "OBSERVATION", 17, 32], ["active", "OBSERVATION_MODIFIER", 65, 71]]], ["Overall, dietrelated illnesses are harming the readiness of US military forces and the budgets of the DoD and VA (86, 92, 93) .", [["dietrelated illnesses", "PROBLEM", 9, 30]]], ["A more robust understanding of nutrition is a top DoD priority to maximize the performance of active-duty forces and their recovery from physical and psychologic injuries (11) .The BurdenOur food systems are creating challenges to our climate and natural resources with widespread related health consequences (94) .", [["physical and psychologic injuries", "DISEASE", 137, 170], ["physical and psychologic injuries", "PROBLEM", 137, 170]]], ["While federal nutrition research and coordination is the focus of this white paper, we recognize that nutrition research and agricultural and food systems research are mutually interdependent (95) .", [["nutrition research", "TREATMENT", 102, 120]]], ["Ongoing market forces, food production, and consumption patterns, among other factors, are creating not only poor health but large and unsustainable environmental impacts (96) .", [["large", "OBSERVATION_MODIFIER", 125, 130]]], ["On a global scale, one-quarter of greenhouse gases, 70% of water use, and 90% of tropical deforestation are related to food production.", [["a global scale", "TEST", 3, 17], ["greenhouse gases", "TEST", 34, 50], ["tropical deforestation", "TREATMENT", 81, 103]]], ["Climate change is warming the planet, contributing to lower crop yields and new economic risks for farmers.", [["lower crop yields", "PROBLEM", 54, 71], ["new", "OBSERVATION_MODIFIER", 76, 79]]], ["These issues and corresponding potential solutions are complex: for example, greenhouse gas emissions have global impact, while water use has more regional impact (97) (98) (99) (100) (101) .", [["greenhouse gas emissions", "TEST", 77, 101], ["global", "OBSERVATION_MODIFIER", 107, 113], ["impact", "OBSERVATION_MODIFIER", 114, 120]]], ["Food waste worsens resource losses, with at least one-third of food produced in the US wasted during post-harvest, and consumer losses (102) .", [["waste", "OBSERVATION_MODIFIER", 5, 10], ["worsens", "OBSERVATION_MODIFIER", 11, 18]]], ["The future productivity of US agriculture faces additional growing environmental challenges such as resource scarcity, loss of biodiversity, and soil degradation (96) .", [["loss of biodiversity", "DISEASE", 119, 139], ["US agriculture", "TREATMENT", 27, 41], ["loss of biodiversity", "PROBLEM", 119, 139], ["soil degradation", "PROBLEM", 145, 161]]], ["These sustainability issues have direct relevance for human health, increasing the risk of infectious diseases, respiratory illness, allergies, cardiovascular diseases, food-and waterborne illness, undernutrition, and mental illness (103, 104) .The BurdenAddressing all of these nutrition-related health, equity, societal, and economic burdens requires advancing science to better understand their biological, individual, social, and environmental drivers.", [["respiratory", "ANATOMY", 112, 123], ["cardiovascular", "ANATOMY", 144, 158], ["infectious diseases", "DISEASE", 91, 110], ["respiratory illness", "DISEASE", 112, 131], ["allergies", "DISEASE", 133, 142], ["cardiovascular diseases", "DISEASE", 144, 167], ["food-and waterborne illness", "DISEASE", 169, 196], ["undernutrition", "DISEASE", 198, 212], ["illness", "DISEASE", 225, 232], ["human", "ORGANISM", 54, 59], ["cardiovascular", "ANATOMICAL_SYSTEM", 144, 158], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["infectious diseases", "PROBLEM", 91, 110], ["respiratory illness", "PROBLEM", 112, 131], ["allergies", "PROBLEM", 133, 142], ["cardiovascular diseases", "PROBLEM", 144, 167], ["waterborne illness", "PROBLEM", 178, 196], ["undernutrition", "PROBLEM", 198, 212], ["mental illness", "PROBLEM", 218, 232], ["infectious", "OBSERVATION", 91, 101], ["respiratory illness", "OBSERVATION", 112, 131]]], ["Current scientific knowledge, however, remains insufficient to address the mechanistic determinants and solutions of these complex challenges.The Current Federal Nutrition Research LandscapeThe federal government is the largest supporter of US nutrition research, with a diverse federal nutrition research infrastructure that generates critically important research and surveillance across a range of areas.", [["these complex challenges", "TREATMENT", 117, 141], ["a diverse federal nutrition research infrastructure", "TREATMENT", 269, 320], ["federal government", "OBSERVATION", 194, 212], ["largest", "OBSERVATION_MODIFIER", 220, 227]]], ["A new federal research investment and coordination structure must leverage, harmonize, and catalyzenot diminish or replace-these efforts being led across multiple federal departments and agencies.The Current Federal Nutrition Research LandscapeNo current or complete accounting of all federal nutrition research funding is available (12, 105) .", [["A new federal research investment", "TREATMENT", 0, 33], ["new", "OBSERVATION_MODIFIER", 2, 5]]], ["For this work, we obtained and collated information on the largest departments and agencies focused on nutrition research, and their current estimated spending on nutrition research.", [["nutrition research", "TREATMENT", 163, 181]]], ["The NIH and USDA are by far the 2 largest funders of federal nutrition research.", [["federal nutrition research", "TREATMENT", 53, 79]]], ["The Secretaries of HHS and USDA agreed that NIH would take the lead on research related to the biomedical aspects of nutrition (e.g., diagnosing and treating diseases), while USDA would be responsible for research on healthy diets for the general population.", [["diseases", "PROBLEM", 158, 166], ["the general population", "PROBLEM", 235, 257]]], ["The increase occurred primarily at NIH, while nutrition funding at USDA declined in real dollars during this period.", [["increase", "OBSERVATION_MODIFIER", 4, 12]]], ["Thus, as a share of overall research expenditures, federal nutrition research spending remained generally flat, despite the dramatic increase in diet-related illnesses such as obesity and diabetes from 1980 to the present (12) .", [["obesity", "DISEASE", 176, 183], ["diabetes", "DISEASE", 188, 196], ["obesity", "PROBLEM", 176, 183], ["diabetes", "PROBLEM", 188, 196], ["dramatic", "OBSERVATION_MODIFIER", 124, 132], ["increase", "OBSERVATION_MODIFIER", 133, 141], ["obesity", "OBSERVATION", 176, 183]]], ["For example, funding for research identified as related to \"obesity\" increased nearly 4-fold between 1985 and 2009, and was counted as \"nutrition\" research (108) .NIHThe NIH is the largest biomedical research agency in the world and largest funder of US nutrition research (110) .", [["obesity", "DISEASE", 60, 67], ["NIH", "SPECIES", 163, 166], ["\"obesity", "PROBLEM", 59, 67], ["obesity", "OBSERVATION", 60, 67], ["largest", "OBSERVATION_MODIFIER", 181, 188], ["largest", "OBSERVATION_MODIFIER", 233, 240]]], ["Important intramural and extramural nutrition research occurs across multiple institutes, centers, and offices, in particular the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); National Institute of Aging (NIA); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); and NIH Office of the Director (110) .", [["intramural", "ANATOMY", 10, 20], ["Kidney", "ANATOMY", 179, 185], ["Lung", "ANATOMY", 220, 224], ["Diabetes", "DISEASE", 152, 160], ["Digestive and Kidney Diseases", "DISEASE", 165, 194], ["Heart, Lung, and Blood Institute", "DISEASE", 213, 245], ["Cancer", "DISEASE", 264, 270], ["Digestive", "ORGAN", 165, 174], ["Kidney", "ORGAN", 179, 185], ["Lung", "ORGAN", 220, 224], ["Blood", "ORGANISM_SUBSTANCE", 230, 235], ["Human", "ORGANISM", 385, 390], ["Human", "SPECIES", 385, 390], ["Important intramural and extramural nutrition research", "PROBLEM", 0, 54], ["Diabetes", "PROBLEM", 152, 160], ["Digestive and Kidney Diseases", "PROBLEM", 165, 194], ["intramural", "OBSERVATION_MODIFIER", 10, 20], ["extramural", "OBSERVATION_MODIFIER", 25, 35], ["Diabetes", "OBSERVATION", 152, 160], ["Digestive", "ANATOMY", 165, 174], ["Kidney", "ANATOMY", 179, 185], ["Diseases", "OBSERVATION", 186, 194], ["Heart", "ANATOMY", 213, 218], ["Lung", "ANATOMY", 220, 224]]], ["These institutes focus on diseases or specific subsets of the population, rather than food and nutrition.", [["diseases", "PROBLEM", 26, 34]]], ["For example, NIDDK research efforts include diabetes and other endocrine and metabolic diseases; liver disease and other digestive diseases and conditions; nutritional disorders, such as inborn errors of metabolism; obesity; kidney diseases, such as polycystic kidney disease and glomerular disease; partners and providing programmatic leadership to cooperative extension/land-grant university program implementers for effective nutrition education and obesity-prevention interventions through the land-grant system in conjunction with other implementing agencies and organizations.", [["endocrine", "ANATOMY", 63, 72], ["liver", "ANATOMY", 97, 102], ["digestive", "ANATOMY", 121, 130], ["kidney", "ANATOMY", 225, 231], ["kidney", "ANATOMY", 261, 267], ["glomerular", "ANATOMY", 280, 290], ["diabetes", "DISEASE", 44, 52], ["endocrine and metabolic diseases", "DISEASE", 63, 95], ["liver disease", "DISEASE", 97, 110], ["digestive diseases", "DISEASE", 121, 139], ["nutritional disorders", "DISEASE", 156, 177], ["inborn errors of metabolism", "DISEASE", 187, 214], ["obesity", "DISEASE", 216, 223], ["kidney diseases", "DISEASE", 225, 240], ["polycystic kidney disease", "DISEASE", 250, 275], ["glomerular disease", "DISEASE", 280, 298], ["obesity", "DISEASE", 453, 460], ["liver", "ORGAN", 97, 102], ["digestive", "ORGAN", 121, 130], ["kidney", "ORGAN", 225, 231], ["kidney", "ORGAN", 261, 267], ["glomerular", "MULTI-TISSUE_STRUCTURE", 280, 290], ["diabetes", "PROBLEM", 44, 52], ["other endocrine and metabolic diseases", "PROBLEM", 57, 95], ["liver disease", "PROBLEM", 97, 110], ["other digestive diseases and conditions", "PROBLEM", 115, 154], ["nutritional disorders", "PROBLEM", 156, 177], ["inborn errors of metabolism", "PROBLEM", 187, 214], ["obesity", "PROBLEM", 216, 223], ["kidney diseases", "PROBLEM", 225, 240], ["polycystic kidney disease", "PROBLEM", 250, 275], ["glomerular disease", "PROBLEM", 280, 298], ["effective nutrition education", "TREATMENT", 419, 448], ["obesity", "PROBLEM", 453, 460], ["prevention interventions", "TREATMENT", 461, 485], ["the land-grant system", "TREATMENT", 494, 515], ["metabolic diseases", "OBSERVATION", 77, 95], ["liver", "ANATOMY", 97, 102], ["disease", "OBSERVATION", 103, 110], ["digestive", "ANATOMY", 121, 130], ["diseases", "OBSERVATION", 131, 139], ["obesity", "OBSERVATION", 216, 223], ["kidney", "ANATOMY", 225, 231], ["diseases", "OBSERVATION", 232, 240], ["kidney", "ANATOMY", 261, 267], ["disease", "OBSERVATION", 268, 275], ["glomerular disease", "OBSERVATION", 280, 298]]], ["The USDA National Institute of Food and Agriculture (NIFA) also supports a range of other career development and training programs relevant to human nutrition research.", [["human", "ORGANISM", 143, 148], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148], ["training programs", "TREATMENT", 113, 130]]], ["7 The CDC Division of Nutrition, Physical Activity, and Obesity (DNPAO) funds the Nutrition and Obesity Policy Research Network (NOPREN) at $300,000 each year, which is their only dedicated research project out of the Obesity Branch.", [["Obesity", "DISEASE", 56, 63], ["Obesity", "DISEASE", 96, 103], ["Obesity", "DISEASE", 218, 225], ["Obesity", "PROBLEM", 56, 63], ["Obesity", "OBSERVATION", 56, 63], ["Obesity", "OBSERVATION", 218, 225], ["Branch", "ANATOMY_MODIFIER", 226, 232]]], ["The Obesity Branch has 2 full-time employees (FTEs) dedicated to the epidemiology and surveillance of nutrition/obesity (e.g., fruits and vegetables, added sugars, water, food systems, obesity The largest resource for nutrition research is the Army, which received \u223c$3.3 million in fiscal year 2020 for its intramural nutrition research program.", [["fruits", "ANATOMY", 127, 133], ["vegetables", "ANATOMY", 138, 148], ["Obesity", "DISEASE", 4, 11], ["obesity", "DISEASE", 112, 119], ["obesity", "DISEASE", 185, 192], ["sugars", "CHEMICAL", 156, 162], ["fruits", "ORGANISM_SUBDIVISION", 127, 133], ["vegetables", "ORGANISM_SUBDIVISION", 138, 148], ["sugars", "SIMPLE_CHEMICAL", 156, 162], ["obesity", "PROBLEM", 112, 119], ["obesity", "PROBLEM", 185, 192], ["its intramural nutrition research program", "TREATMENT", 303, 344], ["Obesity", "OBSERVATION", 4, 11], ["Branch", "OBSERVATION_MODIFIER", 12, 18], ["obesity", "OBSERVATION", 112, 119], ["obesity", "OBSERVATION", 185, 192], ["largest", "OBSERVATION_MODIFIER", 197, 204]]], ["The Army nutrition research program also seeks extramural support, which varies from year to year but in fiscal year 2020 is estimated to receive $1.4 million.", [["extramural support", "TREATMENT", 47, 65]]], ["These agreements have covered wide ranging topics including food security, SNAP, WIC, School Meal Programs, promotion of healthier eating, and the food retail environment.", [["SNAP", "CHEMICAL", 75, 79]]], ["12 There is a specific internal budget for the production of Standard Reference Materials (SRMs), which includes but is not limited to the National Institute of Standards and Technology's (NIST's) food matrix items but there is not an exact estimate at this time for other nutrition research-relevant activities across the NIST.", [["Technology's (NIST's)", "TREATMENT", 175, 196]]], ["There is no current budget estimate for the National Oceanic and Atmospheric Administration's (NOAA's) nutrition research relevant activities while current staff are actively engaged in this area.", [["the National Oceanic", "TREATMENT", 40, 60], ["Atmospheric Administration", "TREATMENT", 65, 91], ["NOAA's)", "TREATMENT", 95, 102], ["no", "UNCERTAINTY", 9, 11]]], ["13 The National Aeronautics and Space Administration's (NASA's) complete food capability roadmap is still under construction, and unfortunately it is not at liberty to share these budget details, but this is a high priority area.", [["The National Aeronautics", "TREATMENT", 3, 27], ["Space Administration", "TREATMENT", 32, 52], ["NASA's)", "TREATMENT", 56, 63]]], ["Since about 2010, Congress prohibited the FTC from completing the study they were conducting with FDA, CDC, and USDA on nutrition standards for food marketing to children.", [["children", "ORGANISM", 162, 170], ["children", "SPECIES", 162, 170], ["the study", "TEST", 62, 71]]], ["15 There is no specific nutrition research budget as this work is mainly in-house analyses utilizing the NHANES data.", [["the NHANES data", "TEST", 101, 116], ["no", "UNCERTAINTY", 12, 14]]], ["Other groups within the Environmental Protection Agency such as the Office of Research and Development and the Office of Air and Radiation also rely on the NHANES, but these data are freely available and NHANES is not contracted with the CDC to collect.", [["Radiation", "TREATMENT", 129, 138], ["the NHANES", "TEST", 152, 162], ["these data", "TEST", 168, 178]]], ["16 Nutrition is generally addressed in the context of larger initiatives, so it is not possible for the Health Resources and Services Administration (HRSA) to break out an accurate funding estimate. urologic diseases and conditions; and blood diseases (111) .", [["blood", "ANATOMY", 237, 242], ["urologic diseases", "DISEASE", 199, 216], ["blood diseases", "DISEASE", 237, 251], ["blood", "ORGANISM_SUBSTANCE", 237, 242], ["urologic diseases and conditions", "PROBLEM", 199, 231], ["blood diseases", "PROBLEM", 237, 251], ["not possible", "UNCERTAINTY", 83, 95], ["diseases", "OBSERVATION", 208, 216]]], ["The NHLBI aims to promote the prevention and treatment of heart, lung, and blood diseases, which includes strategic priorities around dietary assessment methodologies that combine objective dietary measures and biomarkers to help identify dietary patterns and food constituents that contribute to weight maintenance and to inform intervention strategies to lower cardiometabolic risks (112) .", [["heart", "ANATOMY", 58, 63], ["lung", "ANATOMY", 65, 69], ["blood", "ANATOMY", 75, 80], ["heart, lung, and blood diseases", "DISEASE", 58, 89], ["heart", "ORGAN", 58, 63], ["lung", "ORGAN", 65, 69], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["treatment", "TREATMENT", 45, 54], ["heart, lung, and blood diseases", "PROBLEM", 58, 89], ["dietary assessment methodologies", "TEST", 134, 166], ["objective dietary measures", "TREATMENT", 180, 206], ["biomarkers", "TEST", 211, 221], ["weight maintenance", "TREATMENT", 297, 315], ["intervention strategies", "TREATMENT", 330, 353], ["heart", "ANATOMY", 58, 63], ["lung", "ANATOMY", 65, 69], ["blood diseases", "OBSERVATION", 75, 89]]], ["The NCI leads, conducts, and supports cancer research to advance scientific knowledge and help all people live longer, healthier lives, which includes efforts to advance dietary assessment methodology (113) .", [["cancer", "ANATOMY", 38, 44], ["cancer", "DISEASE", 38, 44], ["cancer", "CANCER", 38, 44], ["people", "ORGANISM", 99, 105], ["people", "SPECIES", 99, 105]]], ["The NIA leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life, including building the understanding of the roles of nutrition, obesity, sleep, and metabolic status (114) .", [["obesity", "DISEASE", 187, 194], ["obesity", "PROBLEM", 187, 194], ["broad", "OBSERVATION_MODIFIER", 16, 21], ["obesity", "OBSERVATION", 187, 194]]], ["The NICHD aims to investigate human development through the entire life process, including the role of nutrition (115) .NIHWithin the NIH Office of the Director, as one example of several offices relevant to nutrition, the NIH Office of Dietary Supplements works to promote the scientific study of the benefits of dietary supplements in maintaining health and preventing chronic disease and other health-related conditions (116) .NIHFor fiscal year 2019, total NIH expenditures for nutrition research were estimated at $1.9 billion, supporting a total of \u223c4600 active projects across at least 25 of the 27 NIH institutes, centers, and offices ( Figure 3 ) (110) .", [["chronic disease", "DISEASE", 371, 386], ["human", "ORGANISM", 30, 35], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["Dietary Supplements", "TREATMENT", 237, 256], ["dietary supplements", "TREATMENT", 314, 333], ["chronic disease", "PROBLEM", 371, 386], ["total NIH expenditures", "TREATMENT", 455, 477], ["nutrition research", "TREATMENT", 482, 500], ["preventing", "UNCERTAINTY", 360, 370], ["chronic", "OBSERVATION_MODIFIER", 371, 378], ["disease", "OBSERVATION", 379, 386]]], ["A separate analysis of NIH-supported research grants and cooperative research projects between 2012 and 2017 found that only 16.7% of projects and 22.6% of funding supported investigations focused on primary prevention or secondary prevention (treatment) of disease in humans (117) .", [["humans", "ORGANISM", 269, 275], ["humans", "SPECIES", 269, 275], ["humans", "SPECIES", 269, 275], ["A separate analysis", "TEST", 0, 19], ["NIH", "TEST", 23, 26], ["funding supported investigations", "TEST", 156, 188], ["primary prevention", "TREATMENT", 200, 218], ["disease in humans", "PROBLEM", 258, 275]]], ["Thus, this careful analysis suggests that only 1.3% of all research projects supported by NIH in recent years focused on the role of diet in the prevention or treatment of disease in humans (119) .", [["humans", "ORGANISM", 183, 189], ["humans", "SPECIES", 183, 189], ["humans", "SPECIES", 183, 189], ["this careful analysis", "TEST", 6, 27], ["disease in humans", "PROBLEM", 172, 189], ["disease", "OBSERVATION", 172, 179]]], ["Another recent NIH analysis evaluated the leading risk factors and causes of death and disability in the US, compared with NIH funding on these factors, and concluded that large mismatches exist between the top causes of poor health versus research funding to address them, with the largest gap being for nutrition (120) .NIHOver the years, NIH has aimed to coordinate the diverse nutrition science research being conducted or supported across the agency through a range of initiatives, including recent efforts to help accelerate the science of obesity research (Supplemental Table 3 ) (121) .", [["death", "DISEASE", 77, 82], ["disability", "DISEASE", 87, 97], ["obesity", "DISEASE", 546, 553], ["Another recent NIH analysis", "TEST", 0, 27], ["death", "PROBLEM", 77, 82], ["disability", "PROBLEM", 87, 97], ["the US", "TEST", 101, 107], ["large mismatches", "PROBLEM", 172, 188], ["poor health", "PROBLEM", 221, 232], ["obesity research", "PROBLEM", 546, 562], ["large", "OBSERVATION_MODIFIER", 172, 177], ["mismatches", "OBSERVATION", 178, 188], ["obesity", "OBSERVATION", 546, 553]]], ["In 2015, DNRC was disbanded and transitioned from an NIDDK Division into an NIDDK Office, the Office of Nutrition Research (ONR) (123) [within NIDDK, a lower organizational stature and size than a division (124) ].", [["a lower organizational stature", "PROBLEM", 150, 180], ["size", "OBSERVATION_MODIFIER", 185, 189]]], ["The NIH Nutrition Research Task Force was established later in 2016 to guide the development and implementation of the first NIH-wide strategic plan for nutrition research for the next 10 y (126).", [["nutrition research", "TREATMENT", 153, 171]]], ["Including several themes from the 2016 National Nutrition Research Roadmap (11) (see \"ICHNR\" section below), this first-of-its-kind NIH plan is organized around 4 strategic goals (129) The NIH plan includes 5 cross-cutting areas: minority health and health disparities; health of women; rigor and reproducibility; data science, systems science, and artificial intelligence; and training the nutrition scientific workforce (130) .", [["women", "ORGANISM", 280, 285], ["women", "SPECIES", 280, 285], ["rigor", "PROBLEM", 287, 292]]], ["Examples of priority objectives in the 4 strategic areas include to investigate bioinformatic gaps in nutrition-related genes and pathways, diethost-microbiome interrelationships, new tools for microbiome and precision nutrition research, mechanisms of interindividual variability in responses to food-based dietary patterns, influence of diet on infant developmental and health outcomes, the role of nutrition in older adults to promote healthy aging, and interactions between drugs, diseases, and nutrition to improve clinical care and outcomes, among others.", [["infant", "SPECIES", 347, 353], ["interindividual variability", "PROBLEM", 253, 280], ["diseases", "PROBLEM", 485, 493]]], ["The NIH Common Fund is planning a potential program in Precision Nutrition for fiscal year 2021 (131), potentially similar to other Common Fund-supported endeavors such as the All of US Research Program and the NIH Human Microbiome Project (see \"Options\" section below).USDAStarting in 1895, Dr. Wilbur Atwater's pioneering work at USDA laid much of the groundwork for modern nutrition science in the US as well as many current USDA nutrition research programs (132) .", [["Human", "ORGANISM", 215, 220], ["Human", "SPECIES", 215, 220]]], ["The Farm Bill requires the Secretary of USDA to establish and support food and human nutrition research as a distinct mission of the Department, including coordinating nutrition research within the Department and with agencies across the federal government, as well as using formalized mechanisms for external input.", [["human", "ORGANISM", 79, 84], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["external input", "TREATMENT", 301, 315]]], ["The USDA also has a major focus on implementing federal nutrition programs to segments of the public, which constitute the majority of USDA's budget.", [["federal nutrition programs", "TREATMENT", 48, 74]]], ["The importance of the nutrition assistance and associated nutrition education programs for improving food security and health and preventing disease in low-income populations creates a particularly important need to integrate and connect nutrition research from within and outside USDA to inform and guide policy development for these programs.USDAThe agencies in USDA's Research, Education, and Economics (REE) mission area work to integrate research, analysis, and education to create a safe, sustainable, competitive US food and agricultural system and strong, healthy communities, families, and youth (134) .", [["the nutrition assistance", "TREATMENT", 18, 42], ["nutrition education programs", "TREATMENT", 58, 86], ["disease", "PROBLEM", 141, 148], ["these programs", "TREATMENT", 329, 343]]], ["The ARS' Human Nutrition Program emphasizes food-based approaches for health, including a core network of 6 internationally recognized Human Nutrition Research Centers with scientists, equipment, and facilities for long-term, multidisciplinary, translational research (136, 137) .", [["Human", "ORGANISM", 9, 14], ["Human", "ORGANISM", 135, 140], ["Human", "SPECIES", 9, 14], ["Human", "SPECIES", 135, 140]]], ["NIFA supports postsecondary education at 113 land-grant colleges and universities (Public , as well as 21 historically black colleges and universities (Public Law 51-841) and 37 tribal colleges and universities (Public Law 89-329) (138-141).", [["NIFA", "CHEMICAL", 0, 4]]], ["While federal funding for these schools initially focused on agricultural research and extension, over time these schools have increasingly focused on human nutrition and food research and extension nutrition education, although the recent growth in research is largely through additional competitive grant mechanisms rather than direct NIFA support to the Agricultural Experiment Station.", [["human", "ORGANISM", 151, 156], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["human nutrition", "TREATMENT", 151, 166], ["extension nutrition education", "TREATMENT", 189, 218], ["direct NIFA support", "TREATMENT", 330, 349]]], ["NIFA further supports extramural nutrition research, often with a focus on integrating agricultural considerations with promotion of health and decreasing health disparities; this work includes funding projects aiming to identify environmental and behavioral factors that act as barriers to consumption of a high-quality diet, while identifying factors that promote healthy eating behaviors (e.g., increasing home access and availability of fruits and vegetables) (142) .", [["fruits", "ANATOMY", 441, 447], ["vegetables", "ANATOMY", 452, 462], ["NIFA", "CHEMICAL", 0, 4], ["eating behaviors", "DISEASE", 374, 390], ["fruits", "ORGANISM_SUBDIVISION", 441, 447], ["vegetables", "ORGANISM_SUBDIVISION", 452, 462], ["decreasing health disparities", "PROBLEM", 144, 173], ["a high-quality diet", "TREATMENT", 306, 325]]], ["This research includes examining interactions among consumers, food industry, and government as they relate to the food supply, markets, and access; food choice and its impact on diet quality; federal regulations and other aspects of food policy; and the USDA's nutrition assistance programs in meeting public policy and nutrition goals.USDAThe Food and Nutrition Service (FNS) is the only agency of the Food, Nutrition, and Consumer Services mission area.", [["federal regulations", "TREATMENT", 193, 212]]], ["The FNS administers 15 domestic nutrition assistance programs, conducts some limited research, and makes use of nutrition research sponsored by other federal agencies to help assess and improve these programs.", [["domestic nutrition assistance programs", "TREATMENT", 23, 61], ["nutrition research", "TREATMENT", 112, 130]]], ["And, as discussed in the cross-governmental section below, the USDA FNS Center for Nutrition Policy and Promotion (CNPP) conducts the evidence analysis for the DGAs, including nutrition evidence systematic reviews, data analysis, and food pattern modeling, and develops the corresponding consumer-facing education tools (e.g., MyPlate) (144, 145) .USDAUSDA investments in research and statistics, including nutrition, have fallen below 1980s levels in constant dollars ( Figure 3 ) (12, 146) .", [["the DGAs", "PROBLEM", 156, 164], ["systematic reviews", "TEST", 195, 213], ["data analysis", "TEST", 215, 228]]], ["Indeed, as a percentage of GDP, public investment in agrifood (agriculture and food combined) research and development (4.2%) and particularly food research and development (1%) was lower in 2018 than pharmaceutical research and development (4.9%) (147) .", [["GDP", "CHEMICAL", 27, 30], ["agrifood", "CHEMICAL", 53, 61], ["GDP", "CHEMICAL", 27, 30], ["GDP", "SIMPLE_CHEMICAL", 27, 30]]], ["The US fell behind China in public agricultural research in 2009, and now only invests half the amount as China (148) .", [["The US", "TEST", 0, 6]]], ["US public sector funding for agricultural research and development is also lower than India, Western Europe, and the Asia-Pacific region including Canada, using constant 2011 purchasing-power parity (148) .", [["agricultural research", "TEST", 29, 50], ["lower", "OBSERVATION_MODIFIER", 75, 80]]], ["Yet, growth in productivity in the farm sector has come almost exclusively from science-based innovations (146) .", [["growth", "OBSERVATION_MODIFIER", 5, 11], ["productivity", "OBSERVATION_MODIFIER", 15, 27]]], ["Specific to nutrition, as one example, the ARS budget for human nutrition research and monitoring, including funding for 6 important extramural and intramural Human Nutrition Centers nationally, has been flat since 1980 in constant dollars ( Figure 5 ) (132) .", [["human", "ORGANISM", 58, 63], ["Human", "ORGANISM", 159, 164], ["human", "SPECIES", 58, 63], ["Human", "SPECIES", 159, 164], ["human", "SPECIES", 58, 63], ["human nutrition research", "TREATMENT", 58, 82]]], ["In addition, 2 USDA research and statistical agencies that include nutrition research-ERS and NIFA-were relocated to Kansas City, Missouri, at the start of fiscal year 2020 and lost 50% (ERS) and 71% (NIFA) of their workforce (149) .", [["NIFA", "SIMPLE_CHEMICAL", 94, 98], ["nutrition research", "TEST", 67, 85], ["NIFA", "TEST", 94, 98]]], ["The Food Security Act of 1985 (Public required the Secretary of Agriculture to submit to Congress \"a comprehensive plan for implementing a national nutrition research program, including recommendations relating to research directions, educational activities, and funding levels necessary to carry out such a plan.\"", [["a national nutrition research program", "TREATMENT", 137, 174]]], ["In 1993, USDA revised its human nutrition program coordination structure and developed a Human Nutrition Policy Committee that reported to the Secretary's Policy Coordination Council and a USDA Human Nutrition Coordinating Committee (HNCC) that reported to the Policy Committee.", [["human", "ORGANISM", 26, 31], ["Human", "ORGANISM", 89, 94], ["Human", "ORGANISM", 194, 199], ["human", "SPECIES", 26, 31], ["Human", "SPECIES", 89, 94], ["Human", "SPECIES", 194, 199], ["human", "SPECIES", 26, 31]]], ["The Human Nutrition Policy Committee has not been active since the late 1990s.", [["Human", "ORGANISM", 4, 9], ["Human", "SPECIES", 4, 9]]], ["HNCC is chaired by an ARS representative and vice-chaired by an FNS representative and includes members from a variety of USDA agencies with additional liaisons from HHS.", [["HNCC", "DISEASE", 0, 4], ["HHS", "DISEASE", 166, 169]]], ["Over the last 2 decades, HNCC has generally met quarterly.", [["HNCC", "DISEASE", 25, 29], ["HNCC", "CANCER", 25, 29]]], ["These gaps and needs included the following: assessing existing and potential new means of coordination and collaboration; developing new interdepartmental working groups and interest groups; identifying new and improved ways to enhance coordination with USDA food safety efforts; better utilizing the HNCC; and hosting overviews of USDA nutrition relevant databases and related data science trainings and resources.", [["new", "OBSERVATION_MODIFIER", 134, 137]]], ["This Blueprint includes specific objectives in nutrition and health promotion, such as to develop and update the current evidence base to promote proper macro-and micronutrient intake among critical age groups or life stages, such as women who are pregnant or lactating, infants, children, adolescents, working-age adults, tribal members, and seniors; provide guidance and incentives to promote healthier eating patterns so that the US can reduce incidence of, and morbidity from, obesity and diet-related chronic diseases; promote food systems that reduce the prevalence and severity of food insecurity; and expand understanding about the impacts of USDA nutrition assistance programs on human health, communities, and the economy.", [["obesity", "DISEASE", 481, 488], ["chronic diseases", "DISEASE", 506, 522], ["food insecurity", "DISEASE", 588, 603], ["women", "ORGANISM", 234, 239], ["infants", "ORGANISM", 271, 278], ["children", "ORGANISM", 280, 288], ["food", "ORGANISM_SUBDIVISION", 588, 592], ["human", "ORGANISM", 689, 694], ["women", "SPECIES", 234, 239], ["infants", "SPECIES", 271, 278], ["children", "SPECIES", 280, 288], ["adolescents", "SPECIES", 290, 301], ["human", "SPECIES", 689, 694], ["human", "SPECIES", 689, 694], ["morbidity", "PROBLEM", 465, 474], ["obesity", "PROBLEM", 481, 488], ["chronic diseases", "PROBLEM", 506, 522], ["chronic", "OBSERVATION_MODIFIER", 506, 513], ["diseases", "OBSERVATION", 514, 522]]], ["The USDA Science Blueprint has objectives related to infrastructure, innovation, and wellbeing: to develop and evaluate methods to increase access to lowcost and nutritious food as well as sustain efficient agriculture and bioeconomy systems in rural communities; and to evaluate alternative systems that may improve the quality, resiliency, and sustainability of food, fiber, forest, and fuel supplies.", [["lowcost and nutritious food", "TREATMENT", 150, 177], ["alternative systems", "TREATMENT", 280, 299]]], ["How new federal funding streams, leadership, or coordination structures may help achieve these laudable goals were not addressed in the report.", [["new", "OBSERVATION_MODIFIER", 4, 7]]], ["Benchmarks of success included reducing US food loss and waste by 50% by the year 2030 and reducing US nutrient loss in water by 30% by 2050 (157) .Nutrition research in other federal departments and agenciesIn addition to NIH and USDA, many other departments and agencies conduct or utilize nutrition research (Table 1) .", [["food loss", "DISEASE", 43, 52], ["nutrient loss", "DISEASE", 103, 116], ["food loss", "OBSERVATION", 43, 52], ["nutrient loss", "OBSERVATION", 103, 116]]], ["The Roadmap explained each of the participating ICHNR department and agency's missions, roles and responsibilities, and mechanisms for supporting and/or using nutrition research; many include histories and contemporary overviews of research needs and interests.Nutrition research in other federal departments and agenciesThe DoD, for example, focuses on nutrition's role in human performance and resilience.", [["human", "ORGANISM", 374, 379], ["human", "SPECIES", 374, 379], ["human", "SPECIES", 374, 379], ["nutrition research", "TREATMENT", 159, 177]]], ["At the US Army Natick Soldier Systems Center, DoD supports scientists and technologists conducting innovative research to develop foods and combat rations that are nutritious, palatable, and nonperishable (158).", [["combat rations", "TREATMENT", 140, 154]]], ["In Natick, the Combat Feeding Directorate, a part of the Combat Capabilities Development Command of the US Army Futures Command, provides DoD with a joint-service program responsible for research, development, testing, and integration and engineering for materiel solutions such as combat rations, food service equipment technology, and combat feeding systems.", [["testing", "TEST", 210, 217], ["materiel solutions", "TREATMENT", 255, 273], ["joint", "ANATOMY", 149, 154]]], ["The Military Nutrition Division (MND) of the US Army Research Institute of Environmental Medicine, a part of the US Army Medical Research and Materiel Development Command, also of the US Army Futures Command is co-located in Natick with the Combat Feeding Directorate.", [["MND", "DISEASE", 33, 36]]], ["The MND conducts research that provides the biomedical science basis for warfighter nutritional requirements utilized for the development of rations, menus, policies and programs that enable warfighter health and performance, evaluates warfighter nutritional status, and examines interactions between nutrition, health, performance and the operational environment.", [["MND", "DISEASE", 4, 7], ["nutritional requirements", "TREATMENT", 84, 108]]], ["The Consortium for Health and Military Performance (CHAMP) at the Uniformed Services University of the Health Sciences (DoD's health sciences university) conducts various nutrition-related research on the nutrition environment (Go For Green and the Military Nutrition Environment Assessment Tool) and tests strategies to mitigate the consequences of environmental and/or physiological stressors and sustain physical and cognitive performance.", [["tests strategies", "TREATMENT", 301, 317]]], ["CHAMP is also extensively involved in dietary supplement research-from beneficial ingredients to those that could compromise force readiness.", [["CHAMP", "CHEMICAL", 0, 5], ["CHAMP", "SIMPLE_CHEMICAL", 0, 5], ["beneficial ingredients", "TREATMENT", 71, 93]]], ["Both MND and CHAMP collaborate on projects whenever possible to maximize efficiencies and effectiveness.Nutrition research in other federal departments and agenciesNASA conducts nutrition research to understand the dietary requirements of space travelers and the role of nutrition in human adaptation to microgravity, each critical to crew safety and mission success.", [["MND", "DISEASE", 5, 8], ["human", "ORGANISM", 284, 289], ["human", "SPECIES", 284, 289], ["human", "SPECIES", 284, 289], ["space travelers", "TREATMENT", 239, 254]]], ["The CDC addresses population nutrition through surveillance, intramural and extramural research, and translation of research into program implementation.", [["surveillance", "TEST", 47, 59]]], ["The FDA is responsible for protecting the public health by ensuring the safety of our nation's food supply, among other activities (159) .", [["responsible for", "UNCERTAINTY", 11, 26]]], ["This includes providing and supporting accurate and useful nutrition information and education to customers, monitoring and assessing emerging nutrition science and changes in the composition of foods in the marketplace in relation to the health status of Americans, and encouraging and facilitating new products and product reformulation to promote a healthier food supply.", [["emerging nutrition science", "TREATMENT", 134, 160], ["new products and product reformulation", "TREATMENT", 300, 338]]], ["To achieve this mission, FDA depends heavily on federal nutrition research from other departments and agencies and also conducts its own research activities, such as consumer studies to support nutrition labeling and claims, assessments of constituents of the food supply, development of methods for analyzing food constituents, surveys on health, analyses of dietary intake, monitoring of adverse events from dietary foods and supplements, and cost-benefit analyses of various nutrition regulatory activities.", [["nutrition labeling", "TREATMENT", 194, 212], ["adverse events", "PROBLEM", 390, 404], ["supplements", "TREATMENT", 428, 439]]], ["USAID adopts, adapts, modifies, and increases the information, evidence, practices, and technologies of US institutions in human nutrition to be applicable to USAID target populations in developing countries as a key plank of US diplomacy and security.", [["human", "ORGANISM", 123, 128], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128]]], ["Demonstrating its increased prioritization of nutrition, USAID recently hired its first Chief Nutritionist, who aims to galvanize support for the December 2020 Nutrition for Growth Summit and secure commitments from partner countries, private sectors, and nongovernmental organizations to accelerate progress on improving nutrition worldwide (160) .Nutrition research in other federal departments and agenciesThere are a variety of other federal departments and agencies that are not a member of ICHNR that engage with and leverage nutrition research, such as, but not limited to, HHS Centers for Medicare and Medicaid Services (CMS), HHS Center for Medicare and Medicaid Innovation (CMMI), HHS Office of the Surgeon General, Federal Emergency Management Agency (FEMA), and Departments of Veterans Affairs, Education, Energy, Transportation, Labor, Homeland Security, Housing and Urban Development, Interior, and Justice.Current Efforts for Cross-Governmental Nutrition Research CoordinationGiven the diverse investments in nutrition research across separate federal departments and agencies, several initiatives have aimed to better coordinate these efforts.", [["increased", "OBSERVATION_MODIFIER", 18, 27], ["prioritization", "OBSERVATION_MODIFIER", 28, 42], ["variety", "OBSERVATION_MODIFIER", 421, 428]]], ["Major initiatives are summarized below.ICHNRIn 1977, Congress recognized the need and called for improved coordination of human nutrition research (Public (Supplemental Text 1).", [["human", "ORGANISM", 122, 127], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 122, 127], ["human nutrition research", "TREATMENT", 122, 146]]], ["Congress further requested its Office of Technology Assessment to review existing federal human nutrition research, with findings published in the 1978 report Nutrition Research Alternatives (106) .", [["human", "ORGANISM", 90, 95], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95]]], ["This report found that federal nutrition research programs had failed to deal with the changing health problems of the American people.", [["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134]]], ["In response, Congress chartered the Joint Subcommittee on Human Nutrition Research (JSHNR), under the aegis of OSTP, who, in a 1980 report, recommended an improved planning system to coordinate federal nutrition research (161) .", [["Human", "ORGANISM", 58, 63], ["Human", "SPECIES", 58, 63], ["Joint", "ANATOMY", 36, 41]]], ["In 1982, the GAO was also asked to review federal nutrition research and concluded that the government had no overall federal nutrition plan with specific goals or unified and coordinated strategies, while acknowledging the ongoing work of USDA, HHS, and OSTP to develop a coordinated planning system (162) .ICHNRIn 1983, JSHNR completed its review and recommendations, leading to the formation of the ICHNR.", [["the ICHNR", "PROBLEM", 398, 407]]], ["The aim of ICHNR was to fill the identified gaps of insufficient planning and coordination and achieve \"the pursuit of new knowledge to improve the understanding of nutrition as it relates to human health and disease \u2026 in 5 major areas: biomedical and behavioral sciences, food sciences, nutrition monitoring and surveillance, nutrition education, and impact on nutrition of intervention programs and socioeconomic factors\" (161) .", [["human", "ORGANISM", 192, 197], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 192, 197], ["nutrition monitoring", "TEST", 288, 308], ["surveillance", "TREATMENT", 313, 325], ["nutrition education", "TREATMENT", 327, 346], ["nutrition of intervention programs", "TREATMENT", 362, 396]]], ["ICHNR includes representatives from multiple federal departments and agencies (Table 1) .ICHNRAfter some early collaborative successes, ICHNR had a \u226510-y hiatus (Supplemental Table 5 ).", [["a \u226510-y hiatus (Supplemental Table", "TREATMENT", 146, 180], ["early", "OBSERVATION_MODIFIER", 105, 110], ["collaborative", "OBSERVATION_MODIFIER", 111, 124], ["successes", "OBSERVATION", 125, 134]]], ["Reassembled in 2013, ICHNR recognized the need for a new effort to coordinate federal nutrition research.", [["federal nutrition research", "TREATMENT", 78, 104]]], ["The Roadmap was framed around 3 questions:ICHNR1) How can we better understand and define eating patterns to improve and sustain health? 2) What can be done to help people choose healthy eating patterns? 3) How can we develop and engage innovative methods and systems to accelerate discoveries in human nutrition?ICHNRAcross these 3 questions, 11 topical areas were identified based on population impact, feasibility given current technological capacities, and emerging scientific opportunities (Supplemental Figure 1 ) within which 120 short-and long-term research and resource initiatives were defined.", [["people", "ORGANISM", 165, 171], ["human", "ORGANISM", 297, 302], ["people", "SPECIES", 165, 171], ["human", "SPECIES", 297, 302], ["human", "SPECIES", 297, 302], ["resource initiatives", "TREATMENT", 570, 590]]], ["The Roadmap also identified gaps in the US nutrition research workforce and put forth recommendations for developing a diverse, interdisciplinary workforce able to advance nutritional sciences research.ICHNRNotably, the Roadmap did not include any data, findings, or recommendations on current or new nutrition research investment levels, leadership, or structures (11) .", [["nutritional sciences research", "TREATMENT", 172, 201], ["gaps", "OBSERVATION_MODIFIER", 28, 32]]], ["Thus, the Roadmap lacked any prioritization between the 120 identified initiatives, due to variable and nonharmonized funding criteria, priorities, and capacities across federal, nonprofit, and private-sector research agencies in the US and globally.", [["variable and nonharmonized funding criteria", "PROBLEM", 91, 134]]], ["This may be why a 2017 analysis found only early signs of implementation of the Roadmap among ICHNR member departments and agencies (163) .", [["a 2017 analysis", "TEST", 16, 31]]], ["Currently, ICHNR has a narrower focus, meeting about twice per year to discuss the DGAs, DRIs, and a potential new federal database of nutrition research projects.", [["nutrition research", "TREATMENT", 135, 153], ["narrower", "OBSERVATION_MODIFIER", 23, 31]]], ["There are few other indicators of current use or monitoring of the Roadmap's aims or progress (164) .", [["few", "OBSERVATION_MODIFIER", 10, 13]]], ["These include lack of any strong or consistent connection to the White House, no specific budget appropriations, no mechanism for reporting to Congress, and absence of any well-supported infrastructure for external advisory input on cross-governmental strategies for nutrition research.National food and nutrition monitoring and surveillanceNational monitoring and surveillance are integral to nutrition research and translation.", [["external advisory input", "TREATMENT", 206, 229], ["cross-governmental strategies", "TREATMENT", 233, 262], ["nutrition research", "TREATMENT", 267, 285], ["nutrition monitoring", "TEST", 304, 324], ["surveillance", "TEST", 329, 341], ["National monitoring", "TEST", 341, 360]]], ["Several CDC and other federal collaborations (Supplemental Table 6 ) and USDA efforts (Supplemental Table 4 ) focus on food and nutrition monitoring and surveillance surveys and related research (Supplemental Table 7 ).", [["nutrition monitoring", "TEST", 128, 148], ["surveillance surveys", "TEST", 153, 173], ["federal collaborations", "OBSERVATION", 22, 44]]], ["These federal efforts began with an international focus to lend expertise and capacity to developing nations to help them develop nutritional assessment and data-informed food and nutrition policy and programmatic responses, such as food fortification and research and training in nutritional sciences (165) .", [["nutritional assessment", "TEST", 130, 152], ["nutrition policy", "TREATMENT", 180, 196]]], ["For example, in 1955, the Interdepartmental Committee on Nutrition for National Defense was formed after malnutrition was identified to be common among the troops of Korea and China (166, 167) .", [["malnutrition", "DISEASE", 105, 117], ["malnutrition", "PROBLEM", 105, 117]]], ["After initial emphasis on surveillance of nutrition programs among military personnel, this Committee expanded focus to civilians in countries of \"special interest,\" ultimately conducting surveys in 33 developing countries (165) .", [["nutrition programs", "TREATMENT", 42, 60]]], ["In 1967, this international surveillance program was reorganized in response to Congressional amendments to focus on domestic hunger and malnutrition.", [["malnutrition", "DISEASE", 137, 149], ["domestic hunger", "PROBLEM", 117, 132], ["malnutrition", "PROBLEM", 137, 149], ["malnutrition", "OBSERVATION", 137, 149]]], ["In 1968, the Ten State Nutrition Survey identified severe malnutrition in several low-income US states (168) , stimulating Congressional hearings regarding hunger and the formation of the US Senate Select Committee on Nutrition and Related Needs.", [["malnutrition", "DISEASE", 58, 70], ["severe malnutrition", "PROBLEM", 51, 70], ["hunger", "PROBLEM", 156, 162], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["malnutrition", "OBSERVATION", 58, 70]]], ["In 1969, President Nixon commissioned the first and still only White House Conference on Food, Nutrition, and Health, which put numerous concrete recommendations that led to expansion and standardization of school lunch and Food Stamps, and the creation of school breakfast and the USDA Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) (13, 169) .National food and nutrition monitoring and surveillanceIn 1990, Congress (Public Law 101-445) created the National Nutrition Monitoring and Related Research Program (NNM-RRP), with aims to produce a comprehensive, coordinated program for nutrition monitoring and related research to improve assessment of the US population's health and nutrition.", [["Women", "SPECIES", 330, 335], ["Infants", "SPECIES", 337, 344], ["Children", "SPECIES", 350, 358], ["nutrition monitoring", "TEST", 394, 414], ["nutrition monitoring", "TEST", 614, 634], ["assessment", "TEST", 667, 677]]], ["Congress required this program to achieve coordination of federal monitoring efforts within 10 y, guided by a new Interagency Board for Nutrition Monitoring and Related Research (IBNMRR) and a 9-member National Nutrition Monitoring Advisory Council.", [["this program", "TREATMENT", 18, 30], ["federal monitoring efforts", "TREATMENT", 58, 84], ["Nutrition Monitoring", "TEST", 136, 156]]], ["The IBNMRR convened between 1991 and 2002, co-chaired by HHS Assistant Secretary for Health and USDA Undersecretary for Research, Education, and Economics, and was charged with designing and implementing a 10-y comprehensive plan for planning and coordinating the activities of 22 federal agencies that conduct nutrition monitoring and surveillance or related research or are major users of nutrition monitoring data (170) .", [["nutrition monitoring", "TEST", 311, 331], ["surveillance", "TREATMENT", 336, 348], ["nutrition monitoring data", "TEST", 391, 416]]], ["When this program ended in 2002, federal nutrition monitoring efforts returned to being decentralized, without explicit coordination (11, (174) (175) (176) .", [["explicit coordination", "TEST", 111, 132]]], ["Current national nutrition monitoring and surveillance systems face fiscal, infrastructure, and coordination challenges that limit their capacity to respond to evolving data needs, technological advances, and demographic shifts (e.g., barriers to provide sufficient national data for the Congressional mandate in the 2020-2025 DGAs to include infants and women who are pregnant or lactating) (177, 178) .DGAsA key cross-departmental nutrition-related activity is the DGAs, the cornerstone for many federal nutrition programs and policies (Supplemental Table 8 ) (179) .", [["infants", "ORGANISM", 343, 350], ["women", "ORGANISM", 355, 360], ["infants", "SPECIES", 343, 350], ["women", "SPECIES", 355, 360], ["Current national nutrition monitoring", "TEST", 0, 37], ["surveillance systems", "TEST", 42, 62], ["coordination challenges", "TREATMENT", 96, 119], ["many federal nutrition programs", "TREATMENT", 493, 524]]], ["The National Nutrition Monitoring and Related Research Act of 1990 (Public Law 101-445) requires the DGAs be reviewed by the Secretaries of both USDA and HHS.", [["HHS", "DISEASE", 154, 157]]], ["Since 1995, a memorandum of understanding between the 2 departments provides a framework for this joint USDA-HHS endeavor, with each department alternating in leading each 5-y edition (180) .", [["joint", "ANATOMY", 98, 103]]], ["Regardless of departmental lead, the USDA CNPP conducts the evidence analysis and develops the corresponding consumer-facing education tools (144, 145) .", [["the USDA CNPP", "TEST", 33, 46]]], ["The HHS Office of Disease Prevention and Health Promotion (ODPHP) aims to provide technical expertise and develop DGArelated resources for health professionals.DGAsBoth agencies' efforts are constrained by limited funding and staff dedicated to the DGAs (144) .", [["Disease", "OBSERVATION", 18, 25]]], ["In mandating the DGAs, Congress (Public Law 101-445) did not authorize or appropriate any regular funding for the DGA process nor, importantly, for the fundamental research, monitoring, and surveillance processes necessary for developing and translating dietary guidance, among other national needs.", [["the fundamental research", "TEST", 148, 172], ["surveillance processes", "TEST", 190, 212]]], ["For example, there is no consistent funding source to develop the nation's DRIs, which are foundational to the DGAs, nor to ensure sufficient research to develop the necessary evidence base for updates of either the DGAs or DRIs.", [["the DGAs or DRIs", "PROBLEM", 212, 228], ["no consistent", "UNCERTAINTY", 22, 35], ["funding", "OBSERVATION", 36, 43]]], ["Successive DGACs from the 1980 edition onwards have documented persistent, major research gaps for setting evidencebased guidelines (181) .", [["persistent", "OBSERVATION_MODIFIER", 63, 73]]], ["Consistent funding also does not exist to review the impact of the DGAs on the public's understanding of nutrition, food choices, or health, or on the impact on other stakeholders (181) (182) (183) .DGAsIn response to concerns that the DGA process may require updated processes and coordination, in 2016 Congress instructed the National Academies of Sciences, Engineering, and Medicine (NASEM) to review and make recommendations to the process for updating the DGAs (Public .", [["funding", "OBSERVATION", 11, 18]]], ["This report identified the following specific opportunities for improvement in the DGA process: more consistent interpretation of purpose and target audiences of the DGA, greater transparency of the overall process, and more rigorous methodological approaches to the evaluation of the evidence.", [["the DGA", "PROBLEM", 162, 169], ["the evaluation", "TEST", 263, 277], ["greater", "OBSERVATION_MODIFIER", 171, 178], ["transparency", "OBSERVATION_MODIFIER", 179, 191], ["overall", "OBSERVATION_MODIFIER", 199, 206], ["process", "OBSERVATION", 207, 214]]], ["The USDA-HHS responded to NASEM recommendations in September 2018 indicating changes they will be making in the development of the 2020-2025 DGAs, such as asking for public comments on the topics and scientific questions to be examined in the review of the evidence supporting the development of the next edition (185) .DGAsIn part to respond to these recommendations, the FY2019 appropriations bill provided a one-time allocation of $12.3 million to CNPP, divided over 3 y, to support the 2020-2025 DGAs (186) .", [["CNPP", "TREATMENT", 451, 455]]], ["As previously noted, only \u223c1.3% of NIH-supported research focuses on diet for the prevention or treatment of disease in humans, and furthermore, among these, only about half of the projects relate to key research gaps identified by the 2015 DGAC (117) (118) (119) .", [["DGAC", "CHEMICAL", 241, 245], ["humans", "ORGANISM", 120, 126], ["humans", "SPECIES", 120, 126], ["humans", "SPECIES", 120, 126], ["disease in humans", "PROBLEM", 109, 126], ["disease", "OBSERVATION", 109, 116]]], ["In addition, while the 2014 Farm Bill (Public mandated that the DGAs include, for the first time, food-based nutrition guidance for infants and toddlers aged 0-24 mo and women who are pregnant or lactating (prior DGAs did not include or consider these critical populations), no funding was authorized or appropriated to support this new mandate.", [["infants", "ORGANISM", 132, 139], ["women", "ORGANISM", 170, 175], ["infants", "SPECIES", 132, 139], ["toddlers", "SPECIES", 144, 152], ["women", "SPECIES", 170, 175]]], ["However, highlighting the scale and scope of diet-related illness, only 12% of US adults are metabolically healthy (as defined by blood glucose, cholesterol, blood pressure, and waist circumference).", [["blood", "ANATOMY", 130, 135], ["blood", "ANATOMY", 158, 163], ["illness", "DISEASE", 58, 65], ["cholesterol", "CHEMICAL", 145, 156], ["glucose", "CHEMICAL", 136, 143], ["cholesterol", "CHEMICAL", 145, 156], ["adults", "ORGANISM", 82, 88], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["glucose", "SIMPLE_CHEMICAL", 136, 143], ["cholesterol", "SIMPLE_CHEMICAL", 145, 156], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["waist", "ORGANISM_SUBDIVISION", 178, 183], ["circumference", "ORGANISM_SUBDIVISION", 184, 197], ["related illness", "PROBLEM", 50, 65], ["blood glucose", "TEST", 130, 143], ["cholesterol", "TEST", 145, 156], ["blood pressure", "TEST", 158, 172], ["waist circumference", "TEST", 178, 197]]], ["Thus, the DGAs' general focus may exclude the specific dietary needs of the great majority of the US population.", [["the DGAs' general focus", "PROBLEM", 6, 29]]], ["Until 2014, the NIH supported the development of evidence reviews and dietary guidance for patients with health issues such as overweight and obesity, high blood pressure, and high blood cholesterol, among others (188, 189) .", [["blood", "ANATOMY", 156, 161], ["blood", "ANATOMY", 181, 186], ["overweight", "DISEASE", 127, 137], ["obesity", "DISEASE", 142, 149], ["high blood pressure", "DISEASE", 151, 170], ["cholesterol", "CHEMICAL", 187, 198], ["cholesterol", "CHEMICAL", 187, 198], ["patients", "ORGANISM", 91, 99], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["cholesterol", "SIMPLE_CHEMICAL", 187, 198], ["patients", "SPECIES", 91, 99], ["dietary guidance", "TREATMENT", 70, 86], ["obesity", "PROBLEM", 142, 149], ["high blood pressure", "PROBLEM", 151, 170], ["high blood cholesterol", "PROBLEM", 176, 198], ["high blood cholesterol", "OBSERVATION", 176, 198]]], ["The NIH ceased these reports in 2014, in part because the CDC's mandate deals with disease prevention activities and the mandate of the HHS Agency for Healthcare Research and Quality (AHRQ) includes development of systematic evidence reviews to inform clinical practice guidelines (189) (190) (191) .", [["disease prevention activities", "TREATMENT", 83, 112]]], ["Certain nongovernmental professional and clinical organizations provide nutrition guidance for populations with or at risk for various chronic conditions, but these various recommendations are not coordinated (192, 193) .", [["nutrition guidance", "TREATMENT", 72, 90], ["various chronic conditions", "PROBLEM", 127, 153], ["chronic", "OBSERVATION_MODIFIER", 135, 142], ["conditions", "OBSERVATION", 143, 153]]], ["Little work has been done to understand the short-or long-term implications of NIH's shift in 2014 away from dietary guidance for populations with disease conditions, or whether CDC and AHRQ efforts are addressing this gap.", [["disease conditions", "PROBLEM", 147, 165]]], ["Thus, currently no federal entity takes the lead on the development of evidence reviews or dietary guidance for patients with diet-related health conditions.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120]]], ["Several organizations, including AND, the National Association for the Advancement of Colored People, and the National Hispanic Medical Association, recently formed the Food4Health Alliance to advocate for additional federal nutrition guidelines tailored to the needs of tens of millions of Americans who have diet-related diseases such as hypertension, obesity, and type 2 diabetes-conditions that also disproportionately affect minorities and underserved communities (194) .DGAsIn addition to the lack of consistent funding and staff for the evidence reviews, fundamental research, monitoring, and surveillance processes needed to develop and translate dietary guidance, concerns have been raised that the process of updating the DGAs every 5 y is not protected from political or external influences (e.g., political appointees, Congress, food and beverage industries, agribusiness interests, advocacy groups) (182, 184, 195) .", [["hypertension", "DISEASE", 340, 352], ["obesity", "DISEASE", 354, 361], ["type 2 diabetes", "DISEASE", 367, 382], ["People", "SPECIES", 94, 100], ["additional federal nutrition guidelines", "TREATMENT", 206, 245], ["related diseases", "PROBLEM", 315, 331], ["hypertension", "PROBLEM", 340, 352], ["obesity", "PROBLEM", 354, 361], ["type 2 diabetes", "PROBLEM", 367, 382], ["fundamental research", "TEST", 562, 582], ["monitoring", "TEST", 584, 594], ["surveillance processes", "TEST", 600, 622], ["hypertension", "OBSERVATION", 340, 352], ["obesity", "OBSERVATION", 354, 361]]], ["A coordinated federal approach and authority for nutrition research could help strengthen the process for objective and independent development, review, and dissemination of the best science evidence to the American public in the DGAs for both healthy individuals and those with major diet-related illnesses, as well as for the evaluation of corresponding intended and unintended impacts of these guidelines and needed changes to improve these impacts.DRIsDRIs provide specific targets for intakes of relevant nutrients for the general population (196) .", [["A coordinated federal approach", "TREATMENT", 0, 30], ["nutrition research", "TREATMENT", 49, 67], ["the evaluation", "TEST", 324, 338], ["these guidelines", "TREATMENT", 391, 407], ["relevant nutrients", "TREATMENT", 501, 519]]], ["In 1943, the first RDAs (a type of DRI) were published, providing science-based guidelines for target intakes of total calories, protein, calcium, phosphorus, iron, and a few vitamins (198) .", [["calcium", "CHEMICAL", 138, 145], ["phosphorus", "CHEMICAL", 147, 157], ["iron", "CHEMICAL", 159, 163], ["calcium", "CHEMICAL", 138, 145], ["phosphorus", "CHEMICAL", 147, 157], ["iron", "CHEMICAL", 159, 163], ["vitamins", "CHEMICAL", 175, 183], ["calories", "SIMPLE_CHEMICAL", 119, 127], ["calcium", "SIMPLE_CHEMICAL", 138, 145], ["phosphorus", "SIMPLE_CHEMICAL", 147, 157], ["iron", "SIMPLE_CHEMICAL", 159, 163], ["vitamins", "SIMPLE_CHEMICAL", 175, 183], ["total calories", "TREATMENT", 113, 127], ["protein", "TREATMENT", 129, 136], ["calcium", "TEST", 138, 145], ["phosphorus", "TREATMENT", 147, 157], ["iron", "TREATMENT", 159, 163], ["a few vitamins", "TREATMENT", 169, 183]]], ["Although DRIs are foundational to DGAs, the Nutrition Facts label, and other federal policies, there is no dedicated funding stream or statutory requirement for updating DRIs.", [["DRIs", "PROTEIN", 170, 174], ["no", "UNCERTAINTY", 104, 106]]], ["Recently, a NASEM Consensus Study Report determined that crucial research gaps for setting DRIs remain largely unaddressed (200) .", [["a NASEM Consensus Study", "TEST", 10, 33], ["setting DRIs", "TREATMENT", 83, 95]]], ["In 1994, the GAO recommended that USDA and FDA work together to perform laboratory analyses to independently verify the accuracy of nutrition labels; review labels for compliance with formatting requirements, nutrient content claims, and health claims; work with companies to correct identified inaccuracies; and where appropriate, pursue legal action against products with inappropriate labels (205) .", [["laboratory analyses", "TEST", 72, 91]]], ["Examples include the determination that partially hydrogenated oils (high in industrial trans fat) were no longer Generally Recognized As Safe (GRAS), for which NIHand USDA-funded research, CDC surveillance data, and HHS regulatory reviews supported the FDA determination (206) ; and FDA's amendment of the food additive regulations to change the standard of identity of enriched flour and corn masa flour (207) to allow folic acid fortification to help prevent neural tube defects in developing infants, which required similar inputs from diverse federal research, surveillance, and regulatory efforts.", [["neural tube", "ANATOMY", 462, 473], ["hydrogenated oils", "CHEMICAL", 50, 67], ["folic acid", "CHEMICAL", 421, 431], ["neural tube defects", "DISEASE", 462, 481], ["folic acid", "CHEMICAL", 421, 431], ["fat", "TISSUE", 94, 97], ["flour", "ORGANISM_SUBSTANCE", 380, 385], ["folic acid", "SIMPLE_CHEMICAL", 421, 431], ["neural tube", "MULTI-TISSUE_STRUCTURE", 462, 473], ["infants", "ORGANISM", 496, 503], ["corn", "SPECIES", 390, 394], ["infants", "SPECIES", 496, 503], ["corn", "SPECIES", 390, 394], ["partially hydrogenated oils", "PROBLEM", 40, 67], ["CDC surveillance data", "TEST", 190, 211], ["enriched flour", "TREATMENT", 371, 385], ["corn masa flour", "TREATMENT", 390, 405], ["folic acid fortification", "TREATMENT", 421, 445], ["neural tube defects", "PROBLEM", 462, 481], ["surveillance", "TEST", 566, 578], ["high", "OBSERVATION_MODIFIER", 69, 73], ["no longer", "UNCERTAINTY", 104, 113], ["neural", "OBSERVATION", 462, 468], ["tube defects", "OBSERVATION", 469, 481]]], ["Another example is the 2016 Nutrition Facts updates (e.g., requiring labeling of added sugar) based on new scientific research, updated DGAs, consensus reports, and national survey data, along with input obtained through proposed rulemaking processes (208, 209) .Food and nutrition regulatory activitiesIn 2018, FDA announced their Nutrition Innovation Strategy that outlined key activities to take a \"fresh look\" at what can be done to reduce diet-related chronic diseases (210) .", [["chronic diseases", "DISEASE", 457, 473], ["sugar", "CHEMICAL", 87, 92], ["sugar", "SIMPLE_CHEMICAL", 87, 92], ["added sugar", "TREATMENT", 81, 92], ["national survey data", "TEST", 165, 185], ["chronic diseases", "PROBLEM", 457, 473], ["chronic", "OBSERVATION_MODIFIER", 457, 464], ["diseases", "OBSERVATION", 465, 473]]], ["Key elements included the following: modernizing claims such as \"healthy,\" modernizing ingredient labels and standards of identity, implementing the Nutrition Facts Label and Menu Labeling, reducing sodium, and expanding nutrition education (e.g., launching a new Nutrition Facts label education campaign).", [["sodium", "CHEMICAL", 199, 205], ["sodium", "CHEMICAL", 199, 205], ["sodium", "SIMPLE_CHEMICAL", 199, 205], ["reducing sodium", "TREATMENT", 190, 205], ["expanding nutrition education", "TREATMENT", 211, 240]]], ["Insufficient scientific evidence on dietary supplement contents, health effects, and potential risks limits the FDA's ability to provide oversight for this $40 billon/y industry (212) (213) (214) .", [["dietary supplement contents", "TREATMENT", 36, 63]]], ["As another example, there is no DRI or listing on Nutrition Facts for many compounds that appear relevant for health such as omega-3 fatty acids, phenolics, and other phytonutrients (212, 215) .", [["omega-3 fatty acids", "CHEMICAL", 125, 144], ["phenolics", "CHEMICAL", 146, 155], ["omega-3 fatty acids", "CHEMICAL", 125, 144], ["phytonutrients", "CHEMICAL", 167, 181], ["omega-3 fatty acids", "SIMPLE_CHEMICAL", 125, 144], ["phenolics", "SIMPLE_CHEMICAL", 146, 155], ["DRI", "PROBLEM", 32, 35], ["Nutrition Facts", "TREATMENT", 50, 65], ["many compounds", "PROBLEM", 70, 84], ["no", "UNCERTAINTY", 29, 31]]], ["Further, many processing methods and additives banned in the European Union are permitted in the US, based on insufficient science for a definitive determination by FDA (216) .Food and nutrition regulatory activitiesThe Federal Trade Commission (FTC) has not been able to engage in any research on the impacts of food marketing to children in nearly 10 y (11).", [["children", "ORGANISM", 331, 339], ["children", "SPECIES", 331, 339]]], ["Congress prohibited FTC from completing their joint study with FDA, CDC, and USDA on nutrition standards for food marketing to children, even though this Interagency Working Group on Food Marketed to Children was established by the 2009 Omnibus Appropriations Act (Public (11) .", [["children", "ORGANISM", 127, 135], ["children", "SPECIES", 127, 135], ["Children", "SPECIES", 200, 208], ["their joint study", "TEST", 40, 57], ["joint", "ANATOMY", 46, 51]]], ["Taken together, these FDA and FTC examples, among others, illustrate the crucial role of robust and coordinated federal nutrition research for numerous regulatory decisions and activities.Federal nutrition education and promotionCongress requires federal departments and agencies to coordinate review processes to ensure that nutrition education materials produced by the federal government are consistent with the latest DGAs (Public .", [["Federal nutrition education", "TREATMENT", 188, 215], ["nutrition education materials", "TREATMENT", 326, 355]]], ["More recently, DoD worked with USDA and HHS to integrate DGAs into their Go for Green\u00ae joint-service performance-nutrition initiative that aims to improve the food environment where military service members live and work (217) .", [["joint", "ANATOMY", 87, 92]]], ["There is no direct, consistent Congressional investment in nutrition education for the general public, except for limited support of CNPP's dietary guidance translation activities and of USDA Food and Nutrition Service's nutrition education and promotion materials associated with the federal nutrition assistance programs.", [["nutrition education", "TREATMENT", 59, 78], ["CNPP", "TREATMENT", 133, 137], ["nutrition education", "TREATMENT", 221, 240], ["promotion materials", "TREATMENT", 245, 264], ["the federal nutrition assistance programs", "TREATMENT", 281, 322], ["no", "UNCERTAINTY", 9, 11]]], ["Over the years, various efforts have examined the impacts of USDA investments in nutrition education and promotion with mixed success (218) .", [["nutrition education", "TREATMENT", 81, 100]]], ["A 2019 GAO evaluation found that USDA administers 5 key programs that provide nutrition education but does not have formal coordination mechanisms for its nutrition education efforts and does not fully leverage the department's nutrition expertise (155) .", [["GAO evaluation", "TEST", 7, 21], ["nutrition education", "TREATMENT", 78, 97]]], ["The GAO recommended that USDA develop a formal mechanism for coordinating nutrition education, improve the information it gathers on Supplemental Nutrition Assistance Program Education (SNAP-Ed), and take steps to fully leverage the department's expertise for nutrition education efforts.National nutrition research databaseThere is no dedicated, consistent funding to identify and track federal investments in nutrition research.", [["coordinating nutrition education", "TREATMENT", 61, 93], ["nutrition education efforts", "TREATMENT", 260, 287], ["no", "UNCERTAINTY", 333, 335]]], ["In 1981, Congress authorized the Human Nutrition Research and Information Management (HNRIM) system to track funding of nutrition research projects across the federal government (Public .", [["Human", "ORGANISM", 33, 38], ["Human", "SPECIES", 33, 38], ["Management (HNRIM) system", "TREATMENT", 74, 99], ["nutrition research", "TREATMENT", 120, 138]]], ["From 1985 to 2015, HNRIM was maintained by NIH and, at its peak, included \u2265100,000 records on federal nutrition research and training expenditures.", [["federal nutrition research", "TREATMENT", 94, 120], ["training expenditures", "TREATMENT", 125, 146]]], ["For instance, a single project and its total dollars may be counted as 100% nutrition, obesity, cardiovascular disease, diabetes, and prevention, among others.", [["cardiovascular", "ANATOMY", 96, 110], ["obesity", "DISEASE", 87, 94], ["cardiovascular disease", "DISEASE", 96, 118], ["diabetes", "DISEASE", 120, 128], ["cardiovascular", "ANATOMICAL_SYSTEM", 96, 110], ["its total dollars", "TREATMENT", 35, 52], ["obesity", "PROBLEM", 87, 94], ["cardiovascular disease", "PROBLEM", 96, 118], ["diabetes", "PROBLEM", 120, 128], ["obesity", "OBSERVATION", 87, 94], ["cardiovascular disease", "OBSERVATION", 96, 118], ["diabetes", "OBSERVATION", 120, 128]]], ["Besides NIH systems, a variety of other websites and databases aim to capture federal investments in human nutrition research, each using different methods with uncertain accuracy (Supplemental Table 9 ).Current landscape: summarySignificant efforts are occurring across diverse federal departments and agencies to leverage existing personnel and funding and coordinate existing activities to advance nutrition research.", [["human", "ORGANISM", 101, 106], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["human nutrition research", "TREATMENT", 101, 125], ["nutrition research", "TREATMENT", 401, 419]]], ["However, these efforts are not sufficiently coordinated or expansive enough to address the current and future diet-related disease burdens, or the corresponding health care spending, food insecurity and health disparities; strains on government budgets and American businesses; challenges to military readiness; and intersections with supply chains and sustainability.", [["related disease burdens", "PROBLEM", 115, 138]]], ["Many new opportunities exist to be seized, as reviewed next.The OpportunityA strengthening of federal nutrition research has significant potential to generate new discoveries to improve and sustain the health of all Americans.", [["new", "OBSERVATION_MODIFIER", 5, 8]]], ["We identified and collated multiple specific priority areas that have been set forth by various federal and nongovernmental organizations (Table 2 , Figure 2 ), and most of these have not been adequately addressed (11, 81, 147, 196, (219) (220) (221) (222) (223) (224) (225) (226) .Cross-governmental strategic planning and prioritizationAn expanded, coordinated federal nutrition research effort could more effectively plan and prioritize scientific discoveries across critical areas.", [["Cross-governmental strategic planning", "TREATMENT", 282, 319], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["specific", "OBSERVATION_MODIFIER", 36, 44], ["priority", "OBSERVATION_MODIFIER", 45, 53], ["areas", "OBSERVATION", 54, 59], ["various", "OBSERVATION_MODIFIER", 88, 95], ["federal", "OBSERVATION_MODIFIER", 96, 103], ["nongovernmental organizations", "OBSERVATION", 108, 137], ["expanded", "OBSERVATION_MODIFIER", 341, 349]]], ["This would include accelerated translation of scientific findings into practice-for example, relevant for USDA nutrition assistance programs, FDA regulatory activities, CMS health care improvements, CDC public health efforts, DoD and VA priorities for active-duty forces and veterans, USDA agricultural priorities, and additional interests of communities, schools, and worksites.", [["nutrition assistance programs", "TREATMENT", 111, 140]]], ["A coordinated federal nutrition research authority would also facilitate appropriate expertise on review panels to identify meritorious projects and multidisciplinary investigative teams to achieve project goals and foster the development and application of high standards for scientific rigor, reproducibility, and transparency (11, 227) .Greater science for dietary guidance to the publicWhile current science permits broad recommendations on healthy eating patterns, significant scientific debate and public confusion remain on many topics.", [["confusion", "DISEASE", 511, 520], ["scientific rigor", "PROBLEM", 277, 293], ["dietary guidance", "TREATMENT", 360, 376], ["public confusion", "PROBLEM", 504, 520]]], ["As reviewed earlier, the 2015 DGAC identified numerous critical areas for national dietary guidance that require greater scientific evidence (Supplemental Table 2 ).", [["national dietary guidance", "TREATMENT", 74, 99]]], ["A 2020 DGAC member described their continuing inability to draw many conclusions from an inadequate evidence base in 2 words: \"It's disheartening\" (228) .", [["2020 DGAC member", "PROTEIN", 2, 18]]], ["Additional areas for accelerated research include major food groups for which health effects are currently poorly understood, and the interrelationships between nutrition and the gut microbiome, immunity, epigenetics, vascular health, food allergies, and other physiological systems-all with tremendous implications for human health (229) (230) (231) (232) .", [["gut microbiome", "ANATOMY", 179, 193], ["vascular", "ANATOMY", 218, 226], ["food allergies", "DISEASE", 235, 249], ["gut", "ORGANISM_SUBDIVISION", 179, 182], ["vascular", "MULTI-TISSUE_STRUCTURE", 218, 226], ["human", "ORGANISM", 320, 325], ["human", "SPECIES", 320, 325], ["human", "SPECIES", 320, 325], ["food allergies", "PROBLEM", 235, 249], ["vascular", "ANATOMY", 218, 226]]], ["The complex effects of nutrition on health, the often provocative messages from the media and other influencers, and the many real unanswered and emerging questions in nutrition science have created significant public confusion (233) .", [["confusion", "DISEASE", 218, 227], ["significant public confusion", "PROBLEM", 199, 227], ["complex", "OBSERVATION_MODIFIER", 4, 11], ["effects", "OBSERVATION_MODIFIER", 12, 19], ["significant", "OBSERVATION_MODIFIER", 199, 210]]], ["As a result, the public is awash with insufficient and conflicting information on many topics, such as on popular diets for weight loss, the effects of caloric restriction or intermittent fasting, and many other topics, with limited rigorous science to provide confident guidance.", [["weight loss", "DISEASE", 124, 135], ["weight loss", "PROBLEM", 124, 135], ["caloric restriction", "TREATMENT", 152, 171], ["intermittent fasting", "TREATMENT", 175, 195]]], ["A broadly expanded and coordinated effort to generate and disseminate scientifically sound nutrition research is an essential need for the American people.Leverage new technologies and data scienceExponential growth has occurred in technology, genomics, proteomics, and metabolomics platforms; personalized and environmental sensors; and other big-data resources.", [["people", "ORGANISM", 148, 154], ["people", "SPECIES", 148, 154], ["Exponential growth", "PROBLEM", 197, 215], ["proteomics", "TEST", 254, 264], ["metabolomics platforms", "TEST", 270, 292], ["broadly", "OBSERVATION_MODIFIER", 2, 9], ["expanded", "OBSERVATION", 10, 18], ["growth", "OBSERVATION_MODIFIER", 209, 215]]], ["Yet, the implications of these advances for a new era of nutrition research have not been realized.", [["nutrition research", "TREATMENT", 57, 75]]], ["The untapped potential of new technology and data science approaches extends far beyond precision nutrition, with promise for additional basic, clinical, environmental, and public health research on food and nutrition (236) .Foundational basic science and discoveryFundamental research in nutrition is essential to accelerate progress but is hampered by the absence of any federal home for its investment and coordination.", [["new", "OBSERVATION_MODIFIER", 26, 29]]], ["Pathways of nutritional influences during the first 1000 days of life, when critical metabolic programming can alter lifelong and possibly epigenerational disease risk, remain critically understudied (237) .", [["nutritional influences", "PROBLEM", 12, 34], ["epigenerational disease risk", "PROBLEM", 139, 167], ["nutritional influences", "OBSERVATION", 12, 34], ["possibly", "UNCERTAINTY", 130, 138], ["epigenerational disease", "OBSERVATION", 139, 162]]], ["Food allergies have exploded among US children, yet with little understanding of their underlying determinants or effective preventive measures (238) .", [["Food allergies", "DISEASE", 0, 14], ["children", "ORGANISM", 38, 46], ["children", "SPECIES", 38, 46], ["Food allergies", "PROBLEM", 0, 14]]], ["The molecular and metabolic influences of food on aging-including frailty, suppressed immune responses, brain function, sarcopenia, macular degeneration, renal decline, and functional decline-are essential areas of research for an aging population (11) .", [["brain", "ANATOMY", 104, 109], ["macular", "ANATOMY", 132, 139], ["renal", "ANATOMY", 154, 159], ["frailty", "DISEASE", 66, 73], ["sarcopenia", "DISEASE", 120, 130], ["macular degeneration", "DISEASE", 132, 152], ["renal decline", "DISEASE", 154, 167], ["brain", "ORGAN", 104, 109], ["macular", "TISSUE", 132, 139], ["renal", "ORGAN", 154, 159], ["sarcopenia", "PROBLEM", 120, 130], ["macular degeneration", "PROBLEM", 132, 152], ["renal decline", "PROBLEM", 154, 167], ["functional decline", "PROBLEM", 173, 191], ["metabolic influences", "OBSERVATION", 18, 38], ["brain", "ANATOMY", 104, 109], ["sarcopenia", "OBSERVATION", 120, 130], ["macular degeneration", "OBSERVATION", 132, 152], ["renal", "ANATOMY", 154, 159], ["decline", "OBSERVATION", 160, 167], ["areas", "OBSERVATION_MODIFIER", 206, 211]]], ["Thousands of poorly characterized bioactive compounds in foods, such as flavanols and other phenolics, require basic research to elucidate their biochemical and physiologic effects.", [["flavanols", "CHEMICAL", 72, 81], ["flavanols", "CHEMICAL", 72, 81], ["flavanols", "SIMPLE_CHEMICAL", 72, 81], ["phenolics", "SIMPLE_CHEMICAL", 92, 101], ["basic research", "TREATMENT", 111, 125], ["poorly characterized", "OBSERVATION_MODIFIER", 13, 33], ["bioactive compounds", "OBSERVATION", 34, 53]]], ["Accelerated basic research is also essential to assess the molecular and health impacts of other factors such as food additives, gluten, FODMAPS (fermentable oligo-,Cross-governmental strategic planning and prioritization\u2022 Develop a national strategic planning process including optimal leadership, coordination, monitoring, and funding structures \u2022 Develop criteria for prioritization such as based on population impact, feasibility, emerging scientific opportunities and methodologic advances, and relevance for cross-governmental regulatory priorities \u2022 Enhance the scope, interdisciplinary nature, and impact of individual research projects and research initiatives \u2022 Accelerate translation \u2022 Develop new research mechanisms and transparent private-public partnerships that stimulate and reward science-driven innovations for health, health equity, and sustainability \u2022 Develop common guidance and standards on project reviews and scientific rigor, reproducibility, and transparency Advance the science for dietary recommendations to the public \u2022 Comparative effects of different popular diet patterns, eating frequency, intermittent fasting, and diet quantity vs. different foods on weight loss and weight maintenance; and heterogeneity in these effects based on a person's characteristics \u2022 Optimal dietary recommendations for specific disease conditions, such as hypertension, type 2 diabetes, cardiovascular diseases, specific cancers, infections, autoimmune diseases, and more \u2022 Rigorous studies on food groups with unclear or controversial evidence, such as different dairy foods (cheese, yogurt, milk, butter), red meats, tropical oils, organic vs. nonorganic foods, among others \u2022 Numerous other critical areas requiring more scientific evidence as identified by the 2015 DGAC (see Supplemental Table 2) \u2022 A stronger intergovernmental process and more consistent funding for establishing DGAs and DRIs Leverage new technologies and data science resources and approaches \u2022 Interactions between diet, the gut microbiome, immunity, epigenetics, vascular health, and other physiological systems \u2022 Personalized or precision nutrition, including based on personal backgrounds, habits, genes, microbiomes, medications, and chronic medical conditions \u2022 Interrelationships of nutrition and epigenetics for health \u2022 Using innovative technology and data science for diverse fundamental, clinical, environmental, and public health research questions in food and nutrition Advance foundational and basic science knowledge and discoveries \u2022 Molecular basis of nutritional needs across the lifespan, physical activity levels, and disease conditions \u2022 Pathways of nutritional effects in the first 1000 days of life for programming of lifelong health \u2022 Origins of and treatments for food allergies \u2022 Optimal nutrition for healthy aging \u2022 Nutritional treatments for reducing side effects of and more effectively targeting cancer chemo-and radiation therapy \u2022 Comprehensive characterization of and molecular and health effects of trace bioactives and phenolics, such as in extra-virgin olive oil, cocoa, green tea, coffee, red wine, and blueberries, among others \u2022 Assessing the molecular and health impacts of additives, gluten, FODMAPS (fermentable oligo-, di-, mono-saccharides and polyols), low-calorie sweeteners, and other food components of public interest and confusion \u2022 Assessing the opportunities, controversies and confusion around food processing and processed foods Understand and address diet-related health disparities \u2022 Community-based participatory research to understand and address community priorities around nutrition \u2022 Influence of the food environment, and intersections with individual and social determinants, of diet-related health disparities, and the corresponding translational solutions \u2022 Causal interrelationships between food insecurity and diet-related chronic diseases like obesity, diabetes, cardiovascular diseases, and certain cancers \u2022 Influence of education, knowledge, personal choice, sociocultural influences, industry marketing, and diverse food environment characteristics \u2022 Roles of past and current discriminatory policies and practices that alter employment opportunities, homeownership, and community development Support and enhance translational and implementation science \u2022 Intersections of nutrition with shared risk factors such as low physical activity and tobacco use, among others \u2022 Developing effective behavior change strategies and policy, systems, and environmental supports for promoting healthy eating \u2022 Understanding characteristics of effective communication channels for diverse audiences \u2022 Enhancing nutrition science literacy \u2022 Rigorous evaluation of the major federal investments (DGAs, food labeling, health claims, menu labeling, SNAP-Ed, etc.) for informing public choices around nutrition \u2022 Nutrition policy and food environment research including efficacy, cost-effectiveness, equity, and feasibility \u2022 Coordinated interagency research on food marketing to children \u2022 Strengthen medical nutrition therapy for an array of acute and chronic diseases and conditions \u2022 Coordinated interagency research on Food is Medicine interventions within health care systems, including medical and other allied health professional education, medically tailored meals with enhanced medical nutrition therapy, produce prescriptions, and other nutrition-focused flexible benefit services Coordinate key cross-agency research priorities for nutrition-related investments \u2022 Optimizing nutrition-related investments for diplomacy, development, and defense, such as by USAID ($27 billion/y) \u2022 DoD priorities around nutrition for human performance, military readiness, and treatment of musculoskeletal and battlefield injuries \u2022 VHA opportunities to reduce high rates of diet-related illnesses among veterans \u2022 Understand and define basic nutrient requirements during extended stays in microgravity, among other research and translation needs to support NASA astronauts \u2022 Strengthen and leverage the nearly $100 billion/y national investment across \u226515 USDA nutrition assistance programs \u2022 Food safety research, relevant to FDA, USDA, and NIH \u2022 FDA regulatory issues including Nutrition Facts labeling, front-of-pack labeling, restaurant menu labeling, health claims, food category standards of identity, cellular agriculture, food additives, and dietary supplements \u2022 Intersections of nutrition science and food, nutrition, and health regulatory activities coordinated between FDA, USDA, NIH, among others Intersections with food production, supply chains, and sustainability \u2022 Interplay of livestock and farming practices on the joint nutritional quality of foods and natural resource use \u2022 Nutritional innovations and collaborations for healthier crops and manufactured food products including novel ingredients and biofortification as a means to increase nutrient content and availability \u2022 Nutritional implications of novel regenerative agriculture approaches \u2022 Impacts of plant-based meat and dairy alternatives and cellular agriculture on health and sustainability \u2022 Joint impacts of climate on nutrition, production, and resource use (Continued) Monitoring and surveillance \u2022 Diets and health nationally, by state, and in population subgroups \u2022 Food security and diet-related health disparities, including monitoring food access and affordability \u2022 Neighborhood food environments, school meals, and retail and restaurant purchases \u2022 Nutritional aspects of federal nutrition assistance programs \u2022 Structures, strengths, and weaknesses of local, regional, national, and global supply chains 1 These examples were identified and adapted from several governmental and nongovernmental consensus recommendations on current priority areas for new nutrition research along with an assessment of additional research literature (11, 81, 147, 196, (219) (220) (221) (222) (223) (224) (225) (226) di-, mono-saccharides and polyols), low-calorie sweeteners, and other food components of public health interest.Diet-related health disparitiesMany health disparities are closely linked to nutritional disparities (71) (72) (73) 239) .", [["cardiovascular", "ANATOMY", 1401, 1415], ["cancers", "ANATOMY", 1435, 1442], ["milk", "ANATOMY", 1607, 1611], ["red meats", "ANATOMY", 1622, 1631], ["oils", "ANATOMY", 1642, 1646], ["gut microbiome", "ANATOMY", 2015, 2029], ["vascular", "ANATOMY", 2054, 2062], ["cancer", "ANATOMY", 2916, 2922], ["olive oil", "ANATOMY", 3079, 3088], ["tea", "ANATOMY", 3103, 3106], ["cardiovascular", "ANATOMY", 3921, 3935], ["cancers", "ANATOMY", 3958, 3965], ["cellular", "ANATOMY", 6347, 6355], ["meat", "ANATOMY", 7032, 7036], ["cellular", "ANATOMY", 7064, 7072], ["FODMAPS", "CHEMICAL", 137, 144], ["weight loss", "DISEASE", 1188, 1199], ["hypertension", "DISEASE", 1370, 1382], ["type 2 diabetes", "DISEASE", 1384, 1399], ["cardiovascular diseases", "DISEASE", 1401, 1424], ["cancers", "DISEASE", 1435, 1442], ["infections", "DISEASE", 1444, 1454], ["autoimmune diseases", "DISEASE", 1456, 1475], ["cheese, yogurt, milk, butter", "CHEMICAL", 1591, 1619], ["food allergies", "DISEASE", 2778, 2792], ["cancer", "DISEASE", 2916, 2922], ["phenolics", "CHEMICAL", 3044, 3053], ["cocoa, green tea, coffee, red wine", "CHEMICAL", 3090, 3124], ["FODMAPS", "CHEMICAL", 3223, 3230], ["di-, mono-saccharides", "CHEMICAL", 3252, 3273], ["polyols", "CHEMICAL", 3278, 3285], ["confusion", "DISEASE", 3361, 3370], ["confusion", "DISEASE", 3420, 3429], ["food insecurity", "DISEASE", 3847, 3862], ["chronic diseases", "DISEASE", 3880, 3896], ["obesity", "DISEASE", 3902, 3909], ["diabetes", "DISEASE", 3911, 3919], ["cardiovascular diseases", "DISEASE", 3921, 3944], ["cancers", "DISEASE", 3958, 3965], ["SNAP", "CHEMICAL", 4793, 4797], ["chronic diseases", "DISEASE", 5097, 5113], ["musculoskeletal and battlefield injuries", "DISEASE", 5728, 5768], ["mono-saccharides", "CHEMICAL", 7940, 7956], ["polyols", "CHEMICAL", 7961, 7968], ["polyols", "CHEMICAL", 3278, 3285], ["polyols", "CHEMICAL", 7961, 7968], ["FODMAPS", "SIMPLE_CHEMICAL", 137, 144], ["cardiovascular", "ANATOMICAL_SYSTEM", 1401, 1415], ["cancers", "CANCER", 1435, 1442], ["cheese", "ORGANISM_SUBDIVISION", 1591, 1597], ["yogurt", "ORGANISM_SUBDIVISION", 1599, 1605], ["milk", "ORGANISM_SUBDIVISION", 1607, 1611], ["butter", "ORGANISM_SUBDIVISION", 1613, 1619], ["meats", "ORGANISM_SUBDIVISION", 1626, 1631], ["gut", "ORGANISM_SUBDIVISION", 2015, 2018], ["vascular", "MULTI-TISSUE_STRUCTURE", 2054, 2062], ["cancer", "CANCER", 2916, 2922], ["bioactives", "SIMPLE_CHEMICAL", 3029, 3039], ["phenolics", "SIMPLE_CHEMICAL", 3044, 3053], ["olive oil", "ORGANISM", 3079, 3088], ["cocoa", "ORGANISM_SUBDIVISION", 3090, 3095], ["green tea", "ORGANISM", 3097, 3106], ["blueberries", "ORGANISM_SUBDIVISION", 3130, 3141], ["gluten", "SIMPLE_CHEMICAL", 3215, 3221], ["FODMAPS", "SIMPLE_CHEMICAL", 3223, 3230], ["di-", "SIMPLE_CHEMICAL", 3252, 3255], ["mono-saccharides", "SIMPLE_CHEMICAL", 3257, 3273], ["polyols", "SIMPLE_CHEMICAL", 3278, 3285], ["cardiovascular", "ANATOMICAL_SYSTEM", 3921, 3935], ["cancers", "CANCER", 3958, 3965], ["tobacco", "ORGANISM", 4404, 4411], ["children", "ORGANISM", 5023, 5031], ["human", "ORGANISM", 5672, 5677], ["cellular", "CELL", 6347, 6355], ["meat", "ORGANISM_SUBDIVISION", 7032, 7036], ["cellular", "CELL", 7064, 7072], ["mono-saccharides", "SIMPLE_CHEMICAL", 7940, 7956], ["polyols", "SIMPLE_CHEMICAL", 7961, 7968], ["person", "SPECIES", 1270, 1276], ["milk", "SPECIES", 1607, 1611], ["olive", "SPECIES", 3079, 3084], ["tea", "SPECIES", 3103, 3106], ["blueberries", "SPECIES", 3130, 3141], ["children", "SPECIES", 5023, 5031], ["human", "SPECIES", 5672, 5677], ["red wine", "SPECIES", 3116, 3124], ["tobacco", "SPECIES", 4404, 4411], ["human", "SPECIES", 5672, 5677], ["other factors", "PROBLEM", 91, 104], ["research initiatives", "TREATMENT", 649, 669], ["dietary recommendations", "TREATMENT", 1011, 1034], ["different popular diet patterns", "TREATMENT", 1074, 1105], ["weight loss", "PROBLEM", 1188, 1199], ["weight maintenance", "TREATMENT", 1204, 1222], ["specific disease conditions", "PROBLEM", 1333, 1360], ["hypertension", "PROBLEM", 1370, 1382], ["type 2 diabetes", "PROBLEM", 1384, 1399], ["cardiovascular diseases", "PROBLEM", 1401, 1424], ["specific cancers", "PROBLEM", 1426, 1442], ["infections", "PROBLEM", 1444, 1454], ["autoimmune diseases", "PROBLEM", 1456, 1475], ["red meats", "PROBLEM", 1622, 1631], ["tropical oils", "TREATMENT", 1633, 1646], ["organic vs. nonorganic foods", "PROBLEM", 1648, 1676], ["A stronger intergovernmental process", "PROBLEM", 1818, 1854], ["medications", "TREATMENT", 2211, 2222], ["chronic medical conditions", "PROBLEM", 2228, 2254], ["disease conditions", "PROBLEM", 2627, 2645], ["nutritional effects", "PROBLEM", 2660, 2679], ["food allergies", "PROBLEM", 2778, 2792], ["healthy aging", "TREATMENT", 2817, 2830], ["Nutritional treatments", "TREATMENT", 2833, 2855], ["reducing side effects", "TREATMENT", 2860, 2881], ["cancer chemo", "TREATMENT", 2916, 2928], ["radiation therapy", "TREATMENT", 2933, 2950], ["Comprehensive characterization", "TEST", 2953, 2983], ["trace bioactives", "PROBLEM", 3023, 3039], ["phenolics", "TREATMENT", 3044, 3053], ["gluten", "TREATMENT", 3215, 3221], ["fermentable oligo-", "TREATMENT", 3232, 3250], ["di-", "TEST", 3252, 3255], ["mono-saccharides", "TREATMENT", 3257, 3273], ["polyols", "TREATMENT", 3278, 3285], ["low-calorie sweeteners", "TREATMENT", 3288, 3310], ["confusion", "PROBLEM", 3361, 3370], ["confusion", "PROBLEM", 3420, 3429], ["chronic diseases", "PROBLEM", 3880, 3896], ["obesity", "PROBLEM", 3902, 3909], ["diabetes", "PROBLEM", 3911, 3919], ["cardiovascular diseases", "PROBLEM", 3921, 3944], ["certain cancers", "PROBLEM", 3950, 3965], ["Rigorous evaluation", "TEST", 4688, 4707], ["Strengthen medical nutrition therapy", "TREATMENT", 5034, 5070], ["acute and chronic diseases and conditions", "PROBLEM", 5087, 5128], ["Medicine interventions", "TREATMENT", 5175, 5197], ["enhanced medical nutrition therapy", "TREATMENT", 5322, 5356], ["musculoskeletal and battlefield injuries", "PROBLEM", 5728, 5768], ["NASA astronauts", "TREATMENT", 5996, 6011], ["nutrition assistance programs", "TREATMENT", 6100, 6129], ["dietary supplements", "TREATMENT", 6389, 6408], ["Nutritional innovations", "TREATMENT", 6735, 6758], ["healthier crops", "TREATMENT", 6782, 6797], ["manufactured food products", "TREATMENT", 6802, 6828], ["novel ingredients", "TREATMENT", 6839, 6856], ["biofortification", "TREATMENT", 6861, 6877], ["novel regenerative agriculture approaches", "TREATMENT", 6965, 7006], ["dairy alternatives", "TREATMENT", 7041, 7059], ["federal nutrition assistance", "TREATMENT", 7506, 7534], ["new nutrition research", "TREATMENT", 7786, 7808], ["an assessment", "TEST", 7820, 7833], ["di-", "TEST", 7935, 7938], ["mono", "TEST", 7940, 7944], ["polyols", "TEST", 7961, 7968], ["low-calorie sweeteners", "TREATMENT", 7971, 7993], ["cardiovascular", "ANATOMY", 1401, 1415], ["diseases", "OBSERVATION", 1416, 1424], ["cancers", "OBSERVATION", 1435, 1442], ["vascular", "ANATOMY", 2054, 2062], ["cancer", "OBSERVATION", 2916, 2922], ["chronic", "OBSERVATION_MODIFIER", 3880, 3887], ["diseases", "OBSERVATION", 3888, 3896], ["obesity", "OBSERVATION", 3902, 3909], ["acute", "OBSERVATION_MODIFIER", 5087, 5092], ["musculoskeletal", "ANATOMY", 5728, 5743], ["joint", "ANATOMY", 6673, 6678], ["Joint", "ANATOMY", 7116, 7121]]], ["Hunger and food insecurity remain pervasive in the US, with great costs for society and our health care system (76, 218, 240, 241) .", [["Hunger", "PROBLEM", 0, 6]]], ["Yet, while it is now evident that calories alone are an insufficient solution, scientific understanding remains limited on the causal intersections of food insecurity and risk of diet-related chronic diseases, and on the optimal nutritional and other translational approaches to address these challenges (78, 80, 240, 242) .", [["chronic diseases", "DISEASE", 192, 208], ["calories", "SIMPLE_CHEMICAL", 34, 42], ["an insufficient solution", "TREATMENT", 53, 77], ["chronic diseases", "PROBLEM", 192, 208], ["chronic", "OBSERVATION_MODIFIER", 192, 199], ["diseases", "OBSERVATION", 200, 208]]], ["Research priorities for greater investment and cross-agency coordination include the influence of context on food-related decisions and behaviors across diverse retail food environments, including but not limited to the influence of price and marketing, food access and availability, transportation options and use, perceptions of neighborhood and traffic safety, rapidly growing online purchasing including with federal nutrition programs, the short-and long-term impacts of the Public Charge Rule on federal nutrition assistance participation, and the influences of past and current discriminatory policies and practices impacting employment opportunities, homeownership, and community development (218, (245) (246) (247) (248) (249) (250) (251) (252) (253) (254) (255) (256) .Translational and implementation scienceMajor research initiatives are needed to better understand how eating behaviors can be positively influenced in diverse populations.", [["eating behaviors", "DISEASE", 882, 898], ["federal nutrition programs", "TREATMENT", 413, 439]]], ["In the 2015 DGAC report, for example, the scientific evidence was considered limited or not assignable for many crucial translational questions, such as whether food insecurity affects body weight; whether acculturation influences diet, body weight, or cardiovascular risk factors; whether menu calorie labels influence food selection or consumption; or whether access to farmers' markets, supermarkets, grocery stores, or convenience/corner stores influences dietary intakes, diet quality, or body weight (Supplemental Table 1 ).Translational and implementation scienceImplementation research is also crucial to assess and optimize intended benefits of the numerous federal policies and investments around public communication and education, including the DGAs, food labeling, health claims, menu labeling, and SNAP-Ed.", [["body", "ANATOMY", 185, 189], ["body", "ANATOMY", 237, 241], ["cardiovascular", "ANATOMY", 253, 267], ["body", "ANATOMY", 494, 498], ["SNAP", "CHEMICAL", 812, 816], ["body", "ORGANISM_SUBDIVISION", 185, 189], ["body", "ORGANISM_SUBDIVISION", 237, 241], ["body", "ORGANISM_SUBDIVISION", 494, 498], ["cardiovascular risk factors", "PROBLEM", 253, 280]]], ["This should include coordinated research efforts on evidencebased nutrition education and promotion strategies for healthy populations (the current focus of the DGAs), those with specific diet-related illnesses (the majority of the US population, but not included in the DGAs), and those with resource limitations and food insecurity (194, 259, 260) .", [["food insecurity", "DISEASE", 318, 333], ["evidencebased nutrition education", "TREATMENT", 52, 85], ["promotion strategies", "TREATMENT", 90, 110], ["healthy populations", "PROBLEM", 115, 134], ["related illnesses", "PROBLEM", 193, 210], ["the US population", "TEST", 228, 245]]], ["Understanding how and why effectiveness of communication channels may vary, such as according to print or health literacy, numeracy, culture, income, or neighborhood (e.g., food access), is critical.", [["culture", "TEST", 133, 140]]], ["Effective approaches to increase nutrition science literacy can be assessed through new and enhanced research collaborations, such as between the DoE, USDA, NIH, and CDC.", [["Effective approaches", "TREATMENT", 0, 20]]], ["Coordinated interagency research is also needed on the effects and appropriateness of food marketing to children (e.g., between the FTC, CDC, FDA, and USDA).", [["children", "ORGANISM", 104, 112], ["children", "SPECIES", 104, 112]]], ["Together, such research can inform both current and alternative federal approaches for disseminating evidence-based information to inform choice and reduce confusion among a public hungering for scientifically sound guidance.Translational and implementation scienceTranslational research is also needed to leverage allied health professionals and the health care infrastructure to reduce diet-related illnesses.", [["confusion", "DISEASE", 156, 165], ["confusion", "PROBLEM", 156, 165], ["scientifically sound guidance", "TREATMENT", 195, 224]]], ["Innovative translational and implementation science research has tremendous potential to strengthen medical nutrition therapy led by registered dietitian nutritionists for an array of acute and chronic diseases and conditions (11, (264) (265) (266) (267) .", [["strengthen medical nutrition therapy", "TREATMENT", 89, 125], ["acute and chronic diseases", "PROBLEM", 184, 210], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["chronic", "OBSERVATION_MODIFIER", 194, 201], ["diseases", "OBSERVATION", 202, 210]]], ["Many other promising strategies warrant significant research, including the following: expanding the integration of food security and diet quality assessments into electronic medical records or Fast Healthcare Interoperability Resources, updating of medical and other health care licensing and certification standards to include nutrition education, assessing health and cost impacts of medically tailored meals and produce prescriptions, and leveraging Medicaid flexible benefit services and Medicare Advantage for better nutrition and health (268, 269) .", [["nutrition education", "TREATMENT", 329, 348], ["medically tailored meals", "TREATMENT", 387, 411], ["Medicare Advantage", "TREATMENT", 493, 511]]], ["The rapidly growing private and public interest and investment in such \"Food is Medicine\" approaches must be informed by robust research.", [["rapidly", "OBSERVATION_MODIFIER", 4, 11], ["growing", "OBSERVATION_MODIFIER", 12, 19]]], ["This includes the $27 billion annual investment in USAID, 1 of the 3 foundational pillars for promoting and protecting US national security interests abroad, for which expanded research in nutrition and agricultural innovation is central (11, 270, 271) .", [["the 3 foundational pillars", "TREATMENT", 63, 89], ["central", "OBSERVATION_MODIFIER", 230, 237]]], ["The DoD also has key nutrition research priorities around human performance and military readiness that would benefit from cross-agency coordination (11) .", [["human", "ORGANISM", 58, 63], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63]]], ["Increased investment in nutrition research would also benefit many active-duty families who suffer from diet-related chronic illnesses as well as often coexisting food insecurity (87) (88) (89) (90) (91) .", [["chronic illnesses", "DISEASE", 117, 134], ["chronic illnesses", "PROBLEM", 117, 134], ["chronic", "OBSERVATION_MODIFIER", 117, 124], ["illnesses", "OBSERVATION", 125, 134]]], ["The majority of veterans receiving care at VHA, the largest integrated health care system in the US, suffer from \u22651 diet-related conditions (86) .", [["veterans", "ORGANISM", 16, 24]]], ["NASA conducts some of its own nutrition research but relies heavily on other federal departments and agencies to help define nutrient requirements and healthy eating strategies for extended space exploration (11) .", [["extended space exploration", "TEST", 181, 207]]], ["Other cross-governmental opportunities for coordinated nutrition research include how best to strengthen and leverage the nearly $100 billion annual national investment in USDA nutrition assistance programs (241) and research on food safety, a joint FDA and USDA priority.", [["joint", "ANATOMY", 244, 249]]], ["This includes decisions on Nutrition Facts labeling, front-of-pack labels, restaurant menu labeling, health claims, dietary supplements, food additives, standards of identity (e.g., around plant-based dairy and meat alternatives), and cellular agriculture (210) .", [["meat", "ANATOMY", 211, 215], ["cellular", "ANATOMY", 235, 243], ["dairy", "ORGANISM_SUBDIVISION", 201, 206], ["meat", "ORGANISM_SUBDIVISION", 211, 215], ["cellular", "CELL", 235, 243], ["dietary supplements", "TREATMENT", 116, 135]]], ["An expanded federal nutrition research effort to better support regulatory actions could create renewed industry support for nutrition research as well as interest in developing innovative public-private partnerships (272) .Intersections with food production, supply chains, and sustainabilityThe federal government has many priorities around US farming, rural development, food production, food manufacturing, and supply chains (9, 156, 157) .", [["An expanded federal nutrition", "TREATMENT", 0, 29], ["nutrition research", "TREATMENT", 125, 143], ["food manufacturing", "OBSERVATION", 391, 409]]], ["Nutrition research intersects with each of these, such as on how to increase production of and access to affordable, healthful food; develop technologies and collaborations to produce new high-value products for farmers and food manufacturers; foster public-private partnerships for innovation and adoption of novel technologies; and expand technology development and other entrepreneurship efforts between academic institutions and small businesses (147) .", [["novel technologies", "TREATMENT", 310, 328], ["small", "OBSERVATION_MODIFIER", 433, 438]]], ["As summarized in earlier sections, fundamental research questions are also emerging on how food production jointly intersects with human and planetary health, including effects of different strategies for plant and animal breeding, livestock and farming practices, regenerative agriculture, production of plant-based meat and dairy alternatives, and cellular agriculture (11, 156, 273) .Monitoring and surveillanceNutrition-related monitoring and surveillance are critical to inform nutrition research, which then bidirectionally guides surveillance priorities (11, 274) .", [["sections", "ANATOMY", 25, 33], ["meat", "ANATOMY", 317, 321], ["cellular", "ANATOMY", 350, 358], ["human", "ORGANISM", 131, 136], ["meat", "ORGANISM_SUBDIVISION", 317, 321], ["cellular", "CELL", 350, 358], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["different strategies", "TREATMENT", 180, 200], ["Monitoring", "TEST", 387, 397], ["surveillance", "TEST", 402, 414], ["surveillance", "TEST", 447, 459]]], ["The COVID-19 crisis has highlighted the fragmented and often incomplete national infrastructure for monitoring food-and nutrition-related questions in real time, including, for example, information on local, regional, and national food insecurity; dietary choices; diet-related health disparities; neighborhood food environments; and supply chains (3) (4) (5) (6) (7) (8) (9) .", [["The COVID", "TEST", 0, 9], ["crisis", "PROBLEM", 13, 19], ["fragmented", "OBSERVATION_MODIFIER", 40, 50]]], ["Expanded and modernized monitoring and surveillance are essential components of a strategy to strengthen and better coordinate federal nutrition research.Return on investmentThe ROI for federal research has been documented across several metrics (275) .", [["modernized monitoring", "TEST", 13, 34], ["surveillance", "TEST", 39, 51], ["federal research", "TEST", 186, 202]]], ["In a 2012 analysis, each $1 increase in NIH funding was estimated to increase the size (output) of the bioscience industry by between $1.70 and $3.20 (277) .", [["NIH funding", "TREATMENT", 40, 51], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["size", "OBSERVATION_MODIFIER", 82, 86], ["output", "OBSERVATION_MODIFIER", 88, 94]]], ["A $3.8 billion federal investment in the human genome project plus an additional $8.5 billion in related research and support have been estimated to produce nearly $1 trillion of economic growth, amounting to a 180-fold ROI (278) .", [["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["A $3.8 billion federal investment", "TREATMENT", 0, 33], ["an additional $8.5 billion", "TREATMENT", 67, 93], ["economic growth", "PROBLEM", 179, 194]]], ["In 2014 Senate testimony, NIH Director Francis Collins reported that NIH funding supported >402,000 jobs and $58 billion in economic output nationwide, whereas NIH discoveries contributed $69 billion to GDP and supported 7 million jobs in 2011 (279) .Return on investmentOur review suggests that expanded federal coordination and investment in nutrition research will generate similarly meaningful ROI.", [["GDP", "CHEMICAL", 203, 206], ["economic output", "TEST", 124, 139], ["nutrition research", "TREATMENT", 344, 362], ["expanded", "OBSERVATION_MODIFIER", 296, 304], ["federal coordination", "OBSERVATION", 305, 325]]], ["Opportunities include more efficient leveraging of existing nutrition research infrastructure and investments, as well as other current federal investments in nutrition-related programs and policies at USDA (\u223c$100 billion/y), USAID (\u223c$27 billion/y), DoD, VA, FDA, CDC, CMS, FEMA, and more.", [["CDC", "TEST", 264, 267], ["CMS", "PROBLEM", 269, 272], ["FEMA", "TEST", 274, 278], ["FDA", "ANATOMY", 259, 262], ["CMS", "ANATOMY", 269, 272], ["FEMA", "ANATOMY", 274, 278]]], ["Such investments could also be crucial to help reduce population diet and health inequities across diverse population subgroups.Return on investmentOne of the most promising areas for ROI would be advancing basic, clinical, and implementation science to reduce dietrelated diseases.", [["dietrelated diseases", "PROBLEM", 261, 281]]], ["As mentioned in earlier sections, a recent NIH prevention research portfolio analysis compared national risk factors for death with NIH research investments (120) .", [["death", "DISEASE", 121, 126], ["death", "PROBLEM", 121, 126], ["NIH research investments", "TREATMENT", 132, 156]]], ["The largest gap was for nutrition, which was the top cause of attributable deaths (estimated to cause 19.1% of all deaths) but represented only 6.7% of all NIH prevention research funding (\u223c$0.43 billion based on the 2019 NIH budget, or \u223c1.1% of all NIH funding) (117, 120) .", [["deaths", "DISEASE", 75, 81], ["deaths", "DISEASE", 115, 121], ["\u223c", "TEST", 237, 238], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["gap", "OBSERVATION_MODIFIER", 12, 15]]], ["In comparison, estimated government spending on direct health care for diabetes alone was \u223c$160 billion/y in 2017, with an expected growth rate of 5% (\u223c$8 billion) per year (280) .", [["diabetes", "DISEASE", 71, 79], ["diabetes alone", "PROBLEM", 71, 85]]], ["Medical care for people with diagnosed diabetes accounts for \u223c1 in 4 health care dollars in the US, with more than half of these costs being directly attributable to diabetes (280) .", [["diabetes", "DISEASE", 39, 47], ["diabetes", "DISEASE", 166, 174], ["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23], ["diagnosed diabetes", "PROBLEM", 29, 47], ["diabetes", "PROBLEM", 166, 174], ["diabetes", "OBSERVATION", 166, 174]]], ["And, while mounting evidence suggests that severity, complications, and costs of type 2 diabetes can be rapidly reduced through better lifestyle including dietary changes (281) (282) (283) (284) , the optimal dietary priorities, behavior change strategies, microbiome implications, and personalization needs to most effectively improve diabetes remain uncertain.", [["type 2 diabetes", "DISEASE", 81, 96], ["diabetes", "DISEASE", 336, 344], ["complications", "PROBLEM", 53, 66], ["type 2 diabetes", "PROBLEM", 81, 96], ["behavior change strategies", "PROBLEM", 229, 255], ["diabetes", "PROBLEM", 336, 344], ["severity", "OBSERVATION_MODIFIER", 43, 51], ["complications", "OBSERVATION", 53, 66]]], ["A major effort to expand and harmonize federal nutrition research could have rapid ROI based on reduced health care costs alone.", [["rapid ROI", "PROBLEM", 77, 86]]], ["For instance, a new, additive $1-2 billion annual investment in nutrition research could potentially generate a several-fold ROI if this helped flatten the anticipated \u223c$8 billion/y annual increase in government expenditures on medical care for diabetes (280) .", [["diabetes", "DISEASE", 245, 253], ["2 billion annual investment", "TREATMENT", 33, 60], ["a several-fold ROI", "TREATMENT", 110, 128], ["medical care", "TREATMENT", 228, 240], ["diabetes", "PROBLEM", 245, 253], ["new", "OBSERVATION_MODIFIER", 16, 19], ["increase", "OBSERVATION_MODIFIER", 189, 197]]], ["Estimates of potential ROI of expanded federal nutrition research can be considered against health care and other societal costs of other diet-sensitive conditions, such as hypertension, food allergies, coronary heart disease, certain cancers, and more.", [["coronary", "ANATOMY", 203, 211], ["heart", "ANATOMY", 212, 217], ["cancers", "ANATOMY", 235, 242], ["hypertension", "DISEASE", 173, 185], ["food allergies", "DISEASE", 187, 201], ["coronary heart disease", "DISEASE", 203, 225], ["cancers", "DISEASE", 235, 242], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 203, 217], ["cancers", "CANCER", 235, 242], ["hypertension", "PROBLEM", 173, 185], ["food allergies", "PROBLEM", 187, 201], ["coronary heart disease", "PROBLEM", 203, 225], ["certain cancers", "PROBLEM", 227, 242], ["hypertension", "OBSERVATION", 173, 185], ["coronary", "ANATOMY", 203, 211], ["heart", "ANATOMY", 212, 217], ["disease", "OBSERVATION", 218, 225], ["cancers", "OBSERVATION", 235, 242]]], ["As stated by the FDA Commissioner in 2018, \"Improvements in diet and nutrition offer us one of our greatest opportunities to have a profound and generational impact on human health \u2026 The public health gains of such efforts would almost certainly dwarf any single medical innovation or intervention we could discover\" (285) .Return on investmentGreater coordination and investment in federal nutrition research could also catalyze and unlock economic growth through new public-private partnerships and new private capital investment, small businesses, jobs, and inventions.", [["human", "ORGANISM", 168, 173], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["intervention", "TREATMENT", 285, 297], ["small", "OBSERVATION_MODIFIER", 533, 538], ["businesses", "OBSERVATION", 539, 549]]], ["In addition to potential for lower health care spending, accelerated nutrition research could help foster a healthier and more productive workforce, more active and thriving children, and healthier and more independent seniors.", [["children", "ORGANISM", 174, 182], ["children", "SPECIES", 174, 182]]], ["Enhanced nutrition science and cross-governmental authority can also strengthen dietary guidance, reduce public confusion, and improve consumer food choices.Return on investmentTogether with increased investment in food and agricultural research, strengthened multidisciplinary nutrition science could better support the long-term economic vibrancy of US farmers and rural communities.", [["confusion", "DISEASE", 112, 121], ["public confusion", "PROBLEM", 105, 121], ["increased investment in food", "PROBLEM", 191, 219], ["agricultural research", "TREATMENT", 224, 245], ["increased", "OBSERVATION_MODIFIER", 191, 200], ["investment", "OBSERVATION_MODIFIER", 201, 211]]], ["Past increases in agricultural productivity, for example, have come almost entirely from science-based innovations (146) .", [["agricultural productivity", "PROBLEM", 18, 43], ["increases", "OBSERVATION_MODIFIER", 5, 14], ["agricultural productivity", "OBSERVATION", 18, 43]]], ["Such integrated efforts would also be able to address the critical emerging nexus of health, food, agriculture, climate, and sustainability (147, 286, 287) , positioning the US as the global leader in this area.", [["positioning the US", "TEST", 158, 176]]], ["In sum, this would strengthen long-term US food security, farmers' incomes, national and rural economic growth, and resilience of the food and agricultural sector, which accounts for 1 in 9 US jobs (288) .Return on investmentAppropriate federal investment and coordination of nutrition research could improve national resilience against chronic threats and acute crises.", [["nutrition research", "TREATMENT", 276, 294], ["chronic threats", "PROBLEM", 337, 352], ["acute crises", "PROBLEM", 357, 369], ["federal investment", "OBSERVATION", 237, 255], ["acute", "OBSERVATION_MODIFIER", 357, 362], ["crises", "OBSERVATION", 363, 369]]], ["The COVID-19 pandemic highlights the need to have a coordinated, vigorous scientific research infrastructure before crises strike (3) (4) (5) (6) (7) (8) .", [["4) (5) (6) (7", "SIMPLE_CHEMICAL", 135, 148], ["The COVID", "TEST", 0, 9], ["vigorous", "OBSERVATION_MODIFIER", 65, 73]]], ["The bidirectional impacts between food and nutrition and COVID-19 have also revealed a vital new area for research and policy that requires significant investment and coordination (289) .Return on investmentIn 2019, the Director of National Intelligence reported to Congress that our national disinvestment in science and technology is 1 of 10 global threats because, without the research to produce disruptive US technologies, we weaken our economic competitiveness (290) .", [["COVID", "TEST", 57, 62]]], ["A new structure for coordination of existing federal nutrition research, combined with a major new investment-for example, increasing federal nutrition funding by $1-2 billion or more each year-could together provide highly cost-effective approaches to addressing the poor health, rising disparities, spiraling health care costs, declining qualified military recruits, and other pressing food and agricultural challenges facing the US.Options for Strengthening National Nutrition ResearchBased on our review, a strengthened federal nutrition research effort is necessary and should be additive to and synergistic with existing efforts across departments and agencies.", [["existing federal nutrition research", "TREATMENT", 36, 71], ["the US", "TEST", 428, 434], ["new", "OBSERVATION_MODIFIER", 2, 5]]], ["Expanded coordination and investment in nutrition science, rather than a silo-ing of nutrition research or a rearrangement of existing investments, are essential.", [["investment in nutrition science", "TREATMENT", 26, 57], ["a silo", "TREATMENT", 71, 77], ["nutrition research", "TREATMENT", 85, 103], ["coordination", "OBSERVATION_MODIFIER", 9, 21]]], ["These were as follows: 1) a new authority for robust cross-governmental coordination of nutrition research and other nutrition-related policy and 2) strengthened authority, investment, and coordination for nutrition research within NIH.Options for Strengthening National Nutrition ResearchThese 2 strategies were identified as complementary, with benefits accruing independently and further synergies to be gained by joint implementation.", [["nutrition research", "TREATMENT", 88, 106], ["Strengthening National Nutrition ResearchThese 2 strategies", "TREATMENT", 248, 307], ["joint", "ANATOMY", 417, 422]]], ["A third important, and further complementary, identified strategy was to strengthen authority, investment, and coordination at USDA for human nutrition research, food and agricultural research, education, extension, and economics.Options for Strengthening National Nutrition ResearchTo achieve success, a key identified theme was the need for not just additional investment but also new authority and structure.", [["human", "ORGANISM", 136, 141], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 136, 141], ["human nutrition research", "TREATMENT", 136, 160], ["Strengthening National Nutrition ResearchTo", "TREATMENT", 242, 285]]], ["Multiple assessments over many decades have identified the fundamental need to strengthen federal nutrition research in the US.", [["Multiple assessments", "TEST", 0, 20]]], ["This includes, among others, the 1969 White House Conference; the 1977 Congressional call for improved coordination of human nutrition research; the 1983 creation of ICHNR; the 1994 Institute of Medicine report on nutrition and food sciences; the 1996 joint OSTP and the National Science and Technology Council (NSTC) report on health, safety, and food; the 2000 National Nutrition Summit; and more (Supplemental Table 5 and Supplemental Table 10 ).", [["human", "ORGANISM", 119, 124], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124], ["Supplemental Table 5 and Supplemental Table", "TREATMENT", 400, 443], ["joint", "ANATOMY", 252, 257]]], ["Yet, the full intended impacts of these important efforts were mostly not achieved, in large part because they lacked any new federal structure with strong and sustained authority, robust coordination capacity, and dedicated appropriations.Options for Strengthening National Nutrition ResearchThe following sections describe the identified promising options for strengthening nutrition research through 1) increased cross-governmental coordination; 2) increased authority, investment, and coordination within NIH; and 3) increased authority, investment, and coordination at USDA.", [["strengthening nutrition research", "TREATMENT", 362, 394], ["increased cross-governmental coordination", "TREATMENT", 406, 447]]], ["The majority of these options are being set forth for the first time and, where possible, we reference comparable examples.Identified cross-governmental coordination strategies for strengthening national nutrition researchImproved coordination between federal departments and agencies conducting nutrition research has tremendous potential for strengthening our nation's ability to achieve essential fundamental, clinical, public health, and translational discoveries.", [["cross-governmental coordination strategies", "TREATMENT", 134, 176], ["strengthening national nutrition", "TREATMENT", 181, 213]]], ["These options were not found to be mutually exclusive and could be even more effective in combination.New Office of the National Director of Food and Nutrition.Modeled after the Office of the Director of National Intelligence (ODNI) (291), but with a smaller budget and staffing scale, an Office of the National Director of Food and Nutrition (ONDFN) would provide essential coordination and harmonization of the work of the \u226510 US departments and agencies comprising the federal nutrition community (Supplemental Figure 3 ).", [["Nutrition (ONDFN)", "TREATMENT", 333, 350]]], ["Working as one team, ODNI helps synchronize intelligence collection, analysis, and counterintelligence, forging a harmonized system to deliver the most insightful intelligence possible.", [["ODNI", "DNA", 21, 25], ["analysis", "TEST", 69, 77]]], ["Of note, the combined budgets of ODNI members ($50 billion/y) are of a similar scale as the overall current nutrition-related programs (including research) of ICHNR members.", [["a similar scale", "TREATMENT", 69, 84]]], ["ONDFN would be led by a new, cabinet-level Director of National Food and Nutrition, serving as the Principal Food and Nutrition Advisor to the White House, heads of executive branch departments and agencies, senior military commanders, and Congress.", [["ONDFN", "CHEMICAL", 0, 5]]], ["Similar to ODNI, ONDFN functions would include reviewing and coordinating priorities and strategies to maximize nutrition research efforts across various federal investments; establishing objectives and priorities for the collection, analysis, and dissemination of national nutrition monitoring and surveillance; ensuring provision of accurate and timely nutrition information to decision makers; evaluating and improving the effectiveness and synergies of federal nutrition research and policy efforts; overseeing the coordination of external advisory groups and public-private partnerships around nutrition research and policy; developing policies and programs to leverage the distinct efforts of departments and agencies around nutrition; and developing and reporting on performance goals and program milestone criteria.New Office of the National Director of Food and Nutrition.Advantages.", [["strategies", "TREATMENT", 89, 99], ["nutrition research", "TREATMENT", 112, 130], ["the collection, analysis", "TEST", 218, 242], ["national nutrition monitoring", "TEST", 265, 294], ["surveillance", "TEST", 299, 311], ["federal nutrition research", "TREATMENT", 457, 483]]], ["This tested and successful model is on a comparable area of national importance and with a similar size and breadth of relevant involved departments and agencies.", [["size", "OBSERVATION_MODIFIER", 99, 103]]], ["ONDFN would build on ICHNR, but with a much stronger platform to create effective coordination and synergies.", [["ONDFN", "CHEMICAL", 0, 5], ["ONDFN", "SIMPLE_CHEMICAL", 0, 5], ["ICHNR", "TREATMENT", 21, 26]]], ["ONDFN would deliver relevant harmonized information to the President, Cabinet, other executive branch leadership, senior military commanders, and Congress for developing policy, programmatic, and budget initiatives.", [["ONDFN", "CHEMICAL", 0, 5]]], ["ONDFN would also provide dedicated leadership and staff in the executive branch cabinet for federal nutrition research and policy, providing a crucial bridge between research and implementation.", [["federal nutrition research", "TREATMENT", 92, 118]]], ["A broad focus would increase synergies, shared priorities, and effectiveness and efficiency of different departments and agencies engaged in activities related to innovation in nutrition, agriculture, and food systems.New Office of the National Director of Food and Nutrition.Like ODNI, a meaningful number of staff would be drawn from existing departments and agencies, creating budgetary efficiencies while maximizing cross-fertilization of ideas and innovations.", [["creating budgetary efficiencies", "PROBLEM", 371, 402], ["broad", "OBSERVATION_MODIFIER", 2, 7], ["focus", "OBSERVATION", 8, 13], ["budgetary efficiencies", "OBSERVATION", 380, 402]]], ["ONDFN would have the infrastructure and authority necessary for true cross-department/agency coordination-for example, to develop a modernized approach to the nexus between the agriculture-food-health value chain-including research, policy, and practice from farm inputs and food processing/production to consumer behavior to human health.", [["ONDFN", "CHEMICAL", 0, 5], ["human", "ORGANISM", 326, 331], ["human", "SPECIES", 326, 331], ["human", "SPECIES", 326, 331]]], ["ONDFN would also advance the coordination for communication of trusted nutrition information to the American public, which occurs across separate departments and agencies including CMS and VHA (health care providers), USDA (DGAs, SNAP-Ed, WIC education, food safety for meat and poultry), FDA (food safety for other foods, Nutrition Facts, health claims, package warning labels, restaurant menu labeling), NIH (scientific studies), DoE (nutrition and STEM curricula), CDC (school, community, and public health nutrition education), and more.", [["SNAP", "CHEMICAL", 230, 234], ["meat", "ORGANISM_SUBDIVISION", 270, 274]]], ["ONDFN would combine a national food strategy with coordinated new science, considered crucial to better harmonize law and policymaking around food and agriculture, food safety and nutrition research, and establishing, prioritizing, and pursuing common goals (292) .", [["ONDFN", "CHEMICAL", 0, 5], ["nutrition research", "TREATMENT", 180, 198]]], ["Such a strategic plan would create transparency and accountability, including tasks of identifying and monitoring budgets and metrics of success across its purview.", [["tasks", "TEST", 78, 83]]], ["A high-level, cross-governmental structure like ONDFN would also be crucial for effective and timely responses on urgent nutrition and food challenges during complex situations like COVID-19, which require immediate and ongoing leadership and coordination at the highest levels of the government (9, 293) .New Office of the National Director of Food and Nutrition.Disadvantages.", [["A high-level, cross-governmental structure", "PROBLEM", 0, 42], ["urgent nutrition", "TREATMENT", 114, 130], ["COVID", "TEST", 182, 187], ["high", "OBSERVATION_MODIFIER", 2, 6]]], ["As a cabinet-level office, ONDFN would naturally focus on major federal nutrition issues beyond research (e.g., nutrition assistance programs), which could dilute its relative focus on research and innovation.", [["ONDFN", "TREATMENT", 27, 32], ["nutrition assistance programs", "TREATMENT", 112, 141]]], ["ONDFN may also be too politically high-level to directly address ways to strengthen on-the-ground infrastructural and investment needs within key federal nutrition research departments and agencies.New Office of the National Director of Food and Nutrition.Path forward.", [["ONDFN", "CHEMICAL", 0, 5], ["ONDFN", "SIMPLE_CHEMICAL", 0, 5]]], ["Congress can authorize the establishment of ONDFN to advise the President on food and nutrition and lead the coordination of multiple federal departments and agencies, policies, budgets, and programs.", [["nutrition", "TREATMENT", 86, 95]]], ["The mandate should include a clear emphasis on strengthening national nutrition research.", [["strengthening national nutrition research", "TREATMENT", 47, 88]]], ["Congress would also indicate the required frequency of reporting (e.g., annual reporting and quadrennial assessments) and indicate the committees of oversight in the House and Senate.", [["quadrennial assessments", "TEST", 93, 116]]], ["This Act required a comprehensive and integrated US research program to assist the nation to assess, predict, and respond to humaninduced and natural processes of global climate change.", [["humaninduced", "TREATMENT", 125, 137], ["global climate change", "PROBLEM", 163, 184], ["global", "OBSERVATION_MODIFIER", 163, 169], ["climate", "OBSERVATION", 170, 177]]], ["USGCRP has its own budget that mainly supports the National Coordination Office, staffed with professional coordination support staff.", [["USGCRP", "CHEMICAL", 0, 6]]], ["Annual USGCRP reports and other scientific assessments and resources highlight key program accomplishments, such as observing and understanding changes in climate, the ozone layer, and land cover; identifying impacts of these changes on ecosystems and society; estimating future changes in the physical environment, and associated vulnerabilities and risks; and providing scientific information to enable effective decision making to address corresponding threats and opportunities (297) .New US Global Nutrition Research Program.Similar to USGCRP, USGNRP leadership would be overseen by the Executive Office of the President.", [["ozone", "CHEMICAL", 168, 173], ["ozone", "CHEMICAL", 168, 173], ["scientific assessments", "TEST", 32, 54]]], ["Like USGCRP, functions of USGNRP would include multi-stakeholder-informed strategic planning; Interagency Working Groups to identify and coordinate shared priority research and translation; assessment and modernization of nutrition monitoring and surveillance; and creating partnerships with academic, private, and international science stakeholders.New US Global Nutrition Research Program.Advantages.", [["USGCRP", "PROTEIN", 5, 11], ["USGNRP", "PROTEIN", 26, 32], ["assessment", "TEST", 190, 200], ["nutrition monitoring", "TEST", 222, 242], ["surveillance", "TEST", 247, 259]]], ["This is a tested, successful model on a similarly crucial area of science.", [["crucial", "OBSERVATION_MODIFIER", 50, 57], ["area", "OBSERVATION_MODIFIER", 58, 62], ["science", "OBSERVATION", 66, 73]]], ["USGNRP could build on ICHNR but with the establishment of a dedicated budget from participating departments and agencies.", [["USGNRP", "PROTEIN", 0, 6]]], ["Through strategic planning, new and additive budget initiatives could be formulated and implemented through more sustained appropriations.", [["strategic planning", "TREATMENT", 8, 26], ["additive budget initiatives", "TREATMENT", 36, 63]]], ["Compared with ICHNR, USGNRP would have a renewed and clear mandate around improved coordination and harmonization, with explicit requirements for programmatic review, strategic planning, annual reporting, fiscal coordination on new initiatives, quadrennial assessments submitted to the President, and international research and cooperation.", [["strategic planning", "TREATMENT", 167, 185], ["quadrennial assessments", "TEST", 245, 268]]], ["Also like ONDFN, a strategic planning process would create transparency and accountability, including tasks of identifying and monitoring budgets and metrics of success.New US Global Nutrition Research Program.ICHNR subcommittees could be transitioned to Interagency Working Groups to effectively and efficiently foster crossdepartment and cross-agency actions.", [["a strategic planning process", "TREATMENT", 17, 45]]], ["USGNRP would also intersect with other high-level coordinating structures, such as USGCRP's Interagency Working Group on Climate Change and Health, to enable effective and rapid responses to acute threats such as COVID-19, other pandemics, or other future challenges.New US Global Nutrition Research Program.Disadvantages.", [["USGNRP", "PROTEIN", 0, 6], ["acute threats", "PROBLEM", 191, 204]]], ["If based on the USGCRP appropriations model, USGCRP would be funded by a legislative mandate for contributions by participating members (rather than any new appropriations), so its budget would vary with the size and consistency of commitment of participating departments or agencies to its research areas of interest.", [["size", "OBSERVATION_MODIFIER", 208, 212]]], ["Ideally, Congress would also authorize and appropriate some core funding for USGNRP, although no new, dedicated funding has emerged for USGCRP thus far.", [["USGCRP", "TEST", 136, 142], ["no", "UNCERTAINTY", 94, 96], ["new", "OBSERVATION_MODIFIER", 97, 100]]], ["Also, significant staffing in the National Coordination Office would be temporary (\"detailed\") personnel from participating members, which could reduce continuity.New US Global Nutrition Research Program.Path forward.", [["significant", "OBSERVATION_MODIFIER", 6, 17]]], ["USGNRP could be established by a Presidential Initiative, without legislative action.", [["USGNRP", "CHEMICAL", 0, 6], ["legislative action", "TREATMENT", 66, 84]]], ["For longer-term success, Congress could later codify USGNRP into law (296).", [["USGNRP", "PROTEIN", 53, 59]]], ["Alternatively, Congress could directly establish USGNRP (e.g., in place of ICHNR).", [["USGNRP", "PROTEIN", 49, 55], ["ICHNR", "PROTEIN", 75, 80]]], ["In any of these cases, separate Congressional appropriations are not needed but would be ideal.New Associate Director for Nutrition Science within the OSTP.A new OSTP Associate Director for Nutrition Science would be a non-cabinet-level position, President-appointed and Senateconfirmed, who would serve as the President's advisor on issues related to nutrition research (Supplemental Figure 5) .", [["nutrition research", "TREATMENT", 352, 370]]], ["The statute provides great flexibility to the President with respect to corresponding areas of focus, expertise, and responsibility.", [["focus", "OBSERVATION", 95, 100]]], ["President Obama's 4 Associate Directors focused on similar areas, with additional joint appointments of OSTP staff to the National Economic Council, National Security Council (NSC), Domestic Policy Council (DPC), and White House Office of Management and Budget (OMB) (300) .", [["Budget (OMB)", "TREATMENT", 254, 266], ["joint", "ANATOMY", 82, 87]]], ["President Trump's OSTP Director, confirmed in January 2019, has expressed interest in military readiness and national security, communication networks, energy and environmental leadership, health and bioeconomic innovation, and space exploration, among other areas (301) .", [["bioeconomic innovation", "TREATMENT", 200, 222], ["space exploration", "TEST", 228, 245]]], ["OSTP has a long history of identifying and elevating science and technology opportunities for the President to help shape policy, programmatic, and resource allocation decisions.", [["OSTP", "CHEMICAL", 0, 4]]], ["For example, OSTP support was instrumental to the doubling of the NIH's budget between 1998 and 2003 (303) .", [["OSTP support", "TREATMENT", 13, 25]]], ["OSTP can lead important coordination activities and reports among different federal departments and agencies as well as external stakeholders (304) .", [["OSTP", "CHEMICAL", 0, 4], ["OSTP", "SIMPLE_CHEMICAL", 0, 4]]], ["The Associate Director would also work closely with and elevate the communication and impact of individual federal departments and agencies and the ICHNR.", [["the ICHNR", "TREATMENT", 144, 153]]], ["OSTP positions and areas of focus can dramatically change across administrations, greatly diminishing continuity and long-term effectiveness.", [["greatly diminishing continuity", "PROBLEM", 82, 112], ["long-term effectiveness", "PROBLEM", 117, 140], ["positions", "OBSERVATION_MODIFIER", 5, 14], ["areas", "OBSERVATION_MODIFIER", 19, 24], ["focus", "OBSERVATION", 28, 33], ["diminishing", "OBSERVATION_MODIFIER", 90, 101], ["continuity", "OBSERVATION_MODIFIER", 102, 112], ["long-term effectiveness", "OBSERVATION_MODIFIER", 117, 140]]], ["OSTP staffing is often small, transient, and reliant on temporary (\"detailed\") staff from relevant departments and agencies.", [["small", "OBSERVATION_MODIFIER", 23, 28]]], ["Success of this approach would be highly dependent on the skills and interests of the new Associate Director, rather than any concrete or consistent structure or process for strengthening federal nutrition research through increased coordination, funding, and alignment.", [["this approach", "TREATMENT", 11, 24], ["increased coordination, funding, and alignment", "PROBLEM", 223, 269], ["increased", "OBSERVATION_MODIFIER", 223, 232], ["coordination", "OBSERVATION_MODIFIER", 233, 245]]], ["OSTP initiatives may not align with focus or levels of research funding.New US Task Force on Federal Nutrition Research.A new US Task Force on Federal Nutrition Research would be charged with improving coordination and integration of federal nutrition research-for example, modeled after other timely US task forces such as on Combating Antibiotic-Resistant Bacteria (305); on Veteran Wellness, Empowerment, and Suicide Prevention (306) ; or on Combating Drug Addiction and the Opioid Crisis (307) .", [["Suicide", "DISEASE", 412, 419], ["research funding", "TREATMENT", 55, 71], ["federal nutrition research", "TREATMENT", 234, 260], ["Antibiotic", "TREATMENT", 337, 347], ["Resistant Bacteria", "PROBLEM", 348, 366], ["new", "OBSERVATION_MODIFIER", 122, 125]]], ["As an example, in 2013, CDC, G7, and WHO each released reports or statements on the importance of dedicated prevention and infection-control efforts for antibiotic-resistant bacteria (305, 308, 309) .", [["infection", "DISEASE", 123, 132], ["dedicated prevention", "TREATMENT", 98, 118], ["infection", "PROBLEM", 123, 132], ["antibiotic", "TREATMENT", 153, 163], ["resistant bacteria", "PROBLEM", 164, 182], ["infection", "OBSERVATION", 123, 132]]], ["In 2014, a Presidential Executive Order established combating antibioticresistant bacteria as a federal priority and created a new high-level task force (310) .", [["antibioticresistant bacteria", "PROBLEM", 62, 90]]], ["This Task Force for Combating Antibiotic-Resistant Bacteria was co-chaired by the Secretaries of HHS, USDA, and DoD, with representatives from Departments of State, DoJ, VA, and DHS and the EPA, USAID, OMB, DPC, NSC, OSTP, and NSF.", [["NSC", "CELL", 212, 215], ["Combating Antibiotic", "TREATMENT", 20, 40], ["Resistant Bacteria", "PROBLEM", 41, 59], ["DPC", "PROBLEM", 207, 210], ["NSC", "PROBLEM", 212, 215], ["OSTP", "PROBLEM", 217, 221], ["NSF", "PROBLEM", 227, 230], ["NSC", "ANATOMY", 212, 215]]], ["In addition, a Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria composed of up to 30 members, appointed or designated by the co-chairs, was required to help advise the task force, culminating in a report to the President with recommended actions (311) .", [["Antibiotic", "TREATMENT", 58, 68], ["Resistant Bacteria", "PROBLEM", 69, 87]]], ["The resulting National Action Plan, put forward in 2015, continues to guide federal actions toward a coordinated response to this pressing public health issue, directing efforts, personnel, and funding of participating departments and agencies toward a common critical agenda (312) .New US Task Force on Federal Nutrition Research.Modeled on that successful task force, the leadership, members, and general functions of a Task Force on Federal Nutrition Research would develop and report to the President on a major new National Action Plan for accelerating and strengthening nutrition discoveries (Supplemental Figure 6 ).", [["accelerating and strengthening nutrition", "TREATMENT", 545, 585]]], ["This task force could also work well with ONDFN and/or the Associate Director of Nutrition Sciences in the OSTP.New US Task Force on Federal Nutrition Research.Advantages.", [["ONDFN", "TREATMENT", 42, 47]]], ["The Presidential Executive Order would appropriately elevate the prioritization of nutrition research, create a concrete action plan, and include reporting on progress.", [["nutrition research", "TREATMENT", 83, 101]]], ["The task force would benefit from cross-governmental cabinetlevel leadership and include diverse relevant departments and agencies.", [["cross-governmental cabinetlevel leadership", "TREATMENT", 34, 76]]], ["This approach does not require legislation.New US Task Force on Federal Nutrition Research.Disadvantages.", [["does not require", "UNCERTAINTY", 14, 30], ["legislation", "OBSERVATION", 31, 42]]], ["Despite its successes, no new funding was provided nor has emerged for the Task Force on Combating Antibiotic-Resistant Bacteria.", [["Antibiotic", "TREATMENT", 99, 109], ["Resistant Bacteria", "PROBLEM", 110, 128], ["no", "UNCERTAINTY", 23, 25], ["new", "OBSERVATION_MODIFIER", 26, 29], ["funding", "OBSERVATION", 30, 37]]], ["A Presidential Executive Order remains in effect only until revoked, although it can endure across administrations (e.g., the Task Force for Combating Antibiotic-Resistant Bacteria has remained in place).", [["Combating Antibiotic", "TREATMENT", 141, 161], ["Resistant Bacteria", "PROBLEM", 162, 180]]], ["The President can also direct the heads of OSTP, DPC, and NSC to revise ICHNR coordination structure to more closely follow the Task Force model.", [["NSC", "CELL", 58, 61], ["DPC", "TEST", 49, 52], ["NSC", "TREATMENT", 58, 61]]], ["Congress could also revise the charge, structure, and funding of ICHNR via legislation to create appropriate activities consistent with such a task force.Other new cross-governmental options.\u2022 At the cabinet level, the Joint Chiefs of Staff could be called upon to focus on necessary nutrition research to address escalating diet-related health burdens on military readiness and national security (25, 86, 92, (314) (315) (316) (317) (318) , NASEM to assess the gaps and options to strengthen and coordinate federal nutrition research to address escalating diet-related health burdens and related economic, equity, national security, and sustainability challenges (320). \u2022 Congress could appoint a global health coordinator to lead a new interagency council that reaffirms domestic and global health as a core national security interest.", [["nutrition research", "TREATMENT", 284, 302], ["new", "OBSERVATION_MODIFIER", 160, 163], ["cross-governmental options", "OBSERVATION", 164, 190], ["Joint", "ANATOMY", 219, 224]]], ["The coordinator and council would be charged with developing strategic plans to detect and prevent acute and chronic health threats, such as new infectious pandemics.", [["acute and chronic health threats", "PROBLEM", 99, 131], ["new infectious pandemics", "PROBLEM", 141, 165], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["chronic", "OBSERVATION_MODIFIER", 109, 116]]], ["Such a focus should incorporate the critical role of food and nutrition in population health and resilience, including against infectious diseases, and appropriate and coordinate the necessary activities for relevant research.Identified NIH strategies for strengthening national nutrition researchAs the nation's largest funder of research, NIH is one essential (although not exclusive) home for increased authority, coordination, and funding for nutrition science (110) .", [["infectious diseases", "DISEASE", 127, 146], ["infectious diseases", "PROBLEM", 127, 146], ["strengthening national nutrition", "TREATMENT", 256, 288]]], ["Key identified strategies are summarized in Table 4 and reviewed below.New National Institute of Nutrition.A new NIH National Institute of Nutrition (NIN) would be additive to the 27 current institutes and centers leading research within NIH (Supplemental Figure 8) .", [["Nutrition (NIN)", "TREATMENT", 139, 154]]], ["NIN would be a crucial new asset for NIH to accomplish its mission \"to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability\" (321) .", [["NIN", "DISEASE", 0, 3], ["illness", "DISEASE", 229, 236], ["disability", "DISEASE", 241, 251]]], ["NIN would be tasked with leading innovative, cross-cutting, and foundational research on nutrition and health, including intramural and extramural programs and training and outreach activities.", [["intramural and extramural programs", "TREATMENT", 121, 155]]], ["NIN priority areas and funding should be coordinated with, additive to, and synergistic with existing NIH nutrition research efforts, such as within NIDDK, NHLBI, and NCI, among others, as well as with USDA, CDC, FDA, DoD, VHA, and NASA, among others.", [["priority", "OBSERVATION_MODIFIER", 4, 12], ["areas", "OBSERVATION_MODIFIER", 13, 18]]], ["A new NIH National Advisory Council on Nutrition Research-comprising research experts, health professionals, and community members-would advise the HHS Secretary, NIH Director, and NIN Director on matters related to the NIN's mission.New National Institute of Nutrition.NIN would expand the knowledge base of research on dietrelated illnesses and their intersections with other fields through strategic planning, coordination, and evaluation of NIH nutrition research and through conduct and support of research in nutrition science and related areas.", [["strategic planning", "TREATMENT", 393, 411], ["evaluation", "TEST", 431, 441], ["NIH nutrition research", "TREATMENT", 445, 467], ["research in nutrition science", "TREATMENT", 503, 532]]], ["Relevant cross-cutting areas of focus could include many priority areas from genetic, molecular, and biological science to clinical, behavioral, and translational research, as well as research on health systems, workforce development, and health equity ( Table 2 ).", [["cross-cutting", "OBSERVATION_MODIFIER", 9, 22]]], ["NIN's efforts would support, expand, and amplify key science relevant to other NIH institutes, centers, and offices, such as on nutrition and diabetes, obesity, cardiovascular disease, cancer, brain health, minority health and disparities, child health, and more.", [["cardiovascular", "ANATOMY", 161, 175], ["cancer", "ANATOMY", 185, 191], ["brain", "ANATOMY", 193, 198], ["diabetes", "DISEASE", 142, 150], ["obesity", "DISEASE", 152, 159], ["cardiovascular disease", "DISEASE", 161, 183], ["cancer", "DISEASE", 185, 191], ["cardiovascular", "ANATOMICAL_SYSTEM", 161, 175], ["cancer", "CANCER", 185, 191], ["brain", "ORGAN", 193, 198], ["diabetes", "PROBLEM", 142, 150], ["obesity", "PROBLEM", 152, 159], ["cardiovascular disease", "PROBLEM", 161, 183], ["cancer", "PROBLEM", 185, 191], ["obesity", "OBSERVATION", 152, 159], ["cardiovascular", "ANATOMY", 161, 175], ["disease", "OBSERVATION", 176, 183], ["cancer", "OBSERVATION", 185, 191], ["brain", "ANATOMY", 193, 198]]], ["Given NIH's roles in supporting training of health care professionals, NIN would also guide and support innovative programs to build a cadre of well-trained health professionals for both clinical care and basic and translational science in nutrition (269, 323) .", [["innovative programs", "TREATMENT", 104, 123]]], ["For example, this role could include development of joint requests with USDA for applications investigating the interlinkages between food, nutrition, health, and agricultural practices.", [["applications", "TREATMENT", 81, 93], ["joint", "ANATOMY", 52, 57]]], ["NIN would similarly support collaborative new science to inform the DRIs, FDA food safety and regulatory activities, USDA nutrition assistance programs, CDC surveillance and public health activities, USAID priorities, and DoD and VA research needs for US active-duty forces (including enhanced human performance and military readiness), military families, and veterans.", [["human", "ORGANISM", 294, 299], ["human", "SPECIES", 294, 299], ["human", "SPECIES", 294, 299], ["CDC surveillance", "TEST", 153, 169]]], ["NIN would inform and support CMS and CMMI efforts, such as \"Food is Medicine\" interventions to reduce diet-related illness and associated health care costs (268, 324, 325) .", [["illness", "DISEASE", 115, 122], ["Medicine\" interventions", "TREATMENT", 68, 91]]], ["Such joint initiatives will have the greatest impact if nutrition research at these other departments and agencies were simultaneously strengthened with new investments.", [["joint", "ANATOMY", 5, 10]]], ["NIN would add strong authority, infrastructure, investment, and external advisory mechanisms for nutrition research to the nation's largest funder of science.", [["nutrition research", "TREATMENT", 97, 115]]], ["As a long-term structure, NIN's activities and benefits would provide both expected and unexpected returns over many decades, outlasting shorter-term options such as cross-agency initiatives and changing priorities of individual administrations, and evolving appropriately with changes in science, food systems, nutritional needs, and disease conditions of the US public.", [["a long-term structure", "PROBLEM", 3, 24], ["shorter-term options", "TREATMENT", 137, 157], ["cross-agency initiatives", "TREATMENT", 166, 190], ["individual administrations", "TREATMENT", 218, 244], ["disease conditions", "PROBLEM", 335, 353]]], ["The combination of NIN plus a new crossgovernmental approach (Table 3) would provide a powerful strategy to address the scope and scale of the challenges and opportunities we face as a nation.New National Institute of Nutrition.Disadvantages.", [["NIN", "CHEMICAL", 19, 22], ["NIN", "PROTEIN", 19, 22], ["a new crossgovernmental approach", "TREATMENT", 28, 60], ["the scope", "TEST", 116, 125], ["new", "OBSERVATION_MODIFIER", 30, 33]]], ["The addition of a new institute would require legislative action to increase the current limit of 27 NIH institutes and centers (Public and provide additive new appropriations to prevent reductions in any ongoing NIH or other federal nutrition research.", [["legislative action", "TREATMENT", 46, 64], ["additive new appropriations", "TREATMENT", 148, 175]]], ["NIN could increase silo-ing of nutrition research or divestment in nutrition research from other parts of NIH, which has historically been and should remain a component of almost all NIH institutes, offices, and centers.", [["NIN", "CHEMICAL", 0, 3], ["nutrition research", "TREATMENT", 31, 49], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["silo", "OBSERVATION_MODIFIER", 19, 23]]], ["Even with a remit to coordinate and complement existing efforts, a new institute would need to navigate potentially entrenched cultures and perspectives around the \"home\" of certain areas of research.", [["entrenched cultures", "TEST", 116, 135]]], ["Congressional appropriations for expanded nutrition research funding within and outside NIH would be needed to prevent increased competition for resources.New National Institute of Nutrition.Path forward.", [["expanded nutrition research funding", "TREATMENT", 33, 68]]], ["As an intermediary step, Congress could submit an inquiry to appropriate federal departments and agencies, host hearings, as well as appropriate funds, to explore the current status of federal nutrition research and potential options including the NIN.New National Center for Nutrition Research.As a smaller model than a new institute, a new NIH National Center for Nutrition Research (NCNR) could be created, representing a 28th institute or center at NIH that would be broadly similar to a new NIN, although with less stature, staff, and funding (Supplemental Text 3) .", [["NIN", "DISEASE", 496, 499], ["Nutrition Research", "TREATMENT", 276, 294], ["Nutrition Research (NCNR)", "TREATMENT", 366, 391], ["smaller", "OBSERVATION_MODIFIER", 300, 307], ["new", "OBSERVATION_MODIFIER", 492, 495], ["NIN", "OBSERVATION_MODIFIER", 496, 499]]], ["The NCNR could aim to accomplish many of the same goals as an NIN, on a lesser scale.", [["The NCNR", "TREATMENT", 0, 8], ["a lesser scale", "TREATMENT", 70, 84]]], ["Advantages, disadvantages, and the path forward for NCNR are likewise similar, on a reduced scale, to NIN.", [["NIN", "DISEASE", 102, 105], ["NCNR", "TREATMENT", 52, 56], ["a reduced scale", "TREATMENT", 82, 97]]], ["Long term, the NCNR could further evolve into an institute, as has happened to other centers at NIH.", [["the NCNR", "TREATMENT", 11, 19]]], ["Like the NIH Office of Disease Prevention Director who also serves as the Associate Director for Prevention (Public , the Director of the NIH ONR would also serve as the Associate Director for Nutrition Research.New NIH ONR within the NIH Office of the Director.The NIH ONR would lead efforts to build and coordinate new collaborative relationships and synergies within the NIH, with other federal departments and agencies, and with external stakeholders including public-private partnerships to drive nutrition research and innovation.", [["Nutrition Research", "TREATMENT", 193, 211]]], ["The NIH ONR would lead cooperative efforts to identify and stimulate priority areas of science, provide guidance on rigorous methodology, offer trainings, and increase the impact, visibility, and dissemination of findings.", [["rigorous methodology", "TREATMENT", 116, 136], ["trainings", "TREATMENT", 144, 153]]], ["This office could help stimulate new, flexible appropriations for the NIH Office of the Director to focus broadly on nutrition priority areas, outside the Common Fund per se.New NIH ONR within the NIH Office of the Director.In addition to research strategy and harmonization, the new office director and staff (including communications specialists, present in other similar NIH Office of the Director Offices) would increase capacity and expertise for dissemination of nutrition science to the public and other stakeholders.", [["nutrition priority areas", "TREATMENT", 117, 141], ["nutrition science", "TREATMENT", 469, 486]]], ["Based on Congressional prioritization of new national research areas, such an office can transition into a center (e.g., National Center for Complementary and Integrative Health; Public Laws 103-42, or an institute (e.g., NINR, Public Law 103-43; NIMHD, Public Laws 103-43, 106-525, 111-148).New NIH ONR within the NIH Office of the Director.Disadvantages.", [["Public Laws", "TEST", 179, 190], ["NINR", "TEST", 222, 226], ["NIMHD", "TEST", 247, 252], ["Public Laws", "TEST", 254, 265], ["new", "OBSERVATION_MODIFIER", 41, 44]]], ["The size and resources of such an office would remain limited to coordinating and developing nutrition strategy across all NIH institutes, centers, and offices, inform and collaborate with other federal departments and agencies engaged in nutrition-relevant research and programming, assist with communication to the public, work with ODPHP in the USDA-HHS partnership to develop the DGAs, and meaningfully engage in public-private or other external partnerships.", [["size", "OBSERVATION_MODIFIER", 4, 8]]], ["Such an office does not generally have sufficient independent funding to promote major extramural or intramural science.", [["intramural", "OBSERVATION_MODIFIER", 101, 111], ["science", "OBSERVATION", 112, 119]]], ["An office's budget, staff size, and influence can vary widely across offices and over time depending on other NIH priorities.New trans-NIH initiative(s) in nutrition research.Trans-NIH initiatives are efforts to promote collaborative research across NIH in a particular area of science.", [["size", "OBSERVATION_MODIFIER", 26, 30], ["science", "OBSERVATION", 278, 285]]], ["Generally, trans-NIH programs utilize the same mechanisms of grant funding that NIH currently offers: research grants (R series), career development awards (K series), research training and fellowships (T & F series), program project/center grants (P series), and resource grants (various series) (333 (333) .New trans-NIH initiative(s) in nutrition research.The NIH Common Fund has emerged as one approach to support trans-NIH programs and uses the same mechanisms of support.", [["research training", "TREATMENT", 168, 185], ["trans-NIH programs", "TREATMENT", 418, 436], ["the same mechanisms of support", "TREATMENT", 446, 476]]], ["Then, an NIH institute, center, or office or multiple institutes, centers, and offices must continue the support of these time-limited programs.New trans-NIH initiative(s) in nutrition research.As one example, the NIH Human Microbiome Project was a trans-NIH initiative supported by the NIH Common Fund from 2007 to 2016 (334) .", [["Human", "ORGANISM", 218, 223], ["Human", "SPECIES", 218, 223]]], ["Initially funded as an initiative of the NIH Roadmap for Biomedical Research, the NIH Human Microbiome Project was originally established as a 5-y project with a budget of $150 million (335) .", [["Human", "ORGANISM", 86, 91], ["Human", "SPECIES", 86, 91]]], ["These activities were supported by a Data Analysis and Coordination Center and a set of additional grants was awarded for developing new technologies, new software tools, and studying the ethical, legal, and social implications of this work.", [["a Data Analysis", "TEST", 35, 50]]], ["Ultimately, this 10-y $215 million project spanned >20 of the NIH institutes, centers, and offices and resulted in a >40-fold increase in nonproject investment in microbiome research (336) .", [["increase", "OBSERVATION_MODIFIER", 126, 134]]], ["The Trans-NIH Microbiome Working Group established in 2012 provided a forum for coordinating NIH extramural research activities related to the human microbiome and continues to coordinate this work after the NIH Human Microbiome Project was completed.", [["human", "ORGANISM", 143, 148], ["Human", "ORGANISM", 212, 217], ["human", "SPECIES", 143, 148], ["Human", "SPECIES", 212, 217], ["human", "SPECIES", 143, 148], ["Human", "SPECIES", 212, 217]]], ["Notably, the NIH Human Microbiome Project identified several potential priority areas around food and the microbiome, but these topics have not yet been systematically pursued.New trans-NIH initiative(s) in nutrition research.The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) initiative is an example of a trans-NIH initiative (337) , supported by staff within NIH and across federal working groups and providing funding for intramural and extramural research, training, and technology development.", [["Brain", "ANATOMY", 230, 235], ["Human", "ORGANISM", 17, 22], ["Human", "SPECIES", 17, 22], ["Human", "SPECIES", 17, 22], ["several", "OBSERVATION_MODIFIER", 53, 60], ["potential", "OBSERVATION_MODIFIER", 61, 70], ["priority", "OBSERVATION_MODIFIER", 71, 79], ["Brain", "ANATOMY", 230, 235], ["BRAIN", "ANATOMY", 293, 298]]], ["The BRAIN initiative is managed by 10 NIH institutes and centers, with coordination at multiple levels.", [["BRAIN", "ANATOMY", 4, 9]]], ["Extramural program staff and institute and center directors meet regularly to integrate strategic planning, management, and a BRAIN Multi-Council Working Group and Neuroethics Working Group provide further input on a variety of issues.New trans-NIH initiative(s) in nutrition research.Another trans-NIH example is the All of US Research Program (Public , directly supported through annual appropriations from Congress ($1.5 billion over 10 y) (Public .", [["management", "TREATMENT", 108, 118]]], ["The program staff are based in the NIH Office of the Director, with a Trans-NIH Liaisons Coordinating Team made up of scientific leaders from across NIH and has an external advisory panel.New trans-NIH initiative(s) in nutrition research.A potential trans-NIH program in Precision Nutrition is being considered as an NIH Common Fund program for fiscal year 2021 (131, 339) , and the NIH Director included Precision Nutrition in the NIH's congressional budget justification for fiscal year 2021 (131) .", [["an external advisory panel", "TEST", 161, 187]]], ["Legislation is not required.", [["not required", "UNCERTAINTY", 15, 27]]], ["A trans-NIH initiative can help galvanize NIH to develop a coordinated approach to a specific topic on nutrition and human health (e.g., see Table 2 ).", [["human", "ORGANISM", 117, 122], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122]]], ["A trans-NIH initiative brings new strategic planning, working groups, funding opportunities, training, and technology development.", [["new strategic planning", "TREATMENT", 30, 52]]], ["A trans-NIH initiative is complementary to other NIH and cross-governmental strategies to strengthen federal nutrition research.", [["cross-governmental strategies", "TREATMENT", 57, 86]]], ["Addressing the science gaps and opportunities for nutrition-a leading cause of disease in the US-will require greater and more sustained authority, coordination, resources, and collaboration than provided by a single initiative, especially one only limited to precision nutrition.", [["nutrition", "TREATMENT", 50, 59], ["disease", "PROBLEM", 79, 86], ["the US", "TEST", 90, 96], ["disease", "OBSERVATION", 79, 86]]], ["The long-term success of such initiatives can be dependent on a single leading NIH institute, center, and/or office to commit to carry that area of work forward after the initial investments.New trans-NIH initiative(s) in nutrition research.Path forward.", [["long-term", "OBSERVATION_MODIFIER", 4, 13]]], ["Congress could authorize and appropriate funds for this proposed initiative or put forth support for another or additional trans-NIH initiative(s) focused on \u22651 areas of nutrition research.", [["forth support", "TREATMENT", 83, 96], ["nutrition research", "TREATMENT", 170, 188]]], ["External support through the private and nongovernment sectors can also be mobilized through public-private partnerships.Identified USDA strategies for strengthening national nutrition researchIn addition to NIH, the USDA is an important home for increased authority, coordination, and funding for nutrition science (110) .", [["External support through the private and nongovernment sectors", "TREATMENT", 0, 62], ["strengthening national nutrition", "TREATMENT", 152, 184]]], ["As for NIH options, any new USDA strategy must leverage and strengthen, not supplant, existing extramural and intramural nutrition research efforts across USDA as well as other federal departments and agencies.", [["NIH options", "TREATMENT", 7, 18]]], ["Comparative advantages and disadvantages, executive and legislative considerations, and paths forward for these options should be the subject of future reports.Increased investment in nutrition research across REE.Declining appropriations for nutrition-relevant research and statistics at USDA, compounded by declining public investment in agrifood research and development, is limiting the nation's ability to fully understand and leverage the critical nexus between agriculture, food, and health (12, 146, 147) .", [["nutrition research across REE", "TREATMENT", 184, 213], ["investment", "OBSERVATION_MODIFIER", 170, 180]]], ["An emphasis on agricultural production research has created pressure on the USDA nutrition portfolio to respond to these growing research needs and opportunities with its limited budget.", [["pressure", "OBSERVATION_MODIFIER", 60, 68]]], ["Such investment would also maximize cross-governmental coordination and public-private partnerships with the greatest potential to accelerate progress in this complex nexus.Increased investment in nutrition research across REE.The USDA also implements major nutrition programs and thus must rely upon an integrated focus that connects nutrition research to policy and practice to improve the health of the public.", [["public-private partnerships", "TREATMENT", 72, 99], ["nutrition research across REE", "TREATMENT", 197, 226], ["nutrition programs", "TREATMENT", 258, 276], ["investment", "OBSERVATION_MODIFIER", 183, 193]]], ["To accomplish this integrated approach, each of the science mission areas at ARS, ERS, and NIFA must be at full capacity including sufficient staffing and resources.", [["this integrated approach", "TREATMENT", 14, 38]]], ["Nutrition research investment in ARS is essential for food-composition research and development, dietary surveys and food databases instrumental to national surveillance and scientific discovery, and the Human Nutrition Research Center network that pursues long-term, translation research priorities impractical to assess in short-term programs.", [["Human", "ORGANISM", 204, 209], ["Human", "SPECIES", 204, 209], ["national surveillance", "TEST", 148, 169], ["short-term programs", "TREATMENT", 325, 344]]], ["NIFA complements ARS with competitive extramural funding vital to strengthening our nation's capacity to address opportunities related to diet, health, food safety, food security, and food science and technology.", [["NIFA", "CHEMICAL", 0, 4], ["NIFA complements", "TEST", 0, 16]]], ["In addition, ERS provides invaluable food supply data, federal nutrition assistance program evaluations, and surveys on food insecurity and food acquisition and purchases.Expanded USDA research to improve public guidance and education.As detailed in earlier sections, the USDA CNPP plays a major role in the development of the DGAs, with far-reaching implications for many federal and nonfederal policies and programs such as the suite of 15 federal nutrition assistance programs, FDA regulatory policies, and clinical guidance for individuals from allied health professionals.", [["CNPP", "CHEMICAL", 277, 281], ["evaluations", "TEST", 92, 103], ["federal nutrition assistance programs", "TREATMENT", 442, 479]]], ["Further work is needed to provide consistent funding and staff to maintain and protect the scientific integrity for nutrition evidence systematic reviews; fundamental nutrition research, monitoring, and surveillance processes; and to develop, translate, and disseminate dietary guidance.Expanded USDA research to improve public guidance and education.Other USDA investments in public guidance include SNAP-Ed, with $441 million in funding in 2020 (340) .", [["SNAP", "CHEMICAL", 401, 405], ["fundamental nutrition research", "TEST", 155, 185]]], ["The benefits of this major effort could be further amplified by the creation of a robust SNAP-Ed infrastructure [e.g., similar to the USDA NIFA Gus Schumacher Nutrition Incentive Program (GusNIP) or SNAP Employment and Training] to support evaluation of novel educational interventions, including policy and systems changes, online purchasing strategies, and other environmental supports, using SNAP pilot authority (13) .", [["SNAP", "CHEMICAL", 89, 93], ["SNAP", "CHEMICAL", 199, 203], ["SNAP", "CHEMICAL", 395, 399], ["Incentive Program (GusNIP)", "TREATMENT", 169, 195], ["evaluation", "TEST", 240, 250], ["novel educational interventions", "TREATMENT", 254, 285]]], ["Similarly, expanded research on WIC Nutrition Education should address approaches to further strengthen this valuable program, such as new strategies for education on breastfeeding practices, food and beverage choices, sleep, and screen time, as well as novel information systems and technology including online, mobile, and telehealth options to deploy this guidance to WIC participants (13) .Expanded USDA research to improve public guidance and education.Greater research on the USDA's State Nutrition Action Committee (SNAC) program-which helps states coordinate USDA food-assistance programs, Affordable Care Act community benefits, wellness, and other food and nutrition programs-and the USDA Farm to School Grant Program-which funds school districts, state and local agencies, Indian tribal organizations, agricultural producers, and nonprofit organizations to increase local foods served through child nutrition programs, teach children about food and agriculture through garden and classroom education, and develop schools' and farmers' capacities to participate in farm to school-would amplify benefits of these investments (13) .Innovative USDA research to strengthen benefits of nutrition assistance programs.New research efforts supported by USDA, as well as NIH, are critical to develop the evidence base and collaborations to further augment the positive impacts of large federal investments in nutrition assistance (\u223c$100 billion/y).", [["children", "ORGANISM", 936, 944], ["participants", "SPECIES", 375, 387], ["children", "SPECIES", 936, 944], ["education on breastfeeding practices", "TREATMENT", 154, 190], ["Committee (SNAC) program", "TREATMENT", 512, 536], ["nutrition assistance programs", "TREATMENT", 1191, 1220], ["nutrition assistance", "TREATMENT", 1410, 1430], ["large", "OBSERVATION_MODIFIER", 1381, 1386]]], ["Such research must, for example, delineate and address the tremendous increases in food insecurity, associated economic disruptions, and nutritionrelated health disparities stemming from COVID-19.", [["food insecurity", "DISEASE", 83, 98], ["economic disruptions", "PROBLEM", 111, 131], ["COVID", "TEST", 187, 192], ["economic disruptions", "OBSERVATION", 111, 131]]], ["Now is the time to expand our understanding of the best approaches to increase the public health impacts of our suite of 15 federal nutrition assistance programs.", [["15 federal nutrition assistance programs", "TREATMENT", 121, 161]]], ["This approach can include, for instance, new USDA-supported pilots and waivers to evaluate innovations that better support healthier eating in SNAP (e.g., healthy retail approaches, healthy food incentives combined with disincentives, online purchasing technologies) (13, 341) .", [["SNAP", "CHEMICAL", 143, 147]]], ["Further critical research needs include how USDA's nutrition assistance programs can be better integrated and coordinated with other federal and state programs, in particular Medicaid and Medicare, to improve diet-related health outcomes (13) .", [["nutrition assistance programs", "TREATMENT", 51, 80], ["Medicare", "TREATMENT", 188, 196]]], ["These translational research investments will help address the varying geographic, contextual, and cultural needs of Americans and ensure the most effective outcomes from these essential federal programs.Summary and ConclusionsThis report identified stark national challenges in nutrition: diet-related illnesses, food insecurity, diet-related health disparities, health care costs for public and private payers, workforce productivity, military readiness, tremendous scientific debate and public confusion on a variety of critical topics, sustainability, and food system and population resilience to unexpected crises.", [["food insecurity", "DISEASE", 314, 329], ["confusion", "DISEASE", 497, 506], ["Americans", "TREATMENT", 117, 126], ["public confusion", "PROBLEM", 490, 506], ["unexpected crises", "PROBLEM", 601, 618]]], ["However, as a share of total federal research expenditures, investments in nutrition research have been generally flat over the past 4 decades, despite the dramatic increase in diet-related illnesses such as obesity and type 2 diabetes and other identified diet-related challenges.", [["obesity", "DISEASE", 208, 215], ["type 2 diabetes", "DISEASE", 220, 235], ["related illnesses", "PROBLEM", 182, 199], ["obesity", "PROBLEM", 208, 215], ["type 2 diabetes", "PROBLEM", 220, 235], ["flat", "OBSERVATION_MODIFIER", 114, 118], ["dramatic", "OBSERVATION_MODIFIER", 156, 164], ["increase", "OBSERVATION_MODIFIER", 165, 173]]], ["Several current federal initiatives and collaborations aim to increase coordination of specific aspects of nutrition research and related activities across departments and agencies.", [["nutrition research", "TREATMENT", 107, 125]]], ["Yet, the full potential of these efforts has not been realized, as documented by multiple governmental and other assessments since at least 1969, due to insufficient authority and funding.Summary and ConclusionsThe opportunities to be gained by greater coordination and investment in federal nutrition research are clear, with potential for large and rapid ROI.", [["other assessments", "TEST", 107, 124], ["large and rapid ROI", "PROBLEM", 341, 360]]], ["This report identified and described 2 priority strategies to strengthen federal nutrition research: 1) a new authority for cross-governmental coordination of nutrition research and other nutrition-relevant policy and 2) strengthened authority, investment, and coordination for nutrition research within NIH.", [["nutrition research", "TREATMENT", 159, 177]]], ["Optimally, these options would garner full bipartisan support from the executive and legislative branches.", [["full bipartisan support", "TREATMENT", 38, 61], ["branches", "ANATOMY_MODIFIER", 97, 105]]], ["Each of the identified options in this report would help create the new leadership, strategic planning, coordination, and investment the nation requires to address the challenges and grasp the opportunities we face.Summary and ConclusionsWe are indebted to a variety of federal agency staff and other stakeholders for their candid reflections of the past and present, as well as thorough assessments of potential strategies for moving forward.", [["thorough assessments", "TEST", 379, 399]]], ["We are grateful for input from members of the Nutrition Action Alliance (NAA), a coalition of organizations working to advance federal nutrition research, nutrition education, and nutrition monitoring and surveillance, among other activities, which includes ASN, Academy of Nutrition and Dietetics, American Society for Parenteral and Enteral Nutrition, Association of Nutrition Departments and Programs, Institute of Food Technologists, National Board of Physician Nutrition Specialists, Society for Nutrition Education and Behavior, and The Obesity Society.", [["NAA", "CHEMICAL", 73, 76], ["Obesity", "DISEASE", 543, 550], ["federal nutrition research", "TREATMENT", 127, 153], ["nutrition education", "TREATMENT", 155, 174], ["nutrition monitoring", "TEST", 180, 200], ["surveillance", "TEST", 205, 217], ["Parenteral and Enteral Nutrition", "TREATMENT", 320, 352], ["Obesity", "OBSERVATION", 543, 550]]], ["This opportunity to review and provide feedback did not imply that the NAA nor any individual member organization has taken a specific policy position on every strategy option referenced in the paper.", [["NAA", "CHEMICAL", 71, 74], ["NAA", "CHEMICAL", 71, 74], ["NAA", "SIMPLE_CHEMICAL", 71, 74]]], ["We thank Sylara Marie Cruz for outstanding management support.Summary and ConclusionsThe authors' responsibilities were as follows-SEF, CEW, PMC, VSH, and DM: were on the lead writing group of this paper; the remaining authors regularly reviewed drafts and provided substantive feedback during regular calls and rounds of reviews; and all authors: read and approved the final manuscript.", [["DM", "DISEASE", 155, 157], ["outstanding management support", "TREATMENT", 31, 61]]], ["DM reports research funding from the NIH and the Gates Foundation; personal fees from GOED, Bunge, Indigo Agriculture, Motif FoodWorks, Amarin, Acasti Pharma, Cleveland Clinic Foundation, America's Test Kitchen, and Danone; participating on scientific advisory boards of start-up companies focused on innovations for health including Brightseed, DayTwo, Elysium Health, Filtricine, Foodome, HumanCo, and Tiny Organics; and chapter royalties from UpToDate, all outside the submitted work; as well as research funding from The Rockefeller Foundation.", [["DM", "PROBLEM", 0, 2], ["Amarin", "TREATMENT", 136, 142], ["Filtricine", "TREATMENT", 370, 380], ["HumanCo", "TREATMENT", 391, 398]]], ["PJS reports grant/research support from the NIH; participating on scientific advisory and/or membership boards of Marabou Foundation, the National Academy of Sciences, Engineering, and Medicine, the ASN, and International Council on Amino Acid Science; and holding stock in TIAA, all outside the submitted work.", [["PJS", "DISEASE", 0, 3], ["Amino Acid", "CHEMICAL", 233, 243]]]], "aea2f0fe893fb88d797b98e80ed626d3c8fac3d2": [["IntroductionUp to now (July 2020) around 10 million people worldwide have been identified as infected with SARS-CoV-2, of which nearly 500.000 succumbed to COVID-19 (1) .", [["SARS", "DISEASE", 107, 111], ["COVID-19", "CHEMICAL", 156, 164], ["people", "ORGANISM", 52, 58], ["SARS-CoV-2", "ORGANISM", 107, 117], ["people", "SPECIES", 52, 58], ["SARS-CoV", "SPECIES", 107, 115], ["CoV", "TEST", 112, 115], ["infected", "OBSERVATION_MODIFIER", 93, 101]]], ["In addition to China, early outbreaks took place in South Korea, Japan, and Central Europe where by now, the spread of the virus could be contained with great efforts.", [["the virus", "PROBLEM", 119, 128]]], ["However, COVID-19 had been declared a pandemic by the WHO on March 10, 2020 (World Health Organization, 2020) and many countries like the USA, Russia, Brazil, and India are still showing rising daily case numbers.IntroductionHealth care workers are at exceptionally high risk of infection as they work on the frontline of this pandemic (2) .", [["infection", "DISEASE", 279, 288], ["infection", "PROBLEM", 279, 288], ["infection", "OBSERVATION", 279, 288]]], ["Perinatal centers seem to be an underestimated hotspot due to the increased presence of young, often paucisymptomatic patients, high aerosol exposure in the delivery room, and a multidisciplinary care team that requires the close proximity of staff members from multiple hospital departments such as anesthesiologists, midwifes, obstetricians, nurses and others (3).IntroductionIn a well described outbreak at our University perinatal center in Regensburg, Germany, a total of 36 staff members were confirmed virus RNA-positive by reverse transcription, followed by real-time (RT)-PCR and 34 developed COVID-19 (4) .", [["paucisymptomatic", "DISEASE", 101, 117], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["virus RNA", "TEST", 509, 518], ["PCR", "TEST", 581, 584], ["COVID", "TEST", 602, 607]]], ["Our previously reported J o u r n a l P r e -p r o o f observations and initial antibody testing showed that 2-3 weeks after the initial PCR-based screening only a limited number of staff members affected by COVID-19 had developed relevant antibody responses (48.4%).", [["initial antibody testing", "TEST", 72, 96], ["the initial PCR", "TEST", 125, 140], ["based screening", "TEST", 141, 156], ["COVID", "TEST", 208, 213], ["relevant antibody responses", "TEST", 231, 258]]], ["At this time point, very few staff members who were in contact with diseased co-workers but tested negative in the PCR-test, showed any antibody response which was limited to IgA (8.2%) and in one case, to borderline elevated IgG (6) .IntroductionThe objective of this follow up study was now to investigate the progression of the immune response approximately 12 weeks after the outbreak in our hospital staff of COVID-19 affected and contact persons.Study design and participants recruitmentThe study was designed as a prospective cross-sectional study with optional longitudinal analysis, focused on immune response to SARS-CoV-2 in health care workers approximately 12 weeks after a COVID-19 outbreak in a large University children's and maternity hospital.Study design and participants recruitmentDetails of the outbreak have been reported elsewhere (4) .", [["SARS", "DISEASE", 622, 626], ["IgA", "GENE_OR_GENE_PRODUCT", 175, 178], ["persons", "ORGANISM", 444, 451], ["SARS-CoV-2", "ORGANISM", 622, 632], ["children", "ORGANISM", 727, 735], ["IgA", "PROTEIN", 175, 178], ["IgG", "PROTEIN", 226, 229], ["persons", "SPECIES", 444, 451], ["participants", "SPECIES", 469, 481], ["children", "SPECIES", 727, 735], ["participants", "SPECIES", 778, 790], ["SARS-CoV", "SPECIES", 622, 630], ["the PCR", "TEST", 111, 118], ["any antibody response", "PROBLEM", 132, 153], ["IgA", "TEST", 175, 178], ["borderline elevated IgG", "PROBLEM", 206, 229], ["this follow up study", "TEST", 264, 284], ["The study", "TEST", 493, 502], ["a prospective cross-sectional study", "TEST", 519, 554], ["optional longitudinal analysis", "TEST", 560, 590], ["elevated", "OBSERVATION_MODIFIER", 217, 225], ["IgG", "OBSERVATION", 226, 229]]], ["Briefly, extensive RT-PCR testing was performed on hospital employees (n=379) initially and after the first serological test was commercially available, all employees were offered a voluntary participation in a SARS-CoV-2 serological test.Study design and participants recruitmentAll study subjects were categorized into four groups according to their state of infection or exposure to SARS-CoV-2 positive individuals as previously reported (6) weeks) have already been reported (6) .", [["infection", "DISEASE", 361, 370], ["SARS", "DISEASE", 386, 390], ["participants", "SPECIES", 256, 268], ["extensive RT-PCR testing", "TEST", 9, 33], ["the first serological test", "TEST", 98, 124], ["a SARS", "TEST", 209, 215], ["serological test", "TEST", 222, 238], ["All study subjects", "TEST", 280, 298], ["infection", "PROBLEM", 361, 370], ["SARS", "TEST", 386, 390], ["CoV", "TEST", 391, 394], ["infection", "OBSERVATION", 361, 370]]], ["All participants in the first assessment were invited to participate in the second assessment.", [["participants", "SPECIES", 4, 16], ["the first assessment", "TEST", 20, 40], ["the second assessment", "TEST", 72, 93]]], ["As all data in both studies were fully anonymized and only accessible at an individual level to the participant, data from the first study could only be connected to the second study with the individual approval of the study participants and under the condition that the initial personal study log-in was still remembered by the participant.", [["participant", "SPECIES", 100, 111], ["participants", "SPECIES", 225, 237], ["participant", "SPECIES", 329, 340], ["both studies", "TEST", 15, 27], ["the first study", "TEST", 123, 138], ["the second study", "TEST", 166, 182], ["the study", "TEST", 215, 224]]], ["Therefore, longitudinal analyses were possible in 127 of the 166 participants of the second assessment.", [["participants", "SPECIES", 65, 77], ["longitudinal analyses", "TEST", 11, 32], ["the second assessment", "TEST", 81, 102]]], ["The study was approved by the Ethics Committee of the University of Regensburg (file-number: 20-1767-101).SARS-CoV-2 testingSpecific antibody response to SARS-CoV-2 was now evaluated by the use of two different commercially available test kits -the Anti-SARS-CoV-2 IgG and IgA ELISA (EUROIMMUN AG, L\u00fcbeck, Germany; https://www.euroimmun.com) and the Elecsys Anti-SARS-CoV-2 (Roche Diagnostics, Rotkreuz, Switzerland; https://diagnostics.roche.com).SARS-CoV-2 testingBoth tests were performed according to the manufacturer's protocol.", [["SARS", "DISEASE", 154, 158], ["CoV-2", "ORGANISM", 111, 116], ["SARS-CoV-2", "ORGANISM", 154, 164], ["IgA", "GENE_OR_GENE_PRODUCT", 273, 276], ["Anti-SARS-CoV-2 IgG", "PROTEIN", 249, 268], ["IgA", "PROTEIN", 273, 276], ["SARS-CoV", "SPECIES", 154, 162], ["The study", "TEST", 0, 9], ["SARS", "TEST", 106, 110], ["CoV-2 testing", "TEST", 111, 124], ["Specific antibody response", "TEST", 124, 150], ["SARS", "TEST", 154, 158], ["CoV", "TEST", 159, 162], ["test kits", "TEST", 234, 243], ["the Anti-SARS", "TEST", 245, 258], ["CoV", "TEST", 259, 262], ["IgG", "TEST", 265, 268], ["IgA ELISA", "TEST", 273, 282], ["the Elecsys Anti-SARS-CoV", "TEST", 346, 371], ["SARS-CoV-2 testingBoth tests", "TEST", 448, 476], ["the manufacturer's protocol", "TEST", 505, 532]]], ["For EUROIMMUN kits, reagent wells were pre-coated with recombinant structural protein (S1 domain) of SARS-CoV-2 for the IgA and IgG assay as previously reported (6) .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 101, 111], ["IgA", "GENE_OR_GENE_PRODUCT", 120, 123], ["IgG", "GENE_OR_GENE_PRODUCT", 128, 131], ["recombinant structural protein", "PROTEIN", 55, 85], ["S1 domain", "PROTEIN", 87, 96], ["IgA", "PROTEIN", 120, 123], ["IgG", "PROTEIN", 128, 131], ["EUROIMMUN kits", "TREATMENT", 4, 18], ["reagent wells", "TEST", 20, 33], ["SARS", "TEST", 101, 105], ["CoV", "TEST", 106, 109], ["the IgA", "TEST", 116, 123], ["IgG assay", "TEST", 128, 137]]], ["According to manufacturer's recommendations, for the IgA and IgG assay an OD ratio of > 1.0 was considered positive.SARS-CoV-2 testingThe qualitative Elecsys Anti-SARS-CoV-2 Antibody immunoassay analyzer was used.", [["SARS", "DISEASE", 116, 120], ["Anti-SARS-CoV-2", "CHEMICAL", 158, 173], ["IgA", "GENE_OR_GENE_PRODUCT", 53, 56], ["IgG", "GENE_OR_GENE_PRODUCT", 61, 64], ["IgA", "PROTEIN", 53, 56], ["IgG", "PROTEIN", 61, 64], ["the IgA", "TEST", 49, 56], ["IgG assay", "TEST", 61, 70], ["an OD ratio", "TEST", 71, 82], ["SARS", "TEST", 116, 120], ["CoV-2 testing", "TEST", 121, 134], ["Antibody immunoassay analyzer", "TEST", 174, 203]]], ["The assay does not discriminate between the antibody type(s) present and can detect IgA, IgM, and IgG.", [["IgA", "GENE_OR_GENE_PRODUCT", 84, 87], ["IgM", "GENE_OR_GENE_PRODUCT", 89, 92], ["IgG", "GENE_OR_GENE_PRODUCT", 98, 101], ["IgA", "PROTEIN", 84, 87], ["IgM", "PROTEIN", 89, 92], ["IgG", "PROTEIN", 98, 101], ["The assay", "TEST", 0, 9], ["IgA", "TEST", 84, 87], ["IgM", "TEST", 89, 92], ["IgG", "TEST", 98, 101]]], ["The test is based on a recombinant nucleocapsid (N) antigen and has a threshold value of 1.0.", [["nucleocapsid (N) antigen", "GENE_OR_GENE_PRODUCT", 35, 59], ["recombinant nucleocapsid (N) antigen", "PROTEIN", 23, 59], ["The test", "TEST", 0, 8], ["a threshold value", "TEST", 68, 85]]], ["Accordingly, all samples with a value < 1.0 were considered negative.J o u r n a l P r e -p r o o fCharacteristics of the study cohort are presented using descriptive statistics.", [["samples", "ANATOMY", 17, 24], ["all samples", "TEST", 13, 24], ["the study", "TEST", 118, 127]]], ["Fisher's exact test was used to examine group differences.", [["Fisher's exact test", "TEST", 0, 19]]], ["For the comparison of the proportions of participants who showed antibody responses over time the McNemar test for paired samples was used.", [["samples", "ANATOMY", 122, 129], ["participants", "ORGANISM", 41, 53], ["participants", "SPECIES", 41, 53], ["antibody responses", "PROBLEM", 65, 83], ["the McNemar test", "TEST", 94, 110], ["paired samples", "TEST", 115, 129]]], ["To analyze correlation between the two different antibody tests and for correlation of antibody test results with symptoms, Spearman's rank correlation coefficient or coefficient of determination was used, where applicable.", [["the two different antibody tests", "TEST", 31, 63], ["antibody test", "TEST", 87, 100], ["symptoms", "PROBLEM", 114, 122]]], ["All analyses were performed using SPSS 26 (IBM SPSS Statistics for Windows, USA)After a COVID-19 outbreak at the University children's and maternity hospital inRegensburg, Germany, serologic testing was performed 2 to 4 weeks after the outbreak as previously described (6) Table 1 .", [["children", "ORGANISM", 124, 132], ["children", "SPECIES", 124, 132], ["All analyses", "TEST", 0, 12], ["SPSS", "TEST", 34, 38], ["serologic testing", "TEST", 181, 198]]], ["Multisystem inflammatory disease is a rare complication of COVID-19 that typically affects children, but has recently been reported to also affect young adults (8, 9) .After a COVID-19 outbreak at the University children's and maternity hospital inResults of the Euroimmun IgG ELISA and the Roche immunoassay correlated well, while this was not the case for comparison of the IgA ELISA with the Elecsys immunoassay.", [["inflammatory disease", "DISEASE", 12, 32], ["children", "ORGANISM", 91, 99], ["children", "ORGANISM", 212, 220], ["IgA", "GENE_OR_GENE_PRODUCT", 376, 379], ["IgA", "PROTEIN", 376, 379], ["children", "SPECIES", 91, 99], ["children", "SPECIES", 212, 220], ["Multisystem inflammatory disease", "PROBLEM", 0, 32], ["the Euroimmun IgG ELISA", "TEST", 259, 282], ["the Roche immunoassay", "TEST", 287, 308], ["the IgA ELISA", "TEST", 372, 385], ["the Elecsys immunoassay", "TEST", 391, 414], ["inflammatory", "OBSERVATION", 12, 24], ["rare", "OBSERVATION_MODIFIER", 38, 42], ["complication", "OBSERVATION", 43, 55]]], ["These results are in line with other studies confirming good sensitivity and specificity of the IgG ELISA and the Elecsys Immunoassay (13, 14) .", [["IgG", "PROTEIN", 96, 99], ["other studies", "TEST", 31, 44], ["the IgG ELISA", "TEST", 92, 105], ["the Elecsys Immunoassay", "TEST", 110, 133]]], ["Our longitudinal testing with the same assay (Euroimmun) allowed comparison of the two time points.", [["Our longitudinal testing", "TEST", 0, 24]]], ["The additional test with the Elecsys assay confirmed the results of seroconversion and further added to the sensitivity of early detection of humoral responses.After a COVID-19 outbreak at the University children's and maternity hospital inAs expected, the sequential study of IgA antibody levels showed that in the COVID-19 group, the rate of patients with detectable IgA antibodies decreased significantly over time.After a COVID-19 outbreak at the University children's and maternity hospital inThis finding supports the hypothesis already described by other authors, that IgA is not an adequate marker for the long-term course of an immunological response after COVID-19 infection and may only play a role in patients with mild symptoms, especially since our COVID-19 cohort was only affected by mild to moderate symptoms (10) .After a COVID-19 outbreak at the University children's and maternity hospital inFurther, also the number of experienced symptoms of the COVID-19 patient group did not correlate with immune response.", [["COVID-19", "CHEMICAL", 666, 674], ["infection", "DISEASE", 675, 684], ["children", "ORGANISM", 204, 212], ["IgA", "GENE_OR_GENE_PRODUCT", 277, 280], ["patients", "ORGANISM", 344, 352], ["IgA", "GENE_OR_GENE_PRODUCT", 369, 372], ["children", "ORGANISM", 462, 470], ["IgA", "GENE_OR_GENE_PRODUCT", 576, 579], ["patients", "ORGANISM", 713, 721], ["children", "ORGANISM", 876, 884], ["patient", "ORGANISM", 977, 984], ["IgA antibody", "PROTEIN", 277, 289], ["IgA antibodies", "PROTEIN", 369, 383], ["IgA", "PROTEIN", 576, 579], ["children", "SPECIES", 204, 212], ["patients", "SPECIES", 344, 352], ["children", "SPECIES", 462, 470], ["patients", "SPECIES", 713, 721], ["children", "SPECIES", 876, 884], ["patient", "SPECIES", 977, 984], ["COVID-19", "SPECIES", 666, 674], ["The additional test", "TEST", 0, 19], ["the Elecsys assay", "TEST", 25, 42], ["seroconversion", "TREATMENT", 68, 82], ["the sequential study", "TEST", 253, 273], ["IgA antibody levels", "TEST", 277, 296], ["the COVID", "TEST", 312, 321], ["the rate", "TEST", 332, 340], ["detectable IgA antibodies", "PROBLEM", 358, 383], ["COVID-19 infection", "PROBLEM", 666, 684], ["mild symptoms", "PROBLEM", 727, 740], ["our COVID", "TEST", 759, 768], ["mild to moderate symptoms", "PROBLEM", 800, 825], ["symptoms", "PROBLEM", 952, 960], ["the COVID", "TEST", 964, 973], ["immune response", "PROBLEM", 1014, 1029], ["IgA antibodies", "OBSERVATION", 369, 383], ["infection", "OBSERVATION", 675, 684], ["mild", "OBSERVATION_MODIFIER", 800, 804], ["moderate", "OBSERVATION_MODIFIER", 808, 816]]], ["None of our study participants experienced severe symptoms or symptoms correlated with a multisystem inflammatory disease.", [["participants", "SPECIES", 18, 30], ["our study", "TEST", 8, 17], ["severe symptoms", "PROBLEM", 43, 58], ["symptoms", "PROBLEM", 62, 70], ["a multisystem inflammatory disease", "PROBLEM", 87, 121], ["multisystem", "OBSERVATION_MODIFIER", 89, 100], ["inflammatory", "OBSERVATION", 101, 113]]], ["In this respect, the lack of correlation of the number of symptoms with IgG titers might be explained, but the low number of COVID-19 positive patients in our study population must also be taken into account.J o u r n a l P r e -p r o o fWe had initially speculated that exposure to colleagues with COVID-19 might lead to an antibody responses in some hospital staff dependent on the degree of exposure.", [["COVID-19", "CHEMICAL", 299, 307], ["COVID-19", "CHEMICAL", 299, 307], ["IgG", "GENE_OR_GENE_PRODUCT", 72, 75], ["COVID-19", "GENE_OR_GENE_PRODUCT", 125, 133], ["patients", "ORGANISM", 143, 151], ["IgG", "PROTEIN", 72, 75], ["patients", "SPECIES", 143, 151], ["symptoms", "PROBLEM", 58, 66], ["IgG titers", "TEST", 72, 82], ["COVID", "TEST", 125, 130], ["our study population", "TEST", 155, 175], ["fWe", "PROBLEM", 237, 240], ["COVID", "TEST", 299, 304], ["an antibody responses", "PROBLEM", 322, 343], ["antibody", "OBSERVATION", 325, 333]]], ["Interestingly, our results showed no antibody responses in the contact group, rejecting the hypothesis of silent, antibody dependent immunization in this cohort.", [["antibody responses", "PROBLEM", 37, 55], ["antibody dependent immunization", "TREATMENT", 114, 145], ["no", "UNCERTAINTY", 34, 36], ["antibody responses", "OBSERVATION", 37, 55]]], ["These results regarding the immune response of COVID-19 contact subjects are in line with the first reports on development of antibody response to COVID-19 (11, 12) .", [["COVID-19", "CHEMICAL", 147, 155], ["COVID", "TEST", 47, 52], ["antibody response", "TEST", 126, 143], ["COVID", "TEST", 147, 152]]], ["In addition, the significant decrease in IgA levels over time in the contact group fits with reports of unspecific IgA reaction to common cold coronaviruses (10, 13) .J o u r n a l P r e -p r o o fThe fact that we did not identify additional seropositive cases in our study cohort 8-12 weeks after the outbreak also allows the conclusion that no new infections have occurred during the study period, although COVID-19 patients have been treated in our hospital throughout the study period.", [["infections", "DISEASE", 350, 360], ["IgA", "GENE_OR_GENE_PRODUCT", 41, 44], ["IgA", "GENE_OR_GENE_PRODUCT", 115, 118], ["patients", "ORGANISM", 418, 426], ["IgA", "PROTEIN", 41, 44], ["IgA", "PROTEIN", 115, 118], ["patients", "SPECIES", 418, 426], ["the significant decrease in IgA levels", "PROBLEM", 13, 51], ["unspecific IgA reaction", "PROBLEM", 104, 127], ["common cold coronaviruses", "PROBLEM", 131, 156], ["our study", "TEST", 264, 273], ["new infections", "PROBLEM", 346, 360], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["decrease", "OBSERVATION_MODIFIER", 29, 37], ["IgA levels", "OBSERVATION_MODIFIER", 41, 51], ["new", "OBSERVATION_MODIFIER", 346, 349], ["infections", "OBSERVATION", 350, 360]]], ["More importantly, this result underlines the effectiveness of the applied hygiene measures to slow the spread of the virus.J o u r n a l P r e -p r o o fFor our clinical work we can draw some encouraging results from this study.", [["the applied hygiene measures", "TREATMENT", 62, 90], ["the virus", "PROBLEM", 113, 122], ["this study", "TEST", 217, 227]]], ["Firstly, we see that the immunological response of COVID-19 patients has increased significantly over time, and we can therefore assume an increase in immunity.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["COVID", "TEST", 51, 56], ["an increase in immunity", "PROBLEM", 136, 159], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["increase", "OBSERVATION_MODIFIER", 139, 147]]], ["Secondly, we found that none of our hospital staff developed COVID-19 after increased hygiene measures have been applied as described previously (5) .", [["COVID", "TEST", 61, 66], ["increased hygiene measures", "TREATMENT", 76, 102]]], ["This finding confirms the conclusion, that maintaining service in an obstetric unit during an outbreak is feasible when personal protective equipment, workspace distancing and good hand hygiene are implemented (3, 15, 16) .", [["hand", "ANATOMY", 181, 185], ["hand", "ORGANISM_SUBDIVISION", 181, 185], ["personal protective equipment", "TREATMENT", 120, 149]]], ["Further, the details of exposure to COVID-19 have been assessed at the time of the outbreak and are less reliable over time, due to possible exposure outside the hospital.ConclusionWe conclude from our data that immune response after a COVID-19 outbreak increases significantly over time but still approximately 22% of COVID-19 patients did not mount a measurable serologic immune response within 60 days after symptoms have occurred.ConclusionAdditionally, we can summarize that exposed co-workers did not develop any relevant IgG antibody levels over time.", [["COVID-19", "CHEMICAL", 36, 44], ["patients", "ORGANISM", 328, 336], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 528, 540], ["IgG antibody", "PROTEIN", 528, 540], ["patients", "SPECIES", 328, 336], ["COVID", "TEST", 36, 41], ["a COVID", "TEST", 234, 241], ["COVID", "TEST", 319, 324], ["symptoms", "PROBLEM", 411, 419], ["any relevant IgG antibody levels", "PROBLEM", 515, 547]]], ["Maintaining clinical services using protective measures seems to be safe for employees and patients, even in an outbreak situation, if the necessary measures are taken fast and ferociously.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["protective measures", "TREATMENT", 36, 55]]], ["Use of these protective measures need to be continued as neither immunity after infection nor herd immunity are reliable.Figure 1Flow of participants throughout the study with time periods of serologic testing and applied tests including the respective numbers.", [["infection", "DISEASE", 80, 89], ["participants", "SPECIES", 137, 149], ["these protective measures", "TREATMENT", 7, 32], ["infection", "PROBLEM", 80, 89], ["the study", "TEST", 161, 170], ["serologic testing", "TEST", 192, 209], ["applied tests", "TEST", 214, 227]]], ["Correlation of initially reported symptoms and anti-SARS-CoV-2-IgG ratios for COVID-19Figure 1patients.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 62], ["IgG", "GENE_OR_GENE_PRODUCT", 63, 66], ["COVID-19Figure 1patients", "SIMPLE_CHEMICAL", 78, 102], ["IgG", "PROTEIN", 63, 66], ["symptoms", "PROBLEM", 34, 42], ["anti-SARS", "TEST", 47, 56], ["CoV", "TEST", 57, 60], ["IgG ratios", "TEST", 63, 73], ["COVID", "TEST", 78, 83]]], ["The number of ten of the most common symptoms seen with COVID-19 (\"COVID-19 symptoms [n]\", runny nose, sore throat, headache, exhaustion/fatigue, muscle aches, anosmia, shortness of breath, coughing, fever, diarrhea and other (10) is correlated with its respective anti-SARS-CoV-2-IgG ratio (\"IgG ratio\") at the time points \"baseline\" (left) and \"follow up\" (right) for each participating health care worker (\"HCW\") initially suffering from COVID-19 with longitudinal follow up (n=25).", [["muscle", "ANATOMY", 146, 152], ["runny nose", "DISEASE", 91, 101], ["sore throat", "DISEASE", 103, 114], ["headache", "DISEASE", 116, 124], ["fatigue", "DISEASE", 137, 144], ["muscle aches", "DISEASE", 146, 158], ["anosmia", "DISEASE", 160, 167], ["shortness of breath", "DISEASE", 169, 188], ["coughing", "DISEASE", 190, 198], ["fever", "DISEASE", 200, 205], ["diarrhea", "DISEASE", 207, 215], ["nose", "ORGANISM_SUBDIVISION", 97, 101], ["muscle", "ORGAN", 146, 152], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 265, 280], ["IgG", "GENE_OR_GENE_PRODUCT", 281, 284], ["IgG", "GENE_OR_GENE_PRODUCT", 293, 296], ["IgG", "PROTEIN", 281, 284], ["IgG", "PROTEIN", 293, 296], ["the most common symptoms", "PROBLEM", 21, 45], ["COVID", "TEST", 56, 61], ["COVID", "TEST", 67, 72], ["symptoms", "PROBLEM", 76, 84], ["\"", "PROBLEM", 88, 89], ["runny nose", "PROBLEM", 91, 101], ["sore throat", "PROBLEM", 103, 114], ["headache", "PROBLEM", 116, 124], ["exhaustion", "PROBLEM", 126, 136], ["fatigue", "PROBLEM", 137, 144], ["muscle aches", "PROBLEM", 146, 158], ["anosmia", "PROBLEM", 160, 167], ["shortness of breath", "PROBLEM", 169, 188], ["coughing", "PROBLEM", 190, 198], ["fever", "PROBLEM", 200, 205], ["diarrhea", "PROBLEM", 207, 215], ["its respective anti-SARS", "TEST", 250, 274], ["CoV", "TEST", 275, 278], ["IgG ratio", "TEST", 281, 290], ["\"IgG ratio\"", "PROBLEM", 292, 303], ["COVID", "TEST", 441, 446], ["runny nose", "ANATOMY", 91, 101], ["sore throat", "ANATOMY", 103, 114], ["muscle", "ANATOMY", 146, 152], ["left", "ANATOMY_MODIFIER", 336, 340]]], ["The p-value and the Spearman's rho are depicted above each chart.Figure 1J o u r n a l P r e -p r o o f", [["Spearman's rho", "DNA", 20, 34], ["The p-value", "TEST", 0, 11], ["the Spearman's rho", "TEST", 16, 34]]]], "PMC7148239": [["IntroductionEmpowered by the ubiquitous access to computer devices and the Internet, an ever-growing amount of digital images has been emerged [25].", [["digital images", "TEST", 111, 125]]], ["In light of this, image retrieval is considered as an active research topic that aims at retrieving relevant images to a user query from a large database of digital images [11, 14, 21, 26].", [["image retrieval", "TEST", 18, 33], ["digital images", "TEST", 157, 171], ["active", "OBSERVATION_MODIFIER", 54, 60]]], ["Until recently, most of the popular search engines (e.g., Flickr) are built upon the textual information associated with images [4, 7, 24].", [["images", "TEST", 121, 127]]], ["Most of previous hypergraph learning methods adopt a neighborhood-based strategy to build the hypergraph, in which textual results are taken as vertices and each vertex is linked to its k nearest neighbors by an hyperedge.", [["hyperedge", "OBSERVATION", 212, 221]]], ["While obvious, this method suffers from the following drawbacks: (1) it is sensitive to noise (2) lacks the ability to discover the real neighborhood structure (3) the parameter k is fixed as global parameter for all samples regardless their local data distribution.", [["the parameter k", "TEST", 164, 179]]], ["To tackle those issues, recent works have proposed to leverage the regularized regression models, namely the sparse representation and the ridge regression for hypergraph construction [22].", [["hypergraph construction", "TREATMENT", 160, 183]]], ["However, it cannot discover related samples to one hyperedge centroid as thoroughly as possible.", [["samples", "ANATOMY", 36, 43]]], ["Recently, the ridge regression has gained considerable attention not only for its effectiveness in data representation but also for its computational efficiency [41].", [["the ridge regression", "PROBLEM", 10, 30]]], ["In contrast to sparse representation which aims at encouraging the competition between samples to represent a datum, the ridge regression attempt to include all samples in the representation process.", [["a datum", "PROBLEM", 108, 115], ["the ridge regression", "TREATMENT", 117, 137]]], ["The proposed data representation technique adaptively preserve the locality structure and discard irrelevant/outlier samples with respect to a test sample by integrating a distance-regularizer on the representation coefficients.", [["a test sample", "TEST", 141, 154]]], ["At the feature level, we impose a weight matrix on the representation errors to adaptively highlight the important features and reduce the effect of redundant/noisy ones.", [["a weight matrix", "PROBLEM", 32, 47], ["redundant/noisy ones", "PROBLEM", 149, 169]]], ["Moreover, to enhance the representation interpretability, a nonnegativity constraint is added in such a way that the representation coefficients can directly reveal the similarity among samples.", [["samples", "ANATOMY", 186, 193], ["a nonnegativity constraint", "PROBLEM", 58, 84]]], ["Extensive experiments on the public MediaEval benchmarks demonstrate that our re-ranking method achieves consistently superior results, compared to state of-the-art methods.Related WorksIn recent years, many visual re-ranking methods have been proposed in the literature.", [["visual re-ranking methods", "TREATMENT", 208, 233]]], ["The former cast the re-ranking to a classification problem that aims at separating relevant from irrelevant images using data from the initial results as training samples.", [["irrelevant images", "TEST", 97, 114], ["training samples", "TEST", 154, 170], ["cast", "OBSERVATION", 11, 15]]], ["The latter assumes that relevant samples are probably to be close to each other than to irrelevant ones.", [["samples", "ANATOMY", 33, 40], ["samples", "CANCER", 33, 40]]], ["The first is to leverage clustering to group images with respect to their visual closeness.", [["group images", "TEST", 39, 51]]], ["Authors in [28] apply a graph-based clustering method where a similarity graph is initially built to represent relationships among images.", [["a graph", "TEST", 22, 29], ["a similarity graph", "TEST", 60, 78]]], ["The second way is to adopt the graph-based learning for its effectiveness in modeling the intrinsic structure within data.", [["the graph", "TEST", 27, 36]]], ["It applies a random walk on an affinity graph where images are taken as nodes and their visual similarities as probabilistic hyper-links.", [["an affinity graph", "TEST", 28, 45], ["images", "TEST", 52, 58], ["nodes", "OBSERVATION", 72, 77]]], ["Although promising results are achieved, how to represent complex and high-order relationships hidden in data still the performance bottleneck for graph-based re-ranking.", [["graph", "TEST", 147, 152]]], ["Then, a hypergraph ranking is performed to learn the images\u2019 relevance scores.", [["a hypergraph ranking", "TEST", 6, 26], ["the images", "TEST", 49, 59]]], ["Although efficient, this method suffers from some drawbacks.", [["some drawbacks", "TREATMENT", 45, 59]]], ["Second, the neighborhood strategy is very sensitive to noisy data due to the use of the Euclidean distance as similarity measure [22, 37].", [["noisy data", "TEST", 55, 65]]], ["The most widely used model is the sparse representation (SR) in which each sample is represented as a linear combination of the remaining samples [15, 36].", [["most widely", "OBSERVATION_MODIFIER", 4, 15], ["sparse", "OBSERVATION_MODIFIER", 34, 40]]], ["However, it cannot discover related samples to one hyperedge centroid as thoroughly as possible.", [["samples", "ANATOMY", 36, 43]]], ["The matrix", [["matrix", "ANATOMY", 4, 10], ["matrix", "CELLULAR_COMPONENT", 4, 10], ["matrix", "ANATOMY_MODIFIER", 4, 10]]]], "0b35b06902127f13fe98623b233abddea9e80f16": [["The recent emergence of the swine-origin influenza A H1N1 virus (S-OIV) poses a serious global health threat.", [["S-OIV", "CHEMICAL", 65, 70], ["swine-origin", "ORGANISM", 28, 40], ["influenza A H1N1 virus", "ORGANISM", 41, 63], ["S-OIV", "ORGANISM", 65, 70], ["swine", "SPECIES", 28, 33], ["influenza A H1N1 virus", "SPECIES", 41, 63], ["swine-origin influenza A H1N1 virus", "SPECIES", 28, 63], ["OIV", "SPECIES", 67, 70], ["influenza", "PROBLEM", 41, 50], ["A H1N1 virus", "PROBLEM", 51, 63]]], ["Rapid detection and differentiation of S-OIV from seasonal influenza is crucial for patient management and control of the epidemics.", [["S-OIV", "CHEMICAL", 39, 44], ["influenza", "DISEASE", 59, 68], ["S-OIV", "GENE_OR_GENE_PRODUCT", 39, 44], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["Rapid detection", "TEST", 0, 15], ["OIV", "PROBLEM", 41, 44], ["seasonal influenza", "PROBLEM", 50, 68], ["patient management", "TREATMENT", 84, 102], ["the epidemics", "PROBLEM", 118, 131]]], ["A one-step, singletube accelerated and quantitative S-OIV-specific H1 reverse transcription loop-mediated isothermal amplification (RTLAMP) assay for clinical diagnosis of S-OIV by targeting the H1 gene is reported in this article.", [["S-OIV", "GENE_OR_GENE_PRODUCT", 172, 177], ["H1", "GENE_OR_GENE_PRODUCT", 195, 197], ["H1 gene", "DNA", 195, 202], ["S-OIV", "SPECIES", 172, 177], ["specific H1 reverse transcription loop", "TREATMENT", 58, 96], ["S-OIV", "PROBLEM", 172, 177]]], ["A comparative evaluation of the H1-specific RTLAMP assay vis-\u00e0-vis the World HealthOrganization-approved real-time polymerase chain reaction (RTPCR), involving 239 acute-phase throat swab samples, demonstrated exceptionally higher sensitivity by picking up all of the 116 H1N1-positive cases and 36 additional positive cases among the negatives that were sequence-confirmed as S-OIV H1N1.", [["throat swab samples", "ANATOMY", 176, 195], ["S-OIV H1N1", "ORGANISM", 377, 387], ["H1", "PROTEIN", 32, 34], ["RTLAMP", "PROTEIN", 44, 50], ["S-OIV H1N1", "SPECIES", 377, 387], ["A comparative evaluation", "TEST", 0, 24], ["RTPCR", "TEST", 142, 147], ["acute-phase throat swab samples", "TEST", 164, 195], ["exceptionally higher sensitivity", "PROBLEM", 210, 242], ["sequence", "TEST", 355, 363], ["H1N1", "PROBLEM", 383, 387]]], ["None of the real-time RTPCR-positive samples were missed by the RTLAMP system.", [["samples", "ANATOMY", 37, 44], ["RTPCR", "TEST", 22, 27]]], ["The comparative analysis revealed that S-OIV RTLAMP was up to tenfold more sensitive than the World Health Organization real-time RTPCR; it had a detection limit of 0.1 tissue culture infectious dosage of 50 /ml.", [["tissue", "ANATOMY", 169, 175], ["S-OIV", "SIMPLE_CHEMICAL", 39, 44], ["S-OIV", "SPECIES", 39, 44], ["The comparative analysis", "TEST", 0, 24], ["S-OIV RTLAMP", "PROBLEM", 39, 51]]], ["One of the most attractive features of this isothermal gene amplification assay is that it seems to have an advantage in monitoring gene am-plification by means of SYBR Green I dye-mediated naked-eye visualization within 30 minutes compared to 2 to 3 hours for a real-time reverse transcription polymerase chain reaction.", [["eye", "ANATOMY", 196, 199], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 164, 176], ["eye", "ORGAN", 196, 199], ["this isothermal gene amplification assay", "PROBLEM", 39, 79], ["most attractive", "OBSERVATION_MODIFIER", 11, 26], ["eye", "ANATOMY", 196, 199]]], ["This suggests that the RT-LAMP assay is a valuable tool for rapid, real-time detection and quantification of S-OIV in acute-phase throat swab samples without requiring sophisticated equipment. ( The recent emergence of the swine-origin influenza A H1N1 virus (S-OIV), which has a high efficiency of human-to-human transmission, raised concern about a global pandemic.", [["throat swab samples", "ANATOMY", 130, 149], ["S-OIV", "CHEMICAL", 109, 114], ["S-OIV", "CHEMICAL", 260, 265], ["human-to-human transmission", "DISEASE", 299, 326], ["S-OIV", "SIMPLE_CHEMICAL", 109, 114], ["swine-origin", "ORGANISM", 223, 235], ["influenza A H1N1 virus", "ORGANISM", 236, 258], ["S-OIV", "ORGANISM", 260, 265], ["human", "ORGANISM", 299, 304], ["human", "ORGANISM", 308, 313], ["swine", "SPECIES", 223, 228], ["influenza A H1N1 virus", "SPECIES", 236, 258], ["human", "SPECIES", 299, 304], ["human", "SPECIES", 308, 313], ["OIV", "SPECIES", 111, 114], ["swine-origin influenza A H1N1 virus", "SPECIES", 223, 258], ["OIV", "SPECIES", 262, 265], ["human", "SPECIES", 299, 304], ["human", "SPECIES", 308, 313], ["the RT-LAMP assay", "TEST", 19, 36], ["S-OIV", "PROBLEM", 109, 114], ["acute-phase throat swab samples", "PROBLEM", 118, 149], ["sophisticated equipment", "TREATMENT", 168, 191], ["influenza", "PROBLEM", 236, 245], ["A H1N1 virus", "PROBLEM", 246, 258], ["a global pandemic", "PROBLEM", 349, 366], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["high efficiency", "OBSERVATION_MODIFIER", 280, 295], ["global", "OBSERVATION_MODIFIER", 351, 357], ["pandemic", "OBSERVATION", 358, 366]]], ["The 2009 swine flu pandemic was caused by a novel S-OIV that had not been previously recognized in pigs or humans.", [["flu pandemic", "DISEASE", 15, 27], ["S-OIV", "GENE_OR_GENE_PRODUCT", 50, 55], ["pigs", "ORGANISM", 99, 103], ["humans", "ORGANISM", 107, 113], ["swine flu pandemic", "SPECIES", 9, 27], ["pigs", "SPECIES", 99, 103], ["humans", "SPECIES", 107, 113], ["pigs", "SPECIES", 99, 103], ["humans", "SPECIES", 107, 113]]], ["1 This newly emerged virus is a quadruple reassortment of two swine strains, one human strain, and one avian strain of influenza viruses.", [["influenza viruses", "DISEASE", 119, 136], ["swine", "ORGANISM", 62, 67], ["human", "ORGANISM", 81, 86], ["avian strain", "ORGANISM", 103, 115], ["influenza viruses", "ORGANISM", 119, 136], ["swine", "SPECIES", 62, 67], ["human", "SPECIES", 81, 86], ["swine", "SPECIES", 62, 67], ["human", "SPECIES", 81, 86], ["two swine strains", "PROBLEM", 58, 75], ["one human strain", "PROBLEM", 77, 93], ["influenza viruses", "PROBLEM", 119, 136], ["virus", "OBSERVATION", 21, 26], ["influenza viruses", "OBSERVATION", 119, 136]]], ["The largest proportion of genes comes from swine influenza viruses (30.6% from North American swine influenza strains, 17.5% from Eurasian swine influenza strains), followed by North American avian influenza strains (34.4%) and human influenza strains (17.5%).", [["influenza viruses", "DISEASE", 49, 66], ["influenza", "DISEASE", 100, 109], ["influenza", "DISEASE", 145, 154], ["avian influenza", "DISEASE", 192, 207], ["influenza strains", "DISEASE", 234, 251], ["swine influenza viruses", "ORGANISM", 43, 66], ["North American", "ORGANISM", 177, 191], ["avian influenza strains", "ORGANISM", 192, 215], ["human", "ORGANISM", 228, 233], ["swine influenza viruses", "SPECIES", 43, 66], ["swine influenza", "SPECIES", 94, 109], ["Eurasian swine influenza", "SPECIES", 130, 154], ["avian influenza", "SPECIES", 192, 207], ["human", "SPECIES", 228, 233], ["influenza", "SPECIES", 234, 243], ["swine influenza viruses", "SPECIES", 43, 66], ["North American swine influenza", "SPECIES", 79, 109], ["Eurasian swine influenza", "SPECIES", 130, 154], ["North American avian influenza strains", "SPECIES", 177, 215], ["human influenza strains", "SPECIES", 228, 251], ["swine influenza viruses", "PROBLEM", 43, 66], ["swine influenza strains", "PROBLEM", 94, 117], ["Eurasian swine influenza strains", "PROBLEM", 130, 162], ["influenza strains", "PROBLEM", 198, 215], ["human influenza strains", "PROBLEM", 228, 251], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["genes", "OBSERVATION", 26, 31], ["influenza viruses", "OBSERVATION", 49, 66]]], ["2 Pigs play an important role in interspecies transmission of the influenza virus.", [["influenza", "DISEASE", 66, 75], ["Pigs", "ORGANISM", 2, 6], ["influenza virus", "ORGANISM", 66, 81], ["Pigs", "SPECIES", 2, 6], ["influenza virus", "SPECIES", 66, 81], ["the influenza virus", "PROBLEM", 62, 81], ["influenza virus", "OBSERVATION", 66, 81]]], ["Susceptible pig cells possess receptors for both avian (\u2423 2-3-linked sialic acids) and human influenza strains (\u2423 2-6-linked sialic acids), which allow for the reassortment of influenza virus genes from different species if a pig cell is infected with more than one strain.", [["cells", "ANATOMY", 16, 21], ["cell", "ANATOMY", 230, 234], ["\u2423 2-3-linked sialic acids", "CHEMICAL", 56, 81], ["\u2423 2-6-linked sialic acids", "CHEMICAL", 112, 137], ["sialic acids", "CHEMICAL", 69, 81], ["sialic acids", "CHEMICAL", 125, 137], ["pig cells", "CELL", 12, 21], ["\u2423 2-3-linked sialic acids", "SIMPLE_CHEMICAL", 56, 81], ["human", "ORGANISM", 87, 92], ["influenza strains", "ORGANISM", 93, 110], ["\u2423 2-6-linked sialic acids", "SIMPLE_CHEMICAL", 112, 137], ["influenza virus", "ORGANISM", 176, 191], ["pig", "ORGANISM", 226, 229], ["cell", "CELL", 230, 234], ["Susceptible pig cells", "CELL_TYPE", 0, 21], ["influenza virus genes", "DNA", 176, 197], ["pig cell", "CELL_TYPE", 226, 234], ["pig", "SPECIES", 12, 15], ["human", "SPECIES", 87, 92], ["influenza virus", "SPECIES", 176, 191], ["pig", "SPECIES", 226, 229], ["pig", "SPECIES", 12, 15], ["human", "SPECIES", 87, 92], ["influenza virus", "SPECIES", 176, 191], ["pig", "SPECIES", 226, 229], ["Susceptible pig cells", "TREATMENT", 0, 21], ["receptors", "TEST", 30, 39], ["sialic acids", "TEST", 69, 81], ["human influenza strains", "PROBLEM", 87, 110], ["sialic acids", "TREATMENT", 125, 137], ["influenza virus genes", "PROBLEM", 176, 197], ["a pig cell", "PROBLEM", 224, 234], ["pig cells", "OBSERVATION", 12, 21], ["influenza virus", "OBSERVATION", 176, 191], ["pig cell", "OBSERVATION", 226, 234]]], ["3 The S-OIV has caused a considerable number of deaths within a short time since its emergence.The recent emergence of the swine-origin influenza A H1N1 virus (S-OIV) poses a serious global health threat.", [["S-OIV", "CHEMICAL", 6, 11], ["deaths", "DISEASE", 48, 54], ["S-OIV", "CHEMICAL", 160, 165], ["swine-origin", "ORGANISM", 123, 135], ["influenza A H1N1 virus", "ORGANISM", 136, 158], ["S-OIV", "ORGANISM", 160, 165], ["swine", "SPECIES", 123, 128], ["influenza A H1N1 virus", "SPECIES", 136, 158], ["swine-origin influenza A H1N1 virus", "SPECIES", 123, 158], ["OIV", "SPECIES", 162, 165], ["influenza", "PROBLEM", 136, 145], ["A H1N1 virus", "PROBLEM", 146, 158], ["considerable", "OBSERVATION_MODIFIER", 25, 37], ["number", "OBSERVATION_MODIFIER", 38, 44]]], ["Rapid detection and differentiation of S-OIV from seasonal influenza is crucial for patient management and control of the epidemics.", [["S-OIV", "CHEMICAL", 39, 44], ["influenza", "DISEASE", 59, 68], ["S-OIV", "GENE_OR_GENE_PRODUCT", 39, 44], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["Rapid detection", "TEST", 0, 15], ["OIV", "PROBLEM", 41, 44], ["seasonal influenza", "PROBLEM", 50, 68], ["patient management", "TREATMENT", 84, 102], ["the epidemics", "PROBLEM", 118, 131]]], ["A one-step, singletube accelerated and quantitative S-OIV-specific H1 reverse transcription loop-mediated isothermal amplification (RTLAMP) assay for clinical diagnosis of S-OIV by targeting the H1 gene is reported in this article.", [["S-OIV", "GENE_OR_GENE_PRODUCT", 172, 177], ["H1", "GENE_OR_GENE_PRODUCT", 195, 197], ["H1 gene", "DNA", 195, 202], ["S-OIV", "SPECIES", 172, 177], ["specific H1 reverse transcription loop", "TREATMENT", 58, 96], ["S-OIV", "PROBLEM", 172, 177]]], ["A comparative evaluation of the H1-specific RTLAMP assay vis-\u00e0-vis the World HealthThe most common clinical findings of the 2009 H1N1 influenza A pandemic have been fever, cough, sore throat, malaise, and headache; vomiting and diarrhea have also been common, both of which are unusual features of seasonal influenza.", [["influenza A pandemic", "DISEASE", 134, 154], ["fever", "DISEASE", 165, 170], ["cough", "DISEASE", 172, 177], ["sore throat", "DISEASE", 179, 190], ["headache", "DISEASE", 205, 213], ["vomiting", "DISEASE", 215, 223], ["diarrhea", "DISEASE", 228, 236], ["influenza", "DISEASE", 307, 316], ["H1", "PROTEIN", 32, 34], ["RTLAMP", "PROTEIN", 44, 50], ["H1N1 influenza A pandemic", "SPECIES", 129, 154], ["A comparative evaluation", "TEST", 0, 24], ["fever", "PROBLEM", 165, 170], ["cough", "PROBLEM", 172, 177], ["sore throat", "PROBLEM", 179, 190], ["malaise", "PROBLEM", 192, 199], ["headache", "PROBLEM", 205, 213], ["vomiting", "PROBLEM", 215, 223], ["diarrhea", "PROBLEM", 228, 236], ["seasonal influenza", "PROBLEM", 298, 316], ["sore throat", "ANATOMY", 179, 190], ["malaise", "OBSERVATION", 192, 199], ["seasonal", "OBSERVATION_MODIFIER", 298, 306], ["influenza", "OBSERVATION", 307, 316]]], ["1 The emergence of new strains will continue to pose challenges to public health and the scientific communities.", [["new strains", "PROBLEM", 19, 30]]], ["4 Molecular tests for rapid and reliable diagnosis of novel S-OIV are therefore critical for patient management and control of epidemics.The recent emergence of the swine-origin influenza A H1N1 virus (S-OIV) poses a serious global health threat.", [["S-OIV", "CHEMICAL", 202, 207], ["S-OIV", "GENE_OR_GENE_PRODUCT", 60, 65], ["patient", "ORGANISM", 93, 100], ["swine-origin", "ORGANISM", 165, 177], ["influenza A H1N1 virus", "ORGANISM", 178, 200], ["S-OIV", "ORGANISM", 202, 207], ["patient", "SPECIES", 93, 100], ["swine", "SPECIES", 165, 170], ["influenza A H1N1 virus", "SPECIES", 178, 200], ["swine-origin influenza A H1N1 virus", "SPECIES", 165, 200], ["OIV", "SPECIES", 204, 207], ["Molecular tests", "TEST", 2, 17], ["patient management", "TREATMENT", 93, 111], ["epidemics", "PROBLEM", 127, 136], ["influenza", "PROBLEM", 178, 187], ["A H1N1 virus", "PROBLEM", 188, 200]]], ["Rapid detection and differentiation of S-OIV from seasonal influenza is crucial for patient management and control of the epidemics.", [["S-OIV", "CHEMICAL", 39, 44], ["influenza", "DISEASE", 59, 68], ["S-OIV", "GENE_OR_GENE_PRODUCT", 39, 44], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["Rapid detection", "TEST", 0, 15], ["OIV", "PROBLEM", 41, 44], ["seasonal influenza", "PROBLEM", 50, 68], ["patient management", "TREATMENT", 84, 102], ["the epidemics", "PROBLEM", 118, 131]]], ["A one-step, singletube accelerated and quantitative S-OIV-specific H1 reverse transcription loop-mediated isothermal amplification (RTLAMP) assay for clinical diagnosis of S-OIV by targeting the H1 gene is reported in this article.", [["S-OIV", "GENE_OR_GENE_PRODUCT", 172, 177], ["H1", "GENE_OR_GENE_PRODUCT", 195, 197], ["H1 gene", "DNA", 195, 202], ["S-OIV", "SPECIES", 172, 177], ["specific H1 reverse transcription loop", "TREATMENT", 58, 96], ["S-OIV", "PROBLEM", 172, 177]]], ["A comparative evaluation of the H1-specific RTLAMP assay vis-\u00e0-vis the World HealthA confirmed case of pandemic H1N1 influenza A can be made through real-time reverse transcription polymerase chain reaction (RTPCR) or culture.", [["influenza", "DISEASE", 117, 126], ["H1", "PROTEIN", 32, 34], ["pandemic H1N1 influenza", "SPECIES", 103, 126], ["pandemic H1N1 influenza A", "SPECIES", 103, 128], ["A comparative evaluation", "TEST", 0, 24], ["pandemic H1N1 influenza A", "PROBLEM", 103, 128], ["RTPCR", "TEST", 208, 213], ["culture", "TEST", 218, 225]]], ["The recommended test to confirm the diagnosis of pandemic H1N1 influenza A virus is real-time RTPCR for influenza A, B, H1, and H3.", [["influenza A virus", "DISEASE", 63, 80], ["influenza", "DISEASE", 104, 113], ["pandemic H1N1 influenza A virus", "ORGANISM", 49, 80], ["B", "GENE_OR_GENE_PRODUCT", 117, 118], ["H3", "GENE_OR_GENE_PRODUCT", 128, 130], ["pandemic H1N1 influenza A virus", "SPECIES", 49, 80], ["pandemic H1N1 influenza A virus", "SPECIES", 49, 80], ["pandemic H1N1 influenza A virus", "PROBLEM", 49, 80], ["RTPCR", "TEST", 94, 99], ["influenza", "PROBLEM", 104, 113], ["H1", "PROBLEM", 120, 122], ["H3", "PROBLEM", 128, 130]]], ["Isolation of pandemic H1N1 influenza A virus using culture is diagnostic, but culture is usually too slow to help guide clinical management.", [["influenza A virus", "DISEASE", 27, 44], ["pandemic H1N1 influenza A virus", "ORGANISM", 13, 44], ["pandemic H1N1 influenza A virus", "SPECIES", 13, 44], ["pandemic H1N1 influenza A virus", "SPECIES", 13, 44], ["pandemic H1N1 influenza A virus", "PROBLEM", 13, 44], ["culture", "TEST", 51, 58], ["culture", "TEST", 78, 85], ["clinical management", "TREATMENT", 120, 139], ["pandemic", "OBSERVATION_MODIFIER", 13, 21], ["H1N1", "OBSERVATION", 22, 26]]], ["5, 6 A negative viral culture does not exclude infection by H1N1 influenza A. Clinicians may consider using rapid influenza antigen tests as part of their evaluation of patients suspected of having pandemic H1N1 influenza A, but results should be interpreted with caution.", [["infection", "DISEASE", 47, 56], ["influenza A", "DISEASE", 212, 223], ["patients", "ORGANISM", 169, 177], ["H1N1 influenza", "SPECIES", 60, 74], ["patients", "SPECIES", 169, 177], ["pandemic H1N1 influenza", "SPECIES", 198, 221], ["H1N1 influenza A.", "SPECIES", 60, 77], ["pandemic H1N1 influenza A", "SPECIES", 198, 223], ["A negative viral culture", "TEST", 5, 29], ["infection", "PROBLEM", 47, 56], ["rapid influenza antigen tests", "TEST", 108, 137], ["their evaluation", "TEST", 149, 165], ["pandemic H1N1 influenza A", "PROBLEM", 198, 223]]], ["7, 8 A large number of RTPCR tests have been reported, and they use various chemical and multiplexing formats.", [["RTPCR tests", "TEST", 23, 34], ["large", "OBSERVATION_MODIFIER", 7, 12]]], ["9 -16 However, in the current scenario, the only realtime RTPCR validated by the Centers for Disease Control (CDC) is the one approved by the World Health Organization (WHO) for confirmation of pandemic novel swineorigin H1N1 infection.", [["H1N1 infection", "DISEASE", 221, 235], ["swineorigin H1N1", "ORGANISM", 209, 225], ["realtime RTPCR", "TEST", 49, 63], ["pandemic novel swineorigin H1N1 infection", "PROBLEM", 194, 235], ["infection", "OBSERVATION", 226, 235]]], ["This CDC real-time RTPCR is based on a panel of oligonucleotide primers and duallabeled hydrolysis probes that use the Superscript TM III Platinum one-step quantitative kit (Invitrogen, San Diego, CA) with four sets of primers and probes for universal influenza A, swine influenza A, swine H1(new H1N1), and housekeeping gene (RNase P) for testing the quality of the RNA template (http://www.who.int/csr/resources/ publications/swine flu/CDC real-time RTPCR protocol).", [["influenza A", "DISEASE", 252, 263], ["influenza A", "ORGANISM", 252, 263], ["swine influenza A", "ORGANISM", 265, 282], ["swine H1", "ORGANISM", 284, 292], ["RNase", "GENE_OR_GENE_PRODUCT", 327, 332], ["RTPCR", "DNA", 19, 24], ["housekeeping gene", "DNA", 308, 325], ["RNase P", "DNA", 327, 334], ["RNA template", "DNA", 367, 379], ["swine influenza", "SPECIES", 265, 280], ["swine", "SPECIES", 284, 289], ["swine influenza A", "SPECIES", 265, 282], ["swine H1", "SPECIES", 284, 292], ["This CDC", "TEST", 0, 8], ["RTPCR", "TEST", 19, 24], ["a panel", "TEST", 37, 44], ["oligonucleotide primers", "TREATMENT", 48, 71], ["duallabeled hydrolysis probes", "TREATMENT", 76, 105], ["the Superscript TM III Platinum", "TREATMENT", 115, 146], ["four sets of primers", "TREATMENT", 206, 226], ["universal influenza A", "PROBLEM", 242, 263], ["swine influenza A", "PROBLEM", 265, 282], ["swine H1(new H1N1)", "TREATMENT", 284, 302], ["the RNA template", "TREATMENT", 363, 379]]], ["One of the limitations of the existing WHO-approved CDC real-time RTPCR is that the test system is very expensive, considering the large number of primer and probe sets that must be used.", [["the test system", "TEST", 80, 95], ["primer and probe sets", "TREATMENT", 147, 168], ["large", "OBSERVATION_MODIFIER", 131, 136], ["number", "OBSERVATION_MODIFIER", 137, 143]]], ["In addition, the requirement of expensive real-time polymerase chain reaction (PCR) instruments also restricts the system's application to a few referral laboratories that have good financial resources.", [["expensive real-time polymerase chain reaction (PCR) instruments", "TREATMENT", 32, 95]]], ["Overall, the real-time RTPCR test system is expensive and time consuming-it requires 3 to 4 hours.", [["RTPCR test system", "TEST", 23, 40]]], ["Therefore, real-time RTPCR is not the method of choice in basic clinical settings in developing countries for clinical diagnosis of novel S-OIV.", [["S-OIV", "SIMPLE_CHEMICAL", 138, 143]]], ["It is critical to develop simple and economical molecular tests that can be used in field conditions, especially at peripheral health care settings, as a routine test that does not require sophisticated instruments.The recent emergence of the swine-origin influenza A H1N1 virus (S-OIV) poses a serious global health threat.", [["S-OIV", "CHEMICAL", 280, 285], ["swine-origin", "ORGANISM", 243, 255], ["influenza A H1N1 virus", "ORGANISM", 256, 278], ["S-OIV", "ORGANISM", 280, 285], ["swine", "SPECIES", 243, 248], ["influenza A H1N1 virus", "SPECIES", 256, 278], ["swine-origin influenza A H1N1 virus", "SPECIES", 243, 278], ["OIV", "SPECIES", 282, 285], ["economical molecular tests", "TEST", 37, 63], ["a routine test", "TEST", 152, 166], ["sophisticated instruments", "TREATMENT", 189, 214], ["influenza", "PROBLEM", 256, 265], ["A H1N1 virus", "PROBLEM", 266, 278]]], ["Rapid detection and differentiation of S-OIV from seasonal influenza is crucial for patient management and control of the epidemics.", [["S-OIV", "CHEMICAL", 39, 44], ["influenza", "DISEASE", 59, 68], ["S-OIV", "GENE_OR_GENE_PRODUCT", 39, 44], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["Rapid detection", "TEST", 0, 15], ["OIV", "PROBLEM", 41, 44], ["seasonal influenza", "PROBLEM", 50, 68], ["patient management", "TREATMENT", 84, 102], ["the epidemics", "PROBLEM", 118, 131]]], ["A one-step, singletube accelerated and quantitative S-OIV-specific H1 reverse transcription loop-mediated isothermal amplification (RTLAMP) assay for clinical diagnosis of S-OIV by targeting the H1 gene is reported in this article.", [["S-OIV", "GENE_OR_GENE_PRODUCT", 172, 177], ["H1", "GENE_OR_GENE_PRODUCT", 195, 197], ["H1 gene", "DNA", 195, 202], ["S-OIV", "SPECIES", 172, 177], ["specific H1 reverse transcription loop", "TREATMENT", 58, 96], ["S-OIV", "PROBLEM", 172, 177]]], ["A comparative evaluation of the H1-specific RTLAMP assay vis-\u00e0-vis the World HealthLoop-mediated isothermal gene amplification (LAMP) is a novel nucleic acid amplification method developed by the Eiken Chemical Company in Tokyo, Japan.", [["nucleic acid", "CHEMICAL", 145, 157], ["H1", "PROTEIN", 32, 34], ["RTLAMP", "PROTEIN", 44, 50], ["A comparative evaluation", "TEST", 0, 24], ["the H1", "TREATMENT", 28, 34], ["isothermal gene amplification", "TREATMENT", 97, 126], ["a novel nucleic acid amplification method", "TREATMENT", 137, 178]]], ["It has the potential to replace the PCR because of its simplicity, rapidity, specificity, and cost-effectiveness.", [["the PCR", "TEST", 32, 39], ["specificity", "TEST", 77, 88]]], ["17 The reverse transcription LAMP (RTLAMP) assay is a simple diagnostic tool in which the reaction is carried out in a single tube by mixing the buffer, primers, reverse transcriptase, and DNA polymerase and incubating the mixture at 63\u00b0C for 30 minutes.", [["tube", "TISSUE", 126, 130], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["reverse transcriptase", "PROTEIN", 162, 183], ["DNA polymerase", "PROTEIN", 189, 203], ["a simple diagnostic tool", "PROBLEM", 52, 76], ["the reaction", "PROBLEM", 86, 98], ["a single tube", "TREATMENT", 117, 130], ["mixing the buffer, primers", "TREATMENT", 134, 160], ["reverse transcriptase", "TREATMENT", 162, 183], ["DNA polymerase", "TEST", 189, 203]]], ["Compared to RTPCR and real-time PCR, RTLAMP has the advantages of reaction simplicity and detection sensitivity.", [["RTLAMP", "CHEMICAL", 37, 43], ["RTPCR", "DNA", 12, 17], ["RTLAMP", "PROTEIN", 37, 43], ["RTPCR", "TEST", 12, 17], ["real-time PCR", "TEST", 22, 35], ["detection sensitivity", "TEST", 90, 111]]], ["18, 19 The LAMP assay has emerged as a powerful gene amplification tool for the rapid identification of microbial infections and is being increasingly used by various investigators for the rapid detection and typing of emerging viruses, such as West Nile, severe acute respiratory syndrome, dengue, Japanese encephalitis, chikungunya, and so forth.", [["microbial infections", "DISEASE", 104, 124], ["West Nile", "DISEASE", 245, 254], ["acute respiratory syndrome", "DISEASE", 263, 289], ["dengue", "DISEASE", 291, 297], ["Japanese encephalitis", "DISEASE", 299, 320], ["chikungunya", "DISEASE", 322, 333], ["West Nile", "ORGANISM", 245, 254], ["West Nile, severe acute respiratory syndrome, dengue", "SPECIES", 245, 297], ["The LAMP assay", "TEST", 7, 21], ["a powerful gene amplification tool", "PROBLEM", 37, 71], ["microbial infections", "PROBLEM", 104, 124], ["the rapid detection", "TEST", 185, 204], ["emerging viruses", "PROBLEM", 219, 235], ["severe acute respiratory syndrome", "PROBLEM", 256, 289], ["dengue", "PROBLEM", 291, 297], ["Japanese encephalitis", "PROBLEM", 299, 320], ["chikungunya", "PROBLEM", 322, 333], ["microbial", "OBSERVATION_MODIFIER", 104, 113], ["infections", "OBSERVATION", 114, 124], ["viruses", "OBSERVATION", 228, 235], ["severe", "OBSERVATION_MODIFIER", 256, 262], ["acute", "OBSERVATION_MODIFIER", 263, 268], ["respiratory syndrome", "OBSERVATION", 269, 289], ["encephalitis", "OBSERVATION", 308, 320]]], ["20 -25 In the present study, we report the development of a one-step, real-time RTLAMP assay for rapid and real-time detection of novel S-OIV RNA in clinical specimens by targeting the HA gene.", [["specimens", "ANATOMY", 158, 167], ["S-OIV", "GENE_OR_GENE_PRODUCT", 136, 141], ["specimens", "CANCER", 158, 167], ["HA", "GENE_OR_GENE_PRODUCT", 185, 187], ["novel S-OIV RNA", "RNA", 130, 145], ["HA gene", "DNA", 185, 192], ["OIV", "SPECIES", 138, 141], ["novel S-OIV RNA", "PROBLEM", 130, 145], ["clinical specimens", "TEST", 149, 167]]], ["The particular importance is the substantial reduction in the time required for the confirmation of results: 30 minutes as opposed 2 to 3 hours in real time RT-PCR.", [["the substantial reduction", "TREATMENT", 29, 54], ["substantial", "OBSERVATION_MODIFIER", 33, 44], ["reduction", "OBSERVATION_MODIFIER", 45, 54]]], ["The S-OIV H1 gene-specific RTLAMP assay reported in this study was found to be a simple, rapid, reliable, and inexpensive method for the detection as well as the identification of novel S-OIV without requiring any sophisticated instruments or fluorescent probes.", [["S-OIV", "CHEMICAL", 186, 191], ["S-OIV H1", "GENE_OR_GENE_PRODUCT", 4, 12], ["S-OIV", "SIMPLE_CHEMICAL", 186, 191], ["S-OIV H1 gene", "DNA", 4, 17], ["RTLAMP", "DNA", 27, 33], ["The S-OIV H1 gene", "TEST", 0, 17], ["specific RTLAMP assay", "TEST", 18, 39], ["this study", "TEST", 52, 62], ["the detection", "TEST", 133, 146], ["any sophisticated instruments", "TREATMENT", 210, 239], ["fluorescent probes", "TREATMENT", 243, 261]]], ["The data concerning the sensitivity and specificity of the method is discussed, and the applicability of RTLAMP technology to clinical diagnosis of patients with swine flu is validated by evaluation by acute-phase throat swab samples collected from the ongoing epidemic in India.Primer DesignWe designed a set of six primers comprising two outer, two inner, and two loop primers that recognize eight distinct regions spanning more than 188 base pair (bp)conserved regions of the structural HA gene of the novel H1N1 virus, corresponding to the genome position 529 -716.", [["throat swab samples", "ANATOMY", 214, 233], ["swine flu", "DISEASE", 162, 171], ["patients", "ORGANISM", 148, 156], ["HA", "GENE_OR_GENE_PRODUCT", 490, 492], ["H1N1 virus", "ORGANISM", 511, 521], ["Primer DesignWe", "DNA", 279, 294], ["188 base pair (bp)conserved regions", "DNA", 436, 471], ["structural HA gene", "DNA", 479, 497], ["genome position 529 -716", "DNA", 544, 568], ["patients", "SPECIES", 148, 156], ["swine", "SPECIES", 162, 167], ["novel H1N1 virus", "SPECIES", 505, 521], ["swine flu", "SPECIES", 162, 171], ["H1N1 virus", "SPECIES", 511, 521], ["The data", "TEST", 0, 8], ["the sensitivity", "TEST", 20, 35], ["swine flu", "PROBLEM", 162, 171], ["evaluation", "TEST", 188, 198], ["acute-phase throat swab samples", "TEST", 202, 233], ["six primers", "TREATMENT", 313, 324], ["two loop primers", "TREATMENT", 362, 378], ["the novel H1N1 virus", "PROBLEM", 501, 521], ["epidemic", "OBSERVATION_MODIFIER", 261, 269], ["loop primers", "OBSERVATION", 366, 378], ["eight", "OBSERVATION_MODIFIER", 394, 399], ["distinct", "OBSERVATION_MODIFIER", 400, 408], ["H1N1", "OBSERVATION", 511, 515]]], ["The two outer primers were described as the forward outer primer (F3) and the backward outer primer (B3).", [["forward outer primer", "DNA", 44, 64], ["F3", "DNA", 66, 68], ["backward outer primer", "DNA", 78, 99], ["B3", "DNA", 101, 103], ["The two outer primers", "TREATMENT", 0, 21], ["two", "OBSERVATION_MODIFIER", 4, 7], ["outer", "OBSERVATION_MODIFIER", 8, 13], ["primers", "OBSERVATION", 14, 21]]], ["The inner primers were described as the forward inner primer (FIP) and the backward inner primer (BIP).", [["forward inner primer", "DNA", 40, 60], ["FIP", "DNA", 62, 65], ["backward inner primer", "DNA", 75, 96], ["BIP", "DNA", 98, 101], ["The inner primers", "TREATMENT", 0, 17], ["the backward inner primer", "TREATMENT", 71, 96], ["inner", "ANATOMY_MODIFIER", 4, 9]]], ["Further, two loop primers, forward loop primer (FLP) and backward loop primer (BLP), were designed to accelerate the amplification reaction.", [["forward loop primer", "DNA", 27, 46], ["FLP", "DNA", 48, 51], ["backward loop primer", "DNA", 57, 77], ["BLP", "DNA", 79, 82], ["two loop primers", "TREATMENT", 9, 25], ["forward loop primer", "TREATMENT", 27, 46], ["backward loop primer", "TREATMENT", 57, 77], ["the amplification reaction", "PROBLEM", 113, 139], ["loop primers", "OBSERVATION", 13, 25], ["loop", "OBSERVATION_MODIFIER", 35, 39]]], ["The usefulness of the selected primer set for correctly identifying all strains and isolates of S-OIV was established through sequence alignment of all available HA gene sequences in the GenBank, including the circulating strains responsible for the recent pandemic in India, using DNASIS software (MiraiBio, Yokohama, Japan).", [["S-OIV", "ORGANISM", 96, 101], ["HA gene sequences", "DNA", 162, 179], ["S-OIV", "SPECIES", 96, 101], ["all strains", "PROBLEM", 68, 79], ["all available HA gene sequences", "PROBLEM", 148, 179], ["the circulating strains", "PROBLEM", 206, 229]]], ["In addition, the homology study was used to ensure the maximum number of mismatched nucleotides between pandemic S-OIV sequences and seasonal flu (InfA), including other respiratory viruses, such as respiratory syncytial virus, para influenza, adeno virus, and so forth, so as to avoid crossamplification.", [["respiratory viruses", "DISEASE", 170, 189], ["respiratory syncytial virus", "DISEASE", 199, 226], ["influenza", "DISEASE", 233, 242], ["nucleotides", "CHEMICAL", 84, 95], ["respiratory syncytial virus", "ORGANISM", 199, 226], ["para influenza", "ORGANISM", 228, 242], ["adeno virus", "ORGANISM", 244, 255], ["pandemic S-OIV sequences", "DNA", 104, 128], ["respiratory syncytial virus", "SPECIES", 199, 226], ["para influenza", "SPECIES", 228, 242], ["adeno virus", "SPECIES", 244, 255], ["respiratory syncytial virus", "SPECIES", 199, 226], ["adeno virus", "SPECIES", 244, 255], ["the homology study", "TEST", 13, 31], ["mismatched nucleotides", "PROBLEM", 73, 95], ["pandemic S-OIV sequences", "TEST", 104, 128], ["seasonal flu (InfA)", "PROBLEM", 133, 152], ["other respiratory viruses", "PROBLEM", 164, 189], ["respiratory syncytial virus", "PROBLEM", 199, 226], ["para influenza", "PROBLEM", 228, 242], ["adeno virus", "PROBLEM", 244, 255], ["mismatched nucleotides", "OBSERVATION", 73, 95], ["respiratory viruses", "OBSERVATION", 170, 189], ["syncytial virus", "OBSERVATION", 211, 226]]], ["The details of the primer sequences with regard to genome position are depicted in Table 1 .Clinical SamplesA total of 239 acute-phase throat-swab samples were collected from patients when they were between 3 and 7 days of having a fever.", [["samples", "ANATOMY", 147, 154], ["fever", "DISEASE", 232, 237], ["patients", "ORGANISM", 175, 183], ["primer sequences", "DNA", 19, 35], ["patients", "SPECIES", 175, 183], ["the primer sequences", "TEST", 15, 35], ["swab samples", "TEST", 142, 154], ["a fever", "PROBLEM", 230, 237], ["fever", "OBSERVATION", 232, 237]]], ["The patients were referred to the National Centre for Disease Control in Delhi, India; the Post Graduate Institute of Medical Education and Research in Chandigarh, India; and the National Institute of Mental Health and Neuro Sciences in Bangalore, India, for S-OIV H1N1 testing.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["S-OIV H1N1", "SPECIES", 259, 269], ["H1N1 testing", "TEST", 265, 277]]], ["The RNA extracted from these samples was stored at \u03ea80\u00b0C at the respective centers.", [["samples", "ANATOMY", 29, 36], ["samples", "CANCER", 29, 36], ["C", "GENE_OR_GENE_PRODUCT", 55, 56], ["The RNA", "TEST", 0, 7], ["these samples", "TEST", 23, 36]]], ["The testing of S-OIV H1 RTLAMP was performed within one month of storage at the centers.", [["H1", "SPECIES", 21, 23], ["The testing of S-OIV H1 RTLAMP", "TEST", 0, 30]]], ["To check the crossreactivity, 34 real-time RTPCR-confirmed InfA-positive samples were also included in the panel in addition to 20 throat-swab samples collected from apparently healthy individuals who served as negative controls.RNA ExtractionThe genomic viral RNA was extracted from 140 L of throat and nasal swab suspensions using QIAamp viral RNA mini kit (QIAGEN, Hilden, Germany) according to the manufacturer's protocols.One-Step RT-LAMPThe amplification of the HA gene of H1N1 virus was carried out in a total 25 L reaction volume using 12.", [["samples", "ANATOMY", 73, 80], ["throat-swab samples", "ANATOMY", 131, 150], ["throat", "ANATOMY", 293, 299], ["nasal swab", "ANATOMY", 304, 314], ["InfA", "GENE_OR_GENE_PRODUCT", 59, 63], ["throat", "ORGANISM_SUBDIVISION", 293, 299], ["nasal swab", "ORGANISM_SUBSTANCE", 304, 314], ["HA", "GENE_OR_GENE_PRODUCT", 468, 470], ["H1N1 virus", "ORGANISM", 479, 489], ["InfA", "PROTEIN", 59, 63], ["genomic viral RNA", "RNA", 247, 264], ["HA gene", "DNA", 468, 475], ["H1N1 virus", "SPECIES", 479, 489], ["H1N1 virus", "SPECIES", 479, 489], ["the crossreactivity", "TEST", 9, 28], ["RTPCR", "TEST", 43, 48], ["InfA", "TEST", 59, 63], ["the panel", "TEST", 103, 112], ["throat-swab samples", "TEST", 131, 150], ["RNA Extraction", "TREATMENT", 229, 243], ["The genomic viral RNA", "PROBLEM", 243, 264], ["throat", "TEST", 293, 299], ["nasal swab suspensions", "TREATMENT", 304, 326], ["the manufacturer's protocols", "TREATMENT", 398, 426], ["Step RT-LAMPThe amplification", "TREATMENT", 431, 460], ["H1N1 virus", "PROBLEM", 479, 489], ["a total 25 L reaction volume", "TREATMENT", 509, 537], ["genomic", "OBSERVATION_MODIFIER", 247, 254], ["viral RNA", "OBSERVATION", 255, 264], ["throat", "ANATOMY", 293, 299], ["nasal", "ANATOMY", 304, 309]]], ["L of nuclease-free water; and 5 L of RNA at 37\u00b0C for 30 minutes.", [["nuclease", "PROTEIN", 5, 13], ["nuclease-free water", "TREATMENT", 5, 24], ["RNA", "TREATMENT", 37, 40], ["free", "OBSERVATION_MODIFIER", 14, 18]]], ["The gene amplification was accomplished by incubating the reaction mixture at 63\u00b0C for 60 minutes in a routine laboratory water bath/dry heating bath.", [["The gene amplification", "TREATMENT", 0, 22], ["a routine laboratory water bath", "TREATMENT", 101, 132], ["dry heating bath", "TREATMENT", 133, 149]]], ["To rule out contamination issues, proper negative controls, including no template, no primer; and no enzyme, were always kept alongside each run.Real-Time Monitoring of RTLAMPThe real-time monitoring of RTLAMP was observed through spectrophotometric analysis by recording optical density at 400 nm every 6 seconds with the help of a loop amp real-time turbidimeter (LA-200, Teramecs, Kyoto, Japan).", [["LA", "CHEMICAL", 366, 368], ["RTLAMP", "SIMPLE_CHEMICAL", 203, 209], ["RTLAMP", "PROTEIN", 203, 209], ["contamination issues", "PROBLEM", 12, 32], ["primer", "PROBLEM", 86, 92], ["enzyme", "TEST", 101, 107], ["RTLAMP", "TEST", 203, 209], ["spectrophotometric analysis", "TEST", 231, 258], ["a loop amp real-time turbidimeter", "TREATMENT", 331, 364], ["LA", "TEST", 366, 368], ["Teramecs", "TREATMENT", 374, 382], ["contamination", "OBSERVATION", 12, 25]]], ["The cut-off value for positivity by the real time RTLAMP assay was determined by taking into account the time of positivity, in minutes, at which the turbidity increases above the threshold value, fixed at 0.1, which is two times more than the average turbidity value of the negative controls of several replicates.Agarose Gel AnalysisFollowing incubation at 63\u00b0C for 60 minutes, 10 L aliquot of RTLAMP products were electrophoresed on 3% NuSieve 3:1 agarose gel (BMA, Rockland, ME) in Trisborate buffer followed by staining with ethidium bromide and visualization on an UV transilluminator at 302 nm.Naked-Eye VisualizationFollowing amplification, the tubes were inspected by naked eye for white turbidity after pulse spins to deposit the precipitate in the bottom of the tube.", [["eye", "ANATOMY", 683, 686], ["tube", "ANATOMY", 773, 777], ["ethidium bromide", "CHEMICAL", 530, 546], ["ethidium bromide", "CHEMICAL", 530, 546], ["Agarose", "SIMPLE_CHEMICAL", 315, 322], ["agarose", "SIMPLE_CHEMICAL", 451, 458], ["BMA", "SIMPLE_CHEMICAL", 464, 467], ["Trisborate", "SIMPLE_CHEMICAL", 486, 496], ["ethidium bromide", "SIMPLE_CHEMICAL", 530, 546], ["eye", "ORGAN", 683, 686], ["tube", "TISSUE", 773, 777], ["the real time RTLAMP assay", "TEST", 36, 62], ["the turbidity", "TEST", 146, 159], ["the threshold value", "TEST", 176, 195], ["RTLAMP products", "TREATMENT", 396, 411], ["3:1 agarose gel", "TREATMENT", 447, 462], ["Trisborate buffer", "TREATMENT", 486, 503], ["ethidium bromide", "TREATMENT", 530, 546], ["an UV transilluminator", "TREATMENT", 568, 590], ["Eye VisualizationFollowing amplification", "TREATMENT", 607, 647], ["the tubes", "TREATMENT", 649, 658], ["white turbidity", "PROBLEM", 691, 706], ["pulse spins", "TREATMENT", 713, 724], ["the tube", "TREATMENT", 769, 777], ["turbidity", "OBSERVATION", 150, 159], ["Eye", "ANATOMY", 607, 610], ["eye", "ANATOMY", 683, 686], ["tube", "OBSERVATION", 773, 777]]], ["The inspection for amplification was also performed by observation of color change following the addition of 1 L of SYBR Green 1 dye (Cambrex, East Rutherford, NJ) to the tube.", [["tube", "ANATOMY", 171, 175], ["SYBR Green 1 dye", "CHEMICAL", 116, 132], ["tube", "TISSUE", 171, 175], ["The inspection", "TEST", 0, 14], ["SYBR", "TREATMENT", 116, 120], ["the tube", "TREATMENT", 167, 175], ["tube", "OBSERVATION", 171, 175]]], ["In cases of positive amplification, the original orange color of the dye changes to green and can be seen in natural light and under UV light (302 nm).", [["positive amplification", "PROBLEM", 12, 34], ["the dye changes", "PROBLEM", 65, 80], ["positive amplification", "OBSERVATION", 12, 34]]], ["If there is no amplification, the original orange color of the dye is retained.", [["amplification", "PROBLEM", 15, 28], ["no", "UNCERTAINTY", 12, 14]]], ["However, to rule out bias in borderline cases, the result was recorded by three observers in the laboratory, and the sample was considered positive if the score was judged to be positive by more than two observers.Sensitivity of S-OIV RTLAMPThe limit of detection of both S-OIV H1 RTLAMP as well as WHO-approved, CDC-recommended real-time RTPCR was determined by using the titrated infected culture fluid of the H1N1 virus isolate obtained from our clinical collaborators at the National Institute of Mental Health and Neuro Sciences in Bangalore, India.", [["H1N1 virus", "SPECIES", 412, 422], ["H1N1 virus", "SPECIES", 412, 422], ["bias in borderline cases", "PROBLEM", 21, 45], ["the sample", "TEST", 113, 123], ["the score", "TEST", 151, 160], ["CDC", "TEST", 313, 316], ["the titrated infected culture fluid", "TREATMENT", 369, 404], ["the H1N1 virus isolate", "TREATMENT", 408, 430]]], ["The serial tenfold dilutions of extracted RNA from the infected culture fluid were analyzed in triplicate.", [["culture fluid", "ANATOMY", 64, 77], ["The serial tenfold dilutions", "TREATMENT", 0, 28], ["extracted RNA", "PROBLEM", 32, 45], ["the infected culture fluid", "TEST", 51, 77], ["infected", "OBSERVATION_MODIFIER", 55, 63]]], ["To generate the S-OIV H1 gene-specific RTLAMP standard curve, 188 bp target of the H1 gene was amplified by outer (F3) and backward outer (B3) primers.", [["S-OIV H1", "GENE_OR_GENE_PRODUCT", 16, 24], ["H1", "GENE_OR_GENE_PRODUCT", 83, 85], ["S-OIV H1 gene", "DNA", 16, 29], ["RTLAMP standard curve", "DNA", 39, 60], ["188 bp target", "DNA", 62, 75], ["H1 gene", "DNA", 83, 90], ["outer (F3) and backward outer (B3) primers", "DNA", 108, 150], ["bp", "TEST", 66, 68], ["the H1 gene", "TREATMENT", 79, 90], ["backward outer (B3) primers", "TREATMENT", 123, 150]]], ["The amplicon was then purified and cloned using the pC R4-TOPO vector system (Invitrogen, San Diego, CA) according to the manufacturer's specifications.", [["pC R4", "DNA", 52, 57], ["The amplicon", "TREATMENT", 0, 12], ["the pC R4-TOPO vector system", "TREATMENT", 48, 76]]], ["The sequence confirmed that plasmid was linearized using a vector-specific restriction enzyme (NdeI) and then quantified by Quantity One software (Bio-Rad, Hercules, CA).", [["plasmid", "ANATOMY", 28, 35], ["NdeI", "GENE_OR_GENE_PRODUCT", 95, 99], ["plasmid", "DNA", 28, 35], ["restriction enzyme", "PROTEIN", 75, 93], ["NdeI", "PROTEIN", 95, 99], ["The sequence", "TEST", 0, 12], ["a vector", "TREATMENT", 57, 65], ["Bio", "TEST", 147, 150]]], ["The concentration of the plasmid preparation was determined by measuring the OD at 260 nm.", [["plasmid", "ANATOMY", 25, 32], ["the plasmid preparation", "TREATMENT", 21, 44], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["Conversion to genome equivalents was calculated as 1 OD260 equals 50g/ml and one bp equals 660 g/mol, resulting in a molecular weight for the plasmid (4156 bp) of 2.74 \u03eb 10 6 pg/pmol.", [["plasmid", "DNA", 142, 149], ["the plasmid", "TREATMENT", 138, 149], ["bp", "TEST", 156, 158]]], ["The copy numbers per L were determined by using the following formula:Sensitivity of S-OIV RTLAMPCopies L \u03ed Concentration of plasmid in g per L (plasmid length \u03eb 660) \u03eb 6.022 \u03eb 10 23Sensitivity of S-OIV RTLAMPFurther serial tenfold dilution of the linearized plasmid was used in triplicate for detection of sensitivity and for construction of a standard curve using the cycle threshold values obtained from the known concentration of serially diluted plasmid constructs.Evaluation of Throat Swab SamplesThe applicability of S-OIV H1 RTLAMP for clinical diagnosis was validated by the study of 239 human throat swab samples, including those of 34 patients who had seasonal flu and 20 who were apparently healthy, negative controls.", [["plasmid", "ANATOMY", 259, 266], ["plasmid", "ANATOMY", 451, 458], ["throat swab samples", "ANATOMY", 603, 622], ["human", "ORGANISM", 597, 602], ["throat swab samples", "CANCER", 603, 622], ["patients", "ORGANISM", 646, 654], ["plasmid", "DNA", 125, 132], ["linearized plasmid", "DNA", 248, 266], ["serially diluted plasmid constructs", "DNA", 434, 469], ["human", "SPECIES", 597, 602], ["patients", "SPECIES", 646, 654], ["H1", "SPECIES", 530, 532], ["human", "SPECIES", 597, 602], ["Sensitivity", "TEST", 70, 81], ["S-OIV RTLAMPCopies", "TREATMENT", 85, 103], ["Concentration of plasmid", "TREATMENT", 108, 132], ["the linearized plasmid", "TREATMENT", 244, 266], ["sensitivity", "TEST", 307, 318], ["a standard curve", "TEST", 343, 359], ["the cycle threshold values", "TEST", 366, 392], ["serially diluted plasmid constructs", "TREATMENT", 434, 469], ["Evaluation", "TEST", 470, 480], ["Throat Swab Samples", "TEST", 484, 503], ["S-OIV H1 RTLAMP", "TREATMENT", 524, 539], ["the study", "TEST", 580, 589], ["human throat swab samples", "TEST", 597, 622], ["Throat", "ANATOMY", 484, 490]]], ["The results were compared with the results of the WHO-approved, CDC-recommended real-time RTPCR.Real-Time RTPCRBefore the RTLAMP assay, all the samples were analyzed by the CDC-recommended real-time RTPCR.", [["samples", "ANATOMY", 144, 151], ["the CDC", "TEST", 169, 176]]], ["The assay is based on TaqMan assays (Applied Biosystems) that involve a panel of oligonucleotide primers and a duallabeled hydrolysis probe using the Superscript TM III Platinum One-Step quantitative kit (Invitrogen).", [["The assay", "TEST", 0, 9], ["TaqMan assays", "TEST", 22, 35], ["oligonucleotide primers", "TREATMENT", 81, 104], ["a duallabeled hydrolysis probe", "TREATMENT", 109, 139], ["the Superscript TM III Platinum", "TREATMENT", 146, 177]]], ["The amplification was carried out in a 25 L reaction volume according to the manufacturer's instructions and the recommended thermal profile.SYBR Green I-Based Real-Time RTPCRAnalysis of the discrepant additional positive samples was carried out by sequencing more than one target gene-that is, not only RTLAMP, but also 141bp of HA (1010 -1150) and 173 bp of NA (1137-1309).", [["samples", "ANATOMY", 222, 229], ["RTLAMP", "GENE_OR_GENE_PRODUCT", 304, 310], ["target gene", "DNA", 274, 285], ["RTLAMP", "DNA", 304, 310], ["HA", "DNA", 330, 332], ["a 25 L reaction volume", "TREATMENT", 37, 59], ["bp", "TEST", 324, 326], ["HA", "TEST", 330, 332], ["bp", "TEST", 354, 356], ["NA", "TEST", 360, 362]]], ["We used SYBR Green I-based, one-step, real-time RTPCR in an MX 3000P quantitative PCR system (Stratagene, La Jolla, CA) for further confirmation.", [["further confirmation", "TEST", 124, 144]]], ["Following optimization with standard RNA using Brilliant SYBR Green Single-Step QRTPCR Master Mix (Stratagene), test samples were assayed in a 25-L reaction mixture containing 12.5 L of 2x reaction mix, 0.4 L of reference dye (ROX), 1 L (10 pmol) of each forward (F3) and reverse (B3) primers, 1 L of RNA, 0.1 L of reverse transcriptase, and 9.0 L of nuclease-free water.", [["samples", "ANATOMY", 117, 124], ["ROX", "CHEMICAL", 227, 230], ["ROX", "SIMPLE_CHEMICAL", 227, 230], ["reverse transcriptase", "PROTEIN", 315, 336], ["nuclease", "PROTEIN", 351, 359], ["standard RNA", "TREATMENT", 28, 40], ["test samples", "TEST", 112, 124], ["a 25-L reaction mixture", "TREATMENT", 141, 164], ["2x reaction mix", "TREATMENT", 186, 201], ["reference dye (ROX)", "TREATMENT", 212, 231], ["reverse (B3) primers", "TREATMENT", 272, 292], ["RNA", "TEST", 301, 304], ["reverse transcriptase", "TREATMENT", 315, 336], ["nuclease-free water", "TREATMENT", 351, 370]]], ["The thermal profile consists of 1 cycle of 30 minutes of reverse transcription at 50\u00b0C and 10 minutes of TaqDNA polymerase activation at 95\u00b0C, followed by 40 cycles of PCR at 95\u00b0C for 30 seconds (denaturation), 55\u00b0C for 60 seconds (annealing), and 72\u00b0C for 30 seconds (extension).Sequence AnalysisTo establish the authenticity of the S-OIV H1 RTLAMP, the HA and NA genes (resulting amplicons of the real-time RTPCR) were sequenced with two outer LAMP primers (F3 and B3) using a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).", [["S-OIV H1", "GENE_OR_GENE_PRODUCT", 334, 342], ["TaqDNA polymerase", "PROTEIN", 105, 122], ["S-OIV H1 RTLAMP", "DNA", 334, 349], ["HA and NA genes", "DNA", 355, 370], ["RTPCR", "DNA", 409, 414], ["outer LAMP primers", "DNA", 440, 458], ["F3", "DNA", 460, 462], ["B3", "DNA", 467, 469], ["reverse transcription", "TREATMENT", 57, 78], ["TaqDNA polymerase activation", "TREATMENT", 105, 133], ["PCR", "TEST", 168, 171], ["the HA and NA genes", "PROBLEM", 351, 370], ["two outer LAMP primers", "TREATMENT", 436, 458], ["a BigDye Terminator", "TREATMENT", 477, 496]]], ["The sequencing was carried out using a 3130 DNA analyzer (Applied Biosystems), and all of the sequences were assembled using Lasergene software (DNA Star, Madison, WI).", [["DNA", "CELLULAR_COMPONENT", 44, 47], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["DNA Star", "DNA", 145, 153], ["a 3130 DNA analyzer", "TREATMENT", 37, 56], ["the sequences", "TEST", 90, 103]]], ["Along with the RTLAMP target, we also sequenced 141 bp of the HA gene (1010 -1150) and 173 bp of the NA (1137-1309) for confirmation of discrepant additional positive samples.ResultsA one-step, real-time, accelerated quantitative RTLAMP assay was standardized for rapid detection of novel S-OIV.", [["samples", "ANATOMY", 167, 174], ["RTLAMP", "GENE_OR_GENE_PRODUCT", 15, 21], ["S-OIV", "SIMPLE_CHEMICAL", 289, 294], ["RTLAMP target", "DNA", 15, 28], ["HA gene", "DNA", 62, 69], ["1010 -1150", "DNA", 71, 81], ["bp", "TEST", 52, 54], ["the HA gene", "TEST", 58, 69], ["bp", "TEST", 91, 93], ["the NA", "TEST", 97, 103], ["discrepant additional positive samples", "PROBLEM", 136, 174], ["ResultsA", "TEST", 175, 183], ["accelerated quantitative RTLAMP assay", "PROBLEM", 205, 242], ["rapid detection", "TEST", 264, 279], ["positive", "OBSERVATION", 158, 166]]], ["A set of six primers, comprising two outer primers (F3 and B3), two internal primers (FIP and BIP), and two loop primers (FLP and BLP), were designed using the H1 gene strain recommended by the WHO (Human H1N1 virus isolates, California, 2009, Gene Bank Accession No FJ966082).", [["FLP", "GENE_OR_GENE_PRODUCT", 122, 125], ["BLP", "GENE_OR_GENE_PRODUCT", 130, 133], ["Human H1N1 virus", "ORGANISM", 199, 215], ["outer primers", "DNA", 37, 50], ["F3", "DNA", 52, 54], ["B3", "DNA", 59, 61], ["internal primers", "DNA", 68, 84], ["FIP", "DNA", 86, 89], ["BIP", "DNA", 94, 97], ["loop primers", "DNA", 108, 120], ["FLP", "DNA", 122, 125], ["BLP", "DNA", 130, 133], ["Human H1N1 virus", "SPECIES", 199, 215], ["Human H1N1 virus", "SPECIES", 199, 215], ["six primers", "TREATMENT", 9, 20], ["two outer primers", "TEST", 33, 50], ["two loop primers", "TREATMENT", 104, 120], ["the H1 gene strain", "TREATMENT", 156, 174], ["internal primers", "ANATOMY", 68, 84]]], ["Each primer's position in the genomic sequences is shown in Table 1 .ResultsThe monitoring of gene amplification was accomplished by real-time monitoring of turbidity, which is recorded at 400 nm every 6 seconds with the help of a loopamp real-time turbidity meter (Teramecs, Los Angeles, CA).", [["genomic sequences", "DNA", 30, 47], ["gene amplification", "TREATMENT", 94, 112]]], ["It was also observed that there was continuous amplification of the target sequence, as revealed by the increased turbidity; in the negative control, the turbidity remained fixed at about 0.01, well below the threshold value ( Figure 1) .", [["target sequence", "DNA", 68, 83], ["the target sequence", "TEST", 64, 83], ["the increased turbidity", "PROBLEM", 100, 123], ["the turbidity", "TEST", 150, 163], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["turbidity", "OBSERVATION", 114, 123], ["turbidity", "OBSERVATION_MODIFIER", 154, 163]]], ["None of the positive samples, which were tested multiple times, showed increased turbidity after 30 minutes.", [["samples", "ANATOMY", 21, 28], ["the positive samples", "TEST", 8, 28], ["increased turbidity", "PROBLEM", 71, 90], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["turbidity", "OBSERVATION", 81, 90]]], ["Therefore, a sample having time of positivity (Tp) values of 30 minutes or less and turbidity above the threshold value of 0.1 or more was considered to be positive.Sensitivity and Specificity of S-OIV H1 RTLAMPThe comparative limit of detection of S-OIV H1 RTLAMP as well as WHO-approved, CDC-recommended real-time RTPCR were determined by using serial tenfold dilutions of extracted RNA from the infected culture fluid in triplicate.", [["culture fluid", "ANATOMY", 407, 420], ["OIV", "SPECIES", 198, 201], ["H1", "SPECIES", 255, 257], ["a sample", "TEST", 11, 19], ["turbidity", "TEST", 84, 93], ["the threshold value", "TEST", 100, 119], ["Sensitivity", "TEST", 165, 176], ["Specificity", "TEST", 181, 192], ["RTPCR", "TEST", 316, 321], ["serial tenfold dilutions", "TREATMENT", 347, 371], ["extracted RNA", "PROBLEM", 375, 388], ["the infected culture fluid", "TEST", 394, 420], ["positive", "OBSERVATION", 156, 164]]], ["The limit of detection for the S-OIV H1 RTLAMP assay was found to be 0.1 tissue culture infection dosage H1 RTLAMP is as much as tenfold more sensitive than the WHO-CDC real-time RTPCR.Sensitivity and Specificity of S-OIV H1 RTLAMPA standard curve was generated by plotting a graph between different concentrations of gene copy numbers (10 6 to 1) and time of positivity (Tp) in minutes through real-time monitoring (Figure 2A-B) .", [["tissue culture", "ANATOMY", 73, 87], ["infection", "DISEASE", 88, 97], ["H1", "SPECIES", 37, 39], ["H1", "SPECIES", 105, 107], ["OIV", "SPECIES", 218, 221], ["the S-OIV H1 RTLAMP assay", "TEST", 27, 52], ["tissue culture infection dosage H1 RTLAMP", "PROBLEM", 73, 114], ["RTPCR", "TEST", 179, 184], ["Sensitivity", "TEST", 185, 196], ["Specificity", "TEST", 201, 212]]], ["The quantification of the virus load in the positive samples was extrapolated on the basis of their Tp by using the standard curve.Sensitivity and Specificity of S-OIV H1 RTLAMPThe specificity of the RTLAMP primers for the H1 gene of S-OIV was established by ruling out the cross-reactivity with seasonal flu viruses having similar clinical symptoms.", [["samples", "ANATOMY", 53, 60], ["flu viruses", "DISEASE", 305, 316], ["S-OIV", "GENE_OR_GENE_PRODUCT", 234, 239], ["RTLAMP primers", "DNA", 200, 214], ["H1 gene", "DNA", 223, 230], ["H1", "SPECIES", 168, 170], ["H1", "SPECIES", 223, 225], ["S-OIV", "SPECIES", 234, 239], ["seasonal flu viruses", "SPECIES", 296, 316], ["the virus load", "PROBLEM", 22, 36], ["the positive samples", "PROBLEM", 40, 60], ["the standard curve", "TEST", 112, 130], ["Sensitivity", "TEST", 131, 142], ["Specificity", "TEST", 147, 158], ["the RTLAMP primers", "TREATMENT", 196, 214], ["the cross-reactivity", "PROBLEM", 270, 290], ["seasonal flu viruses", "PROBLEM", 296, 316], ["similar clinical symptoms", "PROBLEM", 324, 349], ["virus load", "OBSERVATION", 26, 36]]], ["The S-OIV H1 gene-specific RTLAMP primers showed a high degree of specificity for the novel H1N1 virus by amplifying the H1 gene of the novel H1N1 virus only while yielding negative results for seasonal flu as well as for healthy throat-swab samples.", [["samples", "ANATOMY", 242, 249], ["S-OIV H1", "GENE_OR_GENE_PRODUCT", 4, 12], ["RTLAMP", "GENE_OR_GENE_PRODUCT", 27, 33], ["H1N1 virus", "ORGANISM", 92, 102], ["H1", "GENE_OR_GENE_PRODUCT", 121, 123], ["H1N1 virus", "ORGANISM", 142, 152], ["S-OIV H1 gene", "DNA", 4, 17], ["RTLAMP primers", "DNA", 27, 41], ["H1 gene", "DNA", 121, 128], ["H1N1 virus", "SPECIES", 92, 102], ["novel H1N1 virus", "SPECIES", 136, 152], ["H1N1 virus", "SPECIES", 92, 102], ["H1N1 virus", "SPECIES", 142, 152], ["The S-OIV H1 gene", "TEST", 0, 17], ["specific RTLAMP primers", "TEST", 18, 41], ["the novel H1N1 virus", "PROBLEM", 82, 102], ["the novel H1N1 virus", "PROBLEM", 132, 152], ["seasonal flu", "PROBLEM", 194, 206], ["healthy throat-swab samples", "TEST", 222, 249], ["high degree", "OBSERVATION_MODIFIER", 51, 62]]], ["Further confirmation of the structures of the amplified products was also carried out by sequencing; the sequences we obtained perfectly matched the expected nucleotide sequences (data not shown).Evaluation of Efficacy in Clinical SamplesThe feasibility of using S-OIV H1 RTLAMP for clinical diagnosis was validated by studying a panel of 239 human throat-wash samples suspected to be part of the ongoing epidemic.", [["samples", "ANATOMY", 361, 368], ["nucleotide", "CHEMICAL", 158, 168], ["human", "ORGANISM", 343, 348], ["throat", "ORGANISM_SUBDIVISION", 349, 355], ["nucleotide sequences", "DNA", 158, 178], ["human", "SPECIES", 343, 348], ["H1", "SPECIES", 269, 271], ["human", "SPECIES", 343, 348], ["the sequences", "TEST", 101, 114], ["the expected nucleotide sequences", "TEST", 145, 178], ["Evaluation", "TEST", 196, 206], ["Clinical Samples", "TEST", 222, 238], ["S-OIV H1 RTLAMP", "TREATMENT", 263, 278], ["a panel", "TEST", 328, 335], ["human throat", "TEST", 343, 355], ["wash samples", "TEST", 356, 368], ["epidemic", "OBSERVATION", 405, 413]]], ["The comparative evaluation of the S-OIV H1-specific RTLAMP assay using WHO-recommended, CDC-approved, real-time RTPCR demonstrated exceptionally higher sensitivity by picking up 36 additional positive borderline cases (as indicated by higher Tp values).Evaluation of Efficacy in Clinical SamplesFurther analysis of the discrepant additional positive samples was carried out by sequencing both HA and NA genes in addition to the RTLAMP target.", [["samples", "ANATOMY", 350, 357], ["S-OIV H1", "GENE_OR_GENE_PRODUCT", 34, 42], ["OIV H1", "PROTEIN", 36, 42], ["RTLAMP", "PROTEIN", 52, 58], ["HA and NA genes", "DNA", 393, 408], ["RTLAMP target", "DNA", 428, 441], ["The comparative evaluation", "TEST", 0, 26], ["the S", "TEST", 30, 35], ["CDC", "TEST", 88, 91], ["RTPCR", "TEST", 112, 117], ["additional positive borderline cases", "PROBLEM", 181, 217], ["Evaluation", "TEST", 253, 263], ["Clinical SamplesFurther analysis", "TEST", 279, 311], ["the discrepant additional positive samples", "PROBLEM", 315, 357]]], ["All these additional positive samples were amplified by SYBR Green I real-time RTPCR, and the amplicons were then purified and sequenced as indicated earlier.", [["samples", "ANATOMY", 30, 37], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 56, 68], ["SYBR Green I real-time RTPCR", "DNA", 56, 84], ["RTPCR", "TEST", 79, 84], ["the amplicons", "TREATMENT", 90, 103]]], ["Sequence analysis of partial HA genes in all of these samples revealed \u03fe99% nucleotide identity with the A/California/04/2009 (H1N1) prototype strain.", [["samples", "ANATOMY", 54, 61], ["nucleotide", "CHEMICAL", 76, 86], ["nucleotide", "CHEMICAL", 76, 86], ["HA", "GENE_OR_GENE_PRODUCT", 29, 31], ["samples", "CANCER", 54, 61], ["A/California/04/2009 (H1N1)", "ORGANISM", 105, 132], ["HA genes", "DNA", 29, 37], ["A/California/04/2009 (H1N1)", "SPECIES", 105, 132], ["Sequence analysis", "TEST", 0, 17], ["partial HA genes", "PROBLEM", 21, 37], ["these samples", "TEST", 48, 61], ["prototype strain", "PROBLEM", 133, 149]]], ["None of the CDC real-time RT-PCR positive samples were missed by the RTLAMP system (Table 2) .Evaluation of Efficacy in Clinical SamplesFurthermore, the S-OIV H1 RTLAMP assay was found to be specific for the H1 gene of the novel H1N1 virus because it did not cross-react with any of the 34 seasonal flu and 20 apparently healthy human throat-swab samples included in the panel as negative controls.", [["samples", "ANATOMY", 42, 49], ["samples", "ANATOMY", 347, 354], ["H1", "GENE_OR_GENE_PRODUCT", 208, 210], ["H1N1 virus", "ORGANISM", 229, 239], ["human", "ORGANISM", 329, 334], ["throat", "ORGANISM_SUBDIVISION", 335, 341], ["H1 gene", "DNA", 208, 215], ["H1N1 virus", "SPECIES", 229, 239], ["human", "SPECIES", 329, 334], ["H1", "SPECIES", 159, 161], ["H1", "SPECIES", 208, 210], ["H1N1 virus", "SPECIES", 229, 239], ["human", "SPECIES", 329, 334], ["the CDC", "TEST", 8, 15], ["RT-PCR", "TEST", 26, 32], ["Evaluation", "TEST", 94, 104], ["the S-OIV H1 RTLAMP assay", "TEST", 149, 174], ["the novel H1N1 virus", "PROBLEM", 219, 239], ["swab samples", "TEST", 342, 354]]], ["The virus load in the various clinical samples, as determined by S-OIV H1-specific RTLAMP, a standard curve based on Tp, was found to be in the range of 10 6 \u03ea1 copy numbers (Figure 3) .", [["samples", "ANATOMY", 39, 46], ["OIV H1", "PROTEIN", 67, 73], ["RTLAMP", "PROTEIN", 83, 89], ["The virus load", "PROBLEM", 0, 14], ["a standard curve", "TEST", 91, 107], ["Tp", "TEST", 117, 119], ["virus load", "OBSERVATION", 4, 14]]], ["The intra-assay reproducibility and variability of the S-OIV H1 gene-specific RTLAMP assay was determined by repeated experimental setups in several repli- cates.", [["S-OIV H1", "GENE_OR_GENE_PRODUCT", 55, 63], ["S-OIV H1 gene", "DNA", 55, 68], ["RTLAMP", "DNA", 78, 84], ["The intra-assay reproducibility", "TEST", 0, 31], ["the S", "TEST", 51, 56], ["specific RTLAMP assay", "TEST", 69, 90]]], ["The details of intra-assay variability (mean, SD, and CV) are tabulated in Table 3 .", [["intra-assay variability", "TEST", 15, 38]]], ["The positive predictive value and negative predictive value of the reported assay was found to be 100%.Evaluation of Efficacy in Clinical SamplesThe field applicability of RTLAMP assay was also validated by using the SYBR Green I-mediated naked-eye visualization test.", [["eye", "ANATOMY", 245, 248], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 217, 229], ["eye", "ORGAN", 245, 248], ["RTLAMP", "PROTEIN", 172, 178], ["SYBR Green I", "PROTEIN", 217, 229], ["Evaluation", "TEST", 103, 113], ["Clinical Samples", "TEST", 129, 145], ["RTLAMP assay", "TEST", 172, 184], ["eye visualization test", "TEST", 245, 267], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["eye", "ANATOMY", 245, 248]]], ["Following incubation at 63\u00b0C for 30 minutes in the water bath, the monitoring of RTLAMP amplification was accomplished by naked-eye observation enabled by the addition of 1 L of SYBR Green I dye (1:1000) to the amplified products.DiscussionThe emergence of novel S-OIV with transmissibility from human to human poses pandemic concern.", [["eye", "ANATOMY", 128, 131], ["SYBR Green I dye", "CHEMICAL", 178, 194], ["Green I dye", "GENE_OR_GENE_PRODUCT", 183, 194], ["S-OIV", "ORGANISM", 263, 268], ["human", "ORGANISM", 296, 301], ["human", "ORGANISM", 305, 310], ["RTLAMP", "DNA", 81, 87], ["human", "SPECIES", 296, 301], ["human", "SPECIES", 305, 310], ["human", "SPECIES", 296, 301], ["human", "SPECIES", 305, 310], ["the water bath", "TREATMENT", 47, 61], ["RTLAMP amplification", "TREATMENT", 81, 101], ["SYBR Green I dye", "TREATMENT", 178, 194]]], ["During outbreaks of emerging infectious diseases, accurate and rapid diagnosis is critical for minimizing further spread through timely implementation of appropriate vaccines, antiviral treatments, and prophylactic measures.", [["infectious diseases", "DISEASE", 29, 48], ["emerging infectious diseases", "PROBLEM", 20, 48], ["appropriate vaccines", "TREATMENT", 154, 174], ["antiviral treatments", "TREATMENT", 176, 196], ["prophylactic measures", "TREATMENT", 202, 223], ["infectious", "OBSERVATION", 29, 39]]], ["4 A number of different diagnostic laboratory tests can be used for detecting the presence of influenza viruses in respiratory specimens, including direct antigen-detection tests, virus isolation in cell culture, and detection of influenza-specific RNA by real-time RTPCR.", [["respiratory specimens", "ANATOMY", 115, 136], ["cell", "ANATOMY", 199, 203], ["influenza viruses", "DISEASE", 94, 111], ["influenza viruses", "ORGANISM", 94, 111], ["cell", "CELL", 199, 203], ["influenza-specific RNA", "RNA", 230, 252], ["different diagnostic laboratory tests", "TEST", 14, 51], ["influenza viruses in respiratory specimens", "PROBLEM", 94, 136], ["direct antigen", "TEST", 148, 162], ["detection tests", "TEST", 163, 178], ["virus isolation", "PROBLEM", 180, 195], ["cell culture", "TEST", 199, 211], ["influenza-specific RNA", "PROBLEM", 230, 252], ["influenza", "OBSERVATION", 94, 103]]], ["These tests differ in their sensitivity and specificity in detecting influenza viruses.", [["influenza viruses", "DISEASE", 69, 86], ["influenza viruses", "ORGANISM", 69, 86], ["These tests", "TEST", 0, 11], ["their sensitivity", "TEST", 22, 39], ["influenza viruses", "PROBLEM", 69, 86], ["influenza viruses", "OBSERVATION", 69, 86]]], ["The confirmatory and reliable early laboratory diagnosis of S-OIV is currently based on a WHO-approved, CDC-recommended, real-time RT-PCR-based detection method followed by either isolation of the novel H1N1 influenza virus or detection of a fourfold rise of neutralization antibodies to this virus.DiscussionOf the diagnostic tests discussed, only the real-time RTPCR-based detection method allows rapid detection of the swine-like H1N1 influenza virus within a few hours.", [["influenza", "DISEASE", 208, 217], ["influenza", "DISEASE", 438, 447], ["H1N1 influenza virus", "ORGANISM", 203, 223], ["swine-like H1N1 influenza virus", "ORGANISM", 422, 453], ["neutralization antibodies", "PROTEIN", 259, 284], ["H1N1 influenza virus", "SPECIES", 203, 223], ["swine", "SPECIES", 422, 427], ["H1N1 influenza virus", "SPECIES", 433, 453], ["OIV", "SPECIES", 62, 65], ["H1N1 influenza virus", "SPECIES", 203, 223], ["swine", "SPECIES", 422, 427], ["H1N1 influenza virus", "SPECIES", 433, 453], ["The confirmatory", "TEST", 0, 16], ["CDC", "TEST", 104, 107], ["PCR", "TEST", 134, 137], ["the novel H1N1 influenza virus", "PROBLEM", 193, 223], ["neutralization antibodies", "PROBLEM", 259, 284], ["this virus", "PROBLEM", 288, 298], ["the diagnostic tests", "TEST", 312, 332], ["rapid detection", "TEST", 399, 414], ["the swine", "PROBLEM", 418, 427], ["H1N1 influenza virus", "PROBLEM", 433, 453], ["neutralization antibodies", "OBSERVATION", 259, 284]]], ["Real-time is more rapid and sensitive than traditional techniques, including virus isolation by cell culture.", [["cell", "ANATOMY", 96, 100], ["cell", "CELL", 96, 100], ["traditional techniques", "TEST", 43, 65], ["virus isolation", "TREATMENT", 77, 92], ["cell culture", "TEST", 96, 108]]], ["Various investigators have reported several formats for real-time RTPCR, but none of those assays were validated by a defined sample panel.", [["real-time RTPCR", "TEST", 56, 71], ["those assays", "TEST", 85, 97], ["a defined sample panel", "TEST", 116, 138]]], ["Therefore, the WHO approved only the CDC-recommended realtime RTPCR assay for confirmation of infection by pandemic S-OIV H1N1 influenza.", [["infection", "DISEASE", 94, 103], ["influenza", "DISEASE", 127, 136], ["S-OIV H1N1 influenza", "ORGANISM", 116, 136], ["OIV H1N1 influenza", "SPECIES", 118, 136], ["the CDC", "TEST", 33, 40], ["realtime RTPCR assay", "TEST", 53, 73], ["infection", "PROBLEM", 94, 103], ["pandemic", "PROBLEM", 107, 115], ["OIV H1N1 influenza", "PROBLEM", 118, 136], ["infection", "OBSERVATION", 94, 103]]], ["However, the existing WHO-approved, CDC real-time RTPCR system has several limitations, including the high cost because of the use of large number of primer and probe sets.", [["high", "OBSERVATION_MODIFIER", 102, 106], ["large", "OBSERVATION_MODIFIER", 134, 139]]], ["One of the major limitations of the WHO-approved, CDC real-time RTPCR is the requirement of an expensive real-time PCR instrument that can be afforded only by referral laboratories with good financial resources.", [["an expensive real-time PCR instrument", "TREATMENT", 92, 129]]], ["In addition, the limitation of all PCR methods is that falsenegative results may occur because of sequence variations in primer and probe targets, and that is particularly relevant for the detection of emerging viruses.", [["primer and probe targets", "DNA", 121, 145], ["all PCR methods", "TEST", 31, 46], ["sequence variations in primer and probe targets", "PROBLEM", 98, 145], ["emerging viruses", "PROBLEM", 202, 218], ["viruses", "OBSERVATION", 211, 218]]], ["However, the use of multiple targets can reduce such limitations and may serve as a means of confirming positive results.DiscussionThe present study describes the development of a one-step, single-tube isothermal RTLAMP gene-amplification assay for rapid detection of novel S-OIV H1N1 viruses.", [["S-OIV H1N1 viruses", "ORGANISM", 274, 292], ["RTLAMP gene", "DNA", 213, 224], ["S-OIV H1N1 viruses", "SPECIES", 274, 292], ["single-tube isothermal RTLAMP gene", "TREATMENT", 190, 224], ["amplification assay", "TEST", 225, 244], ["rapid detection", "TEST", 249, 264], ["novel S", "PROBLEM", 268, 275], ["OIV H1N1 viruses", "PROBLEM", 276, 292], ["H1N1 viruses", "OBSERVATION", 280, 292]]], ["This is an alternative real-time test system for rapid detection and for identification of novel S-OIV H1N1 viruses.", [["S-OIV H1N1 viruses", "ORGANISM", 97, 115], ["S-OIV H1N1 viruses", "SPECIES", 97, 115], ["rapid detection", "TEST", 49, 64], ["novel S", "PROBLEM", 91, 98], ["OIV H1N1 viruses", "PROBLEM", 99, 115], ["H1N1 viruses", "OBSERVATION", 103, 115]]], ["The assay is based on a simple isothermal geneamplification tool using a specially designed primer set that specifically amplifies the H1 gene of novel S-OIV only.", [["S-OIV", "GENE_OR_GENE_PRODUCT", 152, 157], ["H1 gene", "DNA", 135, 142], ["The assay", "TEST", 0, 9], ["a simple isothermal geneamplification tool", "PROBLEM", 22, 64], ["a specially designed primer set", "TREATMENT", 71, 102]]], ["Unlike PCRs, in which the target gene is flanked by two primers, in the case of LAMP, a set of six primers flanks a small target of approximately 200 bp through recognition of eight different sequences of the target gene.", [["target gene", "DNA", 26, 37], ["LAMP", "DNA", 80, 84], ["target gene", "DNA", 209, 220], ["Unlike PCRs", "PROBLEM", 0, 11], ["six primers flanks", "PROBLEM", 95, 113], ["small", "OBSERVATION_MODIFIER", 116, 121]]], ["LAMP is therefore selective and target specific.", [["selective", "OBSERVATION_MODIFIER", 18, 27]]], ["17 Therefore, a sequence homology of 95% or higher is required for LAMP.", [["a sequence homology", "TEST", 14, 33]]], ["The in-silico specificity testing of S-OIV H1 RTLAMP primer set revealed more than 98% to 99% homology among the circulating S-OINV strains, including the California/Paris/China/Singapore/Indian strains.", [["S-OIV H1", "GENE_OR_GENE_PRODUCT", 37, 45], ["S-OINV strains", "ORGANISM", 125, 139], ["Paris/China", "ORGANISM", 166, 177], ["OIV", "SPECIES", 39, 42], ["S-OIV H1 RTLAMP primer set", "TEST", 37, 63], ["OINV strains", "PROBLEM", 127, 139]]], ["However, the homology between S-OIV and InfA strains in swine H1N1 strains was below 90%.", [["S-OIV", "GENE_OR_GENE_PRODUCT", 30, 35], ["InfA", "GENE_OR_GENE_PRODUCT", 40, 44], ["swine H1N1 strains", "ORGANISM", 56, 74], ["swine", "SPECIES", 56, 61], ["swine H1N1", "SPECIES", 56, 66], ["InfA strains in swine H1N1 strains", "PROBLEM", 40, 74]]], ["Further analysis of other respiratory viruses, such as respiratory synctial, adeno, para influenza, and so forth revealed less than 50% homology.", [["respiratory viruses", "DISEASE", 26, 45], ["respiratory synctial, adeno, para influenza", "DISEASE", 55, 98], ["Further analysis", "TEST", 0, 16], ["other respiratory viruses", "PROBLEM", 20, 45], ["respiratory synctial, adeno, para influenza", "PROBLEM", 55, 98], ["respiratory viruses", "OBSERVATION", 26, 45]]], ["The in-silco analysis of the S-OIV H1 RTLAMP primer set clearly indicates that the designed primer set is highly specific for the S-OIV H1N1 virus strain only.DiscussionThe comparative evaluation of CDC real-time RTPCR that includes a reasonably good number of samples revealed 100% concordance for picking up positive cases.", [["samples", "ANATOMY", 261, 268], ["S-OIV H1N1 virus", "ORGANISM", 130, 146], ["samples", "CANCER", 261, 268], ["OIV H1N1 virus", "SPECIES", 132, 146], ["S-OIV H1N1 virus", "SPECIES", 130, 146], ["the S", "TEST", 25, 30], ["the S-OIV H1N1 virus strain", "PROBLEM", 126, 153], ["The comparative evaluation", "TEST", 169, 195], ["CDC real-time RTPCR", "TEST", 199, 218], ["picking up positive cases", "PROBLEM", 299, 324], ["H1N1 virus", "OBSERVATION", 136, 146]]], ["Overall, S-OIV RTLAMP picked up some additional positive cases that were being missed by WHO-CDC real- time RTPCR and that were found to be true-positives following sequencing.", [["S-OIV RTLAMP", "DNA", 9, 21], ["S-OIV", "SPECIES", 9, 14], ["RTPCR", "TEST", 108, 113], ["sequencing", "TEST", 165, 175]]], ["The presence of the discrepantadditional positive samples is attributed to the higher sensitivity of S-OIV RTLAMP, as already indicated through comparative analytical sensitivity tests for limit of detection.", [["samples", "ANATOMY", 50, 57], ["the discrepantadditional positive samples", "PROBLEM", 16, 57], ["S-OIV RTLAMP", "TREATMENT", 101, 113], ["comparative analytical sensitivity tests", "TEST", 144, 184]]], ["The lower sensitivity of WHO-CDC real-time RTPCR has been reported by Ellis et al. 16 in 2009 in their comparative study that evaluated various H1N1 primer and probe sets.", [["H1N1 primer", "DNA", 144, 155], ["RTPCR", "TEST", 43, 48], ["their comparative study", "TEST", 97, 120], ["various H1N1 primer", "TREATMENT", 136, 155], ["H1N1", "OBSERVATION", 144, 148]]], ["These discrepant additional positive samples were further confirmed as true positives by using SYBR Green I-based real-time RTPCR as the third test, and nucleotide sequencing is considered a polished gold standard.", [["samples", "ANATOMY", 37, 44], ["nucleotide", "CHEMICAL", 153, 163], ["nucleotide", "CHEMICAL", 153, 163], ["SYBR Green I-based real-time RTPCR", "DNA", 95, 129], ["These discrepant additional positive samples", "PROBLEM", 0, 44], ["SYBR", "TEST", 95, 99], ["the third test", "TEST", 133, 147], ["nucleotide sequencing", "TEST", 153, 174]]], ["26 The higher sensitivity and specificity of the reaction is attributed to the continuous amplification under isothermal conditions and the use of six primers that recognize eight distinct regions of the target.", [["The higher sensitivity", "PROBLEM", 3, 25], ["the reaction", "PROBLEM", 45, 57], ["isothermal conditions", "TREATMENT", 110, 131], ["six primers", "TREATMENT", 147, 158], ["eight distinct", "OBSERVATION_MODIFIER", 174, 188]]], ["19 The reproducibility and versatility of the reported S-OIV H1 gene-specific RTLAMP is indicated by the fact that the evaluation is being carried out at three centers and by at least 10 different investigators over a period of three months, using four to five lots of reagents.", [["S-OIV H1", "GENE_OR_GENE_PRODUCT", 55, 63], ["S-OIV H1 gene", "DNA", 55, 68], ["RTLAMP", "DNA", 78, 84], ["the evaluation", "TEST", 115, 129], ["reagents", "TREATMENT", 269, 277]]], ["The quantification of the virus load by the RTLAMP assay can also be a useful marker to assess the therapeutic efficacy of antiviral drug as well as for the quarantine of patients so as to restrict the spread of infection.", [["infection", "DISEASE", 212, 221], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["the virus load", "PROBLEM", 22, 36], ["the RTLAMP assay", "TEST", 40, 56], ["antiviral drug", "TREATMENT", 123, 137], ["infection", "PROBLEM", 212, 221], ["infection", "OBSERVATION", 212, 221]]], ["As indicated by the results, the S-OIV H1 RTLAMP could pick up the borderline cases in which the virus load was in the range of 10 to 1 copy numbers.", [["the virus load", "TEST", 93, 107]]], ["The fact that most of the patients may have either a high or a low virus load, depicting bimodal distribution, may be attributed to late reporting in most cases because all three of the testing centers are being designated referral laboratories for H1N1 testing.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["a high or a low virus load", "PROBLEM", 51, 77], ["H1N1 testing", "TEST", 249, 261], ["bimodal distribution", "OBSERVATION", 89, 109]]], ["One of the most attractive features of this isothermal gene amplification assay seems to be its great advantage in terms of monitoring the amplification that can be accomplished by SYBR Green I dye-mediated nakedeye visualization.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 181, 193], ["this isothermal gene amplification assay", "PROBLEM", 39, 79], ["the amplification", "TREATMENT", 135, 152], ["most attractive", "OBSERVATION_MODIFIER", 11, 26]]], ["The assay is rapid and cost-effective because gene amplification can be accomplished in a heating block/water bath and followed by the naked eye as it monitors the visual fluorescence in the form of color change.", [["eye", "ANATOMY", 141, 144], ["eye", "ORGAN", 141, 144], ["The assay", "TEST", 0, 9], ["gene amplification", "TREATMENT", 46, 64], ["a heating block/water bath", "TREATMENT", 88, 114], ["rapid", "OBSERVATION_MODIFIER", 13, 18]]], ["These simple attributes of the assay make it favorable for adoption as a field gene-amplification technology without requiring any expensive instruments.", [["any expensive instruments", "TREATMENT", 127, 152]]], ["The method is simple and obviates the need for expensive equipment such as real-time PCR instruments, which cost $40,000 to $50,000.", [["expensive equipment", "TREATMENT", 47, 66], ["real-time PCR instruments", "TREATMENT", 75, 100]]], ["The better appreciation of apple-green fluorescence can be achieved by using a simple UV hand-held torch.", [["apple", "ORGANISM", 27, 32], ["apple", "SPECIES", 27, 32], ["apple-green fluorescence", "PROBLEM", 27, 51], ["a simple UV hand", "TREATMENT", 77, 93]]], ["The test is rapid; results can be obtained in 60 minutes as compared to the 3 to 4 hours required by conventional gene amplification assays.", [["The test", "TEST", 0, 8], ["conventional gene amplification assays", "TEST", 101, 139]]], ["The method is highly sensitive and specific and can detect low copy number of viruses, especially in the borderline cases that would be missed by conventional RT-PCR techniques.", [["The method", "TEST", 0, 10], ["low copy number of viruses", "PROBLEM", 59, 85], ["conventional RT-PCR techniques", "TEST", 146, 176], ["viruses", "OBSERVATION", 78, 85]]], ["These findings suggest that the S-OIV H1 gene-specific RTLAMP assay is a valuable tool for rapid, real-time detection as well as for quantification of the H1N1 virus in acute-phase throat-swab samples.", [["samples", "ANATOMY", 193, 200], ["S-OIV H1", "GENE_OR_GENE_PRODUCT", 32, 40], ["H1N1 virus", "ORGANISM", 155, 165], ["throat", "ORGANISM", 181, 187], ["S-OIV H1 gene", "DNA", 32, 45], ["RTLAMP", "PROTEIN", 55, 61], ["H1N1 virus", "SPECIES", 155, 165], ["the S", "TEST", 28, 33], ["specific RTLAMP assay", "TEST", 46, 67], ["the H1N1 virus", "PROBLEM", 151, 165], ["acute-phase throat", "TEST", 169, 187], ["swab samples", "TEST", 188, 200]]], ["It requires no sophisticated equipment, so it is useful for clinical diagnosis in developing countries.", [["sophisticated equipment", "TREATMENT", 15, 38], ["no", "UNCERTAINTY", 12, 14]]]], "f64758a94c481beaa48c4663055f405c51ba831b": [["Introduction:While the world is facing an unprecedented crisis with novel coronavirus disease (nCoV) 2019/ COVID-19, there are no proven effective pharmacological agents (1) .", [["coronavirus disease", "DISEASE", 74, 93], ["an unprecedented crisis", "PROBLEM", 39, 62], ["novel coronavirus disease", "PROBLEM", 68, 93], ["COVID", "TEST", 107, 112], ["no", "UNCERTAINTY", 127, 129]]], ["Following the detection of Severe Acute Respiratory Syndrome coronavirus(2) (SARS-CoV-2) in December 2019 in Wuhan, China, we witnessed a massive surge in the number of cases globally, until WHO declared a pandemic on March 11, 2020 (2).", [["Acute Respiratory Syndrome coronavirus", "DISEASE", 34, 72], ["Severe Acute Respiratory Syndrome coronavirus", "ORGANISM", 27, 72], ["Severe Acute Respiratory Syndrome coronavirus", "SPECIES", 27, 72], ["SARS-CoV-2", "SPECIES", 77, 87], ["the detection", "TEST", 10, 23], ["Severe Acute Respiratory Syndrome coronavirus", "PROBLEM", 27, 72], ["Severe", "OBSERVATION_MODIFIER", 27, 33], ["Acute", "OBSERVATION_MODIFIER", 34, 39], ["Respiratory Syndrome coronavirus", "OBSERVATION", 40, 72], ["massive", "OBSERVATION", 138, 145]]], ["The search for a 'Novel' agent is ongoing and as of 7 April 2020, 'TrialsTracker' project(3) had listed 883 clinical trials on COVID-19, including 344 intervention trials.COVID 19 Real World EvidenceDuring an evolving pandemic the real-world evidence can only be obtained from respected sources.", [["a 'Novel' agent", "TREATMENT", 15, 30], ["COVID", "TEST", 127, 132]]], ["Investigational journalism had the upper hand in exposing the problem with China and later on, in South Korea and Italy.", [["upper hand", "ANATOMY", 35, 45], ["upper hand", "ORGANISM_SUBDIVISION", 35, 45], ["upper", "ANATOMY_MODIFIER", 35, 40], ["hand", "ANATOMY", 41, 45]]], ["When the death rate mushroomed in Italy, everything had exploded, the world knew that a new era had arrived with the greatest lockdown of all time.", [["death", "DISEASE", 9, 14]]], ["Corona's correction will allow us to get rid of all the dinosaurs for every top position in any organization and to evolve to a world of trust and confidence.COVID 19 Real World EvidenceBased on observations in the USA, Spain, Italy, France and the UK, and from the postmortem of lung involvement in COVID 19, all revealed pulmonary thrombosis, which is not typical ARDS.", [["lung", "ANATOMY", 280, 284], ["pulmonary", "ANATOMY", 323, 332], ["pulmonary thrombosis", "DISEASE", 323, 343], ["ARDS", "DISEASE", 366, 370], ["lung", "ORGAN", 280, 284], ["pulmonary", "ORGAN", 323, 332], ["COVID", "TEST", 300, 305], ["pulmonary thrombosis", "PROBLEM", 323, 343], ["typical ARDS", "PROBLEM", 358, 370], ["dinosaurs", "OBSERVATION", 56, 65], ["lung", "ANATOMY", 280, 284], ["pulmonary", "ANATOMY", 323, 332], ["thrombosis", "OBSERVATION", 333, 343], ["not", "UNCERTAINTY", 354, 357], ["typical", "OBSERVATION_MODIFIER", 358, 365], ["ARDS", "OBSERVATION", 366, 370]]], ["More alarming was that patient hypoxemia was not responding to PEEP but high oxygen flow(4).Bioinformatics HypothesisA Chinese scientist(5) used a bio-informatics model to describe the hypothesis of COVID 19 as methemoglobin, where the COVID-19 virus structural protein sticks to heme -displaces oxygen -which alters the iron-free ion, leading to inflammation of alveolar macrophages, which culminate in a systemic response ending in a cytokine storm .", [["alveolar macrophages", "ANATOMY", 363, 383], ["hypoxemia", "DISEASE", 31, 40], ["oxygen", "CHEMICAL", 77, 83], ["oxygen", "CHEMICAL", 296, 302], ["iron", "CHEMICAL", 321, 325], ["inflammation", "DISEASE", 347, 359], ["oxygen", "CHEMICAL", 77, 83], ["methemoglobin", "CHEMICAL", 211, 224], ["heme", "CHEMICAL", 280, 284], ["oxygen", "CHEMICAL", 296, 302], ["iron", "CHEMICAL", 321, 325], ["patient", "ORGANISM", 23, 30], ["oxygen", "SIMPLE_CHEMICAL", 77, 83], ["methemoglobin", "SIMPLE_CHEMICAL", 211, 224], ["COVID-19 virus", "ORGANISM", 236, 250], ["oxygen", "SIMPLE_CHEMICAL", 296, 302], ["iron", "SIMPLE_CHEMICAL", 321, 325], ["alveolar macrophages", "CELL", 363, 383], ["COVID-19 virus structural protein", "PROTEIN", 236, 269], ["heme", "PROTEIN", 280, 284], ["alveolar macrophages", "CELL_TYPE", 363, 383], ["cytokine", "PROTEIN", 436, 444], ["patient", "SPECIES", 23, 30], ["COVID-19 virus", "SPECIES", 236, 250], ["patient hypoxemia", "PROBLEM", 23, 40], ["PEEP", "TREATMENT", 63, 67], ["high oxygen flow", "PROBLEM", 72, 88], ["a bio-informatics model", "TREATMENT", 145, 168], ["COVID", "TEST", 199, 204], ["methemoglobin", "TEST", 211, 224], ["the COVID", "TEST", 232, 241], ["oxygen", "TREATMENT", 296, 302], ["the iron-free ion", "PROBLEM", 317, 334], ["inflammation of alveolar macrophages", "PROBLEM", 347, 383], ["a systemic response", "PROBLEM", 404, 423], ["hypoxemia", "OBSERVATION", 31, 40], ["inflammation", "OBSERVATION", 347, 359], ["alveolar macrophages", "OBSERVATION", 363, 383], ["systemic response", "OBSERVATION", 406, 423], ["cytokine storm", "OBSERVATION", 436, 450]]], ["They suggested that if free radical scavengers and iron chelating agents are added to the protocol of management, these might ameliorate the inflammatory response.Bioinformatics HypothesisWhat we must focus on is that COVID19 attacks RBCs.", [["RBCs", "ANATOMY", 234, 238], ["iron", "CHEMICAL", 51, 55], ["iron", "CHEMICAL", 51, 55], ["free radical scavengers", "SIMPLE_CHEMICAL", 23, 46], ["iron chelating agents", "SIMPLE_CHEMICAL", 51, 72], ["COVID19", "GENE_OR_GENE_PRODUCT", 218, 225], ["RBCs", "CELL", 234, 238], ["COVID19", "PROTEIN", 218, 225], ["RBCs", "CELL_TYPE", 234, 238], ["free radical scavengers", "TREATMENT", 23, 46], ["iron chelating agents", "TREATMENT", 51, 72], ["management", "TREATMENT", 102, 112], ["the inflammatory response", "PROBLEM", 137, 162], ["COVID19 attacks RBCs", "PROBLEM", 218, 238], ["inflammatory", "OBSERVATION", 141, 153]]], ["Patients have frequently been found COVID-19, SARS2 is not 'pneumonia' nor ARDS Through the current experience across the world, invasive ventilation is becoming the last resort, as emergency intubation from the Chinese, Italian and American experience evidences higher mortality, not to mention complications from tracheal scarring and stiff lung during the duration of intubation.", [["tracheal", "ANATOMY", 315, 323], ["lung", "ANATOMY", 343, 347], ["pneumonia", "DISEASE", 60, 69], ["ARDS", "DISEASE", 75, 79], ["tracheal scarring", "DISEASE", 315, 332], ["Patients", "ORGANISM", 0, 8], ["tracheal", "ORGAN", 315, 323], ["lung", "ORGAN", 343, 347], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 36, 41], ["'pneumonia'", "PROBLEM", 59, 70], ["ARDS", "PROBLEM", 75, 79], ["invasive ventilation", "TREATMENT", 129, 149], ["emergency intubation", "TREATMENT", 182, 202], ["complications", "PROBLEM", 296, 309], ["tracheal scarring", "PROBLEM", 315, 332], ["stiff lung", "PROBLEM", 337, 347], ["intubation", "TREATMENT", 371, 381], ["pneumonia", "OBSERVATION", 60, 69], ["ARDS", "OBSERVATION", 75, 79], ["invasive ventilation", "OBSERVATION", 129, 149], ["tracheal", "ANATOMY", 315, 323], ["scarring", "OBSERVATION", 324, 332], ["stiff", "OBSERVATION_MODIFIER", 337, 342], ["lung", "ANATOMY", 343, 347]]], ["Furthermore, a new treatment protocol needs to be established in order to control the prolonged and progressive hypoxia of COVID19(4).Bioinformatics HypothesisPeople are desaturating due to failure of the blood to carry oxygen.", [["blood", "ANATOMY", 205, 210], ["hypoxia", "DISEASE", 112, 119], ["oxygen", "CHEMICAL", 220, 226], ["oxygen", "CHEMICAL", 220, 226], ["blood", "ORGANISM_SUBSTANCE", 205, 210], ["oxygen", "SIMPLE_CHEMICAL", 220, 226], ["a new treatment protocol", "TREATMENT", 13, 37], ["the prolonged and progressive hypoxia of COVID19", "PROBLEM", 82, 130], ["desaturating", "PROBLEM", 170, 182], ["failure of the blood", "PROBLEM", 190, 210], ["carry oxygen", "TREATMENT", 214, 226], ["progressive", "OBSERVATION_MODIFIER", 100, 111], ["hypoxia", "OBSERVATION", 112, 119]]], ["This will lead to multiorgan failure and high mortality.", [["multiorgan", "ANATOMY", 18, 28], ["multiorgan failure", "DISEASE", 18, 36], ["multiorgan failure", "PROBLEM", 18, 36], ["high mortality", "PROBLEM", 41, 55], ["multiorgan", "ANATOMY", 18, 28], ["failure", "OBSERVATION", 29, 36], ["high", "OBSERVATION_MODIFIER", 41, 45], ["mortality", "OBSERVATION", 46, 55]]], ["The lung damage seen on CT scans is due to the oxidative stress released from the hemolysed red blood cells, which in turn overwhelm the natural defenses against pulmonary oxidative stress and cause a cytokine storm.", [["lung", "ANATOMY", 4, 8], ["red blood cells", "ANATOMY", 92, 107], ["pulmonary", "ANATOMY", 162, 171], ["lung damage", "DISEASE", 4, 15], ["lung", "ORGAN", 4, 8], ["red blood cells", "CELL", 92, 107], ["pulmonary", "ORGAN", 162, 171], ["hemolysed red blood cells", "CELL_TYPE", 82, 107], ["cytokine", "PROTEIN", 201, 209], ["The lung damage", "PROBLEM", 0, 15], ["CT scans", "TEST", 24, 32], ["the oxidative stress", "PROBLEM", 43, 63], ["the hemolysed red blood cells", "PROBLEM", 78, 107], ["pulmonary oxidative stress", "PROBLEM", 162, 188], ["a cytokine storm", "PROBLEM", 199, 215], ["lung", "ANATOMY", 4, 8], ["damage", "OBSERVATION", 9, 15], ["pulmonary", "ANATOMY", 162, 171], ["oxidative stress", "OBSERVATION", 172, 188], ["cytokine storm", "OBSERVATION", 201, 215]]], ["There is alwaysbilateral ground-glass opacity in the lungs.", [["lungs", "ANATOMY", 53, 58], ["lungs", "ORGAN", 53, 58], ["alwaysbilateral ground-glass opacity in the lungs", "PROBLEM", 9, 58], ["alwaysbilateral", "OBSERVATION_MODIFIER", 9, 24], ["ground-glass opacity", "OBSERVATION", 25, 45], ["lungs", "ANATOMY", 53, 58]]], ["Recurrent admission for post-hypoxic leukoencephalopathy strengthens the findings of the Italians, Spanish and Americans(4) that COVID-19 patients are suffering from metabolic hypoxia due to blood capacity failure.Bioinformatics HypothesisThe Chinese hypothesis(5) that had been publicized, theoretically, via bioinformatics modeling, postulated that the catastrophic cascade of oxidative stress explains the vicious cycle as follows:Bioinformatics Hypothesis1) Without the iron ion, hemoglobin can no longer bind to oxygen.", [["blood", "ANATOMY", 191, 196], ["leukoencephalopathy", "DISEASE", 37, 56], ["metabolic hypoxia", "DISEASE", 166, 183], ["blood capacity failure", "DISEASE", 191, 213], ["iron", "CHEMICAL", 474, 478], ["oxygen", "CHEMICAL", 517, 523], ["iron", "CHEMICAL", 474, 478], ["oxygen", "CHEMICAL", 517, 523], ["patients", "ORGANISM", 138, 146], ["blood", "ORGANISM_SUBSTANCE", 191, 196], ["iron", "SIMPLE_CHEMICAL", 474, 478], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 484, 494], ["oxygen", "SIMPLE_CHEMICAL", 517, 523], ["hemoglobin", "PROTEIN", 484, 494], ["patients", "SPECIES", 138, 146], ["post-hypoxic leukoencephalopathy", "PROBLEM", 24, 56], ["metabolic hypoxia", "PROBLEM", 166, 183], ["blood capacity failure", "PROBLEM", 191, 213], ["oxidative stress", "PROBLEM", 379, 395], ["the iron ion", "TREATMENT", 470, 482], ["oxygen", "TREATMENT", 517, 523], ["hypoxic", "OBSERVATION_MODIFIER", 29, 36], ["leukoencephalopathy", "OBSERVATION", 37, 56], ["metabolic hypoxia", "OBSERVATION", 166, 183], ["capacity failure", "OBSERVATION", 197, 213]]], ["Once the hemoglobin is impaired, the red blood cell is essentially unable to carry and deliver oxygen to any tissues. drop significantly.Bioinformatics HypothesisIn COVID-19 patients, unlike with CO poisoning in which eventually the CO can break off, the affected hemoglobin is permanently stripped of its ability to carry oxygen.", [["red blood cell", "ANATOMY", 37, 51], ["tissues", "ANATOMY", 109, 116], ["oxygen", "CHEMICAL", 95, 101], ["CO poisoning", "DISEASE", 196, 208], ["oxygen", "CHEMICAL", 323, 329], ["oxygen", "CHEMICAL", 95, 101], ["CO", "CHEMICAL", 196, 198], ["CO", "CHEMICAL", 233, 235], ["oxygen", "CHEMICAL", 323, 329], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 9, 19], ["red blood cell", "CELL", 37, 51], ["oxygen", "SIMPLE_CHEMICAL", 95, 101], ["tissues", "TISSUE", 109, 116], ["patients", "ORGANISM", 174, 182], ["CO", "SIMPLE_CHEMICAL", 233, 235], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 264, 274], ["oxygen", "SIMPLE_CHEMICAL", 323, 329], ["hemoglobin", "PROTEIN", 9, 19], ["red blood cell", "CELL_TYPE", 37, 51], ["hemoglobin", "PROTEIN", 264, 274], ["patients", "SPECIES", 174, 182], ["the hemoglobin", "TEST", 5, 19], ["the red blood cell", "TEST", 33, 51], ["oxygen", "TREATMENT", 95, 101], ["CO poisoning", "PROBLEM", 196, 208], ["the CO", "PROBLEM", 229, 235], ["the affected hemoglobin", "PROBLEM", 251, 274], ["oxygen", "TREATMENT", 323, 329], ["impaired", "OBSERVATION", 23, 31]]], ["The body compensates by secreting excess erythropoietin to stimulate the bone marrow to secrete new red blood cells.", [["body", "ANATOMY", 4, 8], ["bone marrow", "ANATOMY", 73, 84], ["red blood cells", "ANATOMY", 100, 115], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 41, 55], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 73, 84], ["red blood cells", "CELL", 100, 115], ["erythropoietin", "PROTEIN", 41, 55], ["red blood cells", "CELL_TYPE", 100, 115], ["secreting excess erythropoietin", "TREATMENT", 24, 55], ["red blood cells", "TEST", 100, 115], ["body", "ANATOMY_MODIFIER", 4, 8], ["secreting", "OBSERVATION", 24, 33], ["excess erythropoietin", "OBSERVATION", 34, 55], ["bone", "ANATOMY", 73, 77]]], ["This is the reason we find thrombocytosis, or thrombocytopenia depending on the stage and severity of COVID-19, a high ferritin level and D-Dimer with decreased blood oxygen saturation as the primary indicators of the COVID-19 severity score.Bioinformatics Hypothesis2) The free-floating iron ions(5) are highly reactive and cause oxidative damage.", [["blood", "ANATOMY", 161, 166], ["thrombocytosis", "DISEASE", 27, 41], ["thrombocytopenia", "DISEASE", 46, 62], ["oxygen", "CHEMICAL", 167, 173], ["iron", "CHEMICAL", 288, 292], ["D-Dimer", "CHEMICAL", 138, 145], ["oxygen", "CHEMICAL", 167, 173], ["iron", "CHEMICAL", 288, 292], ["ferritin", "GENE_OR_GENE_PRODUCT", 119, 127], ["D-Dimer", "SIMPLE_CHEMICAL", 138, 145], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["oxygen", "SIMPLE_CHEMICAL", 167, 173], ["iron ions", "SIMPLE_CHEMICAL", 288, 297], ["ferritin", "PROTEIN", 119, 127], ["thrombocytosis", "PROBLEM", 27, 41], ["thrombocytopenia", "PROBLEM", 46, 62], ["COVID", "TEST", 102, 107], ["a high ferritin level", "PROBLEM", 112, 133], ["decreased blood oxygen saturation", "PROBLEM", 151, 184], ["the COVID", "TEST", 214, 223], ["Bioinformatics Hypothesis2", "TEST", 242, 268], ["The free-floating iron ions", "TEST", 270, 297], ["highly reactive", "PROBLEM", 305, 320], ["oxidative damage", "PROBLEM", 331, 347], ["thrombocytosis", "OBSERVATION", 27, 41], ["thrombocytopenia", "OBSERVATION", 46, 62], ["free", "OBSERVATION_MODIFIER", 274, 278], ["reactive", "OBSERVATION_MODIFIER", 312, 320], ["oxidative damage", "OBSERVATION", 331, 347]]], ["This always happens physiologically and is natural to a limited extent in our bodies, and such cleanup is a defense mechanism to keep the balance.Bioinformatics HypothesisOf the Three Primary Lung defenses to maintain \"iron homeostasis\", two are in the alveoli.Bioinformatics HypothesisThe first of the two are macrophages that roam around and scavenge the free radicals of the oxidative iron.", [["Lung", "ANATOMY", 192, 196], ["alveoli", "ANATOMY", 253, 260], ["macrophages", "ANATOMY", 311, 322], ["iron", "CHEMICAL", 219, 223], ["iron", "CHEMICAL", 388, 392], ["iron", "CHEMICAL", 219, 223], ["iron", "CHEMICAL", 388, 392], ["Lung", "ORGAN", 192, 196], ["iron", "SIMPLE_CHEMICAL", 219, 223], ["alveoli", "MULTI-TISSUE_STRUCTURE", 253, 260], ["macrophages", "CELL", 311, 322], ["iron", "SIMPLE_CHEMICAL", 388, 392], ["macrophages", "CELL_TYPE", 311, 322], ["iron homeostasis", "PROBLEM", 219, 235], ["the oxidative iron", "TREATMENT", 374, 392], ["Lung", "ANATOMY", 192, 196], ["defenses", "OBSERVATION", 197, 205], ["iron homeostasis", "OBSERVATION", 219, 235], ["alveoli", "ANATOMY", 253, 260], ["macrophages", "OBSERVATION", 311, 322], ["oxidative iron", "OBSERVATION", 378, 392]]], ["The second is a lining on the epithelial surface which has a thin layer of fluid packed with high levels of antioxidant molecules such as ascorbic acid.Bioinformatics HypothesisWhen too much iron is in circulation, it begins to overwhelm the lungs' countermeasures and the process of pulmonary oxidative stress begins.", [["epithelial surface", "ANATOMY", 30, 48], ["fluid", "ANATOMY", 75, 80], ["lungs", "ANATOMY", 242, 247], ["pulmonary", "ANATOMY", 284, 293], ["ascorbic acid", "CHEMICAL", 138, 151], ["iron", "CHEMICAL", 191, 195], ["ascorbic acid", "CHEMICAL", 138, 151], ["iron", "CHEMICAL", 191, 195], ["epithelial surface", "TISSUE", 30, 48], ["fluid", "ORGANISM_SUBSTANCE", 75, 80], ["ascorbic acid", "SIMPLE_CHEMICAL", 138, 151], ["iron", "SIMPLE_CHEMICAL", 191, 195], ["lungs", "ORGAN", 242, 247], ["pulmonary", "ORGAN", 284, 293], ["a thin layer of fluid", "PROBLEM", 59, 80], ["antioxidant molecules", "TREATMENT", 108, 129], ["ascorbic acid", "TREATMENT", 138, 151], ["pulmonary oxidative stress", "PROBLEM", 284, 310], ["second", "OBSERVATION_MODIFIER", 4, 10], ["lining", "OBSERVATION", 16, 22], ["epithelial", "ANATOMY_MODIFIER", 30, 40], ["surface", "ANATOMY_MODIFIER", 41, 48], ["thin", "OBSERVATION_MODIFIER", 61, 65], ["layer", "OBSERVATION_MODIFIER", 66, 71], ["fluid", "OBSERVATION", 75, 80], ["packed", "OBSERVATION_MODIFIER", 81, 87], ["high levels", "OBSERVATION_MODIFIER", 93, 104], ["antioxidant molecules", "OBSERVATION", 108, 129], ["ascorbic acid", "OBSERVATION", 138, 151], ["lungs", "ANATOMY", 242, 247], ["pulmonary", "ANATOMY", 284, 293], ["oxidative stress", "OBSERVATION", 294, 310]]], ["This leads to damage and inflammation, which leads to the so-called cytokine storm (5) ; this can be documented on high-resolution CT scans of COVID-19 patients' lungs.Bioinformatics HypothesisThe liver attempts its best to remove the iron, but only becomes overwhelmed too.", [["lungs", "ANATOMY", 162, 167], ["liver", "ANATOMY", 197, 202], ["inflammation", "DISEASE", 25, 37], ["iron", "CHEMICAL", 235, 239], ["iron", "CHEMICAL", 235, 239], ["patients", "ORGANISM", 152, 160], ["lungs", "ORGAN", 162, 167], ["liver", "ORGAN", 197, 202], ["iron", "SIMPLE_CHEMICAL", 235, 239], ["cytokine", "PROTEIN", 68, 76], ["patients", "SPECIES", 152, 160], ["damage", "PROBLEM", 14, 20], ["inflammation", "PROBLEM", 25, 37], ["COVID", "TEST", 143, 148], ["the iron", "TREATMENT", 231, 239], ["damage", "OBSERVATION", 14, 20], ["inflammation", "OBSERVATION", 25, 37], ["lungs", "ANATOMY", 162, 167], ["liver", "ANATOMY", 197, 202]]], ["It is starved of oxygen.", [["oxygen", "CHEMICAL", 17, 23], ["oxygen", "CHEMICAL", 17, 23], ["oxygen", "SIMPLE_CHEMICAL", 17, 23], ["oxygen", "TREATMENT", 17, 23], ["oxygen", "OBSERVATION_MODIFIER", 17, 23]]], ["The liver function will deteriorate with elevated alanine aminotransferase (ALT), which is one of the primary COVID-19 severity score indicators.Worldwide in time knowledgeThrough extensive discussion with some of our colleagues in Beijing, Milan, Sienna, Paris, Barcelona, London and New York(6), we have reached a consensus to recommend that the patient might be better managed on maximum oxygen flow through a hyperbaric chamber (7, 8) on 100% oxygen at double or multiple atmospheres of pressure for 90 minutes twice per day for five days.", [["liver", "ANATOMY", 4, 9], ["alanine", "CHEMICAL", 50, 57], ["oxygen", "CHEMICAL", 391, 397], ["oxygen", "CHEMICAL", 447, 453], ["alanine", "CHEMICAL", 50, 57], ["oxygen", "CHEMICAL", 391, 397], ["oxygen", "CHEMICAL", 447, 453], ["liver", "ORGAN", 4, 9], ["alanine", "AMINO_ACID", 50, 57], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 58, 74], ["ALT", "SIMPLE_CHEMICAL", 76, 79], ["patient", "ORGANISM", 348, 355], ["oxygen", "SIMPLE_CHEMICAL", 391, 397], ["oxygen", "SIMPLE_CHEMICAL", 447, 453], ["alanine aminotransferase", "PROTEIN", 50, 74], ["ALT", "PROTEIN", 76, 79], ["patient", "SPECIES", 348, 355], ["elevated alanine aminotransferase", "PROBLEM", 41, 74], ["ALT", "TEST", 76, 79], ["the primary COVID", "TEST", 98, 115], ["maximum oxygen flow", "TREATMENT", 383, 402], ["a hyperbaric chamber", "TREATMENT", 411, 431], ["100% oxygen", "TREATMENT", 442, 453], ["multiple atmospheres of pressure", "TREATMENT", 467, 499], ["liver", "ANATOMY", 4, 9], ["hyperbaric chamber", "OBSERVATION", 413, 431]]], ["The randomized clinical trial of hyperbaric medicine started in USA in the first week of April (7) .", [["hyperbaric medicine", "TREATMENT", 33, 52]]], ["This is in order to give what is left of a patient's functioning hemoglobin a chance to carry enough oxygen to the organs and keep them alive.Worldwide in time knowledgeAs we do not have nearly enough of those hyperbaric chambers, we might use all the parked grounded airplanes as a ready-made functional hyperbaric chamber with the advantage of providing double atmospheric pressure with an aerosol of prostacyclin as a pulmonary hypertension modulator.", [["organs", "ANATOMY", 115, 121], ["pulmonary", "ANATOMY", 421, 430], ["oxygen", "CHEMICAL", 101, 107], ["prostacyclin", "CHEMICAL", 403, 415], ["pulmonary hypertension", "DISEASE", 421, 443], ["oxygen", "CHEMICAL", 101, 107], ["prostacyclin", "CHEMICAL", 403, 415], ["patient", "ORGANISM", 43, 50], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 65, 75], ["oxygen", "SIMPLE_CHEMICAL", 101, 107], ["organs", "ORGAN", 115, 121], ["prostacyclin", "SIMPLE_CHEMICAL", 403, 415], ["pulmonary", "ORGAN", 421, 430], ["hemoglobin", "PROTEIN", 65, 75], ["patient", "SPECIES", 43, 50], ["those hyperbaric chambers", "TREATMENT", 204, 229], ["functional hyperbaric chamber", "TREATMENT", 294, 323], ["double atmospheric pressure", "TREATMENT", 356, 383], ["an aerosol of prostacyclin", "TREATMENT", 389, 415], ["a pulmonary hypertension modulator", "TREATMENT", 419, 453], ["pulmonary", "ANATOMY", 421, 430], ["hypertension", "OBSERVATION", 431, 443]]], ["Some Chinese physicians tried blood transfusion with packed fresh red blood cells to patients after plasmapheresis(9,10) , and witnessed some amelioration of the cytokine storm.Worldwide in time knowledgeThe main point is that patients will require ventilators if they present late with multi-organ system failure to tide them over this life or death scenario.", [["blood", "ANATOMY", 30, 35], ["red blood cells", "ANATOMY", 66, 81], ["multi-organ system", "ANATOMY", 287, 305], ["death", "DISEASE", 345, 350], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["blood cells", "CELL", 70, 81], ["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 227, 235], ["packed fresh red blood cells", "CELL_TYPE", 53, 81], ["cytokine", "PROTEIN", 162, 170], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 227, 235], ["blood transfusion", "TREATMENT", 30, 47], ["packed fresh red blood cells", "TREATMENT", 53, 81], ["plasmapheresis", "TREATMENT", 100, 114], ["the cytokine storm", "PROBLEM", 158, 176], ["ventilators", "TREATMENT", 249, 260], ["multi-organ system failure", "PROBLEM", 287, 313], ["cytokine storm", "OBSERVATION", 162, 176], ["main", "OBSERVATION_MODIFIER", 208, 212], ["failure", "OBSERVATION", 306, 313]]], ["However, intubation is futile unless the patient's immune system modulates the situation (11) .", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["intubation", "TREATMENT", 9, 19]]], ["We must address the root of the illness and avoid using traditional teachings to manage a failing system (12, 13) .Worldwide in time knowledgeArmchair pseudo-physicians an no longer sit in their ivory towers proclaiming \"Chloroquine use is stupid as malaria is a bacterium, COVID-19 a virus: anti-bacterial drugs do not work on a virus!\".", [["root", "ANATOMY", 20, 24], ["illness", "DISEASE", 32, 39], ["Chloroquine", "CHEMICAL", 221, 232], ["malaria", "DISEASE", 250, 257], ["Chloroquine", "CHEMICAL", 221, 232], ["Chloroquine", "SIMPLE_CHEMICAL", 221, 232], ["traditional teachings", "TREATMENT", 56, 77], ["Armchair pseudo", "PROBLEM", 142, 157], ["Chloroquine use", "TREATMENT", 221, 236], ["a bacterium", "PROBLEM", 261, 272], ["COVID", "TEST", 274, 279], ["anti-bacterial drugs", "TREATMENT", 292, 312]]], ["A drug does not need to act on the pathogen to be effective.", [["the pathogen", "PROBLEM", 31, 43]]], ["A few key opinion leaders advised that Chloroquine lowers the blood pH and interferes with replication of the virus.", [["blood", "ANATOMY", 62, 67], ["Chloroquine", "CHEMICAL", 39, 50], ["Chloroquine", "CHEMICAL", 39, 50], ["Chloroquine", "SIMPLE_CHEMICAL", 39, 50], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["Chloroquine", "TREATMENT", 39, 50], ["the blood pH", "TEST", 58, 70], ["the virus", "PROBLEM", 106, 115], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["However, a publication in press at the New England Journal of Medicine advises against the use of Chloroquine (14) .", [["Chloroquine", "CHEMICAL", 98, 109], ["Chloroquine", "CHEMICAL", 98, 109], ["Chloroquine", "SIMPLE_CHEMICAL", 98, 109], ["Chloroquine", "TREATMENT", 98, 109]]], ["Sweden has decided to halt its use, as have some parts of France.Worldwide in time knowledgeWe recommend that if COVID-19 positive patients are conscious, alert and compliant, they should be kept on maximum oxygen.", [["oxygen", "CHEMICAL", 207, 213], ["oxygen", "CHEMICAL", 207, 213], ["patients", "ORGANISM", 131, 139], ["oxygen", "SIMPLE_CHEMICAL", 207, 213], ["patients", "SPECIES", 131, 139], ["COVID", "TEST", 113, 118], ["maximum oxygen", "TREATMENT", 199, 213]]], ["A prone position allows better lung perfusion, and we may have to initiate hyperbaric oxygen as early as possible (8, 9, 10) .Worldwide in time knowledgeIf we reach the inevitable and need to ventilate, USA pulmonologists (15) have recommended that this should be performed at low pressure but with maximum oxygen flow.Worldwide in time knowledgeWe must avoid tearing up the lungs with maximum PEEP as this does more harm to the patient because we may be addressing the wrong organ (16) .COVID-19 virus and diabetes mellitusLast week, a discussion on Medscape about COVID 19 Virus and diabetes mellitus illustrated that the virus may be attacking the Islets of Langerhans in the pancreas and causing insulin deficiency (17) .", [["lung", "ANATOMY", 31, 35], ["lungs", "ANATOMY", 375, 380], ["organ", "ANATOMY", 476, 481], ["Islets", "ANATOMY", 651, 657], ["Langerhans", "ANATOMY", 661, 671], ["pancreas", "ANATOMY", 679, 687], ["oxygen", "CHEMICAL", 86, 92], ["oxygen", "CHEMICAL", 307, 313], ["diabetes mellitus", "DISEASE", 507, 524], ["diabetes mellitus", "DISEASE", 585, 602], ["insulin deficiency", "DISEASE", 700, 718], ["oxygen", "CHEMICAL", 86, 92], ["oxygen", "CHEMICAL", 307, 313], ["lung", "ORGAN", 31, 35], ["oxygen", "SIMPLE_CHEMICAL", 86, 92], ["oxygen", "SIMPLE_CHEMICAL", 307, 313], ["lungs", "ORGAN", 375, 380], ["patient", "ORGANISM", 429, 436], ["organ", "ORGAN", 476, 481], ["COVID-19 virus", "ORGANISM", 488, 502], ["COVID 19 Virus", "ORGANISM", 566, 580], ["Langerhans", "TISSUE", 661, 671], ["pancreas", "ORGAN", 679, 687], ["insulin", "GENE_OR_GENE_PRODUCT", 700, 707], ["patient", "SPECIES", 429, 436], ["COVID-19 virus", "SPECIES", 488, 502], ["hyperbaric oxygen", "TREATMENT", 75, 92], ["maximum oxygen flow", "TREATMENT", 299, 318], ["maximum PEEP", "TREATMENT", 386, 398], ["COVID", "TEST", 488, 493], ["diabetes mellitus", "PROBLEM", 507, 524], ["Medscape", "TREATMENT", 551, 559], ["COVID 19 Virus", "PROBLEM", 566, 580], ["diabetes mellitus", "PROBLEM", 585, 602], ["the virus", "PROBLEM", 620, 629], ["Langerhans in the pancreas", "PROBLEM", 661, 687], ["insulin deficiency", "PROBLEM", 700, 718], ["lung", "ANATOMY", 31, 35], ["perfusion", "OBSERVATION", 36, 45], ["hyperbaric oxygen", "OBSERVATION", 75, 92], ["oxygen flow", "OBSERVATION", 307, 318], ["lungs", "ANATOMY", 375, 380], ["Langerhans", "OBSERVATION", 661, 671], ["pancreas", "ANATOMY", 679, 687], ["insulin deficiency", "OBSERVATION", 700, 718]]], ["As those patients had good reserve they present late with diabetic ketoacidosis.", [["diabetic ketoacidosis", "DISEASE", 58, 79], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["diabetic ketoacidosis", "PROBLEM", 58, 79], ["diabetic", "OBSERVATION_MODIFIER", 58, 66], ["ketoacidosis", "OBSERVATION", 67, 79]]], ["The main focus of management I these cases needs to be high flow oxygen plus insulin supplementation.COVID-19 virus and diabetes mellitusIt is crucial not to underestimate COVID-19 severity in patients with diabetes even in the absence of classical worrisome signs and symptoms, and we must develop different clinical early severity scores for patients with diabetes.", [["oxygen", "CHEMICAL", 65, 71], ["insulin", "CHEMICAL", 77, 84], ["diabetes mellitus", "DISEASE", 120, 137], ["diabetes", "DISEASE", 207, 215], ["diabetes", "DISEASE", 358, 366], ["oxygen", "CHEMICAL", 65, 71], ["oxygen", "SIMPLE_CHEMICAL", 65, 71], ["insulin", "GENE_OR_GENE_PRODUCT", 77, 84], ["COVID-19 virus", "ORGANISM", 101, 115], ["patients", "ORGANISM", 193, 201], ["patients", "ORGANISM", 344, 352], ["patients", "SPECIES", 193, 201], ["patients", "SPECIES", 344, 352], ["COVID-19 virus", "SPECIES", 101, 115], ["high flow oxygen", "TREATMENT", 55, 71], ["insulin supplementation", "TREATMENT", 77, 100], ["COVID", "TEST", 101, 106], ["diabetes mellitus", "PROBLEM", 120, 137], ["COVID", "TEST", 172, 177], ["diabetes", "PROBLEM", 207, 215], ["classical worrisome signs and symptoms", "PROBLEM", 239, 277], ["diabetes", "PROBLEM", 358, 366], ["main", "OBSERVATION_MODIFIER", 4, 8], ["diabetes mellitus", "OBSERVATION", 120, 137], ["crucial not to", "UNCERTAINTY", 143, 157], ["19 severity", "OBSERVATION_MODIFIER", 178, 189], ["diabetes", "OBSERVATION", 207, 215]]], ["Although acute inflammatory states and acute stress responses will certainly raise glucose levels, the SARS-CoV-2 virus is actually damaging the pancreatic islet cells.COVID-19 virus and diabetes mellitusA study was done during the SARS 2003 coronavirus outbreak in China in which diabetes developed within two weeks of hospitalization in patients who did not previously have diabetes.", [["pancreatic islet cells", "ANATOMY", 145, 167], ["glucose", "CHEMICAL", 83, 90], ["SARS", "DISEASE", 103, 107], ["diabetes mellitus", "DISEASE", 187, 204], ["SARS", "DISEASE", 232, 236], ["coronavirus", "DISEASE", 242, 253], ["diabetes", "DISEASE", 281, 289], ["diabetes", "DISEASE", 376, 384], ["glucose", "CHEMICAL", 83, 90], ["glucose", "SIMPLE_CHEMICAL", 83, 90], ["SARS-CoV-2 virus", "ORGANISM", 103, 119], ["pancreatic islet cells", "CELL", 145, 167], ["COVID-19 virus", "ORGANISM", 168, 182], ["patients", "ORGANISM", 339, 347], ["pancreatic islet cells", "CELL_TYPE", 145, 167], ["patients", "SPECIES", 339, 347], ["SARS-CoV-2 virus", "SPECIES", 103, 119], ["COVID-19 virus", "SPECIES", 168, 182], ["SARS 2003 coronavirus", "SPECIES", 232, 253], ["acute inflammatory states", "PROBLEM", 9, 34], ["acute stress responses", "PROBLEM", 39, 61], ["glucose levels", "TEST", 83, 97], ["the SARS", "TEST", 99, 107], ["CoV-2 virus", "PROBLEM", 108, 119], ["the pancreatic islet cells", "PROBLEM", 141, 167], ["COVID", "TEST", 168, 173], ["diabetes mellitus", "PROBLEM", 187, 204], ["A study", "TEST", 204, 211], ["the SARS", "PROBLEM", 228, 236], ["diabetes", "PROBLEM", 281, 289], ["diabetes", "PROBLEM", 376, 384], ["acute", "OBSERVATION_MODIFIER", 9, 14], ["inflammatory", "OBSERVATION", 15, 27], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["pancreatic", "ANATOMY", 145, 155], ["islet cells", "OBSERVATION", 156, 167], ["diabetes", "OBSERVATION", 376, 384]]], ["Immuno-staining in patients who had died after contacting COVID-19 showed strong staining of the angiotensin-converting enzyme 2 (ACE2) protein -the coronavirus binding site -in the islets but not the exocrine pancreatic tissue, which means coronavirus causes diabetes by damaging pancreatic islets.COVID-19 virus and diabetes mellitusCOVID-19 causes insulin deficiency, meaning many patients require markedly elevated insulin drip rates.", [["islets", "ANATOMY", 182, 188], ["exocrine pancreatic tissue", "ANATOMY", 201, 227], ["pancreatic islets", "ANATOMY", 281, 298], ["angiotensin", "CHEMICAL", 97, 108], ["diabetes", "DISEASE", 260, 268], ["diabetes", "DISEASE", 318, 326], ["insulin deficiency", "DISEASE", 351, 369], ["COVID-19", "CHEMICAL", 58, 66], ["patients", "ORGANISM", 19, 27], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 97, 128], ["ACE2", "GENE_OR_GENE_PRODUCT", 130, 134], ["coronavirus", "ORGANISM", 149, 160], ["islets", "MULTI-TISSUE_STRUCTURE", 182, 188], ["exocrine pancreatic tissue", "TISSUE", 201, 227], ["coronavirus", "ORGANISM", 241, 252], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 281, 298], ["COVID-19 virus", "ORGANISM", 299, 313], ["insulin", "GENE_OR_GENE_PRODUCT", 351, 358], ["patients", "ORGANISM", 384, 392], ["insulin", "GENE_OR_GENE_PRODUCT", 419, 426], ["angiotensin-converting enzyme 2 (ACE2) protein", "PROTEIN", 97, 143], ["coronavirus binding site", "DNA", 149, 173], ["pancreatic islets", "CELL_TYPE", 281, 298], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 384, 392], ["COVID-19 virus", "SPECIES", 299, 313], ["contacting COVID", "TEST", 47, 63], ["the angiotensin", "TEST", 93, 108], ["converting enzyme", "TEST", 109, 126], ["ACE2", "TEST", 130, 134], ["protein", "TEST", 136, 143], ["the coronavirus binding site", "PROBLEM", 145, 173], ["the exocrine pancreatic tissue", "PROBLEM", 197, 227], ["coronavirus", "PROBLEM", 241, 252], ["diabetes", "PROBLEM", 260, 268], ["damaging pancreatic islets", "PROBLEM", 272, 298], ["COVID", "TEST", 299, 304], ["diabetes mellitusCOVID", "TEST", 318, 340], ["insulin deficiency", "PROBLEM", 351, 369], ["markedly elevated insulin drip rates", "TREATMENT", 401, 437], ["coronavirus binding", "OBSERVATION", 149, 168], ["pancreatic tissue", "ANATOMY", 210, 227], ["insulin deficiency", "OBSERVATION", 351, 369], ["markedly", "OBSERVATION_MODIFIER", 401, 409], ["elevated", "OBSERVATION", 410, 418]]], ["This is not just pressor/steroid related.", [["steroid", "CHEMICAL", 25, 32], ["steroid", "CHEMICAL", 25, 32], ["steroid", "SIMPLE_CHEMICAL", 25, 32], ["pressor/steroid", "TREATMENT", 17, 32]]], ["Something else is going on here.COVID-19 virus and diabetes mellitusWe've not seen this pattern of glycaemia with associated insulin requirements before.", [["diabetes", "DISEASE", 51, 59], ["glycaemia", "DISEASE", 99, 108], ["COVID-19 virus", "ORGANISM", 32, 46], ["insulin", "GENE_OR_GENE_PRODUCT", 125, 132], ["COVID-19 virus", "SPECIES", 32, 46], ["COVID", "TEST", 32, 37], ["diabetes mellitusWe", "PROBLEM", 51, 70], ["associated insulin requirements", "PROBLEM", 114, 145], ["insulin requirements", "OBSERVATION", 125, 145]]], ["This is a new beast.", [["new", "OBSERVATION_MODIFIER", 10, 13], ["beast", "OBSERVATION", 14, 19]]], ["The degree of glucose toxicity is profound and independent of preadmission diabetes control.", [["glucose", "CHEMICAL", 14, 21], ["toxicity", "DISEASE", 22, 30], ["diabetes", "DISEASE", 75, 83], ["glucose", "CHEMICAL", 14, 21], ["glucose", "SIMPLE_CHEMICAL", 14, 21], ["glucose toxicity", "PROBLEM", 14, 30], ["preadmission diabetes control", "TREATMENT", 62, 91], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["glucose toxicity", "OBSERVATION", 14, 30]]], ["Patients with seemingly well-controlled diabetes at home with HBA1cs in the single digits experience severe dysglycaemia.", [["diabetes", "DISEASE", 40, 48], ["HBA1cs", "CHEMICAL", 62, 68], ["dysglycaemia", "DISEASE", 108, 120], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["seemingly well-controlled diabetes", "PROBLEM", 14, 48], ["HBA1cs", "TREATMENT", 62, 68], ["severe dysglycaemia", "PROBLEM", 101, 120], ["well-controlled", "OBSERVATION_MODIFIER", 24, 39], ["diabetes", "OBSERVATION", 40, 48], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["dysglycaemia", "OBSERVATION", 108, 120]]], ["There is a subset of patients presenting with euglycaemic DKA with normal lactate, with other causes of ketoacidosis ruled out.", [["euglycaemic DKA", "DISEASE", 46, 61], ["lactate", "CHEMICAL", 74, 81], ["ketoacidosis", "DISEASE", 104, 116], ["lactate", "CHEMICAL", 74, 81], ["patients", "ORGANISM", 21, 29], ["lactate", "SIMPLE_CHEMICAL", 74, 81], ["patients", "SPECIES", 21, 29], ["euglycaemic DKA", "PROBLEM", 46, 61], ["ketoacidosis", "PROBLEM", 104, 116], ["ketoacidosis", "OBSERVATION", 104, 116]]], ["Diabetics had higher levels of biomarkers due to an inflammatory \"cytokine storm\" preceding rapid deterioration of COVID-19 (17, 20) .COVID-19 virus and diabetes mellitusThere is a small village in northern Italy where the majority of its population suffers from thalassemia.", [["diabetes mellitus", "DISEASE", 153, 170], ["thalassemia", "DISEASE", 263, 274], ["COVID-19", "CHEMICAL", 115, 123], ["COVID-19 virus", "ORGANISM", 134, 148], ["cytokine", "PROTEIN", 66, 74], ["COVID-19 virus", "SPECIES", 134, 148], ["Diabetics", "PROBLEM", 0, 9], ["higher levels of biomarkers", "PROBLEM", 14, 41], ["an inflammatory \"cytokine storm", "PROBLEM", 49, 80], ["COVID", "TEST", 115, 120], ["COVID", "TEST", 134, 139], ["diabetes mellitus", "PROBLEM", 153, 170], ["a small village in northern", "PROBLEM", 179, 206], ["thalassemia", "PROBLEM", 263, 274], ["inflammatory", "OBSERVATION_MODIFIER", 52, 64], ["rapid", "OBSERVATION_MODIFIER", 92, 97], ["deterioration", "OBSERVATION_MODIFIER", 98, 111], ["diabetes mellitus", "OBSERVATION", 153, 170], ["small", "OBSERVATION_MODIFIER", 181, 186], ["village", "OBSERVATION", 187, 194], ["majority", "OBSERVATION_MODIFIER", 223, 231], ["thalassemia", "OBSERVATION", 263, 274]]], ["These individuals have had no deaths and no cross-community spread, due to the abnormal shape of the red blood cells.", [["red blood cells", "ANATOMY", 101, 116], ["deaths", "DISEASE", 30, 36], ["red blood cells", "CELL", 101, 116], ["red blood cells", "CELL_TYPE", 101, 116], ["deaths", "PROBLEM", 30, 36], ["cross-community spread", "PROBLEM", 44, 66], ["the abnormal shape of the red blood cells", "PROBLEM", 75, 116], ["no", "UNCERTAINTY", 27, 29], ["no", "UNCERTAINTY", 41, 43], ["red blood cells", "OBSERVATION", 101, 116]]], ["Moreover, parts of Nepal that are 1km above sea level are COVID-19 free, the same logic applies, abnormal shape of the red blood cell.", [["red blood cell", "ANATOMY", 119, 133], ["red blood cell", "CELL", 119, 133], ["red blood cell", "CELL_TYPE", 119, 133], ["sea level", "TEST", 44, 53], ["COVID", "TEST", 58, 63], ["abnormal shape of the red blood cell", "PROBLEM", 97, 133], ["abnormal", "OBSERVATION_MODIFIER", 97, 105], ["shape", "OBSERVATION_MODIFIER", 106, 111], ["red blood", "ANATOMY", 119, 128], ["cell", "OBSERVATION", 129, 133]]], ["All the evidence suggests that we are chasing the wrong organ: it is not the lungs, it is a blood problem.Big data and artificial intelligenceWe advised a few international organizations that AL & ML must be utilized in analyzing Big data.", [["organ", "ANATOMY", 56, 61], ["lungs", "ANATOMY", 77, 82], ["blood", "ANATOMY", 92, 97], ["organ", "ORGAN", 56, 61], ["lungs", "ORGAN", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["a blood problem", "PROBLEM", 90, 105], ["AL & ML", "TREATMENT", 192, 199], ["lungs", "ANATOMY", 77, 82]]], ["AI, Big data analysis and bioinformatics must be harnessed to allow us to scrutinize how can we provide the best options for our patients, creating bioinformatics modelling that can surpass any RCT.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["Big data analysis", "TEST", 4, 21]]], ["Adaptive platform designs must be structured to promote maximum learning from around the world to adjust how we deliver the best care to our patients (21, 22, 23, 24, 25, 26, 27) .Big data and artificial intelligencePeople are desaturating due to failure of the blood to carry oxygen (17) .", [["blood", "ANATOMY", 262, 267], ["oxygen", "CHEMICAL", 277, 283], ["oxygen", "CHEMICAL", 277, 283], ["patients", "ORGANISM", 141, 149], ["People", "ORGANISM", 216, 222], ["blood", "ORGANISM_SUBSTANCE", 262, 267], ["oxygen", "SIMPLE_CHEMICAL", 277, 283], ["patients", "SPECIES", 141, 149], ["People", "SPECIES", 216, 222], ["Adaptive platform designs", "TREATMENT", 0, 25], ["Big data", "TEST", 180, 188], ["artificial intelligence", "TEST", 193, 216], ["desaturating", "PROBLEM", 227, 239], ["failure of the blood", "PROBLEM", 247, 267], ["carry oxygen", "TREATMENT", 271, 283]]], ["This will lead to multi-organ failure and high mortality due to Cytokine Storm.", [["multi-organ", "ANATOMY", 18, 29], ["multi-organ failure", "DISEASE", 18, 37], ["Cytokine", "GENE_OR_GENE_PRODUCT", 64, 72], ["Cytokine", "PROTEIN", 64, 72], ["multi-organ failure", "PROBLEM", 18, 37], ["high mortality", "PROBLEM", 42, 56], ["Cytokine Storm", "PROBLEM", 64, 78], ["multi-organ", "ANATOMY", 18, 29], ["failure", "OBSERVATION", 30, 37], ["Cytokine Storm", "OBSERVATION", 64, 78]]], ["We believe that management protocols for ARDS should not be applied for COVID-19 patients (18, 19, 21, 22, 23, 24, 25, 26, 27) .Big data and artificial intelligenceWe recommend the following:Big data and artificial intelligence1.", [["ARDS", "DISEASE", 41, 45], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["management protocols", "TREATMENT", 16, 36], ["ARDS", "PROBLEM", 41, 45], ["COVID", "TEST", 72, 77], ["Big data", "TEST", 191, 199], ["artificial intelligence1", "TREATMENT", 204, 228]]], ["Inhibit viral growth and replication by any proven means.", [["viral growth", "PROBLEM", 8, 20], ["viral growth", "OBSERVATION", 8, 20]]], ["Currently the adjuvant use of CHQ+ZPAK+ZINC appears indicated, or the rising star of Ramedesivir, which has proven effectiveness in ameliorating COVID-19 mortality.", [["CHQ", "CHEMICAL", 30, 33], ["ZPAK", "CHEMICAL", 34, 38], ["ZINC", "CHEMICAL", 39, 43], ["Ramedesivir", "CHEMICAL", 85, 96], ["CHQ", "CHEMICAL", 30, 33], ["ZPAK", "CHEMICAL", 34, 38], ["ZINC", "CHEMICAL", 39, 43], ["Ramedesivir", "CHEMICAL", 85, 96], ["CHQ", "SIMPLE_CHEMICAL", 30, 33], ["ZPAK", "SIMPLE_CHEMICAL", 34, 38], ["ZINC", "SIMPLE_CHEMICAL", 39, 43], ["Ramedesivir", "SIMPLE_CHEMICAL", 85, 96], ["CHQ", "TREATMENT", 30, 33], ["ZPAK", "TREATMENT", 34, 38], ["ZINC", "TREATMENT", 39, 43], ["ameliorating COVID", "TEST", 132, 150]]], ["Other retroviral therapies are being studied.", [["retroviral", "ORGANISM", 6, 16], ["Other retroviral therapies", "TREATMENT", 0, 26], ["retroviral therapies", "OBSERVATION", 6, 26]]], ["The less viral load we have, the less severity of the damage with the prevention of cytokine storm.Big data and artificial intelligence2.", [["cytokine", "PROTEIN", 84, 92], ["The less viral load", "PROBLEM", 0, 19], ["the damage", "PROBLEM", 50, 60], ["cytokine storm", "PROBLEM", 84, 98], ["Big data", "TEST", 99, 107], ["artificial intelligence2", "TREATMENT", 112, 136], ["less", "OBSERVATION_MODIFIER", 4, 8], ["viral load", "OBSERVATION", 9, 19], ["less severity", "OBSERVATION_MODIFIER", 33, 46], ["cytokine storm", "OBSERVATION", 84, 98], ["artificial intelligence2", "OBSERVATION", 112, 136]]], ["Theoretical use of hyperbaric medicine or pressurized grounded airplanes may prevent rapid ascent into the abyss.Big data and artificial intelligence3.", [["abyss", "DISEASE", 107, 112], ["hyperbaric medicine", "TREATMENT", 19, 38], ["pressurized grounded airplanes", "TREATMENT", 42, 72], ["Big data", "TEST", 113, 121], ["artificial intelligence3", "TREATMENT", 126, 150], ["artificial intelligence3", "OBSERVATION", 126, 150]]], ["Plasmapheresis and blood transfusions may give supportive symptomatic relief when indicated.Big data and artificial intelligence4.", [["blood", "ANATOMY", 19, 24], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["Plasmapheresis", "TREATMENT", 0, 14], ["blood transfusions", "TREATMENT", 19, 37], ["supportive symptomatic relief", "TREATMENT", 47, 76], ["Big data", "TEST", 92, 100], ["artificial intelligence4", "TREATMENT", 105, 129], ["artificial intelligence4", "OBSERVATION", 105, 129]]], ["No international travel until an effective vaccine is available.Big data and artificial intelligence5.", [["an effective vaccine", "TREATMENT", 30, 50], ["Big data", "TEST", 64, 72], ["artificial intelligence5", "TREATMENT", 77, 101], ["artificial intelligence5", "OBSERVATION", 77, 101]]], ["Cessation of tobacco, vaping, and the use of alcohol products.Big data and artificial intelligenceUntil we create a sound protocol for managing our sick patients and understand why chloroquine and invasive ventilation have failed, as both have been unable to bail out our oxygen-starved patients, the only available option is symptomatic relief.", [["alcohol", "CHEMICAL", 45, 52], ["chloroquine", "CHEMICAL", 181, 192], ["oxygen", "CHEMICAL", 272, 278], ["alcohol", "CHEMICAL", 45, 52], ["chloroquine", "CHEMICAL", 181, 192], ["oxygen", "CHEMICAL", 272, 278], ["tobacco", "ORGANISM", 13, 20], ["alcohol", "SIMPLE_CHEMICAL", 45, 52], ["patients", "ORGANISM", 153, 161], ["chloroquine", "SIMPLE_CHEMICAL", 181, 192], ["oxygen", "SIMPLE_CHEMICAL", 272, 278], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 153, 161], ["patients", "SPECIES", 287, 295], ["tobacco", "SPECIES", 13, 20], ["alcohol products", "TREATMENT", 45, 61], ["Big data", "TEST", 62, 70], ["artificial intelligence", "TEST", 75, 98], ["a sound protocol", "TEST", 114, 130], ["chloroquine", "TREATMENT", 181, 192], ["invasive ventilation", "TREATMENT", 197, 217], ["our oxygen", "TREATMENT", 268, 278], ["symptomatic relief", "PROBLEM", 326, 344]]]], "29e8d184ca8182734aa88bf96cd9fd1ab819c4ce": [["IntroductionThe aim of this contribution is to map the current situation in Bulgaria's public healthcare system with regard to bioterrorism response.IntroductionIn Bulgaria public health and biopreparedness are still regarded as two independent public policies.", [["biopreparedness", "TREATMENT", 191, 206]]], ["Public health, including control of infectious diseases and the counter of epidemics, is a priority of the Ministry of Health while preparation for response to bioterrorism is almost entirely within the scope of the activities of the Ministry of Defence.", [["infectious diseases", "DISEASE", 36, 55], ["infectious diseases", "PROBLEM", 36, 55], ["bioterrorism", "PROBLEM", 160, 172], ["infectious", "OBSERVATION", 36, 46]]], ["Moreover, until recently the efforts of the military experts were focused completely on the problems of biodefence in the event of an attack with biological weapons and the basic protection of the army.", [["biodefence", "TREATMENT", 104, 114]]], ["On one hand, the prioritization of the protection of the civilian population from bioterrorism on the global scene in general, and the emergence of new epidemics of infectious diseases, on the other hand, naturally impose the need for coherence and cooperation of efforts of different institutions in Bulgaria for responding to bioterrorism.IntroductionFurthermore, in the beginning, a covert biological attack cannot be distinguished straightforwardly from a naturally occurring epidemic, in which case the response will be handled by the existing public health structures.IntroductionThe overall evaluation is that Bulgaria has no experience in countering bioterrorism.Current Public Health Threats and PerceptionsThe main public health threats concerning infectious diseases in Bulgaria are de fi ned in the Health Act and its additional regulations.", [["infectious diseases", "DISEASE", 165, 184], ["infectious diseases", "DISEASE", 758, 777], ["infectious diseases", "PROBLEM", 165, 184], ["The overall evaluation", "TEST", 586, 608], ["infectious diseases", "PROBLEM", 758, 777], ["new", "OBSERVATION_MODIFIER", 148, 151], ["infectious", "OBSERVATION", 165, 175], ["main", "OBSERVATION_MODIFIER", 720, 724], ["infectious", "OBSERVATION_MODIFIER", 758, 768]]], ["About 60 diseases are indicated in the of fi cial list of infectious and parasitic diseases, which are subject to mandatory registration, noti fi cation and reporting (Table 8.1 ) .", [["infectious and parasitic diseases", "DISEASE", 58, 91], ["60 diseases", "PROBLEM", 6, 17], ["infectious and parasitic diseases", "PROBLEM", 58, 91], ["infectious", "OBSERVATION", 58, 68], ["parasitic diseases", "OBSERVATION", 73, 91]]], ["However, not all of the items in the list are subject to regular monitoring.", [["regular monitoring", "TEST", 57, 75]]], ["Regular updates are given for 50% of the infectious diseases.Current Public Health Threats and PerceptionsThe data for morbidity of the most important communicable diseases for the country is published in the weekly epidemiological bulletin (Table 8 .2 ), published by the National Centre for Infectious and Parasitic Diseases.Current Public Health Threats and PerceptionsContrary to the existing infectious diseases list, Bulgarian authorities do not have an established of fi cial list of potential agents for bioterrorism.", [["infectious diseases", "DISEASE", 41, 60], ["Infectious and Parasitic Diseases", "DISEASE", 293, 326], ["infectious diseases", "DISEASE", 397, 416], ["the infectious diseases", "PROBLEM", 37, 60], ["morbidity", "PROBLEM", 119, 128], ["Infectious and Parasitic Diseases", "PROBLEM", 293, 326], ["bioterrorism", "PROBLEM", 512, 524], ["Infectious", "OBSERVATION", 293, 303], ["Parasitic Diseases", "OBSERVATION", 308, 326], ["infectious", "OBSERVATION", 397, 407]]], ["3 ) which represent a potential threat for Bulgarian citizens in case of bioterrorism, taking into account the following criteria [ 5 ] :Current Public Health Threats and PerceptionsThe immunization calendar of the country; and \u2022Current Public Health Threats and PerceptionsThe implementation of commitments to peacekeeping and other missions. \u2022 This lack of of fi cial position on the threat of biological agents needs to be further clari fi ed.", [["biological agents", "TREATMENT", 396, 413]]], ["Until very recently according to the Bulgarian authorities there was no risk of terrorism in the country, including risk of bioterrorism.", [["bioterrorism", "PROBLEM", 124, 136], ["no risk of", "UNCERTAINTY", 69, 79], ["terrorism", "OBSERVATION", 80, 89], ["bioterrorism", "OBSERVATION", 124, 136]]], ["This attitude is changing and the new position of the government is that Bulgaria faces the risks and threats common to the Euro-Atlantic area which include terrorism and weapons of mass destruction.Current Public Health Threats and PerceptionsThe new National Security Strategy of the Republic of Bulgaria (NSS), adopted by the National Assembly on 25 February 2011, states that \"risks and threats (including bioterrorism) to the security of the Republic of Bulgaria and its citizens largely coincide or are similar to those that threaten other EU countries and NATO\" [ 4 ] .", [["Euro-Atlantic", "DISEASE", 124, 137], ["the Euro-Atlantic area", "PROBLEM", 120, 142], ["terrorism", "PROBLEM", 157, 166], ["mass destruction", "PROBLEM", 182, 198], ["new", "OBSERVATION_MODIFIER", 34, 37], ["position", "OBSERVATION_MODIFIER", 38, 46], ["mass", "OBSERVATION", 182, 186], ["new", "OBSERVATION_MODIFIER", 248, 251]]], ["The strategy gives special attention to asymmetric threats, especially international terrorism and proliferation of weapons of mass destruction (WMD) and their impact on security in a global and regional context.", [["asymmetric threats", "PROBLEM", 40, 58], ["mass destruction", "PROBLEM", 127, 143], ["asymmetric", "OBSERVATION_MODIFIER", 40, 50], ["threats", "OBSERVATION_MODIFIER", 51, 58], ["proliferation", "OBSERVATION_MODIFIER", 99, 112], ["weapons", "OBSERVATION_MODIFIER", 116, 123], ["mass", "OBSERVATION", 127, 131], ["destruction", "OBSERVATION_MODIFIER", 132, 143]]], ["The document underlines the increasing possibilities of the use of radioactive materials, toxic substances and biological agents, as well as access to information databases and technology for the combat of terrorism.Current Public Health Threats and PerceptionsParticular attention is paid to a number of issues: The new approach indicates the importance of building an integrated, fl exible and sustainable national management system to respond effectively to crises.", [["radioactive materials", "TREATMENT", 67, 88], ["toxic substances", "TREATMENT", 90, 106], ["biological agents", "TREATMENT", 111, 128], ["terrorism", "PROBLEM", 206, 215], ["fl exible", "TREATMENT", 382, 391], ["sustainable national management system", "TREATMENT", 396, 434], ["crises", "PROBLEM", 461, 467], ["terrorism", "OBSERVATION", 206, 215], ["new", "OBSERVATION_MODIFIER", 317, 320]]], ["In order to reach an effective crisis management level, it is necessary to develop integrated military and civilian capabilities for action in the country and the EU.Current Public Health Threats and PerceptionsThis new orientation in the strategic thinking has not been further developed into procedures and other types of documents, including of fi cially recognized bio-threat agents.Legal FrameworkThe perception of risk re fl ected in the new National Security Strategy and the necessity of integrated military and civilian capabilities fully correspond to the existing legal framework.", [["bio-threat agents", "SIMPLE_CHEMICAL", 369, 386], ["an effective crisis management", "TREATMENT", 18, 48]]], ["As a result, Bulgarian authorities have aimed at achieving full alignment with internationally acknowledged crisis management systems.", [["crisis management systems", "TREATMENT", 108, 133]]], ["Even though an overall look at the existing framework, reveals a strong foundation for Bulgaria's anti-terrorism and WMD defence policies, a deeper observation shows lack of a strategy explicitly addressing the threat and response to bioterrorism [ 1 ] .Legal FrameworkThe key acts and plans in Bulgaria on these topics are listed below for information.", [["Bulgaria's anti-terrorism", "TREATMENT", 87, 112], ["a deeper observation", "TEST", 139, 159]]], ["However, their full description and evaluation is beyond the scope and focus of this paper.Overall Coordination of Managing BodiesThe following governmental bodies are engaged in emergency response and preparedness, including in the case of a bioterrorist threat ( The IRS includes the General Direction \"Civil Protection\" (GDCP), the General Direction \"General Fire Safety and Protection of Population\" (GDFSPP) and the regional directions of the Ministry of Interior, as well as the Centres for Emergency Medicine (CEM) and its regional divisions of the Ministry of Health.", [["evaluation", "TEST", 36, 46]]], ["The main components of the IRS are present in all districts and municipalities throughout the country.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["components", "OBSERVATION_MODIFIER", 9, 19], ["all", "OBSERVATION_MODIFIER", 46, 49], ["districts", "OBSERVATION_MODIFIER", 50, 59]]], ["This position is held by the chief of the territorial unit of the GDFSPP.", [["GDFSPP", "DNA", 66, 72]]], ["In the case of epidemics, the activities on the scene are managed by the director of the Regional Health Inspection.Overall Coordination of Managing BodiesIn the following sections, we will have a detailed look at the key bodies involved in emergency response.", [["sections", "ANATOMY", 172, 180], ["epidemics", "PROBLEM", 15, 24], ["epidemics", "OBSERVATION", 15, 24]]], ["Minister of Interior MTITC Ministry of Transport, Information Technologies and Communication RCEM Regional Centres for Emergency Medicine RDCP Regional Direction \"Civil Protection\" RDFSPP Regional Direction \"General Fire Safety and Protection of Population\" RDMI Regional Directions of the Ministry of InteriorGeneral Direction \"Civil Protection\"General Direction \"Civil Protection\" (GDCP), part of the Ministry of Interior, currently performs a number of tasks related to disaster relief.", [["Emergency Medicine", "TREATMENT", 119, 137], ["disaster relief", "TREATMENT", 473, 488]]], ["Firstly, the body warns and signals of the threat of a disaster which also includes the case of state of war ( Fig. 8.2 ) .", [["body", "ANATOMY", 13, 17], ["body", "ORGANISM_SUBDIVISION", 13, 17]]], ["Secondly, it performs search and rescue operations during disasters, including emergency works.", [["rescue operations", "TREATMENT", 33, 50]]], ["In case of incidents and emergencies related to harmful materials and substances, the General Direction is in charge of radiation, chemical and biological protection.", [["harmful materials", "TREATMENT", 48, 65], ["radiation", "TREATMENT", 120, 129], ["chemical and biological protection", "TREATMENT", 131, 165]]], ["In terms of actions for prevention, GDCP organizes education activities and trainings of the population to react during disasters as well as the implementation of protective measures.", [["prevention", "TREATMENT", 24, 34], ["protective measures", "TREATMENT", 163, 182]]], ["Even though GDCP has substantial functions in emergency prevention and response, it lacks tasks directly involved in the use of bioweapons or naturally developing pandemics.", [["GDCP", "CHEMICAL", 12, 16], ["GDCP", "GENE_OR_GENE_PRODUCT", 12, 16], ["GDCP", "PROTEIN", 12, 16], ["emergency prevention", "TREATMENT", 46, 66], ["substantial", "OBSERVATION_MODIFIER", 21, 32], ["functions", "OBSERVATION_MODIFIER", 33, 42], ["pandemics", "OBSERVATION", 163, 172]]], ["For this reason GDCP is working in close coordination with the Centres of Emergency Medicine (CEM).State Agency \"State Reserve and War-Time Stocks\"State Agency \"State Reserve and War-Time Stocks\" is the specialized body of the Council of Ministers that pursues the state policy in the fi eld of the accumulation, In Bulgaria, the main stocks piled into the system of state reserves, for which the State Agency is responsible, are: fuels, chemicals, foods, ferrous and non-ferrous metals, spare parts, timbers and paper, medical provisions, hospital equipment, and tools.State Agency \"State Reserve and War-Time Stocks\"In case of a biological attack these are the available resources of the agency.", [["ferrous", "CHEMICAL", 456, 463], ["ferrous", "CHEMICAL", 456, 463], ["body", "ORGANISM_SUBDIVISION", 215, 219], ["ferrous", "SIMPLE_CHEMICAL", 456, 463], ["a biological attack", "PROBLEM", 629, 648]]], ["It has the main equipment in terms of medical provisions except serums and vaccines which are kept at the National Centre of Infectious and Parasitic Diseases.State Agency for National SecurityThe State Agency for National Security (SANS) was created in 2007 and it is still in the process of development.", [["Infectious and Parasitic Diseases", "DISEASE", 125, 158], ["serums", "ORGANISM_SUBSTANCE", 64, 70], ["medical provisions", "TREATMENT", 38, 56], ["serums", "TREATMENT", 64, 70], ["vaccines", "TREATMENT", 75, 83], ["Parasitic Diseases", "PROBLEM", 140, 158], ["main", "OBSERVATION_MODIFIER", 11, 15], ["Infectious", "OBSERVATION", 125, 135], ["Parasitic Diseases", "OBSERVATION", 140, 158]]], ["The State Agency for National Security is a specialized body for counter-intelligence and security and its chief responsibility is to detect, prevent and neutralize the threats to the Bulgarian national security [ 7 ] .State Agency for National SecurityIn order to ful fi l its duties, SANS uses in its work the whole spectrum of counterintelligence means and resources.", [["body", "ANATOMY", 56, 60], ["body", "ORGANISM_SUBDIVISION", 56, 60]]], ["One of its tasks is the gathering of information regarding time, location and media of dissemination of the biological agent.State Agency for National SecurityMoreover, with respect to prevention of terrorism, including bioterrorism, the Agency performs tasks of surveillance, detection, counteraction and prevention of: The main concern under discussion about SANS's functions and activities is the order, volume and use of the acquired and analyzed information for the planning to counter a biological attack made by other authorities.", [["the biological agent", "TREATMENT", 104, 124], ["terrorism", "PROBLEM", 199, 208], ["surveillance", "TEST", 263, 275], ["SANS's functions", "TEST", 361, 377]]], ["This problem stems from the lack of publicity of the reports evaluating the risk of bioterrorism.", [["bioterrorism", "PROBLEM", 84, 96], ["bioterrorism", "OBSERVATION", 84, 96]]], ["Therefore, due to the classi fi ed nature of the information, further estimates about the activities performed by SANS with respect to biological threats cannot be made.Ministry of Health and Its StructuresThe Ministry of Health's main functions encompass two of its strategic goals with respect to emergency response (Fig. 8.3 ) .", [["Fig.", "TEST", 319, 323]]], ["First of all, it is responsible for surveillance, prevention and protection from infectious diseases.", [["infectious diseases", "DISEASE", 81, 100], ["surveillance", "TEST", 36, 48], ["infectious diseases", "PROBLEM", 81, 100], ["infectious", "OBSERVATION", 81, 91]]], ["Second, it deals with the organization of the medical response in the case of a biological attack.", [["a biological attack", "PROBLEM", 78, 97]]], ["The structures directly involved in performing these two functions are the National Centre for Infectious and Parasitic Diseases (NCIPD), Regional Health Inspections (RHIs), the Centre for Emergency Medicine and the medical facilities throughout the country (regional clinics or departments for infectious diseases).Ministry of Health and Its StructuresThe Ministry of Health has issued a plan for public protection in the case of disasters including terrorism, as well as counteraction to an in fl uenza pandemic, but the structures of the Ministry do not have a speci fi c plan for actions in case of biological attack.National Centre for Infectious and Parasitic DiseasesAs a result of its efforts in the research and surveillance on infectious diseases, in 2007 the European Centre for Disease Control (ECDC) in Stockholm declared Fig. 8.3 Ministry of Health and its structures NCIPD as a leading \"national competent body\" in the fi eld of infectious and parasitic diseases.National Centre for Infectious and Parasitic DiseasesThe NCIPD has the status of scienti fi c organization of the Ministry of Health, which aims to develop a scienti fi c basis for the fi ght against infectious diseases and methods for its implementation.", [["body", "ANATOMY", 921, 925], ["Infectious and Parasitic Diseases", "DISEASE", 95, 128], ["NCIPD", "DISEASE", 130, 135], ["infectious diseases", "DISEASE", 295, 314], ["Infectious and Parasitic DiseasesAs", "DISEASE", 641, 676], ["infectious diseases", "DISEASE", 737, 756], ["infectious and parasitic diseases", "DISEASE", 944, 977], ["Infectious and Parasitic Diseases", "DISEASE", 998, 1031], ["infectious diseases", "DISEASE", 1178, 1197], ["body", "ORGANISM_SUBDIVISION", 921, 925], ["Infectious and Parasitic Diseases", "PROBLEM", 95, 128], ["infectious diseases", "PROBLEM", 295, 314], ["public protection", "TREATMENT", 398, 415], ["terrorism", "PROBLEM", 451, 460], ["actions", "TREATMENT", 584, 591], ["biological attack", "PROBLEM", 603, 620], ["Infectious and Parasitic DiseasesAs", "PROBLEM", 641, 676], ["parasitic diseases", "PROBLEM", 959, 977], ["Infectious and Parasitic Diseases", "PROBLEM", 998, 1031], ["infectious diseases", "PROBLEM", 1178, 1197], ["Infectious", "OBSERVATION_MODIFIER", 95, 105], ["Parasitic Diseases", "OBSERVATION", 110, 128], ["Infectious", "OBSERVATION", 641, 651], ["Parasitic DiseasesAs", "OBSERVATION", 656, 676], ["infectious", "OBSERVATION", 944, 954], ["parasitic diseases", "OBSERVATION", 959, 977], ["Infectious", "OBSERVATION", 998, 1008]]], ["Therefore, the areas of intensive research are: infectious diseases, immune reactivity, epidemiology, laboratory diagnostics, and treatment and prophylaxis of bacterial, viral, and parasitic infections.", [["infectious diseases", "DISEASE", 48, 67], ["bacterial, viral, and parasitic infections", "DISEASE", 159, 201], ["infectious diseases", "PROBLEM", 48, 67], ["laboratory diagnostics", "TEST", 102, 124], ["treatment", "TREATMENT", 130, 139], ["prophylaxis", "TREATMENT", 144, 155], ["bacterial", "PROBLEM", 159, 168], ["viral", "PROBLEM", 170, 175], ["parasitic infections", "PROBLEM", 181, 201], ["areas", "OBSERVATION_MODIFIER", 15, 20], ["intensive", "OBSERVATION_MODIFIER", 24, 33], ["infectious", "OBSERVATION", 48, 58], ["viral", "OBSERVATION", 170, 175], ["parasitic", "OBSERVATION_MODIFIER", 181, 190], ["infections", "OBSERVATION", 191, 201]]], ["NCIPD includes all National Reference Laboratories (NRL) in various bacterial, viral and parasitic infections.National Centre for Infectious and Parasitic DiseasesThe NCIPD, acting in cooperation with the European Centre for Disease Prevention and Control, has developed the capacity for surveillance of the spread of infectious diseases and the modern diagnostic capabilities for Biohazard Level III infections.", [["viral and parasitic infections", "DISEASE", 79, 109], ["Infectious and Parasitic Diseases", "DISEASE", 130, 163], ["infectious diseases", "DISEASE", 318, 337], ["infections", "DISEASE", 401, 411], ["NRL", "PROTEIN", 52, 55], ["various bacterial", "PROBLEM", 60, 77], ["viral and parasitic infections", "PROBLEM", 79, 109], ["Infectious and Parasitic Diseases", "PROBLEM", 130, 163], ["The NCIPD", "TREATMENT", 163, 172], ["Disease Prevention", "TREATMENT", 225, 243], ["the capacity", "PROBLEM", 271, 283], ["infectious diseases", "PROBLEM", 318, 337], ["Biohazard Level III infections", "PROBLEM", 381, 411], ["bacterial", "OBSERVATION_MODIFIER", 68, 77], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["parasitic infections", "OBSERVATION", 89, 109], ["Infectious", "OBSERVATION", 130, 140], ["infectious", "OBSERVATION", 318, 328]]], ["The reaction to the bird fl u pandemic has demonstrated this capacity.", [["The reaction", "PROBLEM", 0, 12], ["this capacity", "PROBLEM", 56, 69]]], ["The Centre is capable of observing the dissemination of one biological agent, but is not designated to coordinate activities to stop it.National Centre for Infectious and Parasitic DiseasesThe NCIPD holds the country's reserves of serums and vaccines to be used in cases of biological attack and epidemics.", [["Infectious and Parasitic Diseases", "DISEASE", 156, 189], ["serums", "ORGANISM_SUBSTANCE", 231, 237], ["Infectious and Parasitic Diseases", "PROBLEM", 156, 189], ["serums", "TREATMENT", 231, 237], ["vaccines", "TREATMENT", 242, 250], ["biological attack", "PROBLEM", 274, 291], ["epidemics", "PROBLEM", 296, 305], ["Infectious", "OBSERVATION_MODIFIER", 156, 166]]], ["NCIPD has developed a plan for a bioresponse; however, access to the documentation is restricted.Regional Health InspectionsThe Regional Health Inspections (RHIs) replaced and merged the functions of the Regional Inspectorate for Protection and Control of Public Health and the Regional Health Centres.", [["NCIPD", "CHEMICAL", 0, 5], ["Protection", "TREATMENT", 230, 240]]], ["The new body started working in January 2011 and it is still in the process of its development.Regional Health InspectionsThe RHIs include the regional authorities, performing practical activities concer ning public health, such as the identi fi cation of the source of communicable diseases, epidemiological studies and health education activities.", [["body", "ANATOMY", 8, 12], ["communicable diseases", "DISEASE", 270, 291], ["body", "ORGANISM_SUBDIVISION", 8, 12], ["communicable diseases", "PROBLEM", 270, 291], ["epidemiological studies", "TEST", 293, 316], ["new", "OBSERVATION_MODIFIER", 4, 7], ["body", "OBSERVATION_MODIFIER", 8, 12]]], ["Similar to the case with its two predecessors, the Ministry of Health has not delegated tasks to the inspections related to planning its activities in case of a bioterrorist attack.Civilian Medical FacilitiesIn addition to the NCIPD and the Regional Health Inspections, the Ministry of Health manages civilian medical facilities which include hospitals, clinics or departments dealing with infectious diseases on the regional, municipal, and district levels.Civilian Medical FacilitiesThe civilian medical facilities have the necessary experience to respond to the most common epidemics, but lack the capacity -administrative, personnel and material -to act during a bio-attack.Role of the Ministry of Defence and the Military Medical AcademyThe state structures having both the capacity and preparedness to act in case of bioterrorism are the Ministry of Defence and the Military Medical Academy (MMA), responsible for the medical treatment of the army [ 2 ] .", [["infectious diseases", "DISEASE", 390, 409], ["infectious diseases", "PROBLEM", 390, 409], ["the medical treatment", "TREATMENT", 920, 941]]], ["That is why MMA is the only organization able to ensure protection both for the military forces and the civilian population during a bio-attack.", [["MMA", "CHEMICAL", 12, 15], ["MMA", "CHEMICAL", 12, 15], ["MMA", "SIMPLE_CHEMICAL", 12, 15]]], ["The goal was to build hospital facilities for the reception, isolation and treatment of patients with infectious diseases, and especially for dangerous infections, naturally occurring outbreaks and response to a potential biological attack [ 3 ] .Role of the Ministry of Defence and the Military Medical AcademyThe reconstructed clinic fi ts the modern construction and technology requirements to prevent disease transmission and reduce morbidity of the victims of naturally occurring epidemics and those from biological attack.Role of the Ministry of Defence and the Military Medical AcademyThe clinic is located in a separate building, which allows protection to prevent the spread of infections in other medical departments of the hospital in So fi a.", [["infectious diseases", "DISEASE", 102, 121], ["infections", "DISEASE", 152, 162], ["infections", "DISEASE", 687, 697], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["isolation", "TREATMENT", 61, 70], ["treatment", "TREATMENT", 75, 84], ["infectious diseases", "PROBLEM", 102, 121], ["dangerous infections", "PROBLEM", 142, 162], ["the modern construction", "TREATMENT", 342, 365], ["technology requirements", "TREATMENT", 370, 393], ["disease transmission", "PROBLEM", 405, 425], ["epidemics", "PROBLEM", 485, 494], ["infections", "OBSERVATION", 687, 697]]], ["CID has:Role of the Ministry of Defence and the Military Medical AcademyCapability for isolation and treatment of especially dangerous infections of the \u2022 bio-safety level 2 and 3; Access through a main road and by helicopter; \u2022 Trained medical personnel for bio-attack situations. \u2022 Contrary to the Clinic of Infectious Diseases in So fi a, other military hospitals in the country do not have the same capacity for response to bio-threats.", [["CID", "DISEASE", 0, 3], ["infections", "DISEASE", 135, 145], ["Infectious Diseases", "DISEASE", 310, 329], ["the Military Medical AcademyCapability", "TREATMENT", 44, 82], ["isolation", "TREATMENT", 87, 96], ["treatment", "TREATMENT", 101, 110], ["dangerous infections", "PROBLEM", 125, 145], ["Infectious", "OBSERVATION", 310, 320]]], ["The latter are intended to be used in these regional military hospitals, which do not have infectious wards.Military-Civilian PartnershipAs a general scenario, the military hospitals without infectious wards sign agreements with the civilian hospitals in the same city or region for the transfer of patients.", [["patients", "ORGANISM", 299, 307], ["patients", "SPECIES", 299, 307], ["infectious", "OBSERVATION", 91, 101]]], ["For this reason the agreements foresee that civilian hospitals will receive support from the medical personnel of MMA.Military-Civilian PartnershipBoth military and civilian hospitals suffer serious shortages of infectious disease professionals which number about 150 medical doctors for the entire country.", [["MMA", "CHEMICAL", 114, 117], ["infectious disease", "DISEASE", 212, 230], ["MMA", "CHEMICAL", 114, 117], ["MMA", "SIMPLE_CHEMICAL", 114, 117]]], ["This is the result of the policies of the Ministry of Health and the National Health Insurance Fund (NHIF) which fail to assure the necessary budget line for infectious diseases.Military-Civilian PartnershipAn issue which has not been subject to public and expert discussions is the interaction between public (civilian and military) and private facilities in case of a bio-attack.", [["infectious diseases", "DISEASE", 158, 177], ["infectious diseases", "PROBLEM", 158, 177]]], ["This is the case due to the rising number of privately owned hospitals which operate within the network of public healthcare fi nanced by the National Health Insurance Fund even though they do not have any responsibility in naturally occurring epidemics and bio-attacks.ConclusionTo sum up, fi rstly the subject of bioterrorism and preparedness in Bulgaria is fairly new.", [["bioterrorism", "PROBLEM", 315, 327], ["bioterrorism", "OBSERVATION", 315, 327], ["fairly", "OBSERVATION_MODIFIER", 360, 366], ["new", "OBSERVATION_MODIFIER", 367, 370]]], ["However, the institutions involved have started developing a strategic approach for this possibility.", [["a strategic approach", "TREATMENT", 59, 79]]], ["These efforts are limited by the continuous changes in the legal framework and the implementing structure.", [["the continuous changes in the legal framework", "PROBLEM", 29, 74]]], ["The changes are re fl ected to a lower extent in the organizations responsible for naturally occurring epidemics.ConclusionSecondly, in this changing environment the military medical structures hold the highest capacity in emergency response to bio-threats.", [["naturally occurring epidemics", "PROBLEM", 83, 112], ["lower extent", "OBSERVATION_MODIFIER", 33, 45], ["responsible for", "UNCERTAINTY", 67, 82]]], ["Here as well, the capacity remains below the necessary level.", [["the capacity", "TEST", 14, 26]]], ["Regardless of this fact, since the resources in the country for the prevention of bioterrorism are very limited and the health care system is undergoing serious reform, the military medical capacity could be used to protect civilians.ConclusionThirdly, as a result of the limited capability and resources, the need for cooperation is increasing.", [["bioterrorism", "PROBLEM", 82, 94], ["the military medical capacity", "TREATMENT", 169, 198]]], ["The most important of these are the relationship between the public healthcare and preparedness for bioterrorism and the relationship between the public healthcare and security and law enforcement structures.", [["bioterrorism", "PROBLEM", 100, 112]]]]}